CA3046894A1 - Heterocyclic compounds useful in the treatment of disease - Google Patents

Heterocyclic compounds useful in the treatment of disease Download PDF

Info

Publication number
CA3046894A1
CA3046894A1 CA3046894A CA3046894A CA3046894A1 CA 3046894 A1 CA3046894 A1 CA 3046894A1 CA 3046894 A CA3046894 A CA 3046894A CA 3046894 A CA3046894 A CA 3046894A CA 3046894 A1 CA3046894 A1 CA 3046894A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
ring
acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3046894A
Other languages
French (fr)
Inventor
Graham Beaton
Fabio C. Tucci
Satheesh B. Ravula
Chandravadan R. Shah
Hiep Luu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EPIGEN BIOSCIENCES Inc
Original Assignee
EPIGEN BIOSCIENCES Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/010,755 external-priority patent/US10526298B2/en
Application filed by EPIGEN BIOSCIENCES Inc filed Critical EPIGEN BIOSCIENCES Inc
Publication of CA3046894A1 publication Critical patent/CA3046894A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung,and scleroderma; inflammatory diseases such as diabetic nephropathy and nonalcoholic steatohepatitis (NASH); ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.

Description

HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE
CROSS REFERENCE TO RELATED APPLICATIONS
[01] This application is a continuation of United States Patent Application No. 14/776,954, filed on September 15, 2015, which is a a 371 National Phase of PCT/US2014/030712, filed on March 17, 2014, which claims the benefit of U.S. Provisional Patent Application Serial No.
61/801,426, filed March 15, 2013, U.S. Provisional Patent Application Serial No. 61/801,231, filed March 15, 2013, and U.S. Provisional Patent Application Serial No.
61/827,409, filed May 24, 2013, the entire contents of all of which are hereby incorporated by reference herein.
STATEMENT OF GOVERNMENT INTEREST
[02] This invention was made with government support under Grants DK092005 and CA174019 awarded by the National Institutes of Health. The US government has certain rights in the invention.
FIELD OF THE INVENTION
[03] The present invention relates to compounds having pharmacological activity, to processes for preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis of disease in a subject in need thereof, in particular for human and veterinarian treatments of pain, pruritus, cancer, inflammation and fibrotic diseases.
BACKGROUND OF THE INVENTION
[04] Lysophospholipids affect fundamental cellular functions that include proliferation, differentiation, survival, migration, adhesion, invasion, and morphogensis.
Abnormal functions influence many biological processes leading to disease that include, but are not limited to fibrotic disease, inflammation, cancer and peripheral nerve injury.
Lysophosphatidic acid (LPA) is a lysophospholipid that has been shown to act through specific G protein-coupled receptors (GPCRs) in an autocrine and paracrine fashion. Antagonists of the LPA
receptors find use in the treatment of diseases, disorders or conditions in which LPA plays a role.
[05] Agents that interact with the lysophosphatidic acid receptors [LPARs] to reduce signal transduction through those receptors (i.e., by competitive or noncompetitive inhibition or acting as inverse agonists) reduce manifestations of the diseases described herein.
Diseases and conditions whose etiology, progression or persistence is effected by in whole or in part by signaling through the lysophosphatidic acid receptor subtype 1 (LPA1R) are considered LPA-dependent. New agents having therapeutic utility for treating those LPA-dependent and other conditions and diseases described herein are needed.
SUMMARY OF THE INVENTION
[06] Disclosed herein are compounds that inhibit the physiological activity of lysophosphatidic acid (LPA), and therefore, are useful as agents for the treatment or prevention of diseases in which inhibition of the physiological activity of LPA is useful.
[07] In one aspect, those compounds are useful for the treatment of fibrosis of organs (e.g., liver, kidney, lung, heart and the like), liver diseases (e.g., acute hepatatis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, and the like), cell proliferative disease such as cancers (including but not limited to solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL), invasive metastasis of cancer cell, and the like), inflammatory diseases (including but not limited to psoriasis, nephropathy, pneumonia and the like), gastrointestinal tract disease (including but not limited to (irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), abnormal pancreatic secretion, and the like), renal disease, urinary tract-associated disease (including but not limited to benign prostatic hyperplasia or symptoms associated with neuropathic bladder disease, spinal cord tumor, hernia of intervertebral disk, spinal canal stenosis, symptoms derived from diabetes, lower urinary tract disease (including but not limited to obstruction of lower urinary tract, and the like), inflammatory disease of lower urinary tract, (including but not limited to dysuria, frequent urination, and the like), pancreas disease, abnormal angiogenesis-associated disease (including but not limited to arterial obstruction and the like), scleroderma, brain-associated disease (including but not limited to cerebral infarction, cerebral hemorrhage, and the like), nervous system diseases (including but not limited to neuropathic pain, peripheral neuropathy, pruritus and the like), ocular disease (including but not limited to age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreo-retinopathy (PVR), cicatricial pemphigoid, glaucoma filtration surgery scarring, and the like).
[08] The compounds of the invention include compounds of Formula I that have the structure:

L¨R Formula I
[09] wherein RA is -CO2H, -CO2RB, -CN, tetrazolyl, -C(=0)NH2, -C(=0)NHRB, -C(=0)NHSO2RB or -C(=0)NHCH2CH2S03H or a carboxylic acid isostere;
[010] L1 is absent or optionally substituted C1-C6 alkylene, optionally substituted C3-C6 cycloalkylene, optionally substituted C1-C6 fluoroalkylene, optionally substituted C1-C6 heteroalkylene, or -UV-Z-, wherein -UV- is defined by -OW-, -WO-, -N(R)W-, -WN(Fe)-, -N(R)C(=O)-, -SW-, -S(=O)W-, or -C(=0)N(RJ)-, wherein W is optionally substituted C1-C3 alkylene or optionally substituted C3-C6 cycloalkylene or W is -C(RL)2-, Z is optionally substituted C1-06 alkylene, optionally substituted C3-06 cycloalkylene or C1-C6fluoroalkylene or Z is -C(RL)2-; and n is 0, 1, 0r2;
[011] L2 is absent, or optionally substituted C1-C6 alkylene, optionally substituted C3-C6 cycloalkylene, C1-C6 fluoroalkylene, optionally substituted C1-C6 heteroalkylene, -0-, -S-, -S(=0)-, -S(=0)2-, -N(RB)-, -C(=0)-, or -C(=0)N(RB)-;
[012] wherein RB is -H or -optionally substituted C1-C4 alkyl, or has the structure of one of:
0y1Z;( )r0
[013] o ;
[014] Ring A is a 5 or 6 membered heteroarene having the structure of one of:
RE
N, I ) RN %--N RD \---RD
c RD Rc)==kRD RC RD
Rc 0 N=c ¨( RD RD Rc RD RD
Rc RD
Rc RE

0 N c r:
Rc/
' T.s.:("H N \ I
/ = R RD Rc µ1 )=RD N RD Re RD
RD
[015] wherein the dashed line indicates the point of attachment of Ring A
to Ring 6;
[016] wherein one of Rc and RD is -H, -CN, -F, -Br, -I, -0C1-C4 alkyl, C1-C4 alkyl, C3-C6 cycloalkyl, or C1-C4fluoroalkyl,
[017] and the other Rc or RD is -N(RE)C(=0)XCH(RG)-CY, -N(RE)C(=0)XC(RG)2-CY, -N(RE)C(=0)X-CY, -C(=0)-N(RE)-CH(RG)X-CY, or -C(=0)-N(RE)-C(RG)2X-CY, wherein X is absent, -0-, -NH- or -CH2-;
[018] RE is -H, C1-C4 alkyl or C1-C4fluoroalkyl;
[019] RE is -H or C1-C4 alkyl;
[020] RG is independently selected RE, or one RG is C1-C4 alkylne and is taken together with CY and the the carbon atom to which RG and CY is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other RG, if present, is as defined for RE;
[021] CY is optionally substituted C1-C6 alkyl, optionally substituted C3-C10 cycloalkyl, optionally substituted 02-C10 heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 independently selected RH,
[022] wherein each RH is independently -H, halogen, -CN, -NO2, -OH, -OR, -SR, -S(=0)R, -S(=0)2RJ, -N (RJ)S(=0)2RJ, -S(=0)2N(R1)2, -C(=0)R, OC(=0)RJ, -C(=0)0RJ, -0C=0)0RJ, -N(RI-)2, -C(=0)N(RI-)2, -0C(=0)N(RI-)2, -N(RJ)C(=0)N(RI-)2, -N(RJ)C(=0)RJ, -N(RJ)C(=0)0RJ, C1-04 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, C1-C4 alkoxy, or C1-C4 heteroalkyl;
[023] wherein each RJ is independently optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C1-C6 fluoroalkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C1-C4 alkylene-(optionally substituted 03-C6 cycloalkyl), -01-04 alkylene-(optionally substituted heterocycloalkyl), -C1-C4 alkylene-(optionally substituted aryl), or -Ci-C4 alkylene-(optionally substituted heteroaryl), and
[024] wherein RI- is independently -H, optionally substituted 01-06 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C1-C6 fluoroalkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -01-C4 alkylene-(optionally substituted C3-C6 cycloalkyl), -Ci-C4 alkylene-( optionally substituted heterocycloalkyl), -C1-C4 alkylene-(optionally substituted aryl), or -Ci-04 alkylene-(optionally substituted heteroaryl),
[025] or when RH is -S(=0)2N(RI-)2, -N(RI)2, -C(=0)N(RI-)2, -0C(=0)N(RI-)2 or -N(W)C(=0)N(RL)2, each RL is independently -H or C1-C6 alkyl, or the RL groups independently are C1-C6 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle,
[026] or when W is -C(RL)2, or Z is -C(RL)2- each RL is independently -H or C1-C6 alkyl, or the RL groups independently are C1-06 alkyl which are taken together with the carbon atom to which they are attached to define a carbocycle;
[027] Ring B is a optionally substituted C3-C10 cycloalkylene, optionally substituted C2-C10 heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroarylene, wherein if ring B is substituted then ring B is substituted with 1,2, or 3 independently selected RH, wherein RH is as previously defined; and
[028] Ring C is absent or optionally substituted C3-C10 cycloalkylene, optionally substituted C2-C10 heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroarylene, where if ring C is substituted then ring C is substituted with 1, 2, or 3 independently selected RH, wherein RH is as previously defined;
[020] wherein when Ring B is substituted or unsubstituted arylene, Ring C
is absent, L2 is absent, Cis -UV-Z-, wherein -UV- is -N(RJ)-C(=0)-, wherein RE is -H, RD is -N(RE)-C(=0)XCH(RG)-CY, wherein X is -0-, RG is -CH3 and RE is -H, and RD is -H, -CH3 or -CF3, [030] or when Ring B is optionally substituted arylene and Ring C is substituted or unsubstituted arylene or is substituted or unsubstituted C3-C10 cycloalkylene, or Ring B is substituted or unsubstituted C3-C10 cycloalkylene and Ring C is substituted or unsubstituted arylene, L2 is absent, Lis C1-C6 alkylene, [031] and RD is -H or -CH3 and RA is -CO2H or -0O2R6 , [032] then Ring A has the structure of one of:

RE
I
N-....! ,,N--N.; = N"Xr RE¨Ni N I
Rc R
D R D Rc c )--''--NRID "----RD
R
N =
:,' s---N ' R -,r .1.-- (N<
ni,,- RE-----ir N...____L.
RD 04 N=( RD Fzc\ RD RD71 RD
RC RD

E N. s=
R--...,Nr- QYNI,N-i- c.:I.Z.:-.' IN11-'-X r r , /
, , , N R, ..'s'N RD Rc''' .....'N-----NRD
N RD/ mc RD
RD RD
t-----[033] RD rc , [034] and when Ring B is C2-C10 heterocycloalkylene, Ring C is substituted or unsubstituted arylene, L2 is absent, L' is C1-C6 alkylene, Rc is -CH3 and RA is -CO2H or -CO2RB, then Ring A has the structure of one of:
N, ,.. E IN......,_>; ,,N....N:.!
p, , R¨N N I
y....
s..
Rc ...;N
R RD We-NW"
Rc N ' µ RcN ' e,,,,..õ- Rõ..e_r ;'' N / ' N .......Aµ
10-- N=( RD / -RD RD
Re RD RD
RE
0 i 0 N , rcrIN N.
E
RNA -:-N( \ j( I
N p.c., \ D R N RD RD N RD
RC/ rx =
[035] R RD RD RD R
[036] Other compounds of the invention have the structures indicated by the numbered embodiment and claims herein.
DETAILED DESCRIPTION OF THE INVENTION
[037] Definitions [0381 As used herein and unless otherwise stated or implied by context, terms that are used herein have the meanings defined below. Unless otherwise contraindicated or implied, e.g., by including mutually exclusive elements or options, in these definitions and throughout this specification, the terms "a" and "an" mean one or more and the term "or" means and/or where permitted by context. Thus, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise.
[039] At various locations in the present disclosure, e.g., in any disclosed embodiments or in the claims, reference is made to compounds, compositions, or methods that "comprise"
one or more specified components, elements or steps. Invention embodiments also specifically include those compounds, compositions, compositions or methods that are or that consist of or that consist essentially of those specified components, elements or steps. The terms "comprising", "consist of" and "consist essentially of" have their normally accepted meanings under U.S. patent law unless otherwise specifically stated. The term "comprised of" is used interchangeably with the term "comprising" and are stated as equivalent terms.
For example, disclosed compositions, devices, articles of manufacture or methods that "comprise" a component or step are open and they include or read on those compositions or methods plus an additional component(s) or step(s). Similarly, disclosed compositions, devices, articles of manufacture or methods that "consist of" a component or step are closed and they would not include or read on those compositions or methods having appreciable amounts of an additional component(s) or an additional step(s). Furthermore, use of the term "including" as well as other forms, such as "include", "includes," and "included," is not limiting.
The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology are employed.
[040] "Bond" or "single bond" as used herein means a chemical bond between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure. As explicitly stated or implied by context, when a group described herein is a bond, the referenced group is absent thereby allowing a bond to be formed between the remaining identified groups.
[041] "Membered ring" as used herein means any cyclic structure. The term "membered" is meant to denote the number of skeletal atoms that constitute the ring. Thus, by way of example and not limitation, those membered rings include cyclohexyl, pyridinyl, pyranyl and thiopyranyl, which are 6-membered rings and cyclopentyl, pyrrolyl, furanyl, and thienyl, which are 5-membered rings.
[042] "Moiety" as used herein means a specific segment, fragment or functional group of a molecule or compound. Chemical moieties are sometimes indicated as chemical entities that are embedded in or appended (i.e., a substituent or variable group) to a molecule or compound.
[043] "Alkyl" as used herein is a collection of carbon atoms that are covalently linked together in normal, secondary, tertiary or cyclic arrangements, i.e., in a linear, branched, cyclic arrangement or some combination thereof. An alkyl substituent to a structure is that chain of carbon atoms that is covalently attached to the structure through a sp3 carbon of the substituent. The alkyl substituents, as used herein, contains one or more saturated moieties or groups and may additionally contain unsaturated alkyl moieties or groups, i.e., the substituent may comprise one, two, three or more independently selected double bonds or triple bonds of a combination thereof, typically one double or one triple bond if such unsaturated alkyl moieties or groups are present.
[044] Unsaturated alkyl moieties or groups include moieties or groups as described below for alkenyl, alkynyl, cycloalkyl, and aryl moieties. Saturated alkyl moieties contain saturated carbon atoms (sp3) and no aromatic, sp2 or sp carbon atoms. The number of carbon atoms in an alkyl moiety or group can vary and typically is 1 to about 50, e.g., about 1-30 or about 1-20, unless otherwise specified, e.g., C1.8 alkyl or C1-C8 alkyl means an alkyl moiety containing 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms and Cl_s alkyl or C1-C6 means an alkyl moiety containing 1, 2, 3, 4, 5 or 6 carbon atoms.
[045] When an alkyl substituent, moiety or group is specified, species may include methyl, ethyl, 1-propyl (n-propyl), 2-propyl (/so-propyl, -CH(CH3)2), 1-butyl (n-butyl), 2-methyl-1-propyl (iso-butyl, -CH2CH(CH3)2), 2-butyl (sec-butyl, -CH(CH3)CH2CH3), 2-methyl-2-propyl (t-butyl, -C(CH3)3), amyl, isoamyl, sec-amyl and other linear, cyclic and branch chain alkyl moieties.
Unless otherwise specified, alkyl groups can contain species and groups described below for cycloalkyl, alkenyl, alkynyl groups, aryl groups, arylalkyl groups, alkylaryl groups and the like.
[046] Cycloalkyl as used here is a monocyclic, bicyclic or tricyclic ring system composed of only carbon atoms. The term "cycloalkyl" encompasses a monocyclic or polycyclic aliphatic, non-aromatic radical, wherein each of the atoms forming the ring (i.e.
skeletal atoms) is a carbon atom. The number of carbon atoms in an cycloalkyl substituent, moiety or group can vary and typically is 3 to about 50, e.g., about 1-30 or about 1-20, unless otherwise specified, e.g., C3.8 alkyl or C3-C8 alkyl means an cycloalkyl substituent, moiety or group containing 3, 4, 5, 6, 7 or 8 carbon atoms and C3.6 alkyl or C3-C6 means an cycloalkyl substituent, moiety or group containing 3, 4, 5 or 6 carbon atoms. Cycloalkyl substituents, moieties or groups will typically have 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms and may contain exo or endo-cyclic double bonds or endo-cyclic triple bonds or a combination of both wherein the endo-cyclic double or triple bonds, or the combination of both, do not form a cyclic conjugated system of 4n + 2 electrons; wherein the bicyclic ring system may share one (i.e., Spiro ring system) or two carbon atoms and the tricyclic ring system may share a total of 2, 3 or 4 carbon atoms, typically 2 or 3.
[047] Unless otherwise specified, cycloalkyl substituents, moieties or groups can contain moieties and groups described for alkenyl, alkynyl, aryl, arylalkyl, alkylaryl and the like and can contain one or more other cycloalkyl moieties. Thus, cycloalkyls may be saturated, or partially unsaturated. Cycloalkyls may be fused with an aromatic ring, and the points of attachment to the aromatic ring are at a carbon or carbons of the cycloalkyl substituent, moiety or group that is not an aromatic ring carbon atom. Cycloalkyl groups include groups having from 3 to 10 ring atoms. Cycloalkyl substituents, moieties or groups include cyclopropyl, cyclopentyl, cyclohexyl, adamantly or other cyclic all carbon containing moieties.
Cycloalkyls further include cyclobutyl, cyclopentenyl, cyclohexenyl, cycloheptyl and cyclooctyl. Cycloalkyl groups may be substituted or unsubstituted. Depending on the substituent structure, a cycloalkyl substituent can be a monoradical or a diradical (i.e., an cycloalkylene, such as, but not limited to, cyclopropan-1,1-diyl, cyclobutan-1,1-diyl, cyclopentan-1,1-diyl, cyclohexan-1,1-diyl, cyclohexan-1,4-diyl, cycloheptan-1,1-diyl, and the like). When cycloalkyl is used as a Markush group (i.e., a substituent) the cycloalkyl is attached to a Markush formula with which it is associated through a carbon involved in a cyclic carbon ring system carbon of the cycloalkyl group that is not an aromatic carbon.
[048]
"Alkylamine" as used herein means an -N(alkyl),Hy group, moiety or substituent where x and y are independently selected from the group x=1, y=1 and x=2, y=0.
Alkylamine includes those -N(alkyl)Fl groups wherein x=2 and y=0 and the alkyl groups taken together with the nitrogen atom to which they are attached form a cyclic ring system.
"Heteroalkylene" as used herein means an alkylene (i.e. alkanediy1) group, moiety or substituent in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof.
Heteroalkylene includes Cr C6 heteroalkylene or Crat heteroalkylene. Exemplary heteroalkylenes include, but are not limited to, -OCH2-, -OCH(CH3)-, -0C(CH3)2-, -OCH2CH2-, -CH20-, -CH(CH3)0-, C(CH3)20-, -CH2CH20-, -CH2OCH2-, -CH2OCH2CH2-, -CH2CH2OCH2-, -SCH2-, -SCH(CH3)-, -SC(CH3)2-, -SCH2CH2-, -CH2S-, -CH(CH3)S-, -C(CH3)2S-, -CH2CH2S-, -CH2SCH2-,-CH2SCH2CH2-, -CH2CH2SCH2-, -S(=0)2CH2-, -S(=0)2CH(CH3)-, -S(=0)2C(CH3)2-, -S(=0)2CH2CH2-, -CH2S(=0)2-, -CH(CH3)S(=0)2-, -C(CH3)2S(=0)2-, -CH2CH2S(=0)2-, -CH2S(=0)20H2-, -CH2S(=0)2CH2CH2-, CH2CH2S(=0)2CH2-, -NHCH2-, -NHCH(CH3)-, -NHC(CH3)2-, -NHCH2CH2-, -CH2NH-, -CH(CH3)NH-, -C(CH3)2NH-, -CH2CH2NH-, -CH2NHCH2-, -CH2NHCH2CH2-, -CH2CH2NHCH2-, and the like.
[049] "Carboxylic acid bioisostere" as used herein means a functional group, moiety or substituent that exhibits similar physical, biological and/or chemical properties as a carboxylic acid moiety. By way of example and not limitation, carboxylic acid bioisosteres include, N,\ N-Ck N-S
\i)t, ,OH µ,I)LN N-,CN \s) /0 µ,ii.' H H
\çX
OH

N F,C\/0F, OH )c0H
OH OH 0 =
[050] "Alkenyl" as used herein means a substituent, moiety or group that comprises one or more double bond moities (e.g., -CH=CH-) or 1, 2, 3, 4, 5 or 6 or more, typically 1, 2 or 3 such moieties and can include an aryl moiety or group such as benzene, and additionally comprises linked normal, secondary, tertiary or cyclic carbon atoms, i.e., linear, branched, cyclic or any combination thereof unless the alkenyl moiety is a vinyl moiety (e.g., -CH=CH2).
An alkenyl moiety, group or substituent with multiple double bonds may have the double bonds arranged contiguously (i.e. a 1,3 butadienyl moiety) or non-contiguously with one or more intervening saturated carbon atoms or a combination thereof, provided that a cyclic, contiguous arrangement of double bonds do not form a cyclically conjugated system of 4n +
2 electrons (i.e., aromatic). The number of carbon atoms in an alkenyl group or moiety can vary and typically is 2 to about 50, e.g., about 2-30 or about 2-20, unless otherwise specified, e.g., C2.8 alkenyl or C2-8 alkenyl means an alkenyl moiety containing 2, 3, 4, 5, 6, 7 or 8 carbon atoms and C2_6 alkenyl or C2-6 alkenyl means an alkenyl moiety containing 2, 3, 4, 5 or 6 carbon atoms. Alkenyl moieties or groups will typically have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms.

[051] When an alkenyl moiety, group or substituent is specified, species include, by way of example and not limitation, any of the alkyl or cycloalkyl, groups moieties or substituents described herein that has one or more double bonds, methylene (=CH2), methylmethylene (=CH-CH3), ethylmethylene (=CH-CH2-CH3), =CH-CH2-CH2-CH3, vinyl (-CH=CH2), ally!, 1-methylvinyl, butenyl, iso-butenyl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl and other linear, cyclic and branched chained all carbon containing moieties containing at least one double bond.
When alkenyl is used as a Markush group (i.e., a substituent) the alkenyl is attached to a Markush formula with which it is associated through an unsaturated carbon of a double bond of the alkenyl moiety or group unless specified otherwise.
[052] "Alkynyl" as used herein means a substituent, moiety or group that comprises one or more triple bond moieties (i.e., -CC-), e.g., 1, 2, 3, 4, 5, 6 or more, typically 1 or 2 triple bonds, optionally comprising 1, 2, 3, 4, 5, 6 or more double bonds, with the remaining bonds (if present) being single bonds and comprising linked normal, secondary, tertiary or cyclic carbon atoms, i.e., linear, branched, cyclic or any combination thereof, unless the alkynyl moiety is ethynyl. The number of carbon atoms in an alkenyl moiety or group can vary and typically is 2 to about 50, e.g., about 2-30 or about 2-20, unless otherwise specified, e.g., C2-8 alkynyl or C2-8 alkynyl means an alkynyl moiety containing 2, 3, 4, 5, 6, 7 or 8 carbon atoms.
Alkynyl groups will typically have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms.
[053] When an alkynyl moiety or group is specified, species include, by way of example and not limitation, any of the alkyl moieties, groups or substituents described herein that has one or more double bonds, ethynyl, propynyl, butynyl, iso-butynyl, 3-methyl-2-butynyl, 1-pentynyl, cyclopentynyl, 1-methyl-cyclopentynyl, 1-hexynyl, 3-hexynyl, cyclohexynyl and other linear, cyclic and branched chained all carbon containing moieties containing at least one triple bond. When an alkynyl is used as a Markush group (i.e., a substituent) the alkynyl is attached to a Markush formula with which it is associated through one of the unsaturated carbons of the alkynyl functional group.
[054] "Aromatic" as used herein refers to a planar ring having a delocalized pi-electron system containing 4n+2 pi electrons, where n is a positive integer. Aromatic rings can be formed from five, six, seven, eight, nine, ten, or more than ten atoms. Aromatics are optionally substituted. The term "aromatic" includes both carboxcylic aryl ("aryl", e.g., phenyl) and heterocyclic aryl (or "heteroaryl" or "heteroaromatic") groups (e.g., pyridine). The term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups.
[055] "Aryl" as used here means an aromatic ring system or a fused ring system with no ring heteroatoms comprising 1, 2, 3 or 4 to 6 rings, typically 1 to 3 rings, wherein the rings are composed of only carbon atoms; and refers to a cyclically conjugated system of 4n + 2 electrons (Huckel rule), typically 6, 10 0114 electrons some of which may additionally participate in exocyclic conjugation (cross-conjugated (e.g., quinone). Aryl substituents, moieties or groups are typically formed by five, six, seven, eight, nine, or more than nine, carbon atoms. Aryl substituents, moieties or groups are optionally substituted. Exemplary aryls include C6-C10 aryls such as phenyl and naphthalenyl and phenanthryl. Depending on the structure, an aryl group can be a monoradical or a diradical (i.e., an arylene group). Exemplary arylenes include, but are not limited to, phenyl-1,2-ene, phenyl-1,3-ene, and phenyl-1,4-ene. When aryl is used as a Markush group (i.e., a substituent) the aryl is attached to a Markush formula with which it is associated through an aromatic carbon of the aryl group.
[056] "Arylalkyl" as used herein means a substituent, moiety or group where an aryl moiety is bonded to an alkyl moiety, i.e., -alkyl-aryl, where alkyl and aryl groups are as described above, e.g., -CH2-C6H5 or -CH2CH(CH3)-C6H5. When arylalkyl is used as a Markush group (i.e., a substituent) the alkyl moiety of the arylalkyl is attached to a Markush formula with which it is associated through a sp3 carbon of the alkyl moiety.

[057] "Alkylaryl" as used herein means a substituent, moiety or group where an alkyl moiety is bonded to an aryl moiety, i.e., -aryl-alkyl, where aryl and alkyl groups are as described above, e.g., -C6H4-CH3 or -C6I-14-CH2CH(CH3). When alkylaryl is used as a Markush group (i.e., a substituent) the aryl moiety of the alkylaryl is attached to a Markush formula with which it is associated through a sp2 carbon of the aryl moiety.
[058] "Substituted alkyl", "substituted cycloalkyl", "substituted alkenyl", "substituted alkynyl", substituted alkylaryl", "substituted arylalkyl", "substituted heterocycle", "substituted aryl" and the like as used herein mean an alkyl, alkenyl, alkynyl, alkylaryl, arylalkyl heterocycle, aryl or other group or moiety as defined or disclosed herein that has a substituent(s) that replaces a hydrogen atom(s) or a substituent(s) that interrupts a carbon atom chain. Alkenyl and alkynyl groups that comprise a substituent(s) are optionally substituted at a carbon that is one or more methylene moieties removed from the double bond.
[059] "Optionally substituted alkyl", "optionally substituted alkenyl", "optionally substituted alkynyl", "optionally substituted alkylaryl", "optionally substituted arylalkyl", "optionally substituted heterocycle", "optionally substituted aryl", "optionally substituted heteroaryl", "optionally substituted alkylheteroaryl", "optionally substituted heteroarylalkyl" and the like as used herein mean an alkyl, alkenyl, alkynyl, alkylaryl, arylalkyl heterocycle, aryl, heteroaryl, alkylheteroaryl, heteroarylalkyl, or other substituent, moiety or group as defined or disclosed herein that has a substituent(s) that optionally replaces a hydrogen atom(s) or a substituent(s) that interrupts a carbon atom chain. Such substituents are as described herein.
For a phenyl moiety, the arrangement of any two substituents present on the aromatic ring can be ortho (o), meta (m), or para (p). An optionally substituted fluoroalkyl is an alkyl or cycloalkyl moiety, typically a linear alkyl, wherein one or more hydrogen atoms is replaced by fluorine and at least one other atom other than carbon and fluorine.

An optionally substituted or substituted substituent, moiety or group includes those having one or more additional group(s) that replace its hydrogen atom(s) individually and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, cyano, halo, nitro, haloalkyl, fluoroalkyl, fluoroalkoxy, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof. By way of example and not limitation an optional substituent(s) may be halide, -CN, -NO2, or LsRs, wherein each Ls is independently selected from a bond, -0-, -C(=0)-, -C(=0)0-, -S-, -S(=0)-, -S(=0)2-, -NH-, -NHC(=0)-, -C(=0)NH-, S(=0)2NH-, -NHS(=0)2, -0C(=0)NH-, -NHC(=0)0-, or -(C1-C6 alkylene)-; and each Rs is selected from -H, alkyl, fluoroalkyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl.
The protecting groups that may form the protective derivatives of the above substituents may be found in sources such as Greene and Wuts, above. Optional substituents include those selected from the group consisting of halogen, -CN, -NH2, -OH, -N(CH3)2, alkyl, fluoroalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, and arylsulfone, those selected from the group consisting of halogen, -CN, -NH2, -OH, NH(0H3), -N(CH3)2, -CO2H, -0O2alkyl, -C(=0)NH2, -C(=0)NHalkyl, -C(=0)N(alky1)2, -S(=0)2NH2, -S(=0)2NH(alkyl), -S(=0)2N(alky1)2, alkyl, cycloalkyl, fluoroalkyl, heteroalkyl, alkoxy, fluoroalkoxy, -S-alkyl and-S(=0)2a1ky1 or those selected from the group consisting of halogen, -CN, -NH2, -OH, -NH(CH3), -N(CH3)2, -CH3, -CH2CH3, -CF3, -OCH3, and -OCF3. Typically, an optionally substituted, substituent, moiety or group is substituted with one or two of the preceding groups, or more typically with one of the preceding groups. An optional substituent on an aliphatic carbon atom (acyclic or cyclic, saturated or unsaturated carbon atoms, excluding aromatic carbon atoms) further includes oxo (=0).
[060] "Heterocycle" or "heterocyclic" as used herein means a cycloalkyl or aromatic ring system wherein one or more, typically 1, 2 or 3, but not all of the carbon atoms comprising the ring system are replaced by a heteroatom which is an atom other than carbon, including, N, 0, S, Se, B, Si, P, typically N, 0 or S wherein two or more heteroatoms may be adjacent to each other or separated by one or more carbon atoms, typically 1-17 carbon atoms, 1-7 atoms or 1-3 atoms. Heterocycles includes heteroaromatic rings (also known as heteroaryls) and heterocycloalkyl rings (also known as heteroalicyclic groups) containing one to four heteroatoms in the ring(s), where each heteroatom in the ring(s) is selected from 0, S and N, wherein each heterocyclic group has from 4 to 10 atoms in its ring system, and with the proviso that the any ring does not contain two adjacent 0 or S atoms.
[061 Non-aromatic heterocyclic, substituents, moieties or groups (also known as heterocycloalkyls) have at least 3 atoms in their ring system, and aromatic heterocyclic groups have at least 5 atoms in their ring system and include benzo-fused ring systems.
Heterocyclics with 3, 4, 5, 6 and 10 atoms include aziridinyl azetidinyl, thiazolyl, pyridyl and quinolinyl, respectively. Nonaromatic heterocyclic substituents, moieties or groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, oxazolidinonyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, pyrrolin-2-yl, pyrrolin-3-yl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0)hexanyl, 3azabicyclo[4.1.0)heptanyl, 3H-indoly1 and quinolizinyl. Aromatic heterocyclic includes, by way of example and not limitation, pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl,triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzo-thiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Non-aromatic heterocycles may be substituted with one or two oxo (=0) moieties, and includes pyrrolidin-2-one.
[062] When heterocycle is used as a Markush group (i.e., a substituent) the heterocycle is attached to a Markush formula with which it is associated through a carbon or a heteroatom of the heterocycle, where such an attachment does not result in an unstable or disallowed formal oxidation state of that carbon or heteroatom. A heterocycle that is C-linked is bonded to a molecule through a carbon atom include moieties such as -(CH2)n-heterocycle where n is 1, 2 or 3 or -C<heterocycle where C< represents a carbon atom in a heterocycle ring. A
heterocycle that is N-linked is a nitrogen containing heterocycle that is bonded a heterocycle ring nitrogen sometimes described as -N<heterocycle where N< represents a nitrogen atom in a heterocycle ring. Thus, nitrogen-containing heterocycles may be C-linked or N-linked and include pyrrole substituents, which may be pyrrol-1-y1 (N-linked) or pyrrol-3-y1 (C-linked), imidazole substituents, which may be imidazol-1-y1 or imidazol-3-y1 (both N-linked) or imidazol-2-yl, imidazol-4-y1 or imidazol-5-y1 (all C-linked).
[063] "Heteroaryl" as used herein means an aryl ring system wherein one or more, typically 1, 2 or 3, but not all of the carbon atoms comprising the aryl ring system are replaced by a heteroatom which is an atom other than carbon, including, N, 0, S, Se, B, Si, P, typically, oxygen (-0-), nitrogen (-NX-) or sulfur (-S-) where X is -H, a protecting group or C1_6 optionally substituted alkyl, wherein the heteroatom participates in the conjugated system either through pi-bonding with an adjacent atom in the ring system or through a lone pair of electrons on the heteroatom and may be optionally substituted on one or more carbons or heteroatoms, or a combination of both, in a manner which retains the cyclically conjugated system.
[064] Heterocycles and heteroaryls, include, by way of example and not limitation, heterocycles and heteroaryls described in Paquette, Leo A.; "Principles of Modern Heterocyclic Chemistry" (W. A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs"
(John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am.
Chem. Soc. 1960, 82:5545-5473 particularly 5566-5573). Examples of heteroaryls include by way of example and not limitation pyridyl, thiazolyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, purinyl, imidazolyl, benzofuranyl, indolyl, isoindoyl, quinolinyl, isoquinolinyl, benzimidazolyl, pyridazinyl, pyrazinyl, benzothiopyran, benzotriazine, isoxazolyl, pyrazolopyrimidinyl, quinoxalinyl, thiadiazolyl, triazolyl and the like.
Heterocycles that are not heteroaryls include, by way of example and not limitation, tetrahydrothiophenyl, tetrahydrofuranyl, indolenyl, piperidinyl, pyrrolidinyl, 2-pyrrolidonyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, 2H-pyrrolyl, 3H-indolyl, 4H-quinolizinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, piperazinyl, quinuclidinyl, morpholinyl, oxazolidinyl and the like.
[065] Other heteroaryls include, by way of example and not limitation, the following moieties:
H H
N rON,s Nµ 4101 0 I II .1µ1 N
N w = N N Na) (N_IN
\ 1\1\\
N N N N _____ N S 0 N,N, c,0) / I
r r N
[066] Monocyclic heteroaryls include, by way of example and not limitation, pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl, thiadiazolyl, and furazanyl. Heteroaryls include those substituents, moieties or groups containing 0-3 N atoms, 1-3 N atoms or 0-3 N atoms, 0-1 0 atoms and 0-1 S atoms. A heteroaryl may be monocyclic or bicyclic. The ring system of a heteroaryls ring typically contains 1-9 carbons (i.e., C1-C9 heteroaryl). Monocyclic heteroaryls include C1-05 heteroaryls. Monocyclic heteroaryls include those having 5-membered or 6-membered ring systems. Bicyclic heteroaryls include C6-Cg heteroaryls. Depending on the structure, a heteroaryl group can be a nnonoradical or a diradical (i.e., a heteroarylene group).
[067] "Heterocycloalkyl" or "heteroalicyclic" as used herein means a cycloalkyl group, moiety or substituent wherein at least on carbon of the cycloalkyl chain is replaces with a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur. The heterocycloalkyl may be fused with an aryl or heteroaryl. Heterocycloalkyls, also referred to as non-aromatic heterocycles, include by way of example and not limitation:

cs 0,,s,2 A N
0 0 o 0 N
i NN
_______________________________________ N-N 0 0 I 1 j NO

N.) ) [068] Heterocycloalkyl includes, by way of example and not limitation, oxazolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, and indolinyl.
Heteroalicyclics further includes all ring forms of carbohydrates, including but not limited to monosaccharides, disaccharides and oligosaccharides. Typically, a heterocycloalkyl is a C2-C10 heterocycloalkyl and includes 04-C10 heterocycloalkyl. A heterocycloalkyl may contain 0-2 N
atoms, 0-2 0 atoms or 0-1 S atoms.

[069] "Heteroarylalkyl" as used herein means a substituent, moiety or group where a heteroaryl moiety is bonded to an alkyl moiety, i.e., -alkyl-heteroaryl, where alkyl and heteroaryl groups are as described above. When heteroarylalkyl is used as a Markush group (i.e., a substituent) the alkyl moiety of the heteroarylalkyl is attached to a Markush formula with which it is associated through a sp3 carbon of the alkyl moiety.
[070] "Alkylheteroaryl" as used herein means a substituent, moiety or group where a heteroaryl moiety is bonded to an alkyl moiety, i.e., -heteroaryl-alkyl, where heteroaryl and alkyl groups are as described above. When heteroarylalkyl is used as a Markush group (i.e., a substituent) the heteroaryl moiety of the heteroarylalkyl is attached to a Markush formula with which it is associated through a sp2 carbon or heteroatom of the alkyl moiety.
[071] "Halogen" or "halo" as used herein means fluorine, chlorine, bromine or iodine.
[072] "Haloalkyl" as used herein means an alkyl substituent moiety or group in which one or more of its hydrogen atoms are replaced by one or more independently selected halide atoms.
Haloalkyl includes C1-C4 haloalkyl. Example but non-limiting C1-C4 haloalkyls are -CH2CI, CH2Br, -CH21, -CHBrCI, -CHCI-CH2CI and ¨CHCI-CH21.
[073] "Haloalkylene" as used herein means an alkylene substituent, moiety or group in which one or more hydrogen atoms are replaced by one or more halide atoms.
Haloalkylene includes C1-C6haloalkylenes or C1-C4 haloalkylenes.
[074] "Fluoroalkyl" as used herein means an alkyl in which one or more hydrogen atoms are replaced by a fluorine atom. Fluoroalkyl includes C1-C6 and C1-C4 fluoroalkyls. Example but non-limiting fluoroalkyls include -CH3F, -CH2F2 and -CF3 and perfluroalkyls.
[075] "Fluoroalkylene" as used herein means an alkylene in which one or more hydrogen atoms are replaced by a fluorine atom. Fluoroalkylene includes C1-06 fluoroalkylenes or C1-C4 fluoroalkylenes.

[076] The term "heteroalkyl" refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof. In one aspect, a heteroalkyl is a C1-C6 heteroalkyl.
[077] "Protecting group" as used here means a moiety that prevents or reduces the ability of the atom or functional group to which it is linked from participating in unwanted reactions.
Non-limiting examples are for -ORPR, wherein RPR is a protecting group for the oxygen atom found in a hydroxyl, while for -C(0)-OR, RPR may be a carboxylic acid protecting group; for -SRPR, RPR may be a protecting group for sulfur in thiols and for -NHRPR or -N(RPR)2-, at least one of RPR is a nitrogen atom protecting group for primary or secondary amines. Hydroxyl, amine, ketones and other reactive groups may require protection against reactions taking place elsewhere in the molecule. The protecting groups for oxygen, sulfur or nitrogen atoms are usually used to prevent unwanted reactions with electrophilic compounds, such as acylating agents. Typical protecting groups for atoms or functional groups are given in Greene (1999), "Protective groups in organic synthesis, 3' ed.", Wiley Interscience.
[078] "Estee' as used herein means a substituent, moiety or group that contains a -C(0)-0- structure (i.e., ester functional group) wherein the carbon atom of the structure is not directly connected to another heteroatom and is directly connected to -H
or another carbon atom. Typically, esters comprise or consist of an organic moiety containing 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e.g., 0, S, N, P, Si), typically 0-2 where the organic moiety is bonded through the -C(0)-0- structure and include ester moieties such as organic moiety-C(0)-0-. The organic moiety usually comprises one or more of any of the organic groups described herein, e.g., C1_20 alkyl moieties, C2-20 alkenyl moieties, C2-20 alkynyl moieties, aryl moieties, C3-8 heterocycles or substituted derivatives of any of these, e.g., comprising 1, 2, 3, 4 or more substituents, where each substituent is independently chosen. Exemplary, non-limiting substitutions for hydrogen or carbon atoms in these organic groups are as described above for substituted alkyl and other substituted moieties and are independently chosen. The substitutions listed above are typically substituents that one can use to replace one or more carbon atoms, e.g., -0- or -C(0)-, or one or more hydrogen atom, e.g., halogen, -NH2 or -OH.
Exemplary esters include by way of example and not limitation, one or more independently selected acetate, propionate, isopropionate, isobutyrate, butyrate, valerate, isovalerate, caproate, isocaproate, hexanoate, heptanoate, octanoate, phenylacetate esters or benzoate esters. When ester is used as a Markush group (i.e., a substituent) the single bonded oxygen of the ester functional group is attached to a Markush formula with which it is associated.
[079] "Acetal", "thioacetal", "ketal", "thioketal" and the like as used herein means a moiety, group or substituent comprising or consisting of a carbon to which is bonded two of the same or different heteroatoms wherein the heteroatoms are independently selected S
and 0. For acetal the carbon has two bonded oxygen atoms, a hydrogen atom and an organic moiety.
For ketal, the carbon has two bonded oxygen atoms and two independently selected organic moieties where the organic moiety is as described herein alkyl or optionally substituted alkyl group. For thioacetals and thioketals one or both of the oxygen atoms in acetal or ketal, respectively, is replaced by sulfur. The oxygen or sulfur atoms in ketals and thioketals are sometimes linked by an optionally substituted alkyl moiety. Typically, the alkyl moiety is an optionally substituted C1-8 alkyl or branched alkyl structure such as -C(CI-13)2-, -CH(CH3)-, -CH2-, -CH2-CH2-, -C[(02-C4 alkyl) 1 /2,0, 2, 3- or ¨[CH(C2-C4 alkyl)]1, Some of these moieties can serve as protecting groups for an aldehyde or ketone include, by way of example and not limitation, acetals for aldehydes and ketals for ketones and contain -0-CH2-CH2-CH2-0- or -0-CH2-CH2-0- moieties that form a Spiro ring with the carbonyl carbon, and can be removed by chemical synthesis methods or by metabolism in cells or biological fluids.
[080] "Ether" as used herein means an organic moiety, group or substituent that comprises or consists of 1, 2, 3, 4 or more -0- moieties, usually 1 or 2, wherein no two -0- moieties are immediately adjacent (i.e., directly attached) to each other. Typically, ethers comprise an organic moiety containing 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to independently selected heteroatoms (e.g., 0, S, N, P, Si), typically 0-2. An ether moiety, group or substituent includes organic moiety-0- wherein the organic moiety is as described herein for alkyl or optionally substituted alkyl group. When ether is used as a Markush group (i.e., a substituent) the oxygen of the ether functional group is attached to a Markush formula with which it is associated. When ether is a used as substituent in a Markush group it is sometimes designated as an "alkoxy" group. Alkoxy includes C1-C4 ether substituents such as, by way of example and not limitation, methoxy, ethoxy, propoxy, iso-propoxy and butoxy. Ether further includes those substituents, moieties or groups that contain one (excluding ketal) or more -OCH2CH20-, moieties in sequence (i.e., polyethylene or PEG moieties).
[081] "Carbonate" as used here means a substituent, moiety or group that contains a -0-C(=0)-0- structure (i.e., carbonate functional group). Typically, carbonate groups as used here comprise or consist of an organic moiety containing 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e.g., 0, S, N, P, Si), typically 0-2, bonded through the -0-C(=0)-0- structure, e.g., organic moiety-0-C(=0)-0-. When carbonate is used as a Markush group (i.e., a substituent) one of the singly bonded oxygen atoms of the carbonate functional group is attached to a Markush formula with which it is associated.
[082] "Carbamate" or "urethane" as used here means a substituent, moiety or group that contains a -0-C(=0)N(RPR)-, -0-C(=0)N(RPR)2, -0-C(=0)NH(optionally substituted alkyl) or -0-C(=0)N(optionally substituted alky1)2- structure (i.e., carbamate functional group) where RPR and optionally substituted alkyl are independently selected and RPR are independently -H, a protecting group or an organic moiety as described for ester, alkyl or optionally substituted alkyl. Typically, carbamate groups as used here comprise or consist of an organic moiety containing about 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e.g., 0, S, N, P, Si), typically 0-2, bonded through the -0-C(=0)-NRPR- structure, e.g., organic moiety-0-C(=0)-NRPR- or -0-C(=0)-NR-organic moiety. When carbamate is used as a Markush group (i.e., a substituent) the singly bonded oxygen (0-linked) or nitrogen (N-linked) of the carbamate functional group is attached to a Markush formula with which it is associated. The linkage of the carbamate substituent is either explicitly stated (N- or 0-linked) or implicit in the context to which this substituent is referred.
[083] For any substituent group or moiety described by a given range of carbon atoms, the designated range means that any individual number of carbon atoms is described. Thus, reference to, e.g., "C1-C4 optionally substituted alkyl", "C2-6 alkenyl optionally substituted alkenyl", "C3-C8 optionally substituted heterocycle" specifically means that a 1, 2, 3 or 4 carbon optionally substituted alkyl moiety as defined herein is present, or a 2, 3, 4, 5 or 6 carbon alkenyl, or a 3, 4, 5, 6, 7 or 8 carbon moiety comprising a heterocycle or optionally substituted alkenyl moiety as defined herein is present. All such designations are expressly intended to disclose all of the individual carbon atom groups and thus ''C1-C4 optionally substituted alkyl"
includes, e.g., 3 carbon alkyl, 4 carbon substituted alkyl and 4 carbon alkyl, including all positional isomers and the like are disclosed and can be expressly referred to or named. For esters, carbonates and carbamates defined by a given range of carbon atoms, the designated range includes the carbonyl carbon of the respective functional group. Thus a Cl ester refers to a formate ester and a C2 ester refers to an acetate ester. The organic substitutents, moieties and groups described herein, and for other any other moieties described herein, usually will exclude unstable moieties except where such unstable moieties are transient species that one can use to make a compound with sufficient chemical stability for the one or more of the uses described herein. Substituents, moieties or groups by operation of the definitions herein that results in those having a pentavalent carbon are specifically excluded.
[084] "LPA-dependent", "LPA-mediated" or like terms as used herein means a disease or condition whose etiology, progression or persistence is effected by in whole or in part by signaling through one or more lysophosphatidic acid receptor subtypes, including by way of example and not limitation lysophosphatidic acid receptor subtypes 1-6 (LPARs). LPA-dependent or LPA-mediated diseases and conditions include but not limited to fibrosis of organs (e.g., liver, kidney, lung, heart and the like), liver diseases (e.g., acute hepatatis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, and the like), cell proliferative disease (e.g., cancers, including but not limited to solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL), invasive metastasis of cancer cell, and the like), inflammatory disease (e.g., psoriasis, nephropathy, pneumonia and the like), gastrointestinal tract disease (e.g., irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), abnormal pancreatic secretion, and the like), renal disease, urinary tract-associated disease (e.g., benign prostatic hyperplasia or symptoms associated with neuropathic bladder disease), spinal cord tumor, hernia of intervertebral disk, spinal canal stenosis, symptoms derived from diabetes, lower urinary tract disease (e.g., obstruction of lower urinary tract, and the like), inflammatory disease of lower urinary tract (e.g., dysuria, frequent urination, and the like), pancreas disease, abnormal angiogenesis-associated disease (e.g., arterial obstruction and the like), scleroderma, brain-associated disease (e.g., cerebral infarction, cerebral hemorrhage, and the like), nervous system diseases (e.g., neuropathic pain, peripheral neuropathy, pruritus and the like), ocular disease (e.g., age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreo-retinopathy (PVR), cicatricial pemphigoid, glaucoma filtration surgery scarring, and the like).
[085]
"LPA1R selective agents", LPA1R selective compounds" and like terms as used herein means agents or compounds that interact with the lysophosphatidic acid subtype 1 receptor in preference to the lysophosphatidic acid receptor 2-6. Typically, that preference is manifested by 10-fold stronger binding affinity of the agent to LPA1R in comparison to other known LPARs as measured by experimentally determined KD values.

[086] "Pharmaceutically acceptable formulation" as used herein means a composition comprising an active pharmaceutical ingredient, such as a compound having the formula of 1-V1 in addition to one or more pharmaceutically acceptable excipients or refers to a composition prepared from an active pharmaceutical ingredient and one or more pharmaceutically acceptable excipients, wherein the composition is suitable for administration to a subject, such as a human or an animal, in need thereof. For a pharmaceutically acceptable formulation to be suitable for administration to a human the formulation must have biological activity for treating or preventing a disease or condition disclosed herein or an expectation must exist that the formulation would have a desired activity towards an "intent to treat" disease or condition.
Typically, the "intent to treat" disease or condition is a lysophosphatidic acid receptor-mediated condition or disease. More typically the disease or condition to be treated or prevented is a lysophosphatidic acid lysophosphatidic acid type 1 receptor-mediated disease or condition. A
pharmaceutically acceptable formulation that is suitable for administration to an animal does not necessarily require a biological activity for treating or preventing a disease or condition, and may be administered to the animal in order to evaluate a potential pharmacological or biological activity of a Formula 1-XII compound. Those formulations must therefore be suitable for treating or preventing a disease or condition disclosed herein in an animal in need thereof or is suitable for evaluating a pharmacological or biological activity of a Formula 1-X11 compound.
Compositions that are suitable only for use in vitro assays or which contain a vehicle, component or excipient in an amount not permitted in a drug product are specifically excluded from the definition of a pharmaceutically acceptable formulation.
[087] The pharmaceutically acceptable formulation may be comprised of, or be prepared from, one, two or more Formula 1-XII compounds, typically one or two, and one or more ' pharmaceutically acceptable excipients. More typically, the formulations will consist essentially of or consist of a single Formula 1-XII compound and one or more pharmaceutically acceptable excipients. Other formulations may be comprised of, consist essentially of, or consist of one, two or more Formula 1-XII compounds and one two or more compounds in current use for treating lysophosphatidic acid lysophosphatidic acid type 1 receptor-mediated disease or condition disclosed herein and one or more pharmaceutically acceptable excipients. Typically those formulations will consist essentially of or consist of a single Formula 1-XII compound, a single compound in current use for treating a lysophosphatidic acid lysophosphatidic acid type 1 receptor-mediated disease or condition and one or more pharmaceutically acceptable excipients.
[088] "Solid formulation" as used herein refers to a pharmaceutically acceptable formulation comprising at least one Formula 1-XII compound and one or more pharmaceutically acceptable excipients in solid form(s) wherein the formulation is in a unit dosage form suitable for administration of a solid. The dosage units include tablets, capsules, caplets, gelcaps, suspensions and other dosage units typically associated with parenteral or enteral (oral) administration of a solid.
[089] "Liquid formulation" as used herein refers to a pharmaceutically acceptable formulation wherein at least one Formula 1-X11 compound has been admixed or contacted with one or more pharmaceutically acceptable excipients, wherein at least one of the excipients is in liquid form in proportions required for a liquid formulation, i.e., such that a majority of the mass amount of the Formula 1-X11 compound(s) is dissolved into the non-solid excipient. Dosage units containing a liquid formulation include syrups, gels, ointments and other dosage units typically associated with parenteral or enteral administration of a pharmaceutical formulation to a subject in need thereof in liquid form.
[090] "Prevent, "preventing" and like terms as used herein takes on its normal and customary meaning in the medical arts and therefore does not require that each instance to which the term refers be avoided with certainty.
[091] Numbered embodiments [092] The following embodiments exemplify the invention and are not meant to limit the invention in any manner. In certain embodiments, the compounds presented herein possess one or more stereocenters and each center independently exists in either the R
or S
configuration. The compounds presented herein include all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof. Stereoisomers are obtained, if desired, by methods such as, stereoselective synthesis and/or the separation of stereoisomers by chiral chromatographic columns. The methods and formulations described herein include the use of pharmaceutically acceptable salts of compounds having the structure of Formulas (I-VI), as well as active metabolites of these compounds having the same type of activity. In some situations, compounds may exist as tautomers. All tautomers are included within the scope of the compounds presented herein. In specific embodiments, the compounds described herein will exist as salts, including pharmaceutically acceptable salts. The salt forms include inorganic addition salts such as F Cr, Br, 1- and sulfate salts and organic addition salts such as mesylate, besylate, tosylate, citrate, succinate, fumarate and malonate. In other embodiments, the compounds described herein exist as quaternary ammonium salts.
[093] 1. A compound of Formula I having the structure Formula I
or a pharmaceutically acceptable salt or prodrug thereof, [094] wherein RA is -CO2H, -0O2R8, -CN, tetrazolyl, -C(=0)NH2, -C(=0)NHR8, -C(=0)NHSO2R8 or -C(=0)NHCH2CH2S03H or a carboxylic acid isostere;
[095] L1 is absent or substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C1-C6 fluoroalkylene, substituted or unsubstituted C3-08 cycloalkylene, substituted or unsubstituted C1-C6 heteroalkylene, or -UV-Z-, wherein -UV-is defined by -OW-, -WO-, -N(RJ)W-, -WN(RJ)-, -N(R)C(=O)-, -SW-, -S(=O)W-, or -C(=0)N(RJ)-, wherein W is substituted or
- 29 -unsubstituted 01-03 alkylene, or W is -C(RI)2; Z is substituted or unsubstituted 01-06 alkylene, substituted or unsubstituted 03-08 cycloalkylene, or C1-C6 fluoroalkylene or Z
is -C(RL)2-; and n is 0, 1, or 2;
[096] L2 is absent, or substituted or unsubstituted 01-06 alkylene, substituted or unsubstituted 03-C8 cycloalkylene, 01-06 fluoroalkylene, substituted or unsubstituted C3-08 cycloalkylene, substituted or unsubstituted 01-C6 heteroalkylene, -0-, -S-, -SO-, -SO2-, -C(=0)-, or -C(=0)N(RJ)-;
[097] wherein RB is substituted or unsubstituted 01-04 alkyl, or has the structure of one of:
ll [098] o ;
[099] Ring A is a 5 or 6 membered heteroarene having the structure of one of:
RE
NI\
,D
Rc Rc RD Rc Rc N
RD
Rc N N
re N =
0 /RD Rc ¨(RD
RD Rc/N¨\RD
RN
RE
0 ,N
rNy Rc RD Re"--N-RD
Rc õD
RC/ RD 7.----CRD RC r%
[0100] wherein the dashed line indicates the point of attachment of Ring A to Ring B;
= [0101] wherein one of Rc and RD is -H, -ON, -F, -01, -Br, -I, -001-04 alkyl, 01-04 alkyl, 03-06 cycloalkyl, or 01-04 fluoroalkyl, [0102] and the other Rc or RD is -NRFC(=0)XCH(RG)-CY, -N(RF)C(=0)XC(RG)2-CY, or -NRFC(=0)X-CY, -C(=0)-N(RF)-CH(RG)X-CY, or -C(=0)-N(RF)-C(RG)2X-CY, [0103] wherein X is absent, -0-, -NH- or -CH2-;
- 30 -[0104] RE is -H, -C1-C4 alkyl or -C1-C4 fluoroalkyl, [0105] fe is -H or C1-C4 alkyl, and [0106] RG is independently selected RE or one RG is C1-C4 alkyl and is taken together with CY
and the the carbon atom to which RG and CY is attached to define a substituted or unsubstituted carbocycle or substituted or unsubstituted heterocycle and the other RG, if present, is as defined for RE;
[0107] wherein CY is substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C2-C10 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 independently selected Rh', [0108] RH is independently -H, halogen, -CN, -NO2, -OH, -OR', -SR, -S(=0)RJ, -S(=0)2RJ, -N(RJ)S(=0)2RJ, -S(=0)2N(RL)2, -C(=0)RJ, OC(=0)RJ, -CO2RJ, -0CO2RJ, -N(RL)2, -C(=0)N(RL)2, -0C(=0)N(RL)2, N(RJ)C(=0)N(RL)2, -N(RJ)C(=0)RJ, -N(RJ)C(=0)ORJ, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, C1-C4 alkoxy, or Ci-C4 heteroalkyl, [0109] wherein each RJ is independently substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted C3-06 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted aryl), and -C1-C4 alkylene-(substituted or unsubstituted heteroaryl), and [0110] wherein each RL is independently -H, 01-C6 alkyl, C1-C6 heteroalkyl, Ci-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-
- 31 -(substituted or unsubstituted C3-C6 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), alkylene(substituted or unsubstituted aryl), or -C1-C4 alkylene-(substituted or unsubstituted heteroaryl), or [0111] when RH is -S(=0)2N(RL)2, -N(RL)2, -C(=0)N(RL)2, -0C(=0)N(RL)2 or -N(RJ)C(=0)N(RL)2, each RL is independently -H or 01-C6 alkyl, or the RL
groups independently are C1-C6 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle, [0112] or when W or Z is -C(RL)2 - each RL is independently -H, C1-06 alkyl, or the RL groups independently are 01-C6 alkyl which are taken together with the carbon atom to which they are attached to define a carbocycle;
[0113] Ring B is substituted or unsubstituted C3-C10 cycloalkylene, substituted or unsubstituted C2-C10 heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, where if ring B is substituted then ring B is substituted with 1,2, or 3 independently selected RH, wherein RH is as previously defined; and [0114] Ring C is absent or substituted or unsubstituted C3-C10 cycloalkylene, substituted or unsubstituted C2-C10 heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, wherein if ring C is substituted then ring C is substituted with 1, 2, or 3 independently selected RH, wherein RH is as previously defined, [0115] wherein when Ring B is substituted or unsubstituted arylene, Ring C is absent, L2 is absent, Lis -UV-Z, wherein -UV- is -N(R)C(=O)-, wherein Rr is -H, RD is -N(RF)C(=0)XCH(RG)-CY, wherein X is -0-, RG is -CH3 and RF is -H, and Re is -H, -CH3 or -CF3, [0116] or when Ring B is substituted or unsubstituted arylene and Ring C is substituted or unsubstituted arylene or is substituted or unsubstituted C3-C10 cycloalkylene, or Ring B is substituted or unsubstituted C3-C10 cycloalkylene and Ring C is substituted or unsubstituted arylene, L2 is absent, Cis C1-C6 alkylene,
- 32 -[0117] and RD is -H or -CH3 and RA is -002H or -CO2RB, [0118] then Ring A has the structure of one of:
RE
I
,N '= / s ,IV, ,,N....N;;=!
IN =
N)jr- RE¨N N
\ -As.
RC)---\ RD Re RD
RC RD N RD
N =
';," c N = / -I--'..-1µ1.:,- rNµ
p,,- Rr N..._____L
RD 04 Nr---( RD RC RD RC)%1 RD
RC RD
RE
0 i E 0 N : c.r..-N ' N-:;-..--NX
R--....1-1(:- TR\11- N \ / c_L I X I
NJ ,c R N RD Rc Ro r.sc/ , rc D
Rc RD
[0119] ' R" R
, [0120] and when Ring B is C2-010 heterocycloalkylene, Ring C is substituted or unsubstituted arylene, L2 is absent, Cis 01-06 alkylene, Rc is -CH3 and RA is -002H or -CO2RB, [0121] then Ring A has the structure of one of:
E ,NX ,,N-...Ns>( N
RC' R=D R¨RNCRD \Nf'---(RD
N ' µ RC,.(,N rN, RE....
hi.:_k_ .N..õ
;., ..;... /..r-RD -4RD Rc)N1---RD
RC RD
RE

E 0.,,, NN, : rczN_r_. rµI''.
IR---õN . N
I \ / , j( X..µõ 1 l-----'5' R N RD Rc N RD
N c)-----( -R , R RD RC RD
[0122] - R- .
[0123] In some embodiments RD is -H, -ON, -F, -Cl, -Br, -I, -001-04 alkyl, 01-04 alkyl, 03-06 cycloalkyl, or 01-04 fluoroalkyl and RD is -N(RF)-0(=0)X0H(RG)-0Y, -N(RF)--0(=0)X0(RG)2-0Y or -N(RF)-0(=0)X-CY, wherein RF and each IR independently are -H or 01-04 alkyl.
- 33 -[0124] In some embodiments RA is -002H, -CO2RB, -CN, tetrazolyl, -C(=0)NH2, -C(=0)NHRB, C(=0)NHSO2RB or -C(=0)NHCH2CH2S03H or a carboxylic acid isostere.
[0125] In preferred embodiments RA is -CO2H, -CO2RB, -CN, or -C(=0)NHSO2RB, wherein RB
is substituted or unsubstituted C1-C4 alkyl or has the structure of one of:
oYo [0126] o [0127] In some embodiments Ll is absent or substituted or unsubstituted 01-C6 alkylene, C-06 fluoroalkylene, fluoroalkylene, or substituted or unsubstituted C1-06 heteroalkylene.
[0128] In some preferred embodiments 12 is absent or substituted or unsubstituted 01-06 alkylene or -UV-Z-, wherein -UV- is defined by -OW-, -WO-, -N(R)W-, -WN(RJ)-, -N(R)C(=O)-, -SW-, -S(=0),W-, or -C(=0)N(RJ)-, wherein W is substituted or unsubstituted 03 alkylene, Z is substituted or unsubstituted C1-06 alkylene or C1-C6 fluoroalkylene; and n is 0,1, or 2.
[0129] In particularly preferred embodiments L1 is -CH2-, X?rs [0130] , dimethylmethane (i.e., -C(CH3)2-), or -UV-Z- wherein -UV-is defined by -WO-, or -C(=0)N(RJ)-, wherein W is substituted or unsubstituted 01-03 alkylene; and Z is substituted or unsubstituted Cl-C6 alkylene.
[0131] In some embodiments L2 is absent, or substituted or unsubstituted C1-C6 alkylene, 01-06 fluoroalkylene, substituted or unsubstituted C1-C6 heteroalkylene, -0-, -S-, -S(=0)-, S(=0)2-, or -C(=0)-.
[0132] In some preferred embodiments L2 is absent, -0-, -S-, -S(=0)-, S(=0)2-, -N(RJ)-, or -C(=0)-.
[0133] In some embodiments Ring A is a 5 or 6 membered heteroarene having one of the structures of:
- 34 -RIE
ci -RD RcR
N, D IR R ,N , N I
N47- RE¨N N
RD N RD
Rc N =
sie" N
= 2;--1µ1.____L N=
RD R ( RD Rcp RD RE RC)I RD
Rc RD
RE

R N \
R N RD RD
D
c RD
[0134] ,c, RR R
[0135] In some embodiments, Formula I compounds have RD defined as -H, -CN, -F, -CI, -Br, -I, -001-04 alkyl, 01-04 alkyl, 03-06cycloalkyl, or 01-04 fluoroalkyl.
[0136] In more preferred embodiments, Formula I compounds have RD defined as -H, -F, -CN, -CH3, or -CF3.
[0137] In some embodiments, Formula I compounds have RD defined as XCH(RG)-CY, -N(RF)C(=0)XC(R3)2-CY, or -N(RF)C(=0)X-CY, wherein X is absent, -0-, -NH- or -CH2-, wherein RF is -H or C1-04 alkyl and X, CY and RG are as previously defined.
[0138] In more preferred embodiments, Formula I compounds have RD defined as -N(RF)0(=0)0CH(RG)-CY, -N(RF)C(=0)NHC(RG)-CY, or -N(RF)C(=0)CH2-CY, wherein RF
is -H
or C1-04 alkyl and X, CY and RG are as previously defined.
[0139] In some embodiments, Formula I compounds have RE defined as -H or 01-C4 alkyl, 01-06 cycloalkyl or 01-C4 fluoroalkyl.
[0140] In more preferred embodiments, Formula I compounds have RE defined as -H, -CH3, cyclopropyl or -CF3.
[0141] In some embodiments, Formula I compounds have RF defined as H, C1-04 alkyl or C3-C6 cycloalkyl.
[0142] In more preferred embodiments, Formula I compounds have RF defined as -H.
- 35 -[0143] In some embodiments of Formula I compounds one RG is -C1-C4 alkyl and is taken together with CY and the the carbon atom to which RD and CY is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle and the other RG, if present is -H.
[0144] In other embodiments of Formula I compounds RG is independently -H or C1-C4 alkyl.
[0145] In some embodiments of Formula I compounds Ring B is substituted or unsubstituted C3-C10 cycloalkylene, substituted or unsubstituted C2-C10 heterocycloalkylene, a substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, wherein if ring B is substituted then ring B is substituted with 1, 2, or 3 independently selected RH.
[0146] In some embodiments of Formula I compounds Ring C is substituted or unsubstituted C3-C10 cycloalkylene, substituted or unsubstituted C2-C10 heterocycloalkylene, a substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, wherein if ring C is substituted then ring C is substituted with 1, 2, or 3 independently selected RH.
[0147] In some embodiments of Formula I compounds CY is substituted or unsubstituted C1"
C6 alkyl, substituted or unsubstituted C3-C cycloalkyl, substituted or unsubstituted C2-C10 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 idependently selected RH.
[0148] In some preferred embodiments Ring A has the structure of one of:
RE
hit ' pi [0149] R = N4'..-\ RE N/
N
\ I
RD
õD \r-NRD N"--NRD
RC RC RD RC
RC
=
[0150] Particularly preferred Formula I compounds have Ring B and Ring C each independently defined as 1,4-substituted aryl or heteroaryl, RA is -CO2H, RD
is -F or -CN, RD is -NRFC(=0)0CH(RG)-CY, RE is -CH3, and RF, RG, and CY are as previously defined.
- 36 -[0151] Other particularly preferred Formula I compounds have Ring B defined as 1,4-substituted aryl or heteroaryl, 12 is -UV-Z- wherein -UV-is defined by -WO-, -WN(R)-, or -C(=0)N(R)-, wherein W is CH2, Z is substituted or unsubstituted 01-C6 alkylene, RA is -CO2H, RD is -N(RF)C(=0)0CH(RG)-CY, RE is -CH3, and RG, RF, RG, and CY are as previously defined.
[0152] 2. The compound of embodiment 1 wherein Ring A has the structureof one of:
RE
_ /1µ1 , N, I N, R h¨ N N I
N,D
[0153] RC Rc RD RC) RE) Rc =
[0154] 3. The compound of embodiment 1 or 2 wherein RD is -H, -ON, -F, -CH3, or -CF3.
[0155] 4. The compound of embodiment 1, 2 or 3 wherein RD is -F or -CN.
[0156] 5. The compound of embodiment 1, 2, 3 or 4 wherein L2, is absent.
[0157] 6 The compound of embodiment 1, 2, 3, 4 or 5 wherein 1_1, when present, is a geminally substituted alkyl, cycloalkyl or heterocycloalkyl group, or is UV-Z-, [0158] wherein -UV-is defined by -OW-, -WO-, -N(R)W-, -WN(Fe)-, -N(W)C(=0)-, -SW-, -S(=0),-,W-, or -C(=0)N(R)-, wherein W is substituted or unsubstituted 01-03 alkylene or W is -C(RL)2, wherein RL independenly are -H or 01-04 alkyl or the two RL are independenly 01-04 alkyl taken together with the carbon to which RL is attached to define a carbocycle, Z is substituted or unsubstituted 01-C6 alkylene or C1-06 fluoroalkylene; and n is 0, 1, or 2.
[0159] 7. The compound of embodiments 6 wherein L1, when present, is -CH2-, Or dimethylmethane, or -UV-Z- wherein -UV- is defined by -WO-, -WN(RJ)-, or -C(=0)N(RJ)-, wherein W is -CH2-, Z is substituted or unsubstituted 01-C6 alkylene.
[0160] 8. The compound of any one of embodiments 1-7 wherein RF is -H.
- 37 -[0161] 9. The compound of any one of embodiments 1-8 wherein RG is -CH3.
[0162] 10. The compound of any one of embodiments 1-9 wherein CY is substituted or unsubstituted substituted phenyl.
[0163] 11. The compound of any one of embodiments 1-10 wherein RH is -H, halogen, -CN, -NO2, -OH,-OR, -SR, -S(=0)RJ, -S(=0)2RJ, -N(RL)2, 01-04 alkyl, 01-04 fluoroalkyl, 01-04 fluoroalkoxy, 01-04 alkoxy, and 01-04 heteroalkyl.
[0164] 12. The compound of any one of embodiments 1-11 wherein RH are independently selected from -H, halogen or substituted or unsubstituted 01-04 alkyl or substituted 01-04 alkoxy.
[0165] 13. The compound of any one of embodiments 1-12 wherein RH is independently -H, -Cl, -F, -CH3, -CF3, -OCH3 or -00F3.
[0166] 14. A compound of Formula II having the structure:

L¨ R Formula II
[0167] or a pharmaceutically acceptable salt or prodrug thereof [0168] wherein RA is -002H, -CO2RB, -CN, tetrazolyl, -0(=0)NH2, -0(=0)NHR6 , C(=0)NHSO2R8 or -0(=0)NHCH2CH2S03H or a carboxylic acid isostere, [0169] RB is optionally substituted 01-C4 alkyl or has the structure of one of:
[0170] o ;
[0171] L1 is absent or optionally substituted C1-C6 alkylene; optionally substituted C1-06 fluoroalkylene, or optionally substituted 01-06 heteroalkylene or -UV-Z-, wherein -UV-is defined by -OW-, -WO-, -N(R)W-, -WN(RJ)-, -N(R)O(0)-, -SW-, -S(=0)W-, or -C(=0)N(RJ)-, wherein W is optionally substituted 01-03 alkylene or W is -0(RL)2-, Z is optionally substituted C1-C6 alkylene or C1-06 fluoroalkylene or Z is -C(RL)2-; and n is 0, 1, or 2;
- 38 -[0172] Ring A is a 5 or 6 membered heteroarene having the structure of one of:
RE
Rc R RcR
N, D Rci RD
N\re' '-----s=
\ RE_N/
Nc_r RD NRD
Rc R

Rc RD C RD
Rc R D
RE

N
R (DT:2(N
N c RD R RD RD N RD R N RD
r. D
[0173]
[0174] wherein RD is -H, -ON, -F, -Cl, -Br, -I, -001-04 alkyl, 01-04 alkyl, C3-C6cycloalkyl, or C1-04 fluoroalkyl;
[0175] RD is -N(RF)C(=0)XCH (RG)-CY, -N(RF)C(=0)XC(RG)2-CY, or -N(RF)C(=0)X-CY; where X is absent, -0-, -NH- or -CH2-;
[0176] RE is -H or 01-04 alkyl, 01-06 cycloalkyl or 01-04fluoroalkyl;
[0177] RF is -H, 01-04 alkyl or 01-06 cycloalkyl;
[0178] RG is independently selected RE, or one of RG is 01-04 alkyl and is taken together with CY and the the carbon atom to which RG and CY are attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle and the other RG, if present, is as defined for RE;
[0179] Ring B is optionally substituted C3-C1,3 cycloalkylene, optionally substituted C2-C10 heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroarylene, where if ring B is substituted then ring B is substituted with 1, 2, or 3 independntly selected RH;
[0180] Ring C is absent or optionally substituted 03-010 cycloalkylene, optionally substituted 02-010 heterocycloalkylene, optionally substituted arylene, or optionally substituted
- 39 -heteroarylene, wherein if ring C is substituted then ring C is substituted with 1, 2, or 3 independently selected RH;
[0181] CY is optionally substituted 01-06 alkyl, optionally substituted C3-C10 cycloalkyl, optionally substituted 02-010 heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 independently selected RH, or [0182] wherein each RH is independently selected -H, halogen, -CN, -NO2, -OH, -OR, -SR, -S(=0)RJ, -S(=0)2RJ, - N(RJ)S(=0)2RJ, -S(=0)2N(RL)2, -C(=0)R, -0C(=0)RJ, -C(=0)ORJ, -0C(=0)0RJ, -N(R1-)2, -C(=0)N(R1-)2, -0C(=0)N (R1)2, -N(RJ)C(=0)N
(RL)2, -N(RJ)C(=0)RJ, -N(RJ)C(=0)ORJ, 01-04 alkyl, C1-C4 fluoroalkyl, 01-04 fluoroalkoxy, 01-04 alkoxy, or 01-04 heteroalkyl, and [0183] wherein RJ is optionally substituted 01-06 alkyl, optionally substituted 01-06 heteroalkyl, optionally substituted 01-06 fluoroalkyl, optionally substituted C3-06 cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -01-04 alkylene-(optionally substituted 03-06 cycloalkyl), -01-04 alkylene-(optionally substituted heterocycloalkyl), -01-04 alkylene-(substituted or unsubstituted aryl), or -01-04 alkylene-(optionally substituted heteroaryl), and [0184] each RL is independently -H, optionally substituted C1-06 alkyl, optionally substituted 01-C6 heteroalkyl, optionally substituted C1-06 fluoroalkyl, optionally substituted 03-06 cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -01-04 alkylene-(optionally substituted 03-C6 cycloalkyl), -01-04 alkylene-(optionally substituted heterocycloalkyl), -01-04 alkylene-(optionally substituted aryl), or -01-04 alkylene-(optionally substituted heteroaryl), or [0185] when RH is -S(=0)2N(R1)2, N(RI)2, -C(=0)N(RI-)2, -0C(=0)N(RI-)2 or
- 40 --N(R)C(=0)N(RL)2, each RL is independently -H or C1-C6 alkyl, or the RL groups independently are 01-06 alkyl which are taken together with the N atom to which they are attached to define an optionally substituted heterocycle, [0186] or when W or Z is -C(RL)2, each RL is independently -H or C1-C6 alkyl, or the RL
groups independently are 01-C6 alkyl which are taken together with the carbon atom to which they are attached to define a carbocycle;
[0187] wherein when Ring B is substituted or unsubstituted arylene, Ring C is absent, L1 is -UV-Z, wherein -UV- is -N(R)C(=O)-, wherein RJ is -H, RD is -N(RE)C(=0)XCH(RG)-CY, wherein X is -0-, RG is -CH3 and RE is -H, and RD is -H, -CH3 or -CF3, or when Ring B
is substituted or unsubstituted arylene and Ring C is substituted or unsubstituted arylene or is substituted or unsubstituted cycloalkylene, or Ring B is substituted or unsubstituted C3-cycloalkylene and Ring C is substituted or unsubstituted arylene and L1 is C1-C6 alkylene, [0188] and Rc is -H or -CH3 and RA is -CO2H or -0O2RB, [0189] then Ring A has the structure of one of:
RE
N, ,N
N\
D ci D
RC R R R
Rc N
s Pc N
/7'N =:r D rNµ
R
RD RC RD RC RD
RE

N1¨ N
RD---j-N I RD R"D
k ' c/N Rc RD
[0190] R R R RcD
[0191] and when Ring B is 02-010 heterocycloalkylene, Ring C is substituted or unsubstituted arylene, L1 is C1-06 alkylene, RD is -CH3 and RA is -CO2H or -0O2R6 , [0192] then Ring A has the structure of one of:
- 41 -NI\ I
Re)---NRD NNRD
RC RD
c m , ' N
N\
NRD o RD N=c ,,D R
RD
RC RD

N
0 N N%;N:)<
14-N \ I
N
rk Rc RD R N RD Re N RD
[0193] RD RD
[0194] In preferred embodiments Ring A has the structure of one of:
E
OXE,NX //1\1,,N*
N, I
R¨N 1\1µ
RC
I = RC RD RC RD
RC/ RD N RD
[0195] R
[0196] Particularly preferred Formula II compounds have Ring B and Ring C
defined each as 1,4-substituted aryl or heteroaryl, RA is CO2H, and RD is -N(RF)C(=0)0CH(RG)-CY.
[0197] Particularly preferred Formula II compounds have Ring B defined as 1,4-substituted aryl or heteroaryl, L1 is -UV-Z-, wherein -UV-is defined by -WO-, -WN(RJ)-, or -C(0)N(R)-, wherein W is -CH2-, Z is substituted or unsubstituted 01-C6 alkylene, RA is -CO2H, RD is -N(RF)C(=0)0CH(RG)-CY.
[0198] 15. A compound of Formula III having the structure:
AI=

co 410 Formula Ill [0199] or a pharmaceutically acceptable salt or prodrug thereof, [0200] wherein RA is -002H, -CO2RB, -ON, tetrazolyl, -C(=0)NH2, -C(=0)NHRB, C(=0)NHSO2R8 or -C(=0)NHCH2CH2S03H or a carboxylic acid isostere;
- 42 -[0201] RB is substituted or unsubstituted 01-C4 alkyl or has the structure of one of [0202] o ;
[0203] L1 is absent or is substituted or unsubstituted 01-C6 alkylene, C1-06 fluoroalkylene; or substituted or unsubstituted 01-06 heteroalkylene or -UV-Z- wherein -UV-is defined by -OW-, -WO-, -N(RJ)W-, -WN(RJ)-, -N(R)C(=O)-, -SW-, -S(=O)W-, or -C(=0)N(RJ)-, wherein W is substituted or unsubstituted C1-C3 alkylene or W is -C(R1-)2-, Z is substituted or unsubstituted C1-06 alkylene or C1-06 fluoroalkylene; and n is 0,1, or 2;
[0204] Ring A is a 5-6 membered heteroarenes having one the structure of one of:
RE
' N, ,N ' ,/(µLN%!
N s\ I R R¨N N
Nr\i-RD
Rc RD RC/ \ RD C RD Rc RCRD N¨( RC/ RD
Rc RD
RE

RN --õ rNi NIT rN..µ,õ
, ' 1- N I
/
c/N RC N D c c RD R N RD Rc".--IN'N RD
R RD R R
[0205] wherein Re is -H, -ON, -F, -Cl, -Br, -I, -001-04 alkyl, C1-04 alkyl, 03-06 cycloalkyl, or C1-C4 fluoroalkyl;
[0206] RD is -N(RF)C(=0)XCH(RG)-CY, -N(RF)C(=0)XC(R3)2-CY, or -N(RF)C(=0)X-CY.
wherein Xis absent, -0-, -NH- or -CH2-;
[0207] RE is -H or 01-04 alkyl, 01-06 cycloalkyl or 01-04 fluoroalkyl;
[0208] RF -H, 01-0.4 alkyl or C1-06 cycloalkyl;
[0209] RG is independently selected RE, or one RG is -C1-04 alkyl and is taken together with CY and the the carbon atom to which RG and CY is attached to define a substituted or
- 43 -unsubstituted carbocycle or a substituted or unsubstituted heterocycle and the other RG, if present, is as defined for RE;, [0210] Al, A2 and A3 are independently =NH-, -N=, =CH- or -CH=;, [0211] Ring C is absent or substituted or unsubstituted C3-C10 cycloalkylene, substituted or unsubstituted 02-C10 heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, wherein if ring C is substituted then ring C is substituted with 1, 2, or 3 independently selected RH;
[0212] CY is substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted 02-010 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1,2, or 3 RH;
[0213] wherein each RH is independently -H, halogen, -CN, -NO2, -OH, -OR, -SR', -S(=0)RJ, -S(=0)2RJ, -N(RJ)S(=0)2RJ, -S(=0)2N(RL)2, -C(=0)RJ, -0C(=0)RJ, -C(=0)ORJ, -0C(=0)0RJ, -N(RL)2, -C(=0)N(RL)2, -0C(=0)N(RL)2, N(RJ)C(=0)N(RL)2, -N(RJ)C(=0)RJ, -NRJC(=0)ORJ, C1-C4 alkyl, C1-04 fluoroalkyl, C1-C4 fluoroalkoxy, C1-C4 alkoxy, or C1-04 heteroalkyl;
[0214] each RJ is independently substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-06 heteroalkyl, substituted or unsubstituted C1-06 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted C3-C6 cycloalkyl), -C1-04 alkylene-(substituted or unsubstituted heterocycloalkyl), -01-C4 alkylene-(substituted or unsubstituted aryl), or C1-C4 alkylene-(substituted or unsubstituted heteroaryl);
[0215] each RL is independently -H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, substituted or
- 44 -unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted cycloalkyl), -C1-04 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene(substituted or unsubstituted aryl), or -C1-C4 alkylene-(substituted or unsubstituted heteroaryl), or [0216] when RH is -S(=0)2N(RL)2, -N(RL)2, -C(=0)N(RL)2, -0C(=0)N(RL)2 or N(RJ)C(=0)N(RL)2, each RL is independently -H or C1-C6 alkyl, or the RL groups independently are C1-C6 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle, or [0217] when W or Z is -C(RL)2, each RI- is independently -H or C1-C6 alkyl, or the RL groups independently are C1-C6 alkyl which are taken together with the carbon atom to which they are attached to define a carbocycle;
[0218] wherein when A', A2 and A3 are =CH- or -CH=, Ring C is absent, Ll is -UV-Z, wherein -UV- is -N(R)C(=O)-, wherein IR is -H, RD is -N(RF)C(=0)XCH(RG)-CY, wherein X
is -0-, RG is -CH3 and RF is -H, and RD is -H, -CH3 or -CF3, [0219] or when Ring C is substituted or unsubstituted arylene or substituted or unsubstituted C3-C10 cycloalkylene [0220] and RD is -H or -CH3 and RA is -CO2H or -0O2RB , [0221] then Ring A has the structure of one of:
- 45 -RE
I
E ,Nz...,s, ,,N--.N.;
R ¨N N 1 RC RD RC RD
RC).---RD NN RD
/ Ns>:, Rc ......,N ..5:7;,:, ,,,.....7, NN...1r.
RE_.......c7,N,isr:,c,.
N\ \N="-(µ

RC (RD Re/NI CRD
RCr NR
RD RD
RE
o i f)=-1qt N.' 1 .
R --,IsA.:_. .......(Ni- N \ / c..,4'--)( ,..,C 1 N
RC RD R N RD Fic N RD
DC/ RD RD RD
[0222] - , [0223] and when Ring C is substituted or unsubstituted arylene, L1 is C1-C6 alkylene, RD is -CH3 and RA is -CO2H or -CO2R13, [0224] then Ring A has the structure of one of:
N, 2....., E 71:)( ,,N1-..N*
pi . R ¨N isk I
\r-s\RD N'\RD
RD RD
R RC
42.s.sN';õ( Rcs.......? N:,:.- RE_......c.7,Nx..
RD 01Z-1- \N-=( RD RD RC / ' /1µ1 RD
RC
RE

RE-, : cl:t "
RC , ri N / ' = N'l- i ' \ c,.--'= ' I
DC/N RD RD RC R-, R N RD Rc RD
[0225] .
[0226] In preferred embodiments Ring A has the structure of one of:
RE
I
'r ,N \ N1-.,),( p rµ1 , ,.!
r- õ N
N , 1 /
D Ni'µRD
RD RD RD RD __ RD RE_N
RCi -R
[0227] RC .
[0228] Particularly preferred Formula III compounds have Ring C is defined as 1,4-substituted phenyl or pyridyl, RA is -CO2H, and RD is -N(RF)C(=0)OCH(RG)-CY; L1 is
- 46 --UV-Z- wherein -UV- is defined by -WO-, -WN(RJ)-, or -C(=0)N(RJ)-, wherein W
is -CH2-, Z is substituted or unsubstituted C1-C6 alkylene, RA is -CO2H, and RD
is -N(RF)C(=0)0CH(RG)-CY.
[0229] 16. A compound of Formula IV having the structure:
RHAi coLiRA Formula IV
[0230] or a pharmaceutically acceptable salt or prodrug thereof, [0231] wherein RA is -CO2H, -CO2RB, -CN, tetrazolyl, -C(=0)NH2, -C(=0)NHRB, -C(=0)NHSO2RB or -C(=0)NHCH2CH2S03H or a carboxylic acid isostere;
[0232] Fe is optionally substituted -C1-C4 alkyl or has the structure of one of:
' 0 ' y, [0233] o ;
[0234] L1 is -UV-Z-, wherein -UV-is defined by -OW-, -WO-, -N(R)W-, -WN(RJ)-, -N(R)C(=O)-, -SW-, -S(=0),W-, or -C(=0)N(RJ)-, wherein W is substituted or unsubstituted C1-C3 alkylene or W is -C(RL)2-, Z is substituted or unsubstituted C1-C6 alkylene or substituted or unsubstituted Cl-C6 fluoroalkylene or Z is -C(RI-)2-; and n is 0, 1, or 2;
[0235] Al is independently =N- or =CH-;
[0236] Ring A is a 5 or 6 membered heteroarene having one of the structures of:
- 47 -RE
I
0 \ N ,,:.-..
Ni;_r 2 Ni r, . RE¨N\ D
N1µ....z...,....L D
\
RD RC RD Rc RD ,r 17Z N R
Rc R--'ssiµls;.( IRc*N \ -::-- eN RE.......r Nv__ a 0 r- N D
RD Rc RD Rc RD
Rcf R
RD
RE
0 i RE N , N = /-;Nr ' 0' \
1 / .
_.
R N RD RD
N c ci R RD Rc RD
R RD
, [0237] wherein RD is -H, -CN, -F, -Cl, -Br, -I, -0C1-C4 alkyl, C1-C4 alkyl, C3-C6 cycloalkyl, or C1-C4 fluoroalkyl;
[0238] RD is -N(RE)C(=0)XCH(RG)-CY, -N(RE)C(=0)XC(RG)2-CY, or -N(RE)C(=0)X-CY, wherein X is absent, -0-, -NH- or -CH2-;
[0239] RE is -H or C1-C4 alkyl, C3-C6 cycloalkyl or C1-C4 fluoroalkyl;
[0240] RE is -H, C1-04 alkyl or C3-C6 cycloalkyl;
[0241] RG is independently selected RE, or one RG is -C1-C4 alkyl and is taken together with CY and the carbon atom to which RG and CY is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other RG, if present, is as defined for RE;
[0242] CY is 01-C6 alkyl, a substituted or unsubstituted C3-Clo cycloalkyl, a substituted or unsubstituted C2-010 heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 RH;
[0243] wherein each RH is independently -H, halogen, -ON, -NO2, -OH, -OR, -SR', -S(=0)RJ, -S(=0)2RJ, -N(RJ)S(=0)2RJ, -S(=0)2N(RI)2, -C(=0)R, -0C(=0)RJ, -C(=0)GRJ, -0C(=0)0RJ, -N(R1-)2, -C(=0)N(RI-)2, -0C(=0)N(RL)2, N(RJ)C(=0)N(RI-)2, -N(RJ)C(=0)RJ,
- 48 --N(RJ)C(=0)ORJ, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, C1-C4 alkoxy, or Cl-C4 heteroalkyl;
[0244] wherein RJ is independently substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C1-06 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted C3-C6 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted aryl), or C1-C4 alkylene-(substituted or unsubstituted heteroaryl); and [0245] each RL is independently -H, substituted or unsubstituted 01-C6 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -01-C4 alkylene-(substituted or unsubstituted C3-C6 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted aryl), or -C1-C4 alkylene-(substituted or unsubstituted heteroaryl), [0246] or when RH is -S(=0)2N(RL)2, -N(RL)2, -C(=0)N(RL)2, -0C(=0)N(RL)2 or -N(R)C(=0)N(RL)2, each RL is independently -H or C1-C6 alkyl, or the RL groups independently are C1-C6 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle, [0247] or when W or Z is -C(RL)2, each RL is independently -H or C1-C6 alkyl, or the RL
groups independently are 01-C6 alkyl which are taken together with the carbon atom to which they are attached to define a carbocycle, [0248] or when RH is -S(=0)2N(RL)2, -N(RL)2, -C(=0)N(R1)2, -0C(=0)N(RL)2 or
- 49 --N(RJ)C(=0)N(RL)2, each RL is independently is -H or C1-C6 alkyl, or the RL
groups independently are C1-06 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle, [0249] or when W is -C(RL)2-, each RL is independently -H, C1-C6 alkyl, or the RL groups independently are C1-C6 alkyl which are taken together with the carbon atom to which they are attached to define a carbocycle;
[0250] wherein A1 is =CH-, L1 is -UV-Z, wherein -UV- is -N(R)C(=O)-, wherein RJ is -H, RD is -N(RF)-C(=0)XCH(RG)-CY, wherein X is -0-, RG is -CH3 and RF is -H, and Re is -H, -CH3 or -CF3, [0251] and Re is -H or -CH3 and RA is -CO2H or CO2RB , [0252] then Ring A has the structure of one of:
RIE
Repi .
N, D R RD,, ) 1._._ E iNX e--N*
N \ /
c;_. R N RD N RD
R
Rc N .

RD
,N, RE-__ r-N).--- 0 rc Re RD
Rc/N¨\RD
Re RD
RE
0 i R..--I"" r- N \ / R c,,,,-.'Xf.
N / Rc 4D N RD RND
Ref R 13 RD R. r, [0253] , [0254] In preferred embodiments Ring A has the structure of one of:
RE
i ,o,..,-( N, ::,.... N, 5Nr\
/ µ N* RE_ N N
) N \ I
'-----NRD \-NRD Rc RD RC' RD
Rc [0255] Rc [0256] Particularly preferred Formula IV compounds have L1 defined as -UV-Z-, wherein
- 50 --UV -is defined by -WO-, -WN(RJ)-, or -C(=0)N(RJ)-, wherein W is -CH2-, Z is substituted or unsubstituted 01-06 alkylene, RA is -CO2H, and RD is -N(RF)C(=0)0CH(RG)-CY.
[0257] 17. A compound of Formula V having the structure:
RH
Al \ / Li¨RA Formula V
RC
RD
[0258] or a pharmaceutically acceptable salt or prodrug thereof, [0259] wherein RA is -CO2H, -CO2R8, -CN, tetrazolyl, -C(=0)NH2, -C(=0)NHR8, C(=0)NHSO2R8 or -C(=0)NHCH2CH2S03H or a carboxylic acid isostere, [0260] wherein R8 is optionally substituted C1-04 alkyl or has the structure of one of [0261] o .
[0262] L1 is -UV-Z-, wherein -UV-is defined by -OW-, -WO-, -N(R)W-, -WN(RJ)-, -N(R)C(=O)--SW-, -S(=0),-,W-, or -C(=0)N(RJ)-, wherein W is substituted or unsubstituted C1-03 alkylene or W is -C(RI-)2-, Z is substituted or unsubstituted C1-C6 alkylene or substituted or unsubstituted C1-06 fluoroalkylene or Z is -C(R1)2-; and n is 0, 1, or 2;
[0263] Al is =N- or =CH-;
[0264] Ring A is a 5 membered heteroarene having the structure of one of:
RE
RN
Nisfk o --"YNRD
Rc RD Rc RD RC RD Rc R
FX E

E N , o ,P4 n RLA
RD Rc RD R- R- Rc/ RD Rc RD
[0265] RD
-51 -[0266] wherein RD is -H, -CN, -F, -Cl, -Br, -I, -0C1-C4 alkyl, C1-C4 alkyl, C3-C6cycloalkyl, or Cr C4 fluoroalkyl;
[0267] RD is -N(RE)C(=0)XCH(RG)-CY, -N(RE)C(=0)XC(RG)2-CY, or -N(RE)C(=0)X-CY;

wherein X is absent, -0-, -NH- or -CH2-;
[0268] RE is -H or C1-C4 alkyl, C3-06 cycloalkyl or C1-C4 fluoroalkyl;
[0269] RE is -H, C1-04 alkyl or -C3-C6 cycloalkyl;
[0270] RG is independently selected RE, or one RG is -C1-C4 alkyl and is taken together with CY and the carbon atom to which RG and CY is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other RG, if present, is as defined for RE;
[0271] CY is substituted or unsubstituted 01-C6 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C2-C10 heterocycloalkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 independently selected RH;
[0272] RH is independently -H, halogen, -CN, -NO2, -OH,-OR, -SR, -S(=0)RJ, -S(=0)2RJ, -N(RJ)S(=0)2RJ, -S(=0)2N(RL)2, -C(=0)RJ, -0C(=0)RJ, -C(=0)0RJ, -0C(=0)0RJ, -C(=0)N(RL)2, -0C(=0)N(RI-)2, NRJC(=0)N(R1-)2, -NRJC(=0)RJ, -NRJC(=0)ORJ, C1-C4 alkyl, C1-C4 fluoroalkyl, 01-C4 fluoroalkoxy, C1-C4 alkoxy,and Ci-C4 heteroalkyl;
[0273] wherein each IR is independently substituted or unsubstituted 01-C6 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C3-06 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -01-04 alkylene-(substituted or unsubstituted 03-C6 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -
- 52 -C1-C4 alkylene-(substituted or unsubstituted aryl), or 01-C4 alkylene-(substituted or unsubstituted heteroaryl);
[0274] wherein each RL is independently -H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted C3-C6 cycloalkyl), -01-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene(substituted or unsubstituted aryl), or -Ci-C4 alkylene-(substituted or unsubstituted heteroaryl), [0275] or when RH is -S(=0)2N(RL)2, -N(RL)2, -C(=0)N(RL)2, -0C(=0)N(RL)2 or -N(RJ)C(=0)N(RL)2, each RL is independently -H or C1-C6 alkyl, or the RL
groups independently are C1-C6 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle, [0276] or when W or Z is -C(RL)2, each RL is independently -H or C1-C6 alkyl, or the RL
groups independently are Cl-C6 alkyl which are taken together with the carbon atom to which they are attached to define a carbocycle.
[0277] wherein when A1 is =CH-, L1 is -UV-Z, wherein -UV- is -N(R)C(0)-, and Rc is -H, -CH3 or -C F3, then Ring A has the structure of one of:
RIE
RCR
N, D RC
Ne/ N
N,µ RN RD
RD N"¨====RD RD
RC

RD Rc RD RLf7 RN
RC/ RD RC/N
Rc [0278] R RDD
[0279] Particularly preferred Formula V compounds have L1 defined as UV-Z-wherein
- 53 --UV-is defined by -WO-, -WN(RJ)-, or -C(=0)N(RJ)-, wherein W is -CH2-, Z is substituted or unsubstituted C1-C6 alkylene, RA is -CO2H, and RD is -N(RF)C(=0)0CH(RG)-CY.
[0280] 18. A compound of Formula VI having the structure:
RH
A' = L1¨R' Formula VI
RC
N, [0281] or a pharmaceutically acceptable salt or prodrug thereof, [0282] wherein RA is -CO2H, -CO2RB, -CN, tetrazolyl, -C(=0)NH2, -C(=0)NHRB, -C(=0)NHS02RB or -C(=0)NHCH2CH2S03H or a carboxylic acid isostere, wherein [0283] RB is optionally substituted C1-a4 alkyl or has the structure of one of:
[0284] o ;
[0285] Ll is UV-Z- wherein -UV-is defined by -OW-, -WO-, -N(R)W-, -WN(RJ)-, -N(R)C(=O)-, -SW-, -S(=0),W-, or -C(=0)N(RJ)-, wherein W is substituted or unsubstituted C1"
C3 alkylene or W is -C(R1)2-, Z is substituted or unsubstituted C1-06 alkylene or substituted or unsubstituted C1-C6fluoroalkylene or Z is -C(RL)2-; and n is 0, 1, or 2;
[0286] Al is independently =N- or =CH-;
[0287] Ring A is a 5 membered heteroarene having one of the structures of:
- 54 -RIE
N, ,N
Ni I s -r = R N NI\ D
Rc DD RDRD Rc ER Re RD Re RD
Rc DE O/µ
' RD
DDC/ D T..
RCR RD
RD
[0288] wherein RD is defined as -H, -CN, -F, -Cl, -Br, -I, -0C1-C4 alkyl, C1-C4 alkyl, C3-C6 cycloalkyl, or C1-C4 fluoroalkyl;
[0289] wherein RD is the -N(RF)C(=0)CH(RG)-CY substituent of Formula VI
wherein CY is phenyl substituted with one RH;
[0290] RG is independently selected RE, or one RG is -C1-C4 alkyl and is taken together with CY and the carbon atom to which RG and CY is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other RG, if present, is as defined for RE;
[0291] RF is -H, -01-C4 alkyl or -C3-06 cycloalkyl;
[0292] RH is independently selected from -H, halogen, -CN, -NO2, -OH, -OR, -SR, -S(=0)RJ, -S(=0)2RJ, -N(RJ)S(=0)2RJ, -S(=0)2N(RL)2, -C(=0)R, OC(=0)RJ, -CO2RJ, -0C(=0)0RJ, -N(R1-)2, -C(=0)N(RL)2, -0C(=0)N(RI-)2, N(RJ)C(=0)N(R1)2, -N(RJ)C(=0)RJ, -N(RJ)C(=0)0Rj, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, Cl-C4 alkoxy,and C1-C4 heteroalkyl;
[0293] wherein IR is substituted or unsubstituted C1-06 alkyl, substituted or unsubstituted Ci-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted C3-C6 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted aryl), or C1-C4 alkylene-(substituted or unsubstituted heteroaryl);
- 55 -[0294] wherein each RL is independently -H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene(substituted or unsubstituted aryl), or -C1-C4 alkylene-(substituted or unsubstituted heteroaryl), [0295] or when RH is -S(=0)2N(RL)2, -N(RL)2, -C(=0)N(RL)2, -0C(=0)N(RI-)2 or N(RJ)C(=0)N(RI-)2, each RL is independently -H or C1-C6 alkyl, or the RL
groups independently are C1-C6 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle, [0296] or when W or Z is -C(RL)2, each RL is independently -H or C1-C6 alkyl, or the RI-groups independently are C1-C6 alkyl which are taken together with the carbon atom to which they are attached to define a carbocycle.
[0297] In preferred embodiments Ring A has the structure of one of:
RE
(-2))( z/N,N:;ar 1,N,N.%( Nr\ I
N RD
R
r` RD RC) RE
¨N
RD
[0298] ry Rc [0299] Particularly preferred Formula VI compounds have L1 as -UV-Z- wherein -UV- is -C(=0)NH-, -CH20- or -CH2NH-, Z is substituted -CH-, and RA is -CO2H.
[0300] 19. A compound of Formula VII having the structure of:
- 56 -RH R\
Al N¨z 110 "RA
Rc 0 N, F
R Formula VII
RG

[0301] or a pharmaceutically acceptable salt or prodrug thereof, [0302] wherein RA is -CO2H, -CO2RE, -CN, tetrazolyl, -C(=0)NH2, -C(=0)NHRE, -C(=0)NHSO2RE or -C(=0)NHCH2CH2S03H or a carboxylic acid isostere;
[0303] RE is optionally substituted C1-C4 alkyl or has the structure of one of:
=====7;rN.,,, [0304]
[0305] A' is independently =N- or =CH-;
[0306] Ring A has the structure of one of:
RE
,0 N Rc R ,..N.2 RC). N. RN' I
)==( D N D
RRD
[0307] R-Rc [0308] RC is -H, -CN, -F, -Cl, -Br, -I, -0C1-C4 alkyl, C1-C4 alkyl, C3-05 cycloalkyl, or C1-C4 fluoroalkyl;
[0309] wherein RD is the -N(RF)C(=0)CH(RG)-CY substituent of Formula VII
wherein CY is phenyl substituted with one RH;
[0310] RE, RF and RG independently are -H or 01-C4 alkyl;
[0311] Z is -C(RL)2-;
- 57 -[0312] RH is independently -H, halogen, -CN, -NO2, -OH,-OR, -SR, -S(=0)RJ, -S(0)2R, -N(RJ)S(=0)2Rj, -S(=0)2N(RL)2, -C(=0)RJ, -0C(=0)RJ, -CO2RJ, -0CO2RJ, -N(RL)2, -C(=O)N (RL)2, -0C(=0)N(RL)2, NRJC(=0)N(RL)2, -NRJC(=0)RJ, -NRJC(=0)0RJ, C1-C4 alkyl, C1-C4 fluoroalkyl, 01-04fluoroalkoxy, 01-04 alkoxy,and 01-04 heteroalkyl;
[0313] RJ is substituted or unsubstituted C1-06 alkyl, substituted or unsubstituted 01-C6 heteroalkyl, 01-06 fluoroalkyl, substituted or unsubstituted 03-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted 03-06 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -01-04 alkylene-(substituted or unsubstituted aryl), or 01-04 alkylene-(substituted or unsubstituted heteroaryl);
[0314] RI- is -H, substituted or unsubstituted C1-06 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted 01-06 fluoroalkyl, substituted or unsubstituted C3-06 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-04 alkylene-(substituted or unsubstituted 03-C6 cycloalkyl), -01-04 alkylene-(substituted or unsubstituted heterocycloalkyl), -alkylene(substituted or unsubstituted aryl), or -01-04 alkylene-(substituted or unsubstituted heteroaryl), [0315] or when RH is -S(=0)2N(RI)2, -N(RL)2, -C(=0)N(RL)2, -0C(=0)N(RL)2 or -N(RJ)C(=0)N(RL)2, each RL is independently -H or C1-C6 alkyl, or the RL
groups independently are C1-06 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle, [0316] or each RL in Z is independently -H or 01-06 alkyl, or the RL groups independently are C1-06 alkyl which are taken together with the carbon atom to which they are attached to define a carbocycle.
- 58 -[0317] In some embodiments, Formula VII compounds have RF defined as -H, C1-C4 alkyl or 01-C6 cycloalkyl and each RH Fe and RI- are as previously defined;
[0318] In particularly preferred Formula VII compounds RA is -CO2H.
[0319] 20. A compound of Formula VIII having the structure:
R- Rk A1 \N¨z 1111 V11 \RA
Rc N, F
R Formula VIII
RG
H
[0320] or a pharmaceutically acceptable salt or prodrug thereof, [0321] wherein RA is -CO2H, -CO2RB, -CN, tetrazolyl, -C(=0)NH2, -C(=0)NHRB, -C(=0)NHS02RB or -C(=0)NHCH2CH2S03H or a carboxylic acid isostere;
[0322] RI' is optionally substituted C1-C4 alkyl or has the structure of one of:
)0y\
[0323] 0 0 0 0 [0324] A1 is =N- or =CH-;
[0325] Ring A has the structure of one of:
RE
E
N I
N\
RD N RD
c R Rc RD RC) RD R ¨N
[0326] R Rc [0327] Rc -H, -CN, -F, -Cl, -Br, -I, -0C1-C4 alkyl, C1-C4 alkyl, C3-C6 cycloalkyl, or Ci-04 fluoroalkyl;
- 59 -[0328] wherein RD is the -N(RE)C(=0)CH(RG)-CY substituent of Formula VII
wherein CY is phenyl substituted with one RH;
[0329] RE and RE independently are -H or 01-C4 alkyl or C3-C6 cycloalkyl;
[0330] RG is -H or C1-C4 alkyl or is C1-C4 alkyl that is taken together with the the RH pheny moiety of the Ring A RD substituent and the carbon atom to which RG and said phenyl moiety is attached to define a carbocycle;
[0331] W is -C(RL)2-;
[0332] Z is -C(RL)2-;
[0333] RH is -H, halogen, -CN, -NO2, -OH,-OR, -SR", -S(=0)RJ, -S(=0)2RJ, -N(R)S(0)2R, -S(=0)2N(RI-)2, -C(=0)RJ, -0C(=0)RJ, -CO2RJ, -0CO2RJ, -C(=0)N(RL)2, -0C(=0)N(RL)2, NRJC(=0)N(RL)2, -NRJC(=0)RJ, -NRJC(=0)ORJ, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-fluoroalkoxy, C1-04 alkoxy,and C1-C4 heteroalkyl;
[0334] RJ is substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, is substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-04 alkylene-(substituted or unsubstituted C3-C6 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -Ci-C4 alkylene-(substituted or unsubstituted aryl), or C1-C4 alkylene-(substituted or unsubstituted heteroaryl);
[0335] RI- independently are -H, substituted or unsubstituted C1-06 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted C3-06 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene(substituted or unsubstituted aryl), or -C1-C4 alkylene-(substituted or unsubstituted heteroaryl),
- 60 -[0336] or when RH is -S(=0)2N(RL)2, -N(RL)2, -0(=0)N(RL)2, -0C(=0)N(RL)2 or -N(RJ)C(=0)N(RL)2, each RL is independently -H or 01-06 alkyl, or the RL groups independently are C1-C6 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle, [0337] or each RL is in W or Z independently -H or C1-C6 alkyl, or the RL
groups independently are 01-C6 alkyl which are taken together with the carbon atom to which they are attached to define a carbocycle.
[0338] In some embodiments, Formula VIII compounds have RF defined as -H, C1-04 alkyl or C3-06 cycloalkyl.
[0339] In particularly preferred Formula VIII compounds RA is -002H and RJ is -H.
[0340] 21. A compound of Formula IX having the structure:
R
RH A
A1 0¨z/
W
R-N, F
R Formula IX

ORH
[0341] or a pharmaceutically acceptable salt or prodrug thereof, [0342] wherein RA is -002H, -CO2RB, -CN, tetrazolyl, -0(=0)NH2, -0(=0)NHRB, 0(=-0)NHSO2R8 or -0(=0)NHCH2CH2S03H or a carboxylic acid isostere;
[0343] RB is optionally substituted 01-04 alkyl or has the structure of one of:
[0344] 0 0 0 0
- 61 -[0345] Ring has the structure of one of:
RE
R ¨N N
Rc Rc R Rc RD RD N RD
[0346] Rc [0347] Rc - H, -CN, -F, -CI, -Br, -I, -0C1-C4 alkyl, C1-C4 alkyl, C3-C6 cycloalkyl, or C1-C4 fluoroalkyl;
[0348] wherein RD is the -N(RE)C(=0)CH(RG)-CY substituent in Formula IX
wherein CY is phenyl substituted with one RH;
[0349] RE, RE and RG independently are -H, C1-C4 alkyl or C1-C6 cycloalkyl or RE and RE
independenly are -H, C1-C4 alkyl or C1-C6 cycloalkyl and RG is C1-C4 alkyl that is taken together with the the RH pheny moiety of the Ring A RD substituent and the carbon atom to which RG and said phenyl moiety is attached to define a carbocycle;
[0350] RH is independently -H, halogen, -CN, -NO2, -OH,-OR, -SR', -S(=0)RJ, -S(=0)2RJ, -N(RJ)S(=0)2RJ, -S(=0)2N(RL)2, -C(=0)RJ, -0C(=0)RJ, -CO2RJ, -0CO2RJ, -N(RL)2, -C(=0)N(RL)2, -0C(=0)N(RI-)2, NRJC(=0)N(RL)2, -NRJC(=0)RJ, -NRJC(=0)ORJ, 01-C4 alkyl, C1-04 fluoroalkyl, C1-C4 fluoroalkoxy, C1-C4 alkoxy,and C1-C4 heteroalkyl;
[0351] RJ is substituted or unsubstituted C1-06 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted C3-06 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted aryl), or C1-C4 alkylene-(substituted or unsubstituted heteroaryl);
[0352] W is -C(RL)2-;
[0353] Z is -C(RL)2-;
- 62 -[0354] RL independently are -H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-06 heteroalkyl, substituted or unsubstituted C1-06 fluoroalkyl, substituted or unsubstituted 03-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-04 alkylene-(substituted or unsubstituted C3-06 cycloalkyl), -01-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-04 alkylene(substituted or unsubstituted aryl), or -01-04 alkylene-(substituted or unsubstituted heteroaryl), [0355] or each RL in W or Z independently are 01-06 alkyl which are taken together with the carbon atom to which they are attached to define a carbocycle.
[0356] In preferred Formula IX compounds RA is -CO2H.
[0357] 22. A compound of Formula X having the structure:
RH RH
Al 4 A L
, 1R Formula X
[0358] or a pharmaceutically acceptable salt or prodrug thereof, [0359] wherein RA is -CO2H, -CO2RB, -CN, tetrazolyl, -C(=0)NH2, -C(=0)NHRB, C(=0)NHSO2RB or -C(=0)NHCH2CH2S03H or a carboxylic acid isostere;
[0360] RB is optionally substituted 01-04 alkyl or has the structure of one of:
oYo yo ).(N
[0361] 0 0 0 0 [0362] L1 is absent or optionally substituted C1-06 alkylene; C1-06 fluoroalkylene; or optionally substituted 01-06 heteroalkylen or L1, when present is -Cn2-, , or disubstituted dimethylmethane.
- 63 -[0363] A' is =N- or =CH-;
[0364] Ring A has the structure of one of::
RE
= N
N;lir E
D
Rc\ ¨N k R N¨NR
R0 RD Re RD
R Is \
Re N =
N =
ciN
NI\ a D "NN<
NRD Rc RD ,E N RD
Rcr RD
RE

RcN N'T

N \
\ ' R N RD RXRD
pc/N R D Rc RD
[0365] - R-[0366] Rc is -H, -CN, -F, -Cl, -Br, -I, -0C1-C4 alkyl, C1-C4 alkyl, C3-C6 cycloalkyl, or C1-C4 fluoroalkyl;
[0367] RD is -NRFC(=0)XCH(RG)-CY, -NRFC(=0)XC(RG)2-CY, or -NRFC(=0)X-CY; where X is absent, -0-, -NH- or -C H2-;
[0368] RE, RF and RG independently are -H or C1-C4 alkyl or C3-C6 cycloalkyl or RE and RF
independently are -H, C1-C4 alkyl or C1-C6 cycloalkyl and one RG is C1-04 alkyl and is taken together with CY and the carbon atom to which RG and CY are attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other RG, if present, is as defined for RE;
[0369] RH is -H, halogen, -CN, -NO2, -OH,-OR, -SR, -S(=O)W, -S(=0)2RJ, -N(RJ)S(=0)2RJ, -S(=0)2N(RL)2, -C(=0)RJ, -0C(=0)RJ, -0O217, -0CO2RJ, -N(RL)2, -C(=0)N(RL)2, -0C(=0)N(RL)2, NRJC(=0)N(RL)2, -NRJC(=0)W, -NRJC(=0)0RJ, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-fluoroalkoxy, C1-C4 alkoxy,and C1-C4 heteroalkyl;
[0370] RJ is substituted or unsubstituted Ci-C6 alkyl, substituted or unsubstituted 01-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C3-C6
- 64 -cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted C3-C6 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted aryl), or Gra, alkylene-(substituted or unsubstituted heteroaryl);
[0371] RL independently are -H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted Cl-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted C3-C6 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), alkylene(substituted or unsubstituted aryl), or -C-C4 alkylene-(substituted or unsubstituted heteroaryl), [0372] or when RH is -S(=0)2N(RL)2, -N(RL)2, -C(=0)N(RL)2, -0C(=0)N(RL)2 or -N(RJ)C(=0)N(RL)2, each RL is independently -H or C1-C6 alkyl, or the RL groups independently are Cl-C6 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle;
[0373] CY is substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C2-C10 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1,2, or 3 RH, [0374] wherein when L1 is not absent and Re is -H or -CH3 and RA is -CO2H or -CO2RB , then Ring A has the structure of one of:
- 65 -RE
I .
piX ,,NI-N>, NI\
RD rsi"--RD
-Y----:-C D
Rc R R- RD Rc DE N , sY c N . / ==--..--N ' RN ,-- (rµl ' p1( r\-----q1/4:-.
N k _1( N=( r. R0 RD RD RC
RD RD
R-Rc RE
0 1 N , N_I:K
E clr Naes' R -.... N / ' c I X I
C,N
1:-- \
R N RD Rc ...s.'N RD
N RcT-------- I
RC RD
RD
[0375] R RD , [0376] In preferred embodiments Ring A has the structure of one of:
RE
I .
zN,N..1:- r,s,lz:1,r- Nõ. ', ,,N,..N.Y, N, I \ / RE--N1 N __IN
D
RC
R Re RD Re RD
RC N RD
RD \ --[0377] R
[0378] 23. A compound of Formula XI having the structure:
RH RH
1_A1 7q \ /\ / L 4-1¨R A Formula XI
. At _________________ RCA

RD
, [0379] or a pharmaceutically acceptable salt or prodrug thereof, [0380] wherein RA is -CO2H, -CO2RB, -CN, tetrazolyl, -C(=0)NH2, -C(=0)NHR6 , C(=0)NHSO2R6 or -C(=0)NHCH2CH2S03H or a carboxylic acid isostere;
[0381] RB is optionally substituted C1-C4 alkyl or has the structure of one of:
H
)r N
[0382] 0 0 0 0
- 66 -[0383] L1 is absent or optionally substituted C1-C6 alkylene; Cl-C6 fluoroalkylene; or optionally X
substituted C1-C6 heteroalkylene or Ll, when present is -CH2-, , or disubstituted dimethylmethane.
[0384] A1 is =N- or =CH-;
[0385] Ring A has the structure of one of:
RE
_ N I N I
RD RC RD RC RD RC
NNRD
[0386] Rc [0387] Rc is -H, -CN, -F, -Cl, -Br, -I, -0C1-C4 alkyl, 01-C4 alkyl, 03-C6 cycloalkyl, or C1-C4 fluoroalkyl;
[0388] RD is -N(RF)C(=0)XCH(RG)-CY, -N(RF)C(=0)XC(RG)2-CY, or -N(RF)C(=0)X-CY;
where X is absent, -0-, -NH- or -CH2-;
[0389] RE, RF and RG independently are -H or C1-04 alkyl or C3-06 cycloalkyl or RE and RF
independently are -H or C1-04 alkyl or C1-C6 cycloalkyl and one RG is C1-C4 alkyl and is taken together with CY and carbon atom to which RG and CY are attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other RG, if present, is as defined for RE;
[0390] RH is -H, halogen, -CN, -NO2, -SRJ, -S(=0)RJ, -S(=0)2RJ, -N(R)S(0)2R, -S(=0)2N(R1-)2, -C(=0)RJ, -0C(=0)RJ, -CO2RJ, -0CO2RJ, -N(RL)2, -C(=0)N(RI-)2, -0C(=0)N(R1)2, NRJC(=0)N(RI-)2, -NRJC(=0)RJ, -NRJC(=0)ORJ, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-fluoroalkoxy, C1-C4 alkoxy,and C1-C4 heteroalkyl;
[0391] RJ is substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 01-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl,
- 67 -substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted C3-C6 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted aryl), or C1-04 alkylene-(substituted or unsubstituted heteroaryl);
[0392] RI- independently are -H, substituted or unsubstituted C1-06 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C1-C8 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted C3-C6 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene(substituted or unsubstituted aryl), or -C1-C4 alkylene-(substituted or unsubstituted heteroaryl), [0393] or when RH is -S(=0)2N(RL)2, -N(RI-)2, -C(=0)N(RI-)2, -0C(=0)N(RL)2 or -N(RJ)C(=0)N(RL)2, each RI- is independently -H or C1-06 alkyl, or the RL
groups independently are C1-C6 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle, [0394] CY is C1-06 alkyl, a substituted or unsubstituted C3-010 cycloalkyl, a substituted or unsubstituted C2-Clo heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 RH, [0395] wherein when L1 is not absent and RD is -H or -CH3 and RA is -CO2H or -0O2R6 , then Ring A has the structure of one of:
RE
gl N\c' RE¨N, N
Rc RD RC RD RC
RD NLRD
[0396]
[0397] In particularly preferred Formula XI compounds RA is -CO2H, and RD is -NRFC(=0)0CH(RG)-CY.
[0398] 24. A compound of Formula XII having the structure:
- 68 -RH RH
A LI-RA Formula XII
RC
N, Rc 0 [0399] or a pharmaceutically acceptable salt or prodrug thereof, [0400] wherein RA is -002H, -CO2RB, -ON, tetrazolyl, -C(=0)NH2, -C(=0)NHRB, C(=0)NHSO2RB or -C(=0)NHCH2CH2S03H or a carboxylic acid isostere;
[0401] RB is optionally substituted Ci-C4 alkyl or has the structure of one of:
H
Oyc) )yN
[0402] 0 0 0 [0403] L1 is absent or optionally substituted C1-C6 alkylene; C1-06 fluoroalkylene; or optionally substituted 01-C6 heteroalkylene, or Ll, when present is -CF12-, , or disubstituted dimethylmethane.
[0404] A1 is =N- or =CH-;
[0405] Ring A has the structure of one of:
RE
m,N E,NX
N \ I R¨N N
D
c Fµ. RC RD RC RD
Rc [0406] R
[0407] RC is - H, -CN, -F, -Cl, -Br,- I, -001-04 alkyl, C1-04 alkyl, 03-C6 cycloalkyl, or 01-04 fluoroalkyl;
- 69 -[0408] wherein RD is the -N(RF)C(=0)CH(RG)-CY substituent in Formula XII
wherein CY is phenyl substituted with one RH;
[0409] RE, RF and RG independently are -H or C1-04 alkyl or 03-C6 cycloalkyl or RE and RF
independently are -H or 01-04 alkyl or Cl-C6 cycloalkyl and one RG is -C1-C4 alkyl and is taken together with the RH pheny moiety of the Ring A RD substituent and the carbon atom to which RG and said phenyl moiety is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other RG, if present, is as defined for RE;
[0410] RH is -H, halogen, -ON, -NO2, -OH,-OR, -SR, -S(=0)RJ, -S(=0)2RJ, -N(RJ)S(=0)2RJ, -S(=0)2N(RL)2, -C(=0)RJ, -0C(=0)RJ, -CO2RJ, -00O2R-1, -N(RL)2, -C(=0)N(RL)2, -0C(=0)N(RL)2, NRJC(=0)N(RL)2, -NRJC(=0)RJ, -NRJC(=0)ORJ, 01-C4 alkyl, C1-C4 fluoroalkyl, C1-fluoroalkoxy, Ci-C4 alkoxy,and C1-C4 heteroalkyl;
[0411] RJ is substituted or unsubstituted 01-C6 alkyl, substituted or unsubstituted 01-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted 03-C6 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C C4 alkylene-(substituted or unsubstituted aryl), or C1-C4 alkylene-(substituted or unsubstituted heteroaryl);
[0412] RL independently are -H, substituted or unsubstituted Cl-C6 alkyl, substituted or unsubstituted Cl-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted 03-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -01-C4 alkylene-(substituted or unsubstituted C3-06 cycloalkyl), -C1-04 alkylene-(substituted or unsubstituted heterocycloalkyl), -01-C4 alkylene(substituted or unsubstituted aryl), or -01-C4 alkylene-(substituted or unsubstituted heteroaryl),
- 70 -[0413] or when RH is -S(=0)2N(RL)2, -N(RL)2, -C(=0)N(RL)2, -0C(=0)N(RL)2 or -N(RJ)C(=0)N(RL)2, each RL is independently -H or 01-06 alkyl, or the RL groups independently are 01-06 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle, [0414] wherein when L1 is not absent and Rc is -H or -CH3 and RA is -CO2H or -CO2R8 then Ring A has the structure of one RE
,N
N\\
N
[0415] /N; RE¨N
N D
RD
RD RD
Re Rci Rc [0416] In particularly preferred Formula XII compounds RA is -CO2H.
[0417] 25. A composition comprising, essentially consisting of or consisting of one or more compounds of Formula I-XII and one or more excipients.
[0418] In preferred embodiments the composition comprises, consists essentially of, or consists of one compound of Formula I-XII and one or more excipients.
[0419] In other preferred embodiments the composition is a pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of one compound of Formula I-XII
and one or more pharmaceutically acceptable excipients.
[0420] 26. A compound of Formula I-XII or a pharmaceutically acceptable salt or prodrug thereof wherein the binding affinity of the compound to lysophosphatidic acid receptor-1 (LPA1R) is between about 10 pM and 1 pM or less [0421] 27. The compound of embodiment 19 wherein the compound is a selective lysophosphatidic acid receptor-1 (LPA1R) compound.
- 71 -[0422] 28. A compound of Formula 1-XII or a pharmaceutically acceptable salt, or prodrug thereof wherein the compound is a selective lysophosphatidic acid receptor-1 (LPA1R) compound.
[0423] 29. The compound of embodiment 20, 21 or 22 wherein the compound is a selective lysophosphatidic acid receptor-1 (LPA1R) compound wherein the binding affinity (i.e., KD) of the LPA1R compound is between about 1 pM and 1 pM or less. In preferred embodiments the KD is 100 nM or less, more preferably 10 nM or less.
[0424] 30. A compound of Table 1.
[0425] 31. The compound of embodiment 30 wherein the compound is 1-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-cyclopropane-carboxylic acid, 2-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-indan-2-carboxylic acid, 2-(S)-(4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxy-carbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl acetic acid, 2-(R)- (4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl propanoic acid, 2(R)4[4-[3-methy1-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyliamino]-3-phenyl-propanoic acid, 2(S)-[[4-[3-methy1-4-((R)-phenylethoxycarbonyl-amino)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid, (R)-2-{443-Methy1-44(S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzoylamino}-3-phenyl-propionic acid, (S)-2-{443-Methy1-4-((S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzoylamino}-3-phenyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylam ino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-phenyl-propionic acid , (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-fluoro-pheny1)-propionic acid , (R)-3-(4-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid , (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(3,4-difluoro-pheny1)-propionic acid , (R)-3-(2-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-
- 72 -chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid , (R)-3-(4-Bromo-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(2-fluoro-pheny1)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-p-tolyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-trifluoromethyl-pheny1)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-cyano-pheny1)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-cyclopropyl-propionic acid, 32. The compound of embodiment 30 wherein the compound is (R)-2-[[4-[2,5-dimethy1-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyliamino]-3-phenyl-propanoic acid, (R)-24[442, 5-dim ethy1-4-((R)-1- phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid, (R)- 3-(4-bromopheny1)-24[442,5-dimethyl-44(R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyljamino]propanoic acid, (R)- 3-(4-chloropheny1)-24[442,5-dimethy1-44(R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid or (R)- 3-(3,4-difluoropheny1)-24[442,5-dimethy1-44(R)-1-phenylethoxycarbonyl-amino)pyrazol-3-ylibenzoyl]amino]propanoic acid.
[0426] 33. The compound of embodiment 30 wherein the compound is 2-[4-[4-[2,5-dimethyl-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]phenyliphenyl]acetic, 2-[4-[4-[4-[1-(2-chloro-phenyl)ethoxycarbonylamino]-2,5-dimethyl-pyrazol-3-yl]phenyliphenyliacetic acid, 24444-[441-(2-fluorophenypethoxycarbonylamino]-2,5-dimethyl-pyrazol-3-yl]pheny1]-phenyl]
acetic acid, 2-[4-[4-[4-[1-(2 ,6-difluorophenypethoxycarbonylami no]-2, 5-dimethyl- pyrazol-3-y11-phenyl] phenyl]acetic acid, 244-[44441-(2-methoxyphenypethoxycarbonyl-amino]-2,5-di-methyl-pyrazol-3-yl]phenyliphenyliacetic acid, 1-[4-[4-[2,5-dimethy1-4-(1-phenylethoxy-carbonylamino)pyrazol-3-yl]phenyliphenylicyclopropanecarboxylic acid, 1-[4-[6-[2,5-di-methy1-4-
- 73 -(1-phenylethoxycarbonylamino)pyrazol-3-y1]-3-pyridyl]phenyl]cyclo-propane carboxylic acid, 1-[4-[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-2,5-dimethyl-pyrazol-3-yl]phenyl]phenyl]cyclopropanecarboxylic acid, 1-[4444441-(2-fluoropheny1)-ethoxycarbonyl-amino]-2,5-dimethyl-pyrazol-3-yl]phenyl]phenyl]cyclopropanecarboxylic acid, 144444441-(2,6-difluorophenypethoxycarbonylamino]-2,5-dimethyl-pyrazol-3-yl]phenyl]phenyl]cyclo-propanecarboxylic acid, 144444441-(2-methoxyphenypethoxy-carbonylamino]-2,5-dimethyl-pyrazol-3-yl]phenyl]phenyl]cyclopropanecarbmlic acid, 2-[44442,5-dimethy1-4-(1-phenyl-ethoxycarbonylamino)pyrazol-3-yl]phenyl]phenyl]-2-methyl-propanoic acid, chlorophenypethoxycarbonylam ino]-2, 5-dim ethyl-pyrazol-3-yl]phenyl] pheny1]-2-methyl-propanoic acid, 2-[4-[4-[4-[1-(2-fluorophenyl)ethoxycarbonyl-amino]-2,5-dimethyl-pyrazol-3-yl]phenyl]pheny1]-2-methyl-propanoic acid, 214444441-(2,6-difluorophenyl)ethoxycarbonyl-amino]-2,5-dimethyl-pyrazol-3-yl]phenyl]pheny1]-2-methyl-propanoic acid or 2-[4-[4-[4-[1-(2-methoxyphenyl)ethoxycarbonylamino]-2, 5-dim ethyl-pyrazol-3-yl]pheny1]-phenyl]-2-methyl-propanoic acid.
[0427] 34. The compound of embodiment 30 wherein the compound is (R)-24[4-[1,5-dimethy1-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyllamino]-3-phenyl-propanoic acid, (R)-2-[[4-[1, 5-dim ethy1-44(R)-1-phenylethoxycarbonylam i no)pyrazol-3-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid, (R)- 3-(4-bromopheny1)-2-[[441,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, ((R)- 3-(4-chloropheny1)-2-[[4-[1,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino) pyrazol-yl]benzoyl]amino]propanoic acid or (R)- 3-(3,4-difluoropheny1)-24[441,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-ami no)pyrazol-3-yl] benzoyl]ami no] propanoic acid.
[0428] 35. The compound of embodiment 30 wherein the compound is (R)- 2-(4-{5-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylam ino]-4-methyl-pyrazol-1-y1}-benzoylamino)-3-phenyl-propionic acid.
- 74 -[0429] 36. The compound of embodiment 30 wherein the compound is (R)-2-{4-[3-Methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzylamino}-3-phenyl-propionic acid, (R)-3-(2-Fluoro-pheny1)-2-{443-methy1-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-A-benzylamino}-propionic acid, (R)-2-{443-Methy1-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-3-(4-trifluoromethyl-pheny1)-propionic acid, (R)-3-Cyclopropy1-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1Fbenzylamino}-propionic acid, (R)-3-(2-Chloro-pheny1)-2-{4-[3-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-A-benzylamino}-propionic acid, (R)-3-(4-Chloro-pheny1)-2-{4-[3-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzylaminol-propionic acid, (R)- 2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-phenyl-propionic acid, (R)- 2-(4-{4-[(R)_1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-(2-fluoro-pheny1)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-(4-trifluoromethyl-pheny1)-propionic acid, (R)- 3-(2-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-propionic acid or (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-cyclopropyl-propionic acid.
[0430] 37. The compound of embodiment 30 wherein the compound is 2-{443-Methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzyloxy}-3-phenyl-propionic acid, 2-{443-Methy1-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzyloxy}-3-phenyl-propionic acid, (RS)-3-Cyclopropy1-2-{413-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzyloxy}-propionic acid or (RS)-3-Cyclopropy1-2-{4-[3-methy1-44(R)-1-phenyl-ethoxycarbonylaminoyisoxazol-5-yli-benzyloxy}-propionic acid.
[0431] 38. The compound of embodiment 30 wherein the compound is 24444454142-chlorophenypethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyliacetic acid, (R)-1-[4-[4-[1, 5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]phenyliphenyl]cyclo-propane
- 75 -carboxylic acid, (R)-1444442, 5-d im ethy1-4-(1- phenyl ethoxycarbo nylam i no) pyrazol-3-yliphenyl]phenylicyclopropane carboxylic acid, (R)-1-(4'-{541-(2-Chloro-pheny1)-ethoxycarbonyl-amino]-4-fluoro-pyrazol-1-y1}-3-fluoro-bipheny1-4-y1)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-pheny1)-ethoxycarbonylam ino]-4-fluoro-pyrazol-1-y1}-2-fluoro-bipheny1-4-y1)-cyclo-propanecarboxylic acid, (R)-1-(2-Chloro-4'-{541-(2-chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-bipheny1-4-y1)-cyclopropanecarboxylic acid, .. (R)-1-(4'-{541-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-2-methyl-biphenyl-4-y1)-cyclopropanecarboxylic acid, (R)-1-(4'-{511-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-biphenyl-4-y1)-cyclopropanecarboxylic acid, (R)-1-{4'-[5-(1-Phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-y1]-bipheny1-4-y1}-cyclopropanecarboxylic acid, (R)-1-{2- Fluoro-4'-[5-(1- ph enyl- ethoxycarbonylam ino)-4-trifluoromethyl-pyrazol-1-y1]- bipheny1-4-y1}-cyclopropanecarboxylic acid or (R)-1-(4-{545-(1-Phenyl-ethoxycarbonylamino)-pyrazol-1-yli-pyridin-2-y1}-pheny1)-cyclopropanecarboxylic acid.
[0432] 39. The compound of embodiment 30 wherein the compound is 2-[[443-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid, 3-cyclopropy1-24[443-methy1-4-(1-phenylethoxycarbonylam ino)isoxazol-5-ylibenzoyliam ino]-propanoic acid, 24[443-methy1-4-(1- ph enylethoxycarbonylam ino)isoxazol-5-yllbenzoy1Fam ino]-3- phenoxy- propanoic acid, 24[443-methy1-4-(1-phenylethoxycarbonylamino)-isoxazol-5-ylibenzoyliamino]-4-phenyl-butanoic acid, 24[44441-(2-chlorophenypethoxy-carbonylamino]-3-methyl-isoxazol-5-ylibenzoyliamino]-3-phenyl-propanoic acid, 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylam ino]-3-methyl-isoxazol-5-yl]benzoyl]am ino]-3-cyclopropyl-propanoic acid, 24[444-[1-(2-chlorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-y11-benzoyl]amino]-4-phenyl-butanoic acid, 24[4-[441-(2-chlorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyl]amino]-3-phenoxy-propanoic acid, 2-[[4-[4-[1-(2-fluoropheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyl]amino]-4-phenyl-butanoic acid, 24[444-[1-(2-fluorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-yllbenzoyl]amino]-3-phenoxy-
- 76 -propanoic acid, 3-cyclopropy1-24[44441-(2-fluorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyllamino]propanoic acid, 24[44441-(2-fluorophenypethoxy-carbonylamino]-3-methyl-isoxazol-5-yl]benzoyflamino]-3-phenyl-propanoic acid, 3-(4-methoxypheny1)-2-[[443-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoy1]-amino]propanoic acid, 3-(4-fluoropheny1)-24[443-methy1-4-(1 -phenylethoxycarbonylam ino)-isoxazol-5-yl]benzoyflamino]propanoic acid, 3-(2,6-difluoropheny1)-2-[[4-[3-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]propanoic acid, 3-(3-cyano-pheny1)-2-[[4-[3-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]-propanoic acid, 3-(2-chloropheny1)-24[4-[3-methy1-4-(1-phenylethoxycarbonylamino)-isoxazol-5-yl]benzoyl]amino]propanoic acid, 3-(4-chloropheny1)-2-[[4-[3-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]propanoic acid, 2-[[4-[3-methy1-4-(1-phenylethoxycarbonylam ino)isoxazol-5-yl]benzoyl]am ino]-3-[4-(trifl uoromethyl)pheny1]-propanoic acid, 3-(4-hydroxypheny1)-2-[[443-methy1-4-(1-phenylethoxycarbonylamino)-isoxazol-5-yl]benzoyl]amino]propanoic acid, 3-(3,4-difluoropheny1)-2-[[4-[3-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]propanoic acid, 3-(4-bromo-pheny1)-2-[[4-[3-methy1-4-(1-phenylethoxycarbonylam ino)isoxazol-5-yl]benzoyl]amino]-propanoic acid, 2-[[4-[3-methy1-4-(1-phenyl ethoxycarbonylam ino)isoxazol-5-yl]benzoyl]-amino]-(trifluoromethoxy)phenyl]propanoic acid, 2-[[44441-(2-chlorophenypethoxy-carbonylamino]-3-methyl-isoxazol-5-yl]benzoyl]amino]-3-(4-methoxyphenyl)propanoic acid, 24[41441-(2-chlorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoynamino]-3-(4-fluorophenyl)propanoic acid, 24[444-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyflamino]-3-(2,6-difluorophenyl)propanoic acid, 24[444-[1-(2-chloro-phenypethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyl]amino]-3-(3-cyanopheny1)-propanoic acid, 3-(2-chloropheny1)-2-[[44441-(2-chlorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyllamino]propanoic acid, 3-(4-chloropheny1)-2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyl]amino]propanoic acid, 2-[[4-
- 77 -[441-(2-chlorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyl]amino]-(trifluoromethyl)phenyl]propanoic acid, .. 21[444-0 -(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyl]amino]-3-(4-hydroxyphenyl)propanoic acid, 3-(4-bromo-pheny1)-2-[[44441-(2-chlorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyli-amino]propanoic acid, 24[41441-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-yllbenzoyl]amino]-3-(3,4-difluorophenyl)propanoic acid, 24[44441-(2-chloropheny1)-ethonicarbonylamino]-3-methyl-isoxazol-5-yl]benzoyliamino]-344-(trifluoromethoxy)-phenyl]propanoic acid, 2-[[4-[4-[1-(2-fluorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyl]amino]-3-(4-methoxyphenyl)propanoic acid, 3-(4-fluorophenyI)-2-[[4-[4-[1-(2-fluorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyl]amino]propanoic acid, 3-(2, 6-d ifluoropheny1)-24[44441 -(2-fluorop henypethoxycarbonylam ino]-3-methyl- isoxazol-5-yl]benzoyflamino]propanoic acid, 3-(3-cyanopheny1)-2-[[4-[4-[1-(2-fluorophenyl)ethoxy-carbonylamino]-3-methyl-isoxazol-5-ylibenzoyl]amino]propanoic acid, 3-(2-chloropheny1)-24[4-[44142-flu oroph enyl) ethoxycarbonylam ino]-3-methyl- isoxazol-5-yl]benzoyliam inoj-propanoic acid, 3-(4-chloropheny1)-24[44441-(2-fluorophenyl)ethoxycarbonylam ino]-3-m ethyl- isoxazol-5-yl] benzoyl]a m in o]propanoi c acid, 24[44441-(2-fluorophenypethoxy-carbonylamino]-3-methyl-isoxazol-5-yl]benzoyliamino]-344-(trifluoromethyl)pheny1]-propanoic acid, 24[4444142-fluorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyliamino]-3-(4-hydroxyphenyl)propanoic acid, 3-(3,4-difluorophenyI)-2-[[4-[4-[1-(2-fluorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyliamino]propanoic acid, 3-(4-bromopheny1)-24[44441-(2-fluorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyl]amino]propanoic acid, 24[44441-(2-fluorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyl]amino]-344-(trifluoromethoxy)phenyl]propanoic acid, ( )-(4-{4-[ 1-(2-Chloro-pheny1)-ethoxycarbonyl-amino]-3-methyl-isoxazol-5-y1}-benzoylaminoyacetic acid, ( )-2-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-2-methyl-propionic acid, ( )-2-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-
- 78 -5-yI}-benzoylamino)-propionic acid, ( )-2-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-hydroxy-propionic acid, ( )-1-(4-{4-[1-(2-Chloro-phenyl)ethoxycarbonyl-amino]-3-methyl-isoxazol-5-y1}-benzoy1)-pyrrolidine-2-carboxylic acid or ( )-2-(4-{441-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid.
[0433] 40. The compound of embodiment 30 wherein the compound is 2-{p43-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolypenzoylamino}-3-phenylpropionic acid, 2-(p-{4-[1-(0-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly1}benzoylamino)-3-phenyl-propionic acid, 3-Cyclopropy1-2-{p-[3-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-benzoylamino}propionic acid, 2-(p-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazolyl}benzoylamino)-3-cyclopropylpropionic acid, 2-[({p-[3-Fluoro-4-(1-phenylethoxy-carbonylamino)-5-isoxazolyl]phenyl}methyl)arnino]-3-phenylpropionic acid, 2-{[(p-{4-[1-(o-Chlorophenypethoxycarbonylam i no]-3-fluoro-5-isoxazolyl}phenyl)methyl]amino}-phenyl propionic acid, 3-Cyclopropy1-24({p43-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methypamino]propionic acid, 2-{[(p-{441-(o-Chlorophenypethoxycarbonyl-amino]-3-fluoro-5-isoxazolyl}phenyl)methyl]amino}-3-cyclopropylpropionic acid, 2-({p-[3-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methoxy)-3-phenylpropionic acid, 2-[(p-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazolyl}pheny1)-methoxy]-3-phenylpropionic acid, 3-Cyclopropy1-2-({p43-fluoro-4-(1-phenylethoxycarbonyl-amino)-5-isoxazolyl]phenyl}methoxy)propionic acid or 2-[(p-{441-(o-Chlorophenypethoxy-carbonylamino]-3-fluoro-5-isoxazolyl}phenyl)methoxy]-3-cyclopropylpropionic acid.
[0434] 41. The compound of embodiment 30 wherein the compound is 2-Benzy1-3-{543-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}propionic acid, 2-Benzy1-3-(5-{441-(o-chlorophenypethoxycarbonylaminol-3-fluoro-5-isoxazoly1}-2-pyridyl-amino)propionic acid, 2-(Cyclopropylmethyl)-3-{543-fluoro-4-(1-phenylethoxycarbonyl-amino)-5-isoxazoly1]-2-pyridylamino}propionic acid, 3-(5-{441-(o-Chlorophenyl)ethoxy-carbonylamino]-3-fluoro-5-
- 79 -isoxazoly11-2-pyridylamino)-2-(cyclopropylmethyl)propionic acid, 2-Benzy1-3-{543-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-propionic acid, 2-Benzy1-3-(5-{4-[1-(o-chlorophenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridyloxy)propionic acid 2-Benzy1-3-(5-{441-(o-chlorophenypethoxycarbonyl-amino]-3-fluoro-5-isoxazoly1}-2-pyridyloxy)propionic acid, 2-(Cyclopropylmethyl)-3-{543-fluoro-4-(1-phenylethoxycarbonyl-amino)-5-isoxazoly1]-2-pyridyloxy}propionic acid, 3-(5-{441-(o-Chlorophenypethoxy-carbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridyloxy)-2-(cyclo-propylmethyl)propionic acid, 2-{543-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}-3-phenyl-propionic acid, 2454441-(o-Chlorophenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridylami no)-3-phenylpropionic acid, 3-Cyclopropy1-2-{543-fluoro-4-(1-phenylethoxy-carbonylamino)-5-isoxazoly1]-2-pyridylamino}propionic acid, 2-(5-{441-(o-Chloropheny1)-ethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridylamino)-3-cyclopropyl-propionic acid, 2-{543-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-3-phenyl-propionic acid, 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-iso-xazoly1}-2-pyridyloxy)-3-phenylpropionic acid, 3-Cyclopropy1-2-{543-fluoro-4-(1-phenyl-ethoxy-carbonylam ino)-5-isoxazoly1]-2-pyridyloxy}propionic acid, 2-(5-{411-(o-Chloro-pheny1)-ethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridyloxy)-3-cyclopropylpropionic acid, 2-{p-[3-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolypenzoylamino}-3-phenylpropionic acid, 2-(p-{441-(o-chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazolyl}benzoyl-amino)-3-phenylpropionic acid, 3-cyclopropy1-2-{p-[3-fluoro-4-(1-phenylethoxycarbonyl-am ino)-5-isoxazolyl]benzoylaminolpropionic acid, 2-(p-{441-(o-chlorophenyl)ethoxy-carbonylamino]-3-fluoro-5-isoxazolyl}benzoylamino)-3-cyclopropylpropionic acid, 24({p-[3-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methyl)amino]-3-phenyl-propionic acid, 2-{[(p-{4-[1 -(o-chlorophenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-phenyl)methyl]amino}-3-phenylpropionic acid, 3-cyclopropy1-2[({p43-fluoro-4-(1-phenyl-ethoxycarbonylam ino)-5-isoxazolyl]phenyl}methyl)amino]propionic acid, 2-{[(p-{441-(o-
- 80 -chlorophenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazolyllphenyl)methyl]amino}-3-cyclo-propylpropionic acid, 2-({p-[3-fluoro-4- (1 -phenylethoxycarbonylam ino)-5-isoxazoly1]-phenyl}methoxy)-3-phenyl propionic acid, 2-[(p-{441-(o-chlorophenypethoxycarbonyl-amino]-3-fluoro-5-isoxazolyl}phenyl)methoxy]-3-phenylpropionic acid, 3-cyclopropy1-2-({p43-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methoxy)propionic acid, 2-[(p-{4-[1-(o-chlorophenyl)ethoxycarbonylam ino]-3-fluoro-5-isoxazolyl}phenyl)methoxy]-3-cyclopropylpropionic acid, 2-benzy1-3-{5-[3-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}propionic acid, 2-benzy1-3-(5-{441-(o-chlorophenypethoxy-carbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridylamino)propionic acid, 2-(cyclopropyl-methyl)-3-{543-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}-propionic acid, 3-(5-{441-(o-chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly11-2-pyridyl-amino)-2-(cyclopropylmethyl)propionic acid, 2-benzy1-3-{543-fluoro-4-(1-phenylethoxy-carbonylamino)-5-isoxazoly1]-2-pyridyloxy}propionic acid, 2-benzy1-3-(5-{4-[1-(o-chloro-phenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridyloxy)propionic acid, 2-(cyclo-propylmethyl)-3-{543-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-propionic acid, 3-(5-{441-(o-chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridyloxy)-2-(cyclopropylmethyl)propionic acid, 2-{543-fluoro-4-(1-phenylethoxycarbonyl-amino)-5-isoxazoly1]-2-pyridylamino}-3-phenylpropionic acid, 2-(5-{441-(o-chloropheny1)-ethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridylamino)-3-phenylpropionic acid, 3-cyclopropy1-2-{543-fluoro-4-(1-phenylethoxycarbonylam ino)-5-isoxazoly1]-2-pyridylam ino}-propionic acid, 2-(5-{441-(o-chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridylamino)-3-cyclopropylpropionic acid, 2-{543-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-3-phenylpropionic acid, 2-(5-{4-[1-(o-chlorophenyl)ethoxy-carbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridyloxy)-3-phenyl-propionic acid, 3-cyclopropy1-2-{5-[3-fluoro-4-(1-phenylethoxycarbonylamino)-5-iso-xazoly1]-2-pyridyloxy}propionic acid or 2-(5-{4-
-81 -[1-(o-chlorophenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazolyI}-2-pyridyloxy)-3-cyclopropylpropionic acid.
[0435] 42. The compound of embodiment 30 wherein the compound is 2-{p43-Cyano-4-(1-phenylethoxycarbonylam ino)-5-isoxazolyl]benzoylam ino}-3- phenylpropionic acid, 2-(p-{411 -(0-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazolyl}benzoylamino)-3-phenyl-propionic acid, 2-{p43-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolypenzoyl-amino}-3-cyclopropylpropionic acid, 2-(p-{441-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazolyl}benzoylamino)-3-cyclopropylpropionic acid, 24({p43-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyliphenyl}methypamino]-3-phenylpropionic acid, 2-{[(p-{441-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazolyl}phenyl)methylFamino)-3-phenylpropionic acid, 2-[({p43-Cyano-4-(1-phenylethoxycarbonylamino)-5-iso-xazolyl]phenyl}methyDamino]-3-cyclopropylpropionic acid, 2-{[(p-{441-(o-Chloropheny1)-ethoxycarbonylamino]-3-cyano-5-isoxazoly1}phenyOmethyl]amino}-3-cyclopropylpropionic acid, 2-({p43-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methoxy)-3-phenylpropionic acid, 2-[(p-{441-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-iso-xazolyl}phenyl)methoxy]-3-phenylpropionic acid, 2-({p43-Cyano-4-(1-phenylethoxycarbonyl-amino)-5-isoxazolyliphenyl}methoxy)-3-cyclopropylpropionic acid or 2-[(p-{441-(o-Chloro-phenypethoxycarbonylamino]-3-cyano-5-isoxazolyl}phenyOmethoxy]-3-cyclopropylpropionic acid.
[0436] 43. A compound of embodiment 30 wherein the compound is 2-Benzy1-3-{543-cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}propionic acid, 2-Benzy1-3-(5-{4-[1-(o-chlorophenyl)ethoxycarbonylamino]-3-cyano-5-isoxazolyI}-2-pyridylamino)-propionic acid, 3-{5-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyl-amino}-2-(cyclopropylmethyl)propionic acid, 3-(5-{441-(o-Chlorophenypethoxycarbonyl-amino]-3-cyano-5-isoxazoly1}-2-pyridylamino)-2-(cyclopropylmethyl)propionic acid, 2-Benzy1-3-{543-cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}propionic acid, 2-Benzy1-3-(5-{441-(0-
- 82 -chlorophenyl)ethoxycarbonylamino]-3-cyano-5-isoxazolyI}-2-pyridyloxy)propionic acid, 34543-Cyano-4-(1-phenylethoxycarbonylam ino)-5- isoxazolyI]-2-pyridyloxy}-2-(cyclopropylmethyppropionic acid, 3-(5-{441-(o-Chlorophenypethoxycarbonyl-amino]-3-cyano-5-isoxazoly1}-2-pyridyloxy)-2-(cyclopropylmethyl)propionic acid, 2-{5-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly11-2-pyridylarnino}-3-phenylpropionic acid, 2-(5-{4-[1-(o-Chlorophenypethoxycarbonylam ino]-3-cyano-5-isoxazoly1}-2-pyridyl-amino)-3-phenylpropionic acid, 2-{543-Cyano-4-(1-phenylethoxycarbonylarnino)-5-iso-xazoly11-2-pyridylarnino}-3-cyclopropylpropionic acid, 2-(5-{441-(o-Chlorophenypethoxy-carbonylamino]-3-cyano-5-isoxazoly11-2-pyridylamino)-3-cyclopropylpropionic acid, .. 2-{543-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-3-phenylpropionic acid, 2-(5-{441-(0-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridyloxy)-3-phenylpropionic acid, 2-{543-Cyano-4-(1-phenylethoxycarbonylann ino)-5-isoxazolyI]-2-pyridyloxy}-3-cyclopropylpropionic acid, 2-(5-{441-(o-Chlorophenyl)ethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridyloxy)-3-cyclopropylpropionic acid, 2-{p-[3-cyano-4-(1-phenyl-ethoxycarbonylamino)-5-isoxazolyl]benzoylamino}-3-phenylpropionic acid, 2-(p-{4-[1-(o-chlorophenyl)ethoxycarbonylam ino]-3-cyano-5-isoxazolyl}benzoylamino)-3-phenylpropionic acid, 2-{p43-cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolylibenzoylamino}-3-cyclo-propylpropionic acid, 2-(p-{441-(o-chlorophenypethoxycarbonylamino]-3-cyano-5-iso-xazolyl}benzoylamino)-3-cyclopropylpropionic acid, 2-[({p-p-cyano-4-(1-phenylethoxy-carbonylamino)-5-isoxazolynphenyl}methyl)amino]-3-phenylpropionic acid, 2-{[(p-{441-(o-chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazolyl}phenyl)methyl]amino}-3-phenyl-propionic acid, 2-[({p43-cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyll-methyl)amino]-3-cyclopropylpropionic acid, 2-{[(p-{441-(o-chlorophenypethoxycarbonyl-amino]-3-cyano-5-isoxazolyl}phenyl)methyliamino}-3-cyclopropylpropionic acid, 2-({p43-cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyliphenyl}methoxy)-3-phenylpropionic acid, 2-[(p-{441-(o-chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazolyllphenyl)-methoxy]-3-
- 83 -phenylpropionic acid, 2-({p[3-cyano-4-(1-phenylethoxycarbonylam ino)-5-isoxazolyl]phenyl}methoxy)-3-cyclopropylpropionic acid, 2-[(p-{411-(o-chlorophenypethoxy-carbonylamino]-3-cyano-5-isoxazolyl}phenyOmethoxy]-3-cyclopropylpropionic acid, 2-benzy1-3-{543-cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}-propionic acid, 2-benzy1-3-(5-{4-0-(o-chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridylamino)propionic acid, 3-{5-[3-cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylam ino}-2-(cyclopropylmethyl)propionic acid, 3-(5-{4-[1-(o-chloro-phenyl)ethoxycarbonylamino]-3-cyano-5-isoxazoly11-2-pyridylamino)-2-(cyclopropylmethyl)-propionic acid, 2-benzy1-3-{5-[3-cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}propionic acid, 2-benzy1-3-(5-{441-(o-chlorophenyl)ethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridyloxy)propionic acid, 3-{5-[3-cyano-4-(1-phenylethoxycarbonyl-amino)-5-isoxazoly1]-2-pyridyloxy}-2-(cyclopropylmethyl)propionic acid, 3-(5-{4-[1-(o-chloro-phenypethoxycarbonylamino]-3-cyano-5-isoxazoly11-2-pyridyloxy)-2-(cyclopropylmethyl)-propionic acid, 2-{543-cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyl-amino}-3-phenylpropionic acid, 2-(5-{441-(o-chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridylamino)-3-phenylpropionic acid, 2-{543-cyano-4-(1-phenylethoxy-carbonylamino)-5-isoxazoly1]-2-pyridylamino}-3-cyclopropylpropionic acid, 2-(5-{4-[1-(o-chlorophenyl) ethoxycarbonylam i no]-3-cyano-5-isoxazoly1}-2-pyridylam ino)-3-cyclopropyl-propionic acid, 2-{543-cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-3-phenylpropionic acid, 2-(5-{441-(o-chlorophenyl)ethoxycarbonylamino]-3-cyano-5-iso-xazoly1}-2-pyridyloxy)-3-phenylpropionic acid, 2-{5-[3-cyano-4-(1-phenylethoxycarbonyl-amino)-5-isoxazoly1]-2-pyridyloxy}-3-cyclopropylpropionic acid or 2-(5-{4-[1-(o-chloropheny1)-ethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridyloxy)-3-cyclopropylpropionic acid.
[0437] 44. A compound of embodiment 30 wherein the compound is 2-Benzy1-3-{543-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}propionic acid, 2-Benzy1-3-(5-{4-[1-(o-chlorophenyl)ethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridylamino)-propionic acid,
- 84 -2-(Cyclopropylmethyl)-3-{543-methyl-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylannino}propionic acid, 3-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-methyl-5-isoxazoly1}-2-pyridylamino)-2-(cyclopropylmethyl)propionic acid, 2-Benzy1-3-{543-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}propionic acid, 2-Benzy1-3-(5-{441-(0-chlorophenypethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridyl-oxy)propionic acid, 2-(Cyclopropylmethyl)-3-{543-methyl-4-(1-phenylethoxycarbonylamino)-5-isoxazoly11-2-pyridyloxy}propionic acid, 3-(5-{441-(o-Chlorophenyl)ethoxycarbonylamino]-3-methyl-5-isoxazoly1}-2-pyridyloxy)-2-(cyclopropylmethyl)propionic acid, 2-{5-[3-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}-3-phenylpropionic acid, 2-(5-{4-0-(o-Chlorophenypethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridylamino)-3-phenylpropionic acid, 2-(5-{4- [1-(o- Chl o rophenypethoxycarbonylam i no]-3- methyl- 5-isoxazoly1}-2- pyridyl am ino)- 3-cyclopropylpropionic acid, 2-{543-Methy1-4-(1-phenylethoxy-carbonylamino)-5-isoxazoly1]-2-pyridyloxy}-3-phenylpropionic acid, 2-(5-{441-(o-Chloro-phenypethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridyloxy)-3-phenylpropionic acid, 3-Cyclopropy1-2-{5-[3-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyl-oxy}propionic acid, 2-(5-{4-[1-(o-Chlorophenyl)ethoxycarbonylam ino]-3-m ethyl-5-isoxazoly1}-2-pyridyloxy)-3-cyclopropylpropionic acid, 2-benzy1-3-{5-[3-m ethy1-4-(1-p he nyl-ethoxycarbonylam ino)-5-isoxazoly1]-2-pyridylamino}propionic acid, 2-benzy1-3-(5-{4-[1-(o-chlorophenypethoxycarbonylamino]-3-methyl-5-isoxazoly1}-2-pyridylamino)propionic acid, 2-(cyclopropylmethyl)-3-{5-[3-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylaminolpropionic acid, 3- (5-{4- [1 -(o-chlorophenyl)ethoxycarbonylam i no]-3-m ethy1-5-i soxazoly1}-2-pyridyl am i no)-2-(cycl op ropylmethyl)propionic acid, 2-benzy1-3-{543-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}propionic acid, 2-benzy1-3-(5-{4-[1-(o-chlorophenyl)ethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridyloxy)propionic acid, 2-(cyclopropylmethyl)-3-{543-m ethy1-4-(1- phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}propionic acid, 3-(5-{441-(o-chlorophenyl) ethoxycarbonyla m n 0]-3- m ethy1-5-
- 85 -isoxazoly1}-2-pyridyloxy)-2-(cyclopropylmethyl)propionic acid, 2-{543-methy1-4-(1-phenyl-ethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}-3-phenylpropionic acid, .. 2-(5-{411-(0-chlorophenypethoxycarbonylamino]-3-methyl-5-isoxazoly1}-2-pyridylamino)-3-phenyl-propionic acid, 3-cydopropy1-2-{543-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}propionic acid, 2-(5-{4-[1-(o-chlorophenyl)ethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridylamino)-3-cyclopropylpropionic acid, 2-{543-methy1-4-(1-phenylethoxy-carbonylamino)-5-isoxazoly1]-2-pyridyloxy}-3-phenylpropionic acid, 2-(5-{4-[1-(o-chloro-phenypethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridyloxy)-3-phenylpropionic acid, 3-cyclopropy1-2-{543-methy1-4-(1-phenylethoxycarbonylam ino)-5- isoxazoly1]-2-pyridyloxy}-propionic acid, 2-(5-{441-(o-chlorophenypethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridyloxy)-3-cyclopropylpropionic acid, 3-{p43-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazolylibenzoylamino}-4-phenylbutyric acid, .. 4-cyclopropy1-3-{p43-methyl-4-(1-phenyl-ethoxycarbonylamino)-5-isoxazolypenzoylamino}butyric acid, 34({p43-methyl-4-(1-phenyl-ethoxycarbonylamino)-5-isoxazolyliphenyl}methypamino]-4-phenylbutyric acid, 4-cyclo-propy1-3-[({p43-methyl-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methyl)-amino]butyric acid, 3-({p[3-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenylymethoxy)-4-phenylbutyric acid, 4-cyclopropy1-3-({p-[3-methy1-4-(1-phenylethoxycarbonyl-amino)-5-isoxazolyl]phenyl}methoxy)butyric acid, 3-{543-methy1-4-(1-phenylethoxycarbonyl-amino)-5-isoxazoly1]-2-pyridylamino}-4-phenylbutyric acid, 4- cyclopropyl- 3-{5-[3- methyl-4- (1-phenylethoxycarbonylam ino)-5-isoxazoly1]-2-pyridylam ino}butyric acid, .. 3-{5-[3-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-4-phenylbutyric acid, 4-cyclo-propy1-3-{543-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}butyric acid.
[0438] 45. A compound of embodiment 30 wherein the compound is 2-[[4-[1,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyliamino]-3-(4-methoxyphenyl)propanoic acid, 2-[[4-[1, 5-dimethy1-4-(1- phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid, 3-(2,6-difluoropheny1)-2-[[4-[1, 5-dimethy1-4- (1- phenylethoxy-
- 86 -carbonylam ino)pyrazol-3-yl]benzoyl]amino]propanoic acid, 3-(3-cyanopheny1)-2-[[441 , 5-dim ethy1-4- (1- phenylethoxycarbonylamino) pyrazol-3-yl]benzoyl]am nolpropanoic acid, 3- (2-chloropheny1)-2-[[4-[1 ,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoy1]-am ino]propanoic acid, 3-(4-chloropheny1)-24[441 , 5-di methy1-4-(1 -phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, 2-[[4-[1,5-dimethy1-4-(1-phenylethoxy-carbonylamino)pyrazol-3-yl]benzoyl]amino]-3-[4-(trifluoromethyl)phenyl]propanoic acid, 2-[[4-[1 ,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-(4-hydroxyphenyl)propanoic acid, 3-(3,4-difluoropheny1)-24[441,5-dimethy1-4-(1-phenylethoxy-carbonylamino)pyrazol-3-yl]benzoyllamino]propanoic acid, 3-(4-brom opheny1)-2-[[4- [1 , 5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]am ino]propanoic acid, 24[4-[1,5-dim ethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-344-(trifluoro-methoxy)phenyl]propanoic acid, 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyl]amino]-3-(4-methoxyphenyl)propanoic acid, 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-1 , 5-di methyl-pyrazol-3-yl]benzoyllam i no]-3- (4-fluoro-phenyl)propanoic acid, 2-[[4-[4-[1 -(2-chlorophenyl)ethoxycarbonylamino]- 1, 5-dimethyl-pyrazol-3-yl]benzoyl]amino]-3-(2,6-difluorophenyl)propanoic acid, 2-[[4-[4-[1-(2-chloro-phenyl) ethoxycarbonylami no]-1 ,5-dimethyl-pyrazol-3-yl]benzoyl]amino]-3-(3-cyanopheny1)-propanoic acid, 3-(2-chloropheny1)-24[44441-(2-chlorophenypethoxycarbonylamino]-1 , 5-dimethyl-pyrazol-3-yl]benzoyllam ino]propanoic acid, 3-(4-chloropheny1)-2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyllamino]propanoic acid, 2-[[4-[4-[1- (2-chlorophenyl)ethoxycarbonylam ino]-1 ,5-dimethyl-pyrazol-3-yl]benzoy1]-am ino]-3-[4-(trifluoromethyl)phenyl]propanoic acid, 2-[[4-[4-[1-(2-chlorophenyl)ethoxy-carbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyl]amino]-3-(4-hydroxyphenyl)propanoic acid, 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-1, 5-di methyl-pyrazol-3-Abenzoyll-ami no]-3-(3,4-difluorophenyl) propanoic acid, 3-(4-bromopheny1)-2-[[4-[4-[1-(2-chloro-phenyl)ethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyl]amino]propanoic acid, 2-[[4-[4-
- 87 -[1-(2-chlorophenypethoxycarbonylamino]- 1, 5-dimethyl-pyrazol-3-yl]benzoyl]am ino]-3- [4-(trifluoromethoxy)phenyl]propanoic acid, 2-[[44411-(2-fluorophenypethoxycarbonyl-amino]-1,5-dimethyl-pyrazol-3-yl]benzoyl]amino]-3-(4-methoxyphenyl)propanoic acid, 3-(4-fluorophenyI)-2-[[4-[4-[1-(2-fluorophenyl)ethoxycarbonylamino]-1 ,5-dimethyl-pyrazol-3-yl]benzoyliamino]propanoic acid, 3-(2,6-difluoropheny1)-2-[[44441-(2-fluorophenyl)ethoxy-carbonylam ino]-1,5-dimethyl-pyrazol-3-ylibenzoyl]amino]propanoic acid, 3-(3-cyanopheny1)-2-[[44441-(2-fluorophenyl)ethoxycarbonylamino]-1 ,5-dimethyl-pyrazol-3-ylibenzoyliamino]-propanoic acid, 3-(2-chloropheny1)-24[4[4[1-(2-fluorophenypethoxycarbonylam ino]- 1 , 5-dimethyl-pyrazol-3-yl]benzoyliam ino]propanoic acid, 3-(4-chloropheny1)-24[44441-(2-fluorophenypethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-ylibenzoyl]amino]propanoic acid, 2-[[44441-(2-fluorophenypethoxycarbonylamino]-1 ,5-dimethyl-pyrazol-3-ylibenzoyl]am ino]-344-(trifluoromethyl)phenyl]propanoic acid, 2-[[444-0 -(241 uorophenypethoxycarbonyl-am inol- 1, 5-dimethyl-pyrazol-3-yl]benzoynamino]-3-(4-hydroxyphenyl)propanoic acid, 3-(3,4-difluoropheny1)-2-[[44441-(2-fluorophenyl)ethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyl]amino]propanoic acid, 3-(4-bromopheny1)-24[44441-(2-fluorophenypethoxy-carbonylamino]-1 ,5-dimethyl-pyrazol-3-yl]benzoyliamino]propanoic acid, 24[4444142-fluorophenypethoxycarbonylamino]-1 ,5-dimethyl-pyrazol-3-yl]benzoyl]amino]-344-(trifluoromethoxy)phenyl]propanoic acid, 2-{p-[1-methy1-5-methy1-4-(1-phenylethoxy-carbonylam i no)- 1 h-pyrazol-3-yl]benzoylamino}-3-phenylpropionic acid, 3-cyclopropy1-2-{p-[1-methyl-5-methyl-4-(1-phenylethoxycarbonylamino)-1h-pyrazol-3-ylibenzoylamino}-propionic acid, 2-(p-{441-(o-chlorophenyl)ethoxycarbonylami no]-1-methy1-5-methyl- 1 h-pyrazol-3-yl}benzoylamino)-3-phenylpropionic acid, 2-(p-{441-(o-chlorophenypethoxy-carbonylamino]-1-methy1-5-methy1-1h-pyrazol-3-yl}benzoylamino)-3-cyclopropylpropionic acid, 24({p41-methyl-5-methyl-4-(1-phenylethoxycarbonylamino)-1 h-pyrazol-3-ylipheny1}-methypamino]-3-phenylpropionic acid, 3-cyclopropy1-24({p41-methyl-5-methyl-4-(1-phenyl-ethoxycarbonylam ino)- 1 h-pyrazol-3-yl]phenyllmethyDamino]propionic acid, 2-{[(p-{441-(o-
- 88 -chlorophenyl)ethoxycarbonylam ino]-1-methy1-5-methy1-1h-pyrazol- 3-yl}phenyl)m ethyl]-am ino}- 3-phenylpropionic acid, 2-{[(p-{441-(o-chlorophenypethoxycarbonylamino]-1-methyl-5-methyl-1h-pyrazol-3-yl}phenyl)methyl]aminol-3-cyclopropylpropionic acid, 2-({p-[1-methy1-5-methy1-4-(1-phenylethoxycarbonylamino)-1h-pyrazol-3-yl]phenyl}methoxy)-3-phenyl-propionic acid, 3-cyclopropy1-2-({p41-methyl-5-methyl-4-(1-phenylethoxycarbonylam ino)-1h-pyrazol-3-yl]phenyl}methoxy)propionic acid, 2-[(p-{441-(o-chlorophenypethoxycarbonyl-amino]-1-methyl-5-methyl-1h-pyrazol-3-yl}phenyOmethoxy]-3-phenylpropionic acid, 2-[(p-{4-[1-(o-chlorophenyl) ethoxycarbonylam ino]-1-methy1-5-methy1-1h-pyrazol-3-y1}pheny1)-methoxy]-3-cyclopropylpropionic acid, 3-{p-[1-methy1-5-methy1-4-(1-phenylethoxycarbonyl-amino)-1h-pyrazol-3-yl]benzoylamino}-4-phenylbutyric acid, 4-cyclopropy1-3-{p41-methy1-5-methyl-4-(1-phenylethoxycarbonylamino)-1h-pyrazol-3-yl]benzoylaminolbutyric acid, 3-[({p-[1-methy1-5-methy1-4-(1-phenylethoxycarbonylamino)-1h-pyrazol-3-yl]phenyl}rnethypamino]-4-phenylbutyric acid, 4-cyclopropy1-34({p-[1-methyl-5-methyl-4-(1-phenylethoxycarbonyl-amino)-1h-pyrazol-3-yl]phenyl}methypamino]butyric acid, 3-({p41-methy1-5-methy1-4-(1-phenylethoxycarbonylamino)-1h-pyrazol-3-yllphenyl}methoxy)-4-phenylbutyric acid or 4-cyclopropy1-3-({p41-methy1-5-methyl-4-(1-phenylethoxycarbonylamino)-1h-pyrazol-3-yl]phenyllmethoxy)butyric acid.
[0439] 46. A compound of embodiment 30 wherein the compound is 244-[444-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yliphenyliphenyl]acetic acid, 14444-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]phenylicyclopropanecarboxylic acid, 1-14-[4-[5-[1-(2-chlorophenypethoxycarbonylamino]-4-cyano-pyrazol-1-yliphenyl]phenylicyclo-propanecarboxylic acid, 2-[4-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-y1]-phenyl]pheny1]-2-methyl-propanoic acid, 244444541-(2-chlorophenypethoxycarbonyl-amino]-4-cyano-pyrazol-1-yl]phenyl]pheny1]-2-methyl-propanoic acid, 1-{4'44-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-4-biphenylyllcyclopropanecarboxylic acid, 1-(4'-{541-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-y1}-4-biphenyly1)-cyclopropanecarboxylic acid, 1-{3-Fluoro-4'-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-
- 89 -pyrazol- 1 -y1]-4- bi phenylyl}cyclopropanecarboxyl ic acid, 144'4541- (o-C hloro ph enyl) ethoxy-carbonylam ino]-4-fluoro-1 H-pyrazol-1-y1}-3-fluoro-4-biphenylyl)cyclopropanecarboxylic acid, 1 -{2-F1 u oro-4'-[4-fl uoro-5- (1- phenylethoxycarbonyla m ino)- 1 H- pyrazol-1 -y1]-4- bi phenyl yI}-cyclopropaneca rboxyl ic acid, 1 -(4'-{5- [1 -(o-Chlo rophenyl) eth oxycarbonyla m n *441 uoro- 1 H-pyrazo 1- 1 -y1}-241 uoro-4-bi p he nyly1) cyclopropanecarboxyl ic acid, 1 -(2- Chlo ro-4'-{541- (o-chlorophenyl) ethoxycarbo nylam ino]-4-fluoro-1 H-pyrazo 1- 1 -y1}-4-biphenylyl)cyclo propane-carboxylic acid, 1 -(4-{p-[4- F 1 uoro-5- (1 -phenylethoxyca rbonylam ino)-1 H-pyrazol-1-y1]-phenyl}toly1) cyclopropanecarboxylic acid, 1-[4-(p-{5-0-(o-Chlorophenypethoxycarbonyl-aminol-441 uoro- 1 H-pyrazol-1-yl}phenyl)tolyl]cyclopropanecarboxyl ic acid, 1-(p-{5-[5-(1-Phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 1-[p- (5-{5-[1-(o-Ch lorop henyl)ethoxycarbonylam no]- 1 H-pyrazol-1-y1}-2-pyridy1)-phenylicyclopropanecarboxyl ic acid, 1 - (p-{5-[4-M ethy1-5-(1- phenyl ethoxycarbonylam i no)- 1 H -pyrazo I- 1-yI]- 2- pyri dyl}phenyl)cyclopropaneca rboxylic acid, 1-[p-(5-{5-[1-(o-Chloro-phenyl)ethoxycarbonylamino]-4-methyl-1 H-pyrazol-1 -y1}-2- pyridyl) phenyl]cyclop ro pa ne-carboxyl ic acid, 1 -(2- Fl uoro-4-{5-[5-(1 -phenylethoxyca rbonylami no)- 1 H-pyrazol- 1 -y1]-2-pyridyl}phenypcyclopropanecarboxylic acid, 144-(5-{541-(o-Chlorophenypethoxycarbonyl-amino]-1H-pyrazol-1-y11-2-pyridy1)-2-fluorophenylicyclopropanecarboxylic acid, 1-(3-Fluoro-4-{5-[5-(1-phenylethoxycarbonylamino)-1 H-pyrazol- 1-y1]-2- pyridyl}phenyl) cycl opropane-carboxyl ic acid, 1 -[4-(5-{5-[1 -(o-Chlorophenyl)ethoxycarbonylam ino]-1 H -pyrazol- 1 -yI}-2-pyri dyI)-3-uorophenyl]cyclopropanecarboxyl ic acid, 1-(p-{5-[4-Methy1-5-(1-phenylethoxy-carbonylamino)-1 H - pyrazol-1 -y1]-2- pyri dyl}p henyl)cyclopropaneca rboxyl i c acid, 1 -(p-{5-[4-M ethy1-5- (1 -phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridyl}phenyl)cyclopropane-carboxylic acid, 1-[p- (5-{541- (o-Chlorop henyl)ethoxycarbo nylam no]-4- m ethyl- 1 H-pyrazol- 1 -y1}-2-pyridyl)phenylicyclopro pa necarboxylic acid, 1 -(2-F1 uoro-4-{5-[4- m ethy1-5- (1 -phenyl-ethoxyca rbonylam i no)- 1 H- pyrazol- 1-y1]- 2- pyridyl} ph enyl) cyclopropaneca rboxyl ic acid, 1 44- (5-{5-[1- (o-Chlorophenyl)ethoxycarbonylami no]-4- methyl-1 H-pyrazo 1-1 -y1}-2-pyri dy1)-2-
- 90 -fluorophenyl]cyclopropanecarboxylic acid, 1-(3-Fluoro-4-{544-methy1-5-(1-phenylethoxy-carbonylamino)-1H-pyrazol- 1-y1]-2-pyridyllphenyl)cyclopropanecarboxylic acid, 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylam ino]-4-methy1-1H-pyrazol-1-y1}-2-pyridy1)-341 uoro-phenyl]cyclopropanecarboxylic acid, 1-(p-{5-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 1-[p-(5-{5-[1-(o-Chloro-phenypethoxycarbonylami no]-4-fluoro-1H-pyrazol-1-y1}-2-pyridyl)phenylicyclopropane-carboxyl ic acid, 1-(2-Fluoro-4-{5-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 144-(5-{541-(o-Chlorophenypethoxy-carbonylamino]-4-fluoro-1H-pyrazol-1-y1}-2-pyridy1)-2-fluorophenylicyclopropanecarboxylic acid, 1-(3-Fluoro-4-{5-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y11-2-pyridyl}phenyl)cyclopropanecarboxylic acid, 144-(5-{541-(o-Chlorophenypethoxycarbonyl-am ino]-4-fluoro-1H-pyrazol-1-y11-2-pyridy1)-3-fluorophenyl]cyclopropanecarboxylic acid, 1-(p-{5-[4-Cyano-5-(1-phenylethoxycarbonylam ino)-1H-pyrazol-1-y1]-2-pyridyl}phenyl)cyclo-propanecarboxylic acid, 14p-(5-{541-(o-Chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-y1}-2-pyridyl)phenylicyclopropanecarboxylic acid, 1-(4-{544-Cyano-5-(1-phenyl-ethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-2-fluorophenyl)cyclopropanecarboxylic acid, 1-[4-(5-{5-[-(o-Chlorophenypethoxycarbonylamino]-4-cyano-1H-pyrazol-1-y1}-2-pyridy1)-2-fluorophenylicyclopropanecarboxylic acid, 1-(4-{544-Cyano-5-(1-phenylethoxy-carbonylam ino)-1H-pyrazol-1-y1]-2-pyridy1}-3-fluorophenyl)cyclopropane-carboxylic acid or 144-(5-{5-[1-(o-Chlorophenypethoxycarbonylamino]-4-cyano-1H-pyrazol-1-y1}-2-pyridy1)-3-fluorophenylicyclopropanecarboxylic acid.
[0440] 47. A compound of embodiment 30 wherein the compound is 3-pheny1-2-[[4-[5-(1-phenylethoxycarbonylamino)oxazol-4-yl]benzoyl]amino]propanoic acid, 3-cyclopropy1-2-[[4-[5-(1-phenylethoxycarbonylamino)oxazol-4-yl]benzoyl]amino]propanoic acid, 4-pheny1-24[445-(1-phenylethoxycarbonylamino)oxazol-4-yl]benzoyl]amino]butanoic acid, 3-phenoxy-2-[[445-(1-phenylethoxycarbonylamino)oxazol-4-yl]benzoyllamino]propanoic acid, 3-Pheny1-2-[({p-[5-(1-
- 91 -phenylethoxycarbonylamino)-1,3-oxazol-4-yl]phenyl}methyl)-amino]propionic acid, 3-Cyclopropy1-2-[({p-[5-(1-phenylethoxycarbonylam ino)- 1, 3-oxazol-4-yl]pheny1}-methyl)amino]propion ic acid, 3-Pheny1-2-({p45-(1-phenylethoxycarbonyl-amino)-1,3-oxazol-4-yl]phenyl}methoxy)propionic acid, 4-Pheny1-3-({p45-(1-phenylethoxy-carbonylamino)-1,3-oxazol-4-yl]phenyl}methoxy)butyric acid or 4-Cyclopropy1-3-({p-[5-(1-phenylethoxycarbonyl-amino)- 1, 3-oxazol-4-yl]phenyl}methoxy)butyric acid.
[0441] 48. A compound of embodiment 30 wherein the compound is 2-[[441-methyl-5-(1-phenylethoxycarbonylamino)imidazol-4-yl]benzoyl]amino]-3-phenyl-propanoic acid, 3-cyclopropy1-24[441 -methy1-5-(1-phenylethoxycarbonylam ino)im idazol-4-ylibenzoy1)-am ino]propanoic acid, 24[441-methy1-541-phenylethoxycarbonylamino)imidazol-4-yl]benzoyliamino]-4-phenyl-butanoic acid, 24[4-0-methyl-5-(1-phenylethoxycarbonyl-amino)imidazol-4-ylibenzoyl]amino]-3-phenoxy-propanoic acid, 2-[({p-[1-Methy1-5-(1-phenylethoxycarbonylamino)-1H-imidazol-4-yl]phenyl}methypamino]-3-phenylpropionic acid, 3-Cyclopropy1-2-[({p-[1-methy1-5-(1-phenylethoxycarbonylam ino)-1H-imidazol-4-yl]phenyl}methyl)amino]propionic acid, 2-({p41-Methy1-5-(1-phenylethoxycarbonylamino)-1H-imidazol-4-yl]phenyl}methoxy)-3-phenylpropionic acid, 3-Cyclopropy1-2-({p-[1-methy1-5-(1-phenylethoxycarbonylamino)-1H-imidazol-4-yl]phenyl}methoxy)propionic acid, 3-[({p-[1-Methy1-5-(1-phenylethoxycarbonylamino)-1H-imidazol-4-yl]phenyl}methypamino]-4-phenylbutyric acid, 4-Cyclopropy1-3- [({p-[1- methy1-5-(1-phenylethoxycarbonylamino)- 1H- imidazol-yl]phenyl}methyl)amino]butyric acid, 3-({p-[1-Methy1-5-(1-phenylethoxycarbonyl-amino)-1H-imidazol-4-yl]phenyl}methoxy)-4-phenylbutyric acid or 4-Cyclopropy1-3-({p-[1-methy1-5-(1-phenylethoxycarbonylamino)-1H-imidazol-4-yl]phenyl}methoxy)butyric acid.
[0442] 49. A compound of embodiment 30 wherein the compound is 2-[[4-[1,2-dimethy1-3-oxo-5-(1-phenylethoxycarbonylamino)pyrazol-4-yl]benzoyl]amino]-3-phenyl-propanoic acid, 3-cyclopropy1-24[4-[1,2-dimethyl-3-oxo-5-(1-phenylethoxycarbonylam ino)pyrazol-4-yl] benzoyliami no]propanoic acid, 24[441,2-di methy1-3-oxo-5-(1-phenylethoxycarbonyl-
- 92 -am i no)pyrazol-4-yl]benzoyl]am ino]-4-phenyl-butanoic acid, 24[441,2- dim ethy1-3-oxo-5-(1-phenylethoxycarbonylamino)pyrazol-4-yl]benzoyl]arnino]-3-phenoxy-propanoic acid, 2-[({p-[1,2-D i methy1-3-oxo-5-(1- phenylethoxyca rbonylam no)- 1, 2- di hyd ropyrazo 1-4-y1]- p he ny1}-methyl)a mi no]-3-p henyl propi on ic acid, 3-Cyclopropy1-2- [({p- [1, 2- di methy1-3- oxo- 5- (1-phenylethoxycarbonylamino)-1,2-dihydropyrazol-4-yl]phenyl}methypamino]propionic acid, 2-({p-[1,2- Dim ethy1-3-oxo-5-(1- phenylethoxycarbonylam i no)- 1,2- di hydropyrazol-4-y1]-phenyl}m ethoxy)-3- phenyl pro pioni c acid, 3-Cyclopropy1-2-({p41,2-dimethyl-3-oxo-5-(1-phenylethoxycarbonylamino)-1,2-dihydropyrazol-4-yl]phenyl}methoxy)propionic acid, 3-[({p-[1,2-Di m ethy1-3-oxo-5-(1-phenyl ethoxycarbonylam no)-1,2-di hyd ropyrazol-4-y1]-pheny1}-m ethyl) am i no]-4-phenyl butyric acid, 4-Cycl opropy1-34({p41,2-d m ethy1-3-oxo-5- (1-phenyl-ethoxycarbonylamino)-1,2-dihydropyrazol-4-yl]phenyl}methypamino]butyric acid, 3-({p-[1,2-Di methy1-3-oxo-5-(1-phenylethoxycarbonyl am i no)-1,2-dihyd ropyrazo 1-4-y1]-p he ny1}- m ethoxy)-4-phenyl butyric acid or 4-Cyclopropy1-3-({p-[1,2-dimethy1-3-oxo-5-(1-phenylethoxy-carbonylamino)-1,2-dihydropyrazol-4-yl]phenyl}methoxy)butyric acid.
[0443] 50. A compound of embodiment 30 wherein the compound is 3-pheny1-2-[[4-[5-(1-phenylethoxycarbonylamino)pyrimidin-4-yl]benzoyliamino]propanoic acid, 3-cyclopropy1-24[4-[5-(1-phenylethoxycarbonylamino)pyrimidin-4-yl]benzoyl]amino]propanoic acid, 4-pheny1-2-[[4-[5-(1-phenylethoxycarbonylamino)pyrimidin-4-yl]benzoyl]amino]butanoic acid, 3-phenoxy-24[4-[5-(1-phenylethoxycarbonylamino)pyrimidin-4-yl]benzoyl]aminoi-propanoic acid, 3-Pheny1-2-[({p-[5-(1- p he nylethoxyca rbonyla mi no)-4- pyri m idinyl]phenylymethyl)-am no]pro pi on ic acid, 3-Cyclopropy1-2-[({p-[5-(1-phenylethoxycarbonylam ino)-4- pyrim idiny1]-phenyl}methyl)amino]propionic acid, 3-Pheny1-2-({p45-(1-phenylethoxy-carbonylamino)-4-pyrimidinyl]phenyl}methoxy)propionic acid, 3-Cyclopropy1-2-({p45-(1-phenylethoxycarbonyl-amino)-4-pyrimidinyl]phenyl}methoxy)propionic acid, 4-Pheny1-34({p45-(1-phenylethoxy-carbonyl am ino)-4-pyrim id i nyl]phenyllm ethyl) am ino]butyric acid, .. 4-Cyclopropy1-3-[({p-[5-(1-phenylethoxycarbonylam i no)-4- pyrim idi nyl]phenyl}methypam noi- butyric acid, 4-Phenyl-3-({p-[5-
- 93 -(1-phenylethoxycarbonylamino)-4-pyrimidinyl]phenylymethoxy)butyric acid, 4-Cyclopropy1-3-({p-[5-(1-phenylethoxycarbonylannino)-4-pyrimidinyl]phenyl}methoxy)butyric acid, 24[446-methy1-5-(1-phenylethoxycarbonyl-amino)pyrimidin-4-yl]benzoyl]amino]-3-phenyl-propanoic acid, 3-cyclopropy1-24[446-methy1-5- (1-phe nyl ethoxycarbonylam no)- pyri m idi n-4-ylibenzoyl]amino]propanoic acid, 24[4-[6-methy1-5-(1-phenylethoxycarbonyl-amino)pyrimidin-4-yl]benzoyl]amino]-4-phenyl-butanoic acid or 24[446-m ethyl-5- (1- phenyl-ethoxycarbonylamino)pyrimidin-4-yl]benzoy1]-amino]-3-phenoxy-propanoic acid.
[0444] 51. A compound of embodiment 30 wherein the compound is 3-pheny1-2-[[4-[4-(1-phenylethoxycarbonylam i no)pyri midi n-5-yl]benzoyl] am ino]propanoic acid, 3-cycl opropy1-24[444-(1-phenylethoxycarbonyla m i no) pyri m id i n-511] be nzoyl]ami no]propanoi c acid, 4-pheny1-24[444-(1-phenylethoxycarbonylamino)pyrimidin-5-yl]benzoyl]amino]butanoic acid or 3-phenoxy-2-[[4-[4-(1-phenylethoxycarbonylamino)pyrimidin-5-yl]benzoyliamino]-propanoic acid, [0445] 52. A compound of embodiment 30 wherein the compound is 3-pheny1-2-[[4-[3-(1-phenylethoxycarbonylamino)pyrazin-2-yl]benzoyliamino]propanoic acid, 3-cyclo propy1-24[443-( 1-phenylethoxycarbonyla m i no) pyrazi n-2-yl] be nzoyl]am no]propanoi c acid, 4-pheny1-2-[[4-[3-(1-phenylethoxycarbonylamino)pyrazin-2-yl]benzoyl]amino]butanoic acid or 3-phenoxy-24[443-(1-phenylethoxycarbonyl am i no) pyrazi n-2-yl]benzoyl] am i no] propa no ic acid.
[0446] 53. A compound of embodiment 30 wherein the compound is 1-{p-[3-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]pheny1}-4-piperidinecarboxylic acid, (1-{p43-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]pheny1}-4-piperidypacetic acid, 1-(1-{p43-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazolylipheny1}-4-piperidyl)cyclo-propanecarboxylic acid, [1-(1-{p43-Methyl-4-(1-phenylethoxyca rbonyl am ino)-5-isoxazoly1]- pheny1}-4-pi peri dyl)cycl opropyl]acetic acid, 1-{543-Methy1-4-(1-phenylethoxycarbonyl-amino)-5-isoxazoly1]-2-pyridy1}-4-piperidinecarboxylic acid, ( 1-{543-M ethy1-44 1- phenyl-ethoxycarbonylam ino)-5-isoxazoly1]-2-pyridy1}-4-piperidyl)acetic acid, 1-(1-{543-Methy1-4-(1-phenylethoxycarbonyl am i no)-5-isoxazoly1]-2- pyridy1}-4- pi peri dyl)cyclopropanecarboxyl ic acid, [1-
- 94 -(1-{543-Methy1-4-(1- phenylethoxycarbonylamino)-5-isoxazoly11-2-pyridy11-4-piperidyl)cyclopropyl]acetic acid, 1-{p43-Fluoro-4-(1- phenylethoxyca rbonylam ino)-5-isoxazolyl]pheny1}-4-piperidinecarboxylic acid, (1-{p43- F luoro-4-(1 -phenyl ethoxycarbonyl-am ino)-5-isoxazo lyl]pheny1}-4- pi peridypaceti c acid, 1 -(1-{ p-[3- Fl uo ro-4-(1- p henylethoxy-carbonyl am i no)- 5- isoxazo lyl] phenyI}-4-piperidyl)cyclopropanecarboxylic acid, [1-(1-{p43-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyllpheny1}-4-piperidyl)cyclopropyl]acetic acid, 1-{5-[3- Fluoro-4-(1- phenyl ethoxycarbonylam ino)-5- isoxazoly1]-2- pyridyI}- 4-pi peridi ne- carboxyl ic acid, (1-{543-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridy1}-4-piperidyl)acetic acid, 1- (1-{5-[3- F luoro-4-(1- phenylethoxycarbonylam i n o)-5-isoxazolyI]-2-pyridyI}-4-pi peridyl)cycl opropanecarboxyl ic acid, [1-(1-{543-Fluoro-4-(1-phenylethoxy-carbonylamino)-5-isoxazolyI]-2-pyridy1}-4-piperidyl)cyclopropyl]acetic acid, 1 -{p-[3-Cyano-4-(1 -phenylethoxycarbonylam ino)-5-isoxazolyl]pheny1}-4-pi peridinecarboxylic acid, (1-{p13-Cyan o-4-(1-phe nylethoxyca rbonylam no)-5- i soxazol yl]phenyI}-4-pi peridyl) acetic acid, 1-(1-{p-p-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolylipheny11-4-piperidypcyclo-propanecarboxylic acid, [1-(1-{p43-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-pheny1}-4-piperidyl)cyclopropyl]acetic acid, 1-{543-Cyano-4-(1-phenylethoxycarbonyl-amino)-5-isoxazoly1]-2-pyridy1}-4-piperidinecarboxylic acid, (1 -{543-Cyano-4-(1- phenyl-ethoxycarbonylam ino)-5-isoxazoly1]-2-pyridy1}-4-piperidyl)acetic acid, 1-(1-{543-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyI]-2-pyridy1}-4-piperidyl)cyclopropanecarboxylic acid, [1-(1-{5-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridy1}-4-piperidyl)cyclopropyl]acetic acid, 1-{p-[5-(1- Phenylethoxycarbonylam i no)-1 H- pyrazol-1-yl]pheny11-4- pi perid necarboxyl ic acid, (1 -{p-[5-(1-Phenylethoxycarbonylamino)-1 H-pyrazol-1 -yl] ph e nyI}-4- pi peridyl) acetic acid, 1-(1-{p-[5- (1-P henylethoxyca rbonyla m no)-1 H-pyrazol-1 -yl] phenyl}-4-piperidyl) cyclopropanecarboxylic acid, [1- (1-{p-[5-(1-Phenylethoxycarbo nyl-a m ino)-1 H-pyrazol-1-yl]pheny1}-4-piperidyl)cyclopropyl]acetic acid, 1-{5-[5-(1-Phenylethoxy-carbonylamino)-1H-pyrazol-1-y1]-2-pyridyI}-4- pi peridi neca rboxyl i c acid, (1-{5-[5-(1- Phenyl-ethoxycarbonylamino)-1 H-pyrazol-1-y1]-2-
- 95 -pyridyI}-4-piperidyl)acetic acid, 1-(1-{545-(1-Phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridyI}-4-piperidyl)cyclopropanecarboxylic acid, [1-(1-{5-[5-(1-Phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-4-piperidy1)-cyclopropyl]acetic acid, 1-{p-[4-Methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-4-piperidinecarboxylic acid, (1 -{p-[4-Methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-4-piperidyl)acetic acid, 1-(1-{p-[4-Methy1-5-(1-phenylethoxy-carbonylamino)-1H-pyrazol-1-yl]pheny1}-4-piperidyl)cyclopropanecarboxylic acid, [1-(1-{p-[4-Methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-Apheny1}-4-piperidyl)cyclopropyHacetic acid, 1-{5-[4-Methy1-5-(1-phenylethoxycarbonylamino)-1 H-pyrazol-1-y1]-2-pyridy1}-4-piperidinecarboxylic acid, (1-{5- [4-Methy1-5-(1 -p henylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-4-piperidyl)acetic acid, 1-(1-{5-[4-Methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy11-4-piperidyl)cyclopropanecarboxylic acid, [1-(1-{5-[4-Methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-4-piperidyl)cyclopropyllacetic acid, 1-{p-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1 H-pyrazol-1-yl]pheny1}-4-piperidine-carboxylic acid, .. (1-{p-[4-Fluoro-5-(1 -phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny11-4-piperidypacetic acid, 1-(1-{p-[4- Fluoro-5-(1-phenylethoxycarbonylamino)-1 H-pyrazol-1-yl]pheny1}-4-piperidypcyclopropanecarboxylic acid, [1-(1-{p44-Fluoro-5-(1-phenylethoxy-carbonylamino)-1H-pyrazol-1-ylipheny1}-4-piperidyl)cyclopropyliacetic acid, 1-{5-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1 H-pyrazol-1-y1]-2-pyridy1}-4-piperidinecarboxylic acid, (1-{5- [4-Fluoro-5-(1 -phenylethoxycarbonylamino)-1 H-pyrazol- 1-y1]-2-pyridy1}-4-piperidyl)acetic acid, 141-{544- Fluoro-5-(1- phenylethmcarbonyla mino)-1 H-pyrazol-1-y1]-2-pyridy11-4-piperidyl)cyclopropanecarboxylic acid, [1-(1-{544-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-4-piperidyl)cyclopropyllacetic acid, 1-{p-[4-Cyano-5-(1-phenyl-ethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-4-piperidinecarboxylic acid, (1-{p44-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-ylipheny11-4-piperidyl)acetic acid, 1-(1-{p44-Cyano-541 -phenylethoxycarbonylam ino)-1 H-pyrazol-1-yl]pheny1}-4-piperidyl)cyclopropane-carboxyl ic
- 96 -acid, [1-(1-{p-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-phenyl}-4-piperidyl)cyclopropyl]acetic acid, 1-{544-Cyano-5-(1-phenylethoxycarbonyl-amino)-1H-pyrazol-1-y1]-2-pyridy1}-4-piperidinecarboxylic acid, (1-{5-[4-Cyano-5-(1-phenyl-ethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-4-piperidypacetic acid, 1-(1-{544-Cyano-5-(1-phenylethoxycarbonylami no)- 1H- pyrazol-1-y11-2-pyridy1}-4- pi peridyl)cyclopropane-carboxylic acid or [1-(1-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-4-piperidyl)cyclopropyl]acetic acid.
[0447] 54. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Table 1 and one or more pharmaceutically acceptable excipients.
[0448] 55. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 31 and one or more pharmaceutically acceptable excipients.
[0449] 56. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 32 and one or more pharmaceutically acceptable excipients.
[0450] 57. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 33 and one or more pharmaceutically acceptable excipients.
[0451] 58. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 34 and one or more pharmaceutically acceptable excipients.
[0452] 59. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 35 and one or more pharmaceutically acceptable excipients.
- 97 -[0453] 60. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 36 and one or more pharmaceutically acceptable excipients.
[0454] 61. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 37 and one or more pharmaceutically acceptable excipients.
[0455] 62. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 38 and one or more pharmaceutically acceptable excipients.
[0456] 63. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 39 and one or more pharmaceutically acceptable excipients.
[0457] 64. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 40 and one or more pharmaceutically acceptable excipients.
[0458] 65. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 41 and one or more pharmaceutically acceptable excipients.
[0459] 66. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 42 and one or more pharmaceutically acceptable excipients.
[0460] 67. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 43 and one or more pharmaceutically acceptable excipients.
- 98 -[0461] 68. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 44 and one or more pharmaceutically acceptable excipients.
[0462] 69. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 45 and one or more pharmaceutically acceptable excipients.
[0463] 70. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 46 and one or more pharmaceutically acceptable excipients.
[0464] 71. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 47 and one or more pharmaceutically acceptable excipients.
[0465] 72. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 48 and one or more pharmaceutically acceptable excipients.
[0466] 73. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 49 and one or more pharmaceutically acceptable excipients.
[0467] 74. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 50 and one or more pharmaceutically acceptable excipients.
[0468] 75. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 51 and one or more pharmaceutically acceptable excipients.
- 99 -[0469] 76. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 52 and one or more pharmaceutically acceptable excipients.
[0470] 77. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of embodiment 53 and one or more pharmaceutically acceptable excipients.
[0471] 78. A method comprising administering an effective amount of a Formula [-XII
compound to a subject having a LPA-dependent or LPA-mediated disease or condition.
[0472] 79. The method of embodiment 78 wherein the LPA-dependent or LPA-mediated disease or condition is a disease with fibrosis of the organs.
[0473] 80. The method of embodiment 79 wherein the fibrosis is of the liver, kidney, lung, heart, eye and the like.
[0474] 81. The method of embodiment 78 wherein the LPA-dependent or LPA-mediated disease or condition is chronic pain [0475] 82. The method of embodiment 78 wherein the LPA-dependent or LPA-mediated disease or condition is pruritus.
[0476] 83. The method of embodiment 78 wherein the LPA-mediated disease is a proliferative disease including cancer (solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL) and the like) and invasive metastasis of cancer cell, including ovarian, breast and triple negative breast cancer and the like, [0477] 84. The method of embodiment 78 wherein the LPA-mediated disease is an inflammatory disease including psoriasis, nephropathy, pneumonia and the like, [0478] 85. The method of embodiment 78 wherein the LPA-mediated disease is a gastrointestinal disease such as inflammatory bowel disease,
- 100 -[0479] 86. The method of embodiment 78 wherein the LPA-mediated disease is an ocular disease including age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreoretinopathy (PVR), cicatricial pemphigoid, glaucoma filtration surgery scarring, uveitis and the like, [0480] 87. The method of embodiment 78 wherein the LPA-mediated disease is a liver disease including acute hepatitis, chronic hepatitis, liver fibrosis, liver cirrhosis, cholestatic pruritus, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, and the like, [0481] 88. The method of embodiment 78 wherein the LPA-mediated disease is a renal disease including chronic kidney disease, end stage renal disease, uremic pruritus, nephropathy including diabetic nephropathy and the like, [0482] 89. The method of embodiment 78 wherein the LPA-mediated disease is a skin disease including scleroderma, skin scarring, atopic dermatitis, psoriasis and the like, [0483] 90. The method of any one of embodiments 78-89 wherein the subject is a human.
[0484] 91. The method of any one of embodiments 78-90 wherein the compound is selected from Table 1.
[0485] 92. The method of any one of embodiments 78-90 wherein the compound is 1-(4-{4-[1-(2-Chloro- phenyl)-ethoxycarbonylam ino]-3-methyl-isoxazol-5-y1}-benzoylamino)-cyclo-propanecarboxylic acid, 2-(4-{4-[1-(2-Chloro-phenyl)-ethoxycarbonyl-amino]-3-methyl-iso-xazol-5-yll-benzoylamino)-indan-2-carboxylic acid, 2-(S)- (4-{4-[(R,S)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl acetic acid, 2-(R)- (4-{4-[(R,S)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-iso-xazol-5-y1}-benzoylamino) phenyl propanoic acid, 2(R)-([4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)isoxazol-5-ylibenzoyl]amino]-3-phenyl-propanoic acid, 2(S)-[[443-methyl-44(R)-phenylethoxycarbonyl-amino)isoxazol-5-ylibenzoyl]amino]-3-phenyl-propanoic acid, (R)-2-{443-Methyl-4-((S)-1-phenyl-
- 101 -ethoxycarbonylam ino)- isoxazo 1-5-y1]- benzoy lam in o}-3-p henyl- propion ic acid, (S)-2-{4-[3- Methyl-4-((S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1Fbenzoylamino}-3-phenyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-phenyl-propionic acid , (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylam ino]-3-methyl-isoxazol-5-y1}-benzoylam ino)-3-(4-fluoro-pheny1)-propionic acid, (R)-3-(4-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}- benzoyl am i no)- propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(3,4-difluoro-pheny1)-propionic acid , (R)-3-(2-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid , (R)-3-(4-Bromo-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(2-fluoro-pheny1)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-p-tolyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylam ino]-3- methyl- isoxazol-5-y1}- benzoyl am ino)- 3-(4-trifluorom ethyl-pheny1)-pro picnic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-cyano-pheny1)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylam ino]-3- methyl- isoxazol-5-y1}- benzoyl amino)-3-cyclo propyl- propi on ic acid , (R)- 24[442, 5-d imethy1-44(R)- 1- phenylethoxycarbonylam ino)pyrazol-3- yl]benzoyl]am ino]-3- phenyl- propanoic acid, (R)-24[4-[2,5-dimethy1-44(R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid, (R)- 3-(4-bromopheny1)-2-[[4-[2,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]arnino]propanoic acid, (R)- 3-(4-chloropheny1)-2-[[4-[2,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-yl]benzoyl]amino]propanoic acid, (R)- 3-(3,4-difluoropheny1)-24[442,5-dimethyl-44(R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)-24[441,5-dimethy1-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyllamino]-3-phenyl-propanoic acid, (R)-
- 102 -24[441, 5-di methy1-4-((R)-1-phenylethoxycarbonylam i no)pyrazol-3-yl]benzoyl]ami no]-3-(4-fluorophenyl)propanoic acid, (R)- 3-(4-bromopheny1)-2-[[441,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyliamino]propanoic acid, ((R)- 3-(4-chloropheny1)-24[441,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyliamino]propanoic acid, (R)- 3-(3,4-difluoropheny1)-2-[[441,5-dimethyl-44(R)-1-phenylethoxycarbonyl-amino)pyrazol-3-ylibenzoyliamino]propanoic acid, (R)- 2-(4-{5-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-methyl-pyrazol-1-y1}-benzoylamino)-3-phenyl-propionic acid, (R)-2-{4-[3-Methyl-4- ((R)- 1-phenyl- ethoxycarbonylam ino)- isoxazol-5-y1]-benzylam i no}-3-phenyl-propionic acid, (R)-3-(2-Fluoro-pheny1)-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzylamino}-propionic acid, (R)-2-{443-Methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-3-(4-trifluoromethyl-pheny1)-propionic acid, (R)-3-Cyclopropy1-2-{4-[3-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y11-benzylamino}-propionic acid, (R)-3-(2-Chloro-pheny1)-2-{4-[3-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y11-benzylamino}-propionic acid, (R)-3-(4-Chloro-pheny1)-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzylamino}-propionic acid, (R)- 2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-phenyl-propionic acid, (R)- 2-(4{4-[(R)_1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-(2-fluoro-pheny1)-propionic acid, (R)- 2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yll-benzylamino)-3-(4-trifluoromethyl-pheny1)-propionic acid, (R)- 3-(2-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yll-benzylamino)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-cyclopropyl-propionic acid, 2-{443-Methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzyloxy}-3-phenyl-propionic acid, 2-{4-[3-Methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzyloxy}-3-phenyl-propionic acid, (RS)-3-Cyclopropy1-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y11-benzyloxy}-
- 103 -propionic acid, (RS)-3-Cyclopropy1-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzyloxy}-propionic acid, 244-[445-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyliphenyl]acetic acid, (R)-1-[4-[4-[1,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yliphenyliphenyl-cyclopropane carboxylic acid, (R)-1-[4-[4-[2, 5-d imethy1-4-(1-phenylethoxycarbonylam ino)-pyrazol-3-yl]phenyl]phenyl]cyclopropane carboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-pheny1)-ethoxycarbonyl-am ino]-4-fluoro-pyrazol-1-y1}-3-fluoro-bipheny1-4-y1)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-2-fluoro-bipheny1-4-y1)-cyclo-propanecarboxylic acid, (R)-1-(2-Chloro-4'-{541-(2-chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-bipheny1-4-y1)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-2-methyl-bipheny1-4-y1)-cyclopropanecarboxylic acid, (R)-1-(4'-{541 -(2-Chloro-pheny1)-ethoxy-carbonylamino]-4-fluoro-pyrazol-1-y1}-biphenyl-4-y1)-cyclopropanecarboxylic acid, (R)- 1-{4'45-(1-Phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-y1]-bipheny1-4-y1}-cyclo-propanecarboxylic acid, (R)-1-{2-Fluoro-4'-[5-(1-phenyl-ethoxycarbonylamino)-4-trifluoro-methyl-pyrazol-1-y1]-bipheny1-4-y1}-cyclopropanecarboxylic acid, (R)-1-(4-{545-(1-Phenyl-ethonicarbonylamino)-pyrazol-1-yli-pyridin-2-y1}-pheny1)-cyclopropanecarboxylic acid, [0486] 93. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 31.
[0487] 94. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 32.
[0488] 95. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 33.
[0489] 96. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 34.
- 104 -[0490] 97. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 35.
[0491] 98. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 36.
[0492] 99. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 37.
[0493] 100. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 38.
[0494] 101. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 39.
[0495] 102. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 40.
[0496] 103. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 41.
[0497] 104. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 42.
[0498] 105. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 43.
[0499] 106. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 44.
[0500] 107. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 45.
[0501] 108. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 46.
- 105 -[0502] 109. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 47.
[0503] 110. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 48.
[0504] 111. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 49.
[0505] 112. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 50.
[0506] 113. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 51.
[0507] 114. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 52.
[0508] 115. The method of any one of embodiments 78-90 wherein the compound is selected from embodiment 53.
[0509] 116. A composition comprising, consisting essentially of or consisting of one or more compounds of Formula (1-XII) and one or more agents currently used to treat a LPA -dependent or LPA -mediated disease or a disease or condition described herein.
[0510] 117. A pharmaceutically acceptable formulation comprising, consisting essentially of or consisting of one or more compounds of Formula (1-X11), one or more agents currently used to treat a LPA -dependent or LPA -mediated disease and one or more pharmaceutically acceptable excipients.
[0511] 118. A method comprising administering in combination with or co-administrating a compound of Formula (I-X11) to a subject with a LPA-dependent or LPA-mediated disease or condition and a currently used agent to treat a LPA -dependent or LPA -mediated disease
- 106 -[0512] The one or more additional therapeutically active agents other than compounds of Formula (I-X11) are selected from: corticosteroids, immunosuppressants, analgesics, anti-cancer agents, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, platelet activating factor receptor antagonists, monoacylglycerol kinase inhibitors, phospholipase A1 inhibitors, phospholipase A2 inhibitors, and lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors, decon-gestants, mast cell stabilizers, antihistamines, mucolytics, anticholinergics, antitussives, expectorants, and 13-2 agonists.
[0513] In preferred embodiments the currently used agent(s) are selected from those described in the Merck Index known to affect lysophosphatidic acid receptor signaling. In other preferred embodiments the Formula (I-X11) compound is selected from Table 1.
[0514] In other embodiments, therapies which combine a compound of Formula (I-X11), with currently used agents that act on differing signalling pathways to the LPA
synthesis or signalling pathway so as to provide complementary clinical outcomes, are encompassed herein for treating LPA-dependent or LPA-mediated diseases or conditions.
[0515] Examples of additional therapeutic agents include, but are not limited to, any of the following: gossypol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib, geldanamycin, 17-N-Allylamino-17 -Demethoxygeldanamycin (17 -AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, or PD 184352, TaxolTM
(paclitaxel), and analogs ofTaxolTm, such as TaxotereTm, U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600 125, BAY 43-9006, wortmannin, or LY294002, Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin;
aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin;
ametantrone acetate;
- 107 -amino glutethimide; amsacrine; anastrozole; anthramycin; asparaginase;
asperlin; azacitidine;
azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine;
busulfan; cactinomycin;
calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride;
carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate;
cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride;
decitabine;
dexormaplatin; deazaguanine; deazaguanine mesylate; diaziquone; doxorubicin;
doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate;
duazomycin;
edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate;
epipropidine;
epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine;
estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine;
fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate;
fluorouracil;
flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride;
hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin II
(including recombinant interleukin II, or rIL2), interferon alfa-2a; interferon alfa-2b;
interferon alfa-n1;
interferon alfa-n3; interferon beta-I a; interferon gamma-I b; iproplatin;
irinotecan hydrochloride;
lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride;
lometrexol sodium;
lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril;
mercaptopurine;
methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide;
mitocarcin;
mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane;
mitoxantrone hydrochloride;
mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran;
pegaspargase; peliomycin;
pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan;
piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin;
prednimustine;
procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin;
riboprine;
rogletimide; safingol; safingol hydrochloride; semustine; simtrazene;
sparfosate sodium;
- 108 -sparsomycin; Spiro germanium hydrochloride; spiromustine; spiroplatin;
streptonigrin;
streptozotocin; sulofenur; talisomycin; tecogalan sodium; tegafur;
teloxantrone hydrochloride;
temoporfm; teniposide; teroxirone; testolactone; thiamiprine; thioguanine;
thiotepa; tiazofurin;
tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate;
trimetrexate;
trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa;
vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine;
vindesine sulfate;
vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride, mechloroethamine, cyclophosphamide, chlorambucil, meiphalan, etc.), ethylenimine, hexamethlymelamine, thiotepa, busulfan), carmustine, lomusitne, semustine, streptozocin, ortriazenes, dacarbazine, methotrexate, fluorouracil, floxouridine, Cytarabine, mercaptopurine, thioguanine, pentostatin, hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate, estrogens, diethlystilbestrol, ethinyl estradiol, tamoxifen), testosterone propionate, fluoxymesterone, flutamide, leuprolide, cisplatin, carboblatin, mitoxantrone), procarbazine, mitotane, amino glutethimide, Erbulozole, Dolastatin 10, Mivobulin isethionate, Vincristine, NSC-639829, Discodermolide, ABT -751, Altorhyrtin A
and Altorhyrtin C), Spongistatins 1-9, Cemadotin hydrochloride, Epothilone A, Epothilone B, Epothilone C, Epothilone D, Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone AN-oxide, 16-aza-epothilone B, 21aminoepothilone B, 21-hydroxyepothilone D, 26-fluoroepothilone, Auristatin PE, Soblidotin, Cryptophycin 52, Vitilevuamide, Tubulysin A, Canadensol, Centaureidin, Oncocidin Al Fijianolide B, Laulimalide, Narcosine, Nascapine, Hemiasterlin, Vanadocene acetylacetonate, lndanocine Eleutherobins (such as Desmethyleleutherobin, Desacetyleleutherobin, lsoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, Diazonamide A, Taccalonolide A, Diozostatin, (-)-Phenylahistin, Myoseverin B, Resverastatin phosphate sodium, Aprepitant, cannabis, marinol, dronabinol, erythropoetin-a, Filgrastim, rituximab, natalizumab, cyclophosphamide, penicillamine, cyclosporine, nitrosoureas, cisplatin,
- 109 -carboplatin, oxaliplatin, methotrexate, azathioprine, mercaptopurine, pyrimidine analogues, protein synthesis inhibitors, dactinomycin, anthracyclines, mitomycin C, bleomycin, mithramycin, Atgame Thymoglobuline , OKT30, basiliximab, daclizumab, cyclosporin, tacrolimus, sirolimus, Interferons, opioids, infliximab, etanercept, adalimumab, golimumab, leflunomide, sulfasalazine, hydroxychloroquinine, minocycline, rapamicin, mycophenolic acid, mycophenolate mofetil, FTY720, Cyclosporin A (CsA) or tacrolimus (FK506), aspirin, salicylic acid, gentisic acid, choline magnesium salicylate, choline salicylate, choline magnesium salicylate, choline salicylate, magnesium salicylate, sodium salicylate, diflunisal, carprofen, fenoprofen, fenoprofen calcium, flurobiprofen, ibuprofen, ketoprofen, nabutone, ketolorac, ketorolac tromethamine, naproxen, oxaprozin, diclofenac, etodolac, indomethacin, sulindac, tolmetin, meclofenamate, meclofenamate sodium, mefenamic acid, piroxicam, meloxicam, valdecoxib, parecoxib, etoricoxib, lumiracoxib, betamethasone, prednisone, alclometasone, aldosterone, amcinonide, beclometasone, betamethasone, budesonide, ciclesonide, clobetasol, clobetasone, clocortolone, cloprednol, cortisone, cortivazol, deflazacort, deoxycorticosterone, desonide, desoximetasone, desoxycortone, dexamethasone, diflorasone, diflucortolone, difluprednate, fluclorolone, fludrocortisone, fludroxycortide, flumetasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin, fluocortolone, fluorometholone, fluperolone, fluprednidene, fluticasone, formocortal , halcinonide, halornetasone, hydrocortisone/cortisol, hydrocortisone aceponate, hydrocortisone buteprate, hydrocortisone butyrate, loteprednol, medrysone, meprednisone, methylprednisolone, methylprednisolone aceponate, mometasone furoate, paramethasone, prednicarbate, prednisone/prednisolone, rimexolone, tixocortol, triamcinolone, ulobetasol, pioglitazone, clofibrate, fenofibrate gemfibrozil, folic acid, isbogrel, ozagrel, ridogrel, dazoxiben, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, nisvastatin, and rosuvastatin, edaravone, vitamin C, TROLOXTm, citicoline and minicycline, (2R)-2-propyloctanoic acid, propranolol, nadolol, timolol, pindolol, labetalol, metoprolol, atenolol, esmolol and acebutolol, memantine, traxoprodil, tirofiban lamifiban, argatroban, enalapril, cyclandelate, losartan,
- 110 -valsartan, candesartan, irbesartan, telmisartan, olmesartan mepyramine (pyrilamine), antazoline, diphenhydramine, carbinoxamine, doxylamine, clemastine, dimenhydrinate, pheniramine, chlorphenamine (chlorpheniramine), dexchlorpheniramine, brompheniramine, triprolidine, cetirizine, cyclizine, chlorcyclizine, hydroxyzine, meclizine, loratadine, desloratidine, promethazine, alimemazine (trimeprazine), cyproheptadine, azatadine, ketotifen, acrivastine, astemizole, cetirizine, mizolastine, terfenadine, azelastine, epinastine, levocabastine, olopatadine, levocetirizine, fexofenadine, rupatadine, bepotastine), mucolytics, anticholinergics, antitussives, analgesics, expectorants, albuterol, ephedrine, epinephrine, fomoterol, metaproterenol, terbutaline, budesonide, ciclesonide, dexamethasone, flunisolide, fluticasone propionate, triamcinolone acetonide, ipratropium bromide, pseudoephedrine, theophylline, montelukast, pranlukast, tomelukast, zafirlukast, ambrisentan, bosentan, enrasentan, sitaxsentan, tezosentan, iloprost, treprostinil, pirfenidone, epinephrine, isoproterenol, orciprenaline, xanthines, zileuton.
[0516] 119. The method of embodiments 116-118 wherein the subject is a human.
[0517] 120. The method of embodiments 116-119 wherein the Formula 1-XII
compound(s) are selected from Table 1.
[0518] 121. The method of embodiments 116-119 wherein the Formula I-XI I
compound(s) are selected from the group consisting of 1-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-cyclo-propanecarboxylic acid, 2-(4-{4-[1-(2-Chloro-phenyI)-ethoxycarbonylam ino]-3-methyl-isoxazol- 5-yI}-benzoylam i no)- indan-2-carboxyl ic acid, 2-(S)- (4-{4-[(R, S)-1-(2-Chloro-pheny1)-ethoxycarbonylam no]-3-methyl- isoxazol-5-y1}-benzoylam ino) phenyl acetic acid, 2-(R)- (4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl propanoic acid, 2(R)4[443-methy1-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yllbenzoyl]amino]-3-phenyl-propanoic acid, 2(S)4[4-[3-methy1-4-((R)-phenylethoxycarbonyl-amino)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid, (R)-2-{443-Methy1-44(S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzoylamino}-3-
- 111 -phenyl-propionic acid, (S)-2-{443-Methy1-44(S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzoylamino}-3-phenyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-phenyl-propionic acid , (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-fluoro-phenyt)-propionic acid , (R)-3-(4-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid , (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(3,4-difluoro-pheny1)-propionic acid , (R)-3-(2-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid , (R)-3-(4-Bromo-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylam ino)-3-(2-fluoro-pheny1)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yll-benzoylamino)-3-p-tolyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-trifluoromethyl-pheny1)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-cyano-pheny1)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-cyclopropyl-propionic acid (R)-2-[[4-[2, 5-dim ethy1-4-((R)-1 -phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-phenyl-propanoic acid, (R)-2- [[4-[2, acid, (R)- 3-(4-bromopheny1)-2-R4-[2, 5-di methy1-4-((R)- 1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)- 3-(4-chloropheny1)-24[4-[2,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyliamino]propanoic acid, (R)- 3-(3,4-difluoropheny1)-2-[[442,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-ylibenzoyliamino]propanoic acid, (R)-2-[[4-[1,5-dimethy1-44(R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyliamino]-3-phenyl-propanoic
- 112 -acid, (R)-24[441 ,5-dimethy1-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyliamino]-3-(4-fluorophenyl)propanoic acid, (R)- 3-(4-bromopheny1)-2-[[441,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-ylibenzoyl]amino]propanoic acid, (R)- 3-(4-chloropheny1)-24[441,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-ylibenzoyliamino]propanoic acid, (R)- 3-(3,4-difluoropheny1)-2-[[4-[1,5-dimethyl-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-ylibenzoyliamino]propanoic acid, (R)- 2-(4-{5-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-methyl-pyrazol-1-y1}-benzoylamino)-3-phenyl-propionic acid, (R)-2-{443-Methy1-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-3-phenyl-propionic acid, (R)-3-(2-Fluoro-pheny1)-2-{4-[3-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylaminol-propionic acid, (R)-2-{4-[3-Methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-3-(4-trifluoromethyl-pheny1)-propionic acid, (R)-3-Cyclopropy1-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y11-benzylaminoypropionic acid, (R)-3-(2-Chloro-pheny1)-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-propionic acid, (R)-3-(4-Chloro-pheny1)-2-{4-[3-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzylam ino}-propionic acid, (R)- 2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-0-benzylamino)-3-phenyl-propionic acid, (R)- 2-(4-{4-[(R)_1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-(2-fluoro-pheny1)-propionic acid, (R)- 2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-(4-trifluoromethyl-pheny1)-propionic acid, (R)- 3-(2-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-propionic acid, (R)-2-(4-{4-[(R)- 1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-cyclopropyl-propionic acid, 2-{4-[3-Methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzyloxy}-3-phenyl-propionic acid, 2-{4-[3-Methyl-4- (( acid, (RS)-3-Cyclopropy1-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yll-benzyloxyl-
- 113 -propionic acid, (RS)-3-Cyclopropy1-2-{443-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzyloxy}-propionic acid, 24444-[541-(2-chlorophenypethoxy-carbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyl]acetic acid, (R)-1-[4-[4-[1,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]phenyliphenylicyclo-propane carboxylic acid, (R)-1-[4-[4-[2, 5-d imethy1-4-(1-phenylethoxycarbonylam ino) pyrazol-3-yl]phenyl]pheny1]-cyclopropane carboxylic acid, (R)-1-(4'-{541-(2-Chloro-pheny1)-ethoxycarbonyl-amino]-4-fluoro-pyrazol-1-y1}-3-fluoro-bipheny1-4-y1)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-2-fluoro-biphenyl-4-y1)-cyclo-propanecarbmlic acid, (R)-1-(2-Chloro-4'-{5-[1-(2-chloro-pheny1)-ethoxycarbonylam ino]-4-fluoro-pyrazol-1-y1}-bipheny1-4-y1)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyI)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-2-methyl-bipheny1-4-y1)-cyclopropane-carboxylic acid, (R)-1-(4'-{541-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-biphenyl-4-y1)-cyclopropanecarboxylic acid, (R)- 1-{4'45-(1-Phenykethoxycarbonyl-amino)-4-trifluoromethyl-pyrazol-1-y1]-bipheny1-4-y1}-cyclopropanecarboxylic acid, (R)-1-{2-Fluoro-4'-[5-(1-phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]-bipheny1-4-y1}-cyclopropanecarbmlic acid, (R)-1-(4-{545-(1-Phenyl-ethoxycarbonylamino)-pyrazol-1-y11-pyridin-2-y1}-pheny1)-cyclopropanecarboxylic acid, [0519] 122. The method of embodiments 116-119 wherein the Formula 1-XII
compound(s) are selected from embodiment 31.
[0520] 123. The method of embodiments 116-119 wherein the Formula 1-XI I
compound(s) are selected from embodiment 32.
[0521] 124. The method of embodiments 116-119 wherein the Formula 1-X11 compound(s) are selected from embodiment 33.
[0522] 125. The method of embodiment 116-119 wherein the Formula 1-X11 compound(s) are selected from embodiment 34.
- 114 -[0523] 126. The method of embodiment 116-119 wherein the Formula 1-XII
compound(s) are selected from embodiment 35.
[0524] 127. The method of embodiment 116-119 wherein the Formula 1-X11 compound(s) are selected from embodiment 36.
[0525] 128. The method of embodiment 116-119 wherein the Formula 1-XII
compound(s) are selected from embodiment 37.
[0526] 129. The method of embodiment 116-119 wherein the Formula 1-XII
compound(s) are selected from embodiment 38.
[0527] 130. The method of embodiment 116-119 wherein the Formula 1-X11 compound(s) are selected from embodiment 39.
[0528] 131. The method of embodiment 116-119 wherein the Formula 1-XII
compound(s) are selected from embodiment 40.
[0529] 132. The method of embodiment 116-119 wherein the Formula 1-XII
compound(s) are selected from embodiment 41.
[0530] 133. The method of embodiment 116-119 wherein the Formula 1-XII
compound(s) are selected from embodiment 42.
[0531] 134. The method of embodiment 116-119 wherein the Formula 1-XII
compound(s) are selected from embodiment 43.
[0532] 135. The method of embodiment 116-119 wherein the Formula 1-X11 compound(s) are selected from embodiment 44.
[0533] 136. The method of embodiment 116-119 wherein the Formula 1-X11 compound(s) are selected from embodiment 45.
[0534] 137. The method of embodiment 116-119 wherein the Formula 1-X11 compound(s) are selected from embodiment 46.
- 115 -[0535] 138. The method of embodiment 116-119 wherein the Formula I-XII
compound(s) are selected from embodiment 47.
[0536] 139. The method of embodiment 116-119 wherein the Formula I-XII
compound(s) are selected from embodiment 48.
[0537] 140. The method of embodiment 116-119 wherein the Formula I-XII
compound(s) are selected from embodiment 49.
[0538] 141. The method of embodiment 116-119 wherein the Formula I-XII
compound(s) are selected from embodiment 50.
[0539] 142. The method of embodiment 116-119 wherein the Formula I-XII
compound(s) are selected from embodiment 51.
[0540] 143. The method of embodiment 116-119 wherein the Formula I-XII
compound(s) are selected from embodiment 52.
[0541] 144. The method of embodiment 116-119 wherein the Formula I-XII
compound(s) are selected from embodiment 53.
[0542] 145. The composition of embodiment 116 where the currently used agent is a mast cell stabilizing agent [0543] 146. The composition of embodiment 116 where the currently used agent is a platelet activating factor receptor antagonist, [0544] 147. The composition of embodiment 145 where the mast cell stabilizing agent is cromoglicate, nedocromil, azelastine, bepotastine, epinastine, ketotifen, olopatadine and rupatadine.
[0545] 148. The composition of embodiment 146 where the platelet activating factor receptor antagonist is rupatadine, SM-12502, CV-3988 and WEB 2170.
[0546] 1A. A compound wherein the compound has the structure of Formula I
- 116 -C _____________ [0547](A)1 A Formula I
L2 L¨R
[0548] or a pharmaceutically acceptable salt or prodrug thereof, [0549] wherein RA is -CO2H, -CO2RB, -CN, tetrazolyl, -C(=0)NH2, -C(=0)NHIRB, -C(=0)NHSO2RB or -C(=0)NHCH2CH2S03H or a carboxylic acid isostere;
wherein RB is -H or -C1-C4 alkyl, or has the structure of one of:
oYo yo [0550] o ;
[0551] L1 is absent or substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C3-C6 cycloalkylene, C1-C6 fluoroalkylene, substituted or unsubstituted C1-C6 heteroalkylene, or -UV-Z-, wherein -UV- is defined by -OW-, -WO-, -N(R)W-, -WN(RJ)-, -N(R)C(=O)-, -SW-, -S(=0)õW- or -C(=0)N(RJ)-, wherein W is substituted or unsubstituted 01-C3 alkylene or substituted or unsubstituted C3-C6 cycloalkylene or W is -C(RL)2-, and wherein Z is substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C3-C6 cycloalkylene, or C1-C6 fluoroalkylene or Z is -C(R1-)2-; wherein n is 0, 1, or 2;
[0552] L2 is absent, or substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C3-C6 cycloalkylene, C1-C6 fluoroalkylene, substituted or unsubstituted C1-C6 heteroalkylene, -0-, -S-, -S(=0)-, -S(=0)2-, -C(=0)-, or -C(=0)N(RJ)-;
[0553] Ring A is a 5-6 membered heteroarene selected from one of:
- 117 -RE
I
,, ,N \ ,N-......) N,N*
NX .1_\1:_r r- RE_ N

D
R Rc R( D Re RD
R-, Rc 1µ1* Rc,rN.,-' eNt=i- ,-NN.;:_. RE........e.
NI\ a õrD )¨( RD Rc __ RD N
i Rc RD
R- RD
RE

., / N, '., RN ,' C'TNR\I j_ 1----1\1\
. N¶ c- I X I
N c D R N RD Rc RD
c/ R
RD Rc R
[0554] R RD , [0555] wherein the dashed line indicates the point of attachment of Ring A to Ring B; wherein one of RD and RD is -H, -ON, -F, -Cl, -Br, -I, -0C1-04 alkyl, -01-C4 alkyl, -03-C6 cycloalkyl, or -C1-C4 fluoroalkyl, and the other RD or RD is -N(RF)-C(=0)XCH(RG)-CY, -N(RF)-C(=0)XC(RG)2-CY, -N(RF)-C(=0)X-CY, -C(=0)-N(RF)-CH(RG)X-CY, -C(=0)-N(RF)-C(RG)2X-CY, or -C(=0)X-N(RF)-X-CY, wherein X is absent, -0-, -NH- or -CH2-;
[0556] RE is -H, -C1-C4 alkyl or -01-C4 fluoroalkyl; RF is -H or C1-04 alkyl;
RG is independently selected RE, or one RG is -C1-04 alkyl and is taken together with the carbon atom to which RG is attached and the carbon or heteroatom to which CY is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other RG, if present, is as defined for RE;
[0557] CY is substituted or unsubstituted 01-06 alkyl, substituted or unsubstituted 03-C10 cycloalkyl, substituted or unsubstituted C2-010 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 independently selected RH;
[0558] wherein each RH is independently selected from -H, halogen, -ON, -NO2, -OH, -OR, -SR, -S(=0)RJ, -S(=0)2RJ, -N(RJ)S(=0)2RJ, -S(=0)2N(RL)2, -C(=0)RJ, OC(=0)RJ, -CO2RJ, -0CO2RJ, -N(RL)2, -C(=0)N(RI-)2, -0C(=0)N(RL)2, -N(RJ)C(=0)N(RL)2, -N(RJ)C(=0)RJ, -
- 118 -N(RJ)C(=0)0RJ, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-04 fluoroalkoxy, C1-C4 alkoxy, and Ci-as heteroalkyl, wherein each R.-I is independently substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 01-C6 heteroalkyl, Cl-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted C3-C6 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -Ci-C4 alkylene-(substituted or unsubstituted aryl), or -C1-04 alkylene-(substituted or unsubstituted heteroaryl);
[0559] wherein each RL is independently -H, substituted or unsubstituted Cl-C6 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, C1-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene(substituted or unsubstituted aryl), or -C1-04 alkylene-(substituted or unsubstituted heteroaryl), or when RH is -S(0)2N(RL)2, -N(RL)2, -C(0)N(RL)2, -0C(0)N(RL)2 or -N(RF)C(=0)N(RL)2, each RL
is independently -H or C1-06 alkyl, or the RL groups independently are C1-C6 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle, or when W is -C(RL)2- or Z is -C(RL)2, each RL is independently -H, C1-C6 alkyl, or the RL groups independently are Ci-C6 alkyl which are taken together with the carbon atom to which they are attached to define a carbocycle;
[0560] Ring B is substituted or unsubstituted C3-C10 cycloalkylene, substituted or unsubstituted 02-C10 heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, where if ring B is substituted then ring B is substituted with 1, 2, or 3 independently selected RH, wherein RH is as previously defined;
[0561] Ring C is absent or substituted or unsubstituted C3-C10 cycloalkylene, substituted or unsubstituted C2-C10 heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, where if ring C is substituted then ring C is substituted with 1, 2, or 3 independently selected RH, wherein RH is as previously defined, [0562] wherein when Ring B is substituted or unsubstituted arylene, Ring C is absent, L2 is absent, L1 is -UV-Z-, wherein -UV- is -N(R)C(=O)-, wherein RJ is -H, RD is -N(RF)-C(=0)XCH(RG)-CY, wherein X is -0-, RG is -CH3 and RF is -H, and Rc is -H, -CH3 or -CF3, [0563] or when Ring B is substituted or unsubstituted arylene and Ring C is substituted or unsubstituted arylene or is substituted or unsubstituted C3-C10 cycloalkylene, or Ring B is substituted or unsubstituted C3-C cycloalkylene and Ring C is substituted or unsubstituted arylene, L2 is absent, L1 is 01-C6 alkylene, [0564] and Rc is -H or -CH3 and RA is -CO2H or CO2RD
[0565] then Ring A has the structure of one of::
RE
N I
Rc, Rc N RD RD
Rc = RcrN\j.--RD Rc RD RcIN
RD
RN c RD
RC
RE

0 N Nj'N

RC ,,D Rc ss'N RD RND
Rc/ RD RD Rc [0566]
[0567] and when Ring B is C2-C10 heterocycloalkylene, Ring C is substituted or unsubstituted arylene, L2 is absent, L1 is C1-C6 alkylene, Rc is -CH3 and RA is -CO2H or CO2RD, then Ring A
has the structure of one of:

N, ., E ,N //N.-Ns)!
I ' R ¨N N 1 \N----- RD
Rd RD Rd .----N ' s;,/... RN c' , zõs.. ,:lr r N \ a D
r RD Rd/N RD
Rd RD
RE

RE , Tw.:,__ Nr\-1;X- c) NV-----'1, eir N , ' I
1 / ' ,, ---TC--D
.F4, C/ N R- R N RD RN RD
[0568] ¨ RD R Rd RD
=
[0569] 2A. The compound of embodiment 1A wherein Rc is -H, -ON, -F, -Cl, -Br, -I, -001-C4 alkyl, -C1-C4 alkyl, -C3-06cycloalkyl, or -C1-04 fluoroalkyl and RD is -N(RF)-C(=0)XCH(RG)-CY, -N(RF)-C(=0)XC(RG)2-CY, -N(RF)-C(=0)X-CY, wherein RF and each RD independently are -H or C1-C4 alkyl.
[0570] 3A. The compound of embodiment 2A wherein Ring A is selected from one of:
RE
Is RN N
/Nõ-z......õ/ //N--Ns)!
i --..-*;"----N D D RD \N------Ro Rd R Rd R RC
¨E
rµl* RN' eN-'-1\/.._::_____L
N=( P;'''' K ----(N---r D RD RC RD i R D Rd RD
Rc R
RE

REN ,, O NI` : r.--;\1.-- Nr<RD R ey , / µ
T\J-:- N \ /'-µ c) A
RD Rc RD C/ N RD
/IN
N Rc R N
c/
[0571] R RD = , [0572] wherein RD is -N(RF)-C(=0)XCH(RD)-CY, and Rc is -H, -CH3 or -CF3, [0573] Ring B is substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene, Ring C is absent; L2 is absent; L1 is -UV-Z-, wherein -UV- is -OW-, -WO-, -N(R)W-, -WN(RJ)-, -N(R)C(=O)-, -SW-, -S(=0)W-, or -C(=0)N(RJ)-, wherein W is substituted or unsubstituted C1-03 alkylene; and n is 0, 1, or 2; or Ring B and Ring C
independently are substituted or unsubstituted arylene or substituted or unsubstituted arylene L2 is absent, Cis C1-C6 alkylene.
[0574] 4A. The compound of embodiment 2A wherein Ring A has the structure of one of:
N., RE¨N
RD N RD
RC RD Rc NI
N=( N I
RD R RD
RC RD
RE

NçN I c I
N Rc N RD RND
RN
[0575]
Rc/ RD - RD Rc RD
[0576] wherein Ring B is substituted or unsubstituted arylene and Ring C is substituted or unsubstituted arylene or is substituted or unsubstituted C3-C10 cycloalkylene, or Ring B is substituted or unsubstituted C3-C10 cycloalkylene and Ring C is substituted or unsubstituted arylene, L2 is absent and Lis C1-C6 alkylene.
[0577] 5A. The compound of embodiment 2A wherein L2 is absent and L1 is C1-C6 alkylene, or substituted or unsubstituted C3-C6 cycloalkylene, substituted or unsubstituted C1-C6 heteroalkylene or L2 and Ring C are absent and L1 is -UV-Z-, wherein -UV- is defined by -OW-, -WO-, -N(R)W-, -WN(RJ)-, -N(R)C(=O)-, -SW-, -S(=O)W-, or -C(=0)N(RJ)-, wherein W is substituted or unsubstituted C1-C3 alkylene; and n is 0, 1, or 2.
[0578] 6A. The compound of embodiment 5A wherein L1 is -UV-Z- wherein -UV- is defined by -OW-, -WO-, -N(R)W-, -WN(R)- or -C(=0)N(RJ)-, wherein W is substituted or unsubstituted C1-C3 alkylene.

[0579] 7A. The compound of embodiment 5A wherein L1 is -UV-Z-, wherein -UV- is defined by -WO-, -WN(RJ)- or -C(=0)N(RJ)-, wherein W is substituted or unsubstituted C1-C3 alkylene, and L2 is absent.
[0580] 8A. The compound of embodiment 7A wherein Z is substituted or unsubstituted 01-C6 alkylene.
[0581] 9A. The compound of embodiment 7A wherein Z is substituted or unsubstituted C1-06 alkylene and RA is -CO2H or -CO2RB.
[0582] 10A. The compound of embodiment 7A, wherein L1 is -UV-Z-, wherein -UV-is defined by -C(=0)N(RJ)-, wherein RJ is -H or -CH3.
[0583] 11A. The compound of embodiment 7A wherein L1 is UV-Z-, wherein -UV-, is defined by -WO-.
[0584] 12A. The compound of embodiment 7A wherein L1 is UV-Z-, wherein -UV-, is defined by - WN(RJ)-, wherein RJ is -H or -CH3.
[0585] 13A. The compound of embodiment 2A wherein L1 is absent or a substituted or unsubstituted substituted C1-C4 alkylene or a substituted or unsubstituted C3 cycloalkylene (i.e., cyclopropyl-di-yl).
X(s [0586] 14A. The compound of embodiment 2 wherein L1 is -CH2-, or -C(CH3)2-=
[0587] 15A. The compound of embodiment 2 wherein Ring A has the structure of one of:
RE
z/N,N.;;;.- E , \
N \ I
D R ¨N RD Ns RD
c R FzcRI) RC) RD
[0588] R Rc [0589] wherein RD is -H, -CN, -CH3, or -CF3, RD is -N(RE)C(=0)XCH(RG)-CY, -N(RE)C(=0)XC(RG)2-CY, or -N(RE)C(=0)X-CY and I: is -UV-Z- wherein -UV- is defined by -WO
-WN(R-1)- or -C(=0)N(R)-.
[0590] 16A. The compound of embodiment 15A wherein RD is -H, -CH3 or -CF3 and RD is -N(RE)C(=0)XCH(RG)-CY.
[0591] 17A. The compound of embodiment 15A wherein RD is -N(RE)C(=0)XCH(RG)-CY, wherein -X- is -N(RE)- or -0-; and wherein RG and each RE, independently selected, are -H or -CH3.
[0592] 18A. The compound of embodiment 17A wherein RG is -CH3, in the R or S
configuration, and CY is substituted or unsubstituted phenyl or substituted or unsubstituted heteroaryl.
[0593] 19A. The compound of embodiment 17A wherein RD is -N(RE)C(=0)0CH(RG)-CY, wherein CY is unsubstituted or substituted phenyl, wherein substituted phenyl is phenyl that is substituted with one or two of independently selected R.
[0594] 20A. The compound of embodiment 17A, wherein RD is -N(RE)C(=0)0CH(CH3)-CY, wherein RE is -H, and wherein CY is unsubstituted phenyl.
[0595] 21A. The compound of embodiment 17A, wherein RD is -N(RE)-C(=0)0CH(CH3)-CY, wherein RE is -H, and wherein CY is substituted phenyl, wherein substituted phenyl is phenyl that is substituted with one or two of independently selected RJ, wherein RJ
are halogens.
[0596] 22A. The compound of embodiment 21A, wherein RD is -NH-C(0)OOH(CH3)-CY
wherein CY is substituted phenyl, wherein substituted phenyl is phenyl that is substituted with one RH, wherein RJ is -F, -Cl or -Br.
[0597] 23A. The compound of embodiment 21A, wherein RD is -NH-C(=0)0CH(CH3)-CY, wherein CY is substituted phenyl, wherein substituted phenyl is phenyl that is substituted with one RH, wherein RJ is -Cl.

[0598] 24A. The compound of embodiment 19A, wherein RD is -NH-C(=0)0CH(CH3)-CY

/*L
40 0 N ' [H, Halogen]
having the structure of [0599] 25A. The compound of claim 19A wherein RD is -NH-C(=0)0CH(CH3)-CY
wherein the methyl group in RD is in the R configuration.
[0600] 26A. The compound of any one of embodiments 5-25 wherein Ring A has the structure N I
RD
of: Rc , wherein L2 is absent and Ring B is substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, [0601] provided that when Ring C is not absent and L1 is C1-C6 alkylene, or Ring C is absent and L1 is -UV-Z, wherein -UV- is -N(R)C(=0)-, and RD has the structure of -N(RF)-C(=0)XCH(RG)-CY, -N(RF)-C(=0)XC(RG)2-CY or -N(RF)-C(=0)X-CY,and RA is -CO2H, then Rc is other than -H, -CH3 and -CF3.
[0602] 27A. The compound of embodiment 26A wherein Rc is -H, -CH3 or -CF3, and RD is -NH-C(=0)0CH(RG)-CY, wherein RG is -H or -CH3, in the R or S configuration, and -CY is substituted or unsubstituted phenyl.
[0603] 28A. The compound of embodiment 26A wherein L2 and Ring C are absent, Ring B is substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, and L1 is -UV-Z-, wherein -UV-, is defined by -WO-, -WN(RJ)- or -C(0)N(R)-.
[0604] 29A. The compound of embodiment 26A wherein L2 and Ring C are absent, Ring B is substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, and L1 is -UV-Z-, wherein -UV-, is defined by -WN(RJ)- or -C(=0)N(RJ)-, wherein RJ is -H
or -CH3.

[0605] 30A. The compound of embodiment 29A wherein L1 is -UV-Z-, wherein -UV-is defined by -C(=0)NH-, and wherein Z is substituted or unsubstituted C1-C6 alkylene.
[0606] 31A. The compound of embodiment 29A wherein L1 is -UV-Z-, wherein -UV-is defined by -WO-, wherein W is substituted or unsubstituted 01-C3 alkylene, and wherein Z is substituted or unsubstituted C1-C6 alkylene.
[0607] 32A. The compound of embodiment 29A wherein L1 is -UV-Z-, wherein -UV-is defined by -W-NH-, wherein W is substituted or unsubstituted Ci-C3 alkylene, and wherein Z is substituted or unsubstituted C1-06 alkylene.
[0608] 33A. The compound of embodiment 26A wherein L1 is -UV-Z-, wherein -UV-is defined by -WO-, -WN(R-1)- or -C(=0)N(RJ), wherein RJ is -H or -CH3, and wherein Z is substituted or unsubstituted C1-C6 alkylene, wherein the alkylene is -CH(CH2-cyclopropyI)-, -CH(CH2-aryl) or -CH(CH2-heteroaryl), wherein the aryl or heteroaryl is substituted or unsubstituted.
[0609] 34A. The compound of embodiment 33A wherein L1 is -UV-Z-, wherein -UV-is defined by -C(=0)NH-, -WO- or -W-NH-, wherein -W- is -CH2-.
[0610] 35A. The compound of embodiment 33A wherein RA is -CO2H or -CO2R8.
[0611] 36A. The compound of embodiment 33A wherein L1 is -UV-Z-, wherein -UV-is defined by -CH20-, -CH2-NH- or -C(=0)NH-, wherein Z is substituted or unsubstituted C1-C6 alkylene, wherein the alkylene is -CH(CH2-cyclopropyl)-, -CH(CH2-aryl) or -CH(CH2-heteroaryl), wherein the aryl or heteroaryl is unsubstituted or substituted with 1, 2, or 3 independently selected substituted or unsubstituted C1-C4 alkyl or halogen.
[0612] 37A. The compound of embodiment 36A wherein said substituted or unsubstituted C1"
C4 alkyl or halogen substituent or substituents of the aryl or heteroaryl of -CH(CH2-aryl) or -CH(CH2-heteroaryl) are selected from the group consisting of -CH3, -CF3, -F, -Cl or -Br.
[0613] 38A. The compound of embodiment 33A, wherein L1 is -UV-Z- and wherein RA is -CO2H to which Z is attached to define -Ll-RA (i.e., -UV-Z-RA), wherein -UV- is defined by -C(=0)NH-, -WO- or -W-NH-, wherein -W- is -CH2-, and Z is -CH(CH2-aryl), wherein the aryl is substituted or unsubstituted, having the structure of one of C C

0 OH [H, CI] 0 OH [H, F, Cl, CH3, CF3]
H
[H, F]

[0614] 0 OH [H, F, CI, Br, CH3, CF3]
[0615] 39A. The compound of embodiment 36A wherein the -CH(CH2-aryl) substituent of Z in the -L1-R' is in the R configuration.
[0616] 40A. The compound of embodiment 33A wherein L1 is -UV-Z- and wherein RA
is -002H to which Z is attached to define -L1-R' (i.e., -UV-Z-RA), wherein -UV- is defined by -C(=0)NH-, -WO- or -W-NH-, wherein -W- is -CH2 -, and Z is -CH(CH2-cyclopropyI)-, having the structure of CA)"14v0x xv [0617] 41A. The compound of embodiment 1A, 2A, 3A, or 4A, wherein the compound has the structure of Formula III

LL-RA Formula III
[0618] A3 , wherein Al, A2 and A3 are independently -N=, =N-, =CH- or -CH=.

[0619] 42A. The compound of embodiment 41A wherein Ring A wherein Ring A has the RE
",1µ11, ,NN(1,(µ ,)=1 N I N\ R_NE N
ppID D
c - R RC RD RC

N N RD
structure of one of: R , wherein when L1 is C1-C6 alkylene, RD is -N(RF)-C(=0)XCH(RG)-CY, -N(RF)-C(=0)XC(RG)2-CY, wherein RF is -H, RG is -H or -CH3; RA is -CO2H or CO2RB, and Re is -H or -CH3, then Ring A has the N,_ e R¨N N
N RD
structure of one of: -[0620] 43A. The compound of embodiment 41A, wherein Ring A wherein Ring A has the RE
N, ,N
N\ RE¨N N N,Npp,D YNRD Nr.---.S\ RD
C RC RD R- RD Rc structure of one of: R
[0621] wherein Ring C is a substituted or unsubstituted arylene or heteroarylene, L1 is 01-C6 alkylene, RA is -CO2H or CO2RB, RD is -N(RF)-C(=0)XCH(RG)-CY, -N(RF)-C(=0)XC(RG)2-CY, wherein RF is -H, RG is -CH3 and CY is substituted phenyl and Rc is - is -CN, -F, -CI, -Br, -I, -0C1-C4 alkyl, -C2-C4 alkyl, -C3-C6cycloalkyl, or -C2-C4 fluoroalkyl.
[0622] 44A. The compound of embodiment 41A, wherein Ring A has the structure of one of:
RE
RD
N
N I
RN NJ\ I
RC RD Rc RD RD
c [0623] R R
c , wherein Ring C is a substituted or unsubstituted arylene or heteroarylene, L1 is C1-C6 alkylene, RA is -CO2H or -002R6, RD is -N(RF)-C(=0)XCH(RG)-CY, -N(RF)-C(=0)XC(RG)2-CY, wherein X is -0-, RF is -CH3, RG is -H or -CH3 and CY is substituted phenyl and RG is - is -H, -CN, -F, -Cl, -Br, -I, -0C1-C4 alkyl, -C1-C4 alkyl, -C3-C6cycloalkyl, or -C1-C4 fluoroalkyl.
[0624] 45A. The compound of embodiment 1A, 2A or 5A wherein the compound has the RH

A \ Ll¨RA Formula IV
structure of Formula IV , wherein Ring A has the RE
E
" N
RY---NRD N¨NRD
R Rc RD Rc) R¨N
RD
structure of one of: Rc , wherein Al is =N- or =C-; RD is -NRFC(=0)0CH(RG)-CY; L1 is -UV-Z-, wherein -UV- is defined by -C(=0)N(1:)-, wherein RJ is -H or -CH3; RF and RG independently are -H or -CH3;
and RA is -CO2H or -CO2RB.
[0625] 46A. The compound of embodiment 2A wherein the compound has the structure of Formula VII
RH

o F
R
RG 0 Formula VI
[0626] RH
, wherein Ring A is a 5 membered heteroarene having one of the structures of:
RE
,N
c D R N"¨NRD
R c RD Rc RD
Rc , wherein RD is the -N(RF)C(=0)CH(RG)-CY substituent of Formula VI wherein CY is phenyl substituted with one RH, and Rc is -H, -CH3, CF3 or -F; RA is -CO2H or -CO2RB; and RF and RG
independently are -H or -CH3; and RH independently are -H, halogen, -CH3 or -CF3.
[0627] 47A. The compound of embodiment 2A wherein the compound has the structure of Formula VII
RH R\
Al N¨z c \ A

N, F
0/ R Formula VII
RG
ORH ., wherein A1 is =CH- or =N-;Ring A is a 5 membered heteroarene having the structure of one of:
RE
E N
N I
c 1:t Rc RD R __________ Nc) RDRD N¨NRD
) Rc , wherein RD is the -N(RF)C(0)CH(RG)CY substituent of Formula VII wherein CY is phenyl substituted with one RH; and RG is -H, -CH3, CF3 or -F; RA is -CO2H or -CO2RB; RE and RF
independently are -H or C1-C4 alkyl; RG is -H or -CH3; RH independently are -H, halogen, -CH3 or -CF3;
and Z is C(RI)2, wherein one RL is -H and the other RI- is -H or C1-04 alkyl.

[0628] 48A The compound of embodiment 2A wherein the compound has the structure of 110 A N¨z \
W R=
RC
0./N"--RF Formula VIII

Formula VIII RH
,wherein A' is =CH- or =N-;
wherein Ring A is a 5 membered heteroarene having the structure of one of RE
I, NiN, I 5=4_ RE
¨N
\N:5-j\RD
Rc RD RC) RD
Rc Rc , wherein RD is the -N(RF)C(=0)CH(RG)-CY substituent of Formula VII wherein CY is phenyl substituted with one RH;
RA is -CO2H or -0O2R8; W is -C(RL)2- or _________________________________ ;
RE and RF independently are -H or C1-C4 alkyl; RG is -H or -CH3; RH independently are -H, halogen, -CH3 or -CF3; and Z
is -C(RL)2, wherein one RL is -H and the other RL is -H or C1-C4 alkyl.

[0629] 49A. The compound of embodiment 2A wherein the compound has the structure of W
RC
0./Ns-RE Formula IX

Formula IX 4111 RH , wherein A1 is =CH- or =N-;
wherein Ring A is a 5 membered heteroarene having the structure of one of RIE
RN
NI-JN
c R Rc R RC R
c [0630] R R
[0631] wherein RD is the -N(RE)C(=0)CH(RG)-CY substituent of Formula VII
wherein CY is phenyl substituted with one RH; RA is -CO2H or -CO2RE;
[0632] wherein W is -C(R1)2- or _________________________________________ ;
RE and RE independently are -H or C1-C4 alkyl; RG
is -H or -CH3; RH independently are -H, halogen, -CH3 or -C F3, and Z is -C(RL)2, wherein one RL
is -H and the other RL is -H or C1-a4 alkyl.

[0633] 50A. The compound of embodiment 2A wherein the compound has the structure of RH RH
A' Formula XII
RC

1.1 RH
Formula XII
,wherein A1 is =CH-or =N-; wherein Ring A is a 5 membered heteroarene having the structure of one of RE
,N
rµ1,\ I N, r RE¨N N
D
R RC RD RC RD
Re Re , wherein RD is the -N(RF)C(=0)CH(RG)-CY substituent of Formula VII wherein CY is phenyl substituted with one RH;
)Xs RA is -CO2H or -CO2RB; wherein W is -C(R1)2- or _________________________ ;
RE and RF independently are -H or C1-C4 alkyl; RG is -H or -CH3; RH independently are -H, halogen, -CH3 or -CF3;
and Z is -C(RL)2, wherein one RL is -H and the other RL is -H or C1-C4 alkyl.
[0634] 51A The compound of embodiment 2A wherein the compound is selected from Table 1.
[0635] 52A. The compound of embodiment 51A wherein the compound is 1-(4-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yll-benzoylamino)-cyclopropanecarboxylic acid, 2-(4-{441-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-indan-2-carboxylic acid, 2-(S)-(4-{4-[(R,S)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl acetic acid, 2-(R)-(4-{4-[(R,S)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl propanoic acid, 2(R)-[[4-[3-methy1-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid, 2(S)4[4-[3-methy1-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyliamino]-3-phenyl-propanoic acid, (R)-24[4-[2, 5-dim ethy1-4-((R)-1-phenylethoxycarbonyla mino) pyrazol-3-yl]benzoyl]amino]-3-phenyl-propanoic acid, (R)-2-[[4-[1 , 5-di methy1-4-((R)-1-phenylethoxycarbonyla mi no) pyrazol-3-yl]benzoyljamino]-3-phenyl-propanoic acid, (R)-24[442,5-dimethy1-44(R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyliamino]-3-(4-fluorophenyl)propanoic acid, (R)-2-[[4-[1, 5-di m ethy1-44(R)-1-phenylethoxycarbonyl amino) pyrazol-3-ylibenzoyl]am ino]-3-(4-fluorophenyl)propanoic acid, (R)- 3-(4-bromopheny1)-2-[[442,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)- 3-(4-bromopheny1)-2-[[4-[1,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-ylibenzoyliamino]propanoic acid, (R)-3-(4-chloropheny1)-24[442,5-dirnethyl-44(R)-1-phenylethoxycarbonyl-amino)pyrazol-3-ylibenzoyl]amino]propanoic acid, (R)- 3-(4-chloropheny1)-24[441 ,5-dim ethy1-4-((R)-1- phenylethoxycarbonyl-ami no) pyrazol-3-yl]benzoyliamino]propanoic acid, (R)- 3-(3,4-difluoropheny1)-2-[[442,5-dimethy1-44(R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyliamino]propanoic acid, (R)- 3-(3,4-difluoropheny1)-2-[[4-[1 , 5-dim ethyl-4-((R)- 1-phenylethoxycarbonyl-a mi no) pyrazol-3-ylibenzoyliamino]propanoic acid, (R)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yll-benzoylamino)-3-cyclopropyl-propionic acid, (R)-2-{443-Methy1-4-((S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzoylaminol-3-phenyl-propionic acid, (S)-2-{443-Methy1-4-((S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzoylamino}-3-phenyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-phenyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-fluoro-pheny1)-propionic acid, (R)-3-(4-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yll-benzoylamino)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(3,4-difluoro-pheny1)-propionic acid, (R)-3-(2-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylarnino]-3-methyl-isoxazol-5-ylybenzoylarnino)-propionic acid, (R)-3-(4-Bromo-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid, (R)-3-(4-Bromo-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(2-fluoro-pheny1)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-ylybenzoylamino)-3-p-tolyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-trifluoromethyl-pheny1)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-cyano-pheny1)-propionic acid, (R)- 2-(4-{5-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-methyl-pyrazol-1-y1}-benzoylamino)-3-phenyl-propionic acid, (R)-2-{443-Methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzylamino}-3-phenyl-propionic acid, (R)-3-(2- Fluoro-pheny1)-2-{443-methy1-4-(( -phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-propionic acid, (R)-2-{4-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylam ino)-isoxazol-5-y1]-benzylamino}-3-(4-trifluoromethyl-pheny1)-propionic acid, (R)-3-Cyclopropy1-2-{4-(3-methyl-4-((R)-1-phenyl-ethoxycarbonylam ino)-isoxazol-5-y1]-benzylamino}-propionic acid, (R)-3- (2-Chloro-pheny1)-2-{443-methy1-4- ((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-propionic acid, (R)-3-(4-Chloro-pheny1)-2-{4-[3-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylaminol-propionic acid, (R)- 2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-phenyl-propionic acid, (R)- 2-(4-{4-[(R)_1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-(2-fluoro-pheny1)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-(4-trifluoromethyl-pheny1)-propionic acid, (R)- 3-(2-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-cyclopropyl-propionic acid, 2-{4-[3-Methy1-44(R)-1-phenyl-ethoxycarbonylam inoyisoxazol-5-y1}-benzyloxy}-3-phenyl-propionic acid, (RS)-3-Cyclopropy1-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzyloxy}-propionic acid, (RS)-3-Cyclopropy1-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzyloxy}-propionic acid, 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yliphenyl]phenyliacetic acid, (R)-1-(444-[1, 5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]phenyl]phenylicyclopropane carboxylic acid, (R)-144-[442,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yliphenyliphenyl]cyclopropane carboxylic acid, (R)-1-(4'-{541-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-3-fluoro-bipheny1-4-y1)-cyclopropanecarboxylic acid, (R)-1-(4-{541-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-2-fluoro-bipheny1-4-y1)-cyclopropanecarboxylic acid, (R)-1-(2-Chloro-4'-{5-[1-(2-chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-bipheny1-4-y1)-cyclopropanecarboxylic acid, (R)-1-(4'-{541-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-2-methyl-bipheny1-4-y1)-cyclopropanecarboxylic acid, (R)-1-(4'-{541-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-bipheny1-4-y1)-cyclopropanecarboxylic acid, (R)-144'4541-Phenyl-ethoxycarbonylam ino)-4-trifl uoromethyl-pyrazol-1-y1]-bipheny1-4-y1}-cyclopropanecarboxylic acid, (R)-1-{2-Fluoro-4.45-(1-phenyl-ethoxycarbonylam ino)-4-trifluoromethyl-pyrazol-1-y1]- biphenyl-4-ylycyclopropanecarboxylic acid, (R)-1-(4-{545-(1-Phenykethoxycarbonylamino)-pyrazol-1-y1}-pyridin-2-y1}-pheny1)-cyclopropanecarboxylic acid.
[0636] 53A. A compound of any one of embodiments 1A-52A for preparation of mendicant for treating a LPA-dependent disease or condition.
[0637] The compounds of Table 1 are exemplary of the invention but not limiting, wherein compounds 57-458 are prepared according to the appropriately modified procedures of the examples for preparation of compounds 1-458.

[0638] TABLE 1 Cpd Name 1 1-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-cyclopropanecarboxylic acid 2 2-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yll-benzoylamino)-indan-2-carboxylic acid 3 2-(S)-(4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl acetic acid 4 2-(R)-(4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl propanoic acid 2(R)-[[4-[3-methy1-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoynamino]-3-phenyl-propanoic acid 6 2(S)-[[4-[3-methy1-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyliamino]-3-phenyl-propanoic acid 7 (R)-24[442,5-dimethy1-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-phenyl-propanoic acid 8 (R)-24[441,5-dimethy1-44(R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-phenyl-propanoic acid 9 (R)-2-[[4-[2,5-dimethy1-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-ylibenzoyliamino]-3-(4-fluorophenyl)propanoic acid (R)-24[441,5-dimethy1-44(R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid 11 (R)- 3-(4-bromopheny1)-24[442,5-dimethy1-44(R)-1-phenylethoxycarbonyl-amino)Pyrazol-3-ylibenzoyl]amino]propanoic acid 12 (R)- 3-(4-bromopheny1)-24[441,5-dimethy1-44(R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yllbenzoyl]amino]propanoic acid 13 (R)- 3-(4-chloropheny1)-2-[[4-[2,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid 14 (R)- 3-(4-chloropheny1)-2-[[441,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid 15 (R)- 3-(3,4-difluoropheny1)-24[442,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid 16 (R)- 3-(3,4-difluoropheny1)-24[441,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid 17 (R)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-cyclopropyl-propionic acid 18 (R)-2-{443-Methy1-4-((S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzoylamino}-3-phenyl-propionic acid 19 (S)-2-{443-Methy1-44(S)-1-phenyl-ethoxycarbonylaminoyisoxazol-5-y1]-benzoylamino}-3-phenyl-propionic acid 20 (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-phenyl-propionic acid 21 (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-fluoro-pheny1)-propionic acid 22 (R)-3-(4-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid 23 (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(3,4-difluoro-pheny1)-propionic acid 24 (R)-3-(2-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid 25 (R)-3-(4-Bromo-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid 26 (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(2-fluoro-phenyl)-propionic acid 27 (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-p-tolyl-propionic acid 28 (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-trifluoromethyl-phenyl)-propionic acid 29 (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-cyano-pheny1)-propionic acid 30 (R)- 2-(4-{5-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-methyl-pyrazol-1-y1}-benzoylamino)-3-phenyl-propionic acid 31 (R)-2-{443-Methy1-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-3-phenyl-propionic acid 32 (R)-3-(2-Fluoro-pheny1)-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-propionic acid 33 (R)-2-{4-[3-Methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-3-(4-trifluoromethyl-pheny1)-propionic acid 34 (R)-3-Cyclopropy1-2-{443-methy1-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzylamino}-propionic acid 35 (R)-3-(2-Chloro-pheny1)-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-propionic acid 36 (R)-3-(4-Chloro-pheny1)-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-A-benzylarnino}-propionic acid 37 (R)- 2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1)-benzylamino)-3-phenyl-propionic acid 38 (R)- 2-(4-{4-[(R)_1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-(2-fluoro-phenyl)-propionic acid 39 (R)- 2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-344-trifluoromethyl-phenyl)-propionic acid 40 (R)- 3-(2-Chloro-phenyl)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino1-3-methyl-isoxazol-5-y1}-benzylamino)-propionic acid 41 (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yll-benzylamino)-3-cyclopropyl-propionic acid 42 2-{443-Methyl-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yll-benzyloxy}-3-phenyl-propionic acid 43 2-{443-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzyloxy}-3-phenyl-propionic acid 44 (RS)-3-Cyclopropy1-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzyloxy}-propionic acid 45 (RS)-3-(4-Chloro-phenyl)-2-{443-methyl-44(R)-1-phenyl-ethoxycarbonyloxy)-isoxazol-5-y1]-benzyloxy}-propionic acid 46 244444541-(2-chlorophenypethoxycarbonylamino]-4-cyano-pyrazol-1-yliphenyl]phenyliacetic acid 47 (R)-144-[411,5-dimethyl-4-(1-phenylethoxycarbonylamino)pyrazol-3-yliphenyliphenyl]cyclopropane carboxylic acid 48 (R)-1-[4-[4-[2,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]phenyl]phenyl]cyclopropane carboxylic acid 49 (R)-1-(4'-{541-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-3-fluoro-biphenyl-4-y1)-cyclopropanecarboxylic acid 50 (R)-1-(4'-{541-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y11-2-fluoro-biphenyl-4-y1)-cyclopropanecarboxylic acid 51 (R)-1-(2-Chloro-4'-{5-[ 1-(2-chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-biphenyl-4-y1)-cyclopropanecarboxylic acid 52 (R)-1-(4'-{541-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-A-2-methyl-biphenyl-4-y1)-cyclopropanecarboxylic acid 53 (R)-1-(4'-{541-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-biphenyl-4-y1)-cyclopropanecarboxylic acid 54 (R)- 1-{4'-[5-(1-Phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-y1]-biphenyl-4-y1}-cyclopropanecarboxylic acid 55 (R)-1-{2-Fluoro-4'45-(1-phenykethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-y1]-biphenyl-4-y1}-cyclopropanecarboxylic acid 56 (R)-1-(4-{545-(1-Phenyl-ethoxycarbonylamino)-pyrazol-1-y1]-pyridin-2-y1}-pheny1)-cyclopropanecarboxylic acid 57 24[443-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-Abenzoyliamino]-3-phenyl-propanoic acid 58 3-cyclopropy1-24[4-[3-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]propanoic acid 59 24[4-[3-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]-3-phenoxy-propanoic acid 60 24[443-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyliamino]-4-phenyl-butanoic acid 61 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyliamino]-3-phenyl-propanoic acid 62 24[44441-(2-chlorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoylJamino]-3-cyclopropyl-propanoic acid 63 24[44441-(2-chlorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyliamino]-4-phenyl-butanoic acid 64 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyliamino]-3-phenoxy-propanoic acid 65 24[44441-(2-fluorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyl]amino]-4-phenyl-butanoic acid 66 21[44441-(2-fluorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyl]amino]-3-phenoxy-propanoic acid 67 3-cyclopropy1-2-[[44441-(2-fluorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyl]amino]propanoic acid 68 24[44441-(2-fluorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid 69 3-(4-methoxypheny1)-2-[[4-[3-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-yl]benzoyl]amino]propanoic acid 70 3-(4-fluoropheny1)-21[443-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]propanoic acid 71 3-(2,6-difluoropheny1)-2-[[4-[3-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyliamino]propanoic acid 72 3-(3-cyanopheny1)-2-[[4-[3-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]propanoic acid 73 3-(2-chloropheny1)-24[443-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-ylibenzoyflamino]propanoic acid 74 3-(4-chloropheny1)-2-[[4-[3-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-yl]benzoyl]amino]propanoic acid 75 24[443-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]-(trifluoromethyl)phenyl]propanoic acid 76 3-(4-hydrowheny1)-2-[[443-methyl-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyliamino]propanoic acid 77 3-(3,4-difluoropheny1)-2-[[4-[3-methyl-4-(1-phenylethoxycarbonylam ino)isoxazol-5-yl]benzoyl]amino]propanoic acid 78 3-(4-bromopheny1)-24[443-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyliamino]propanoic acid 79 24[443-methy1-4-(1-phenylethoxycarbonylamino)isoxazol-5-ylibenzoyliamino]-(trifluoromethoxy)phenyljpropanoic acid 80 2-[[44441-(2-chlorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyl]amino]-3-(4-methoxyphenyl)propanoic acid 81 24[44441-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid 82 24[44441 -(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyliamino]-3-(2,6-difluorophenyl)propanoic acid 83 24[44441 -(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyliamino]-3-(3-cyanophenyl)propanoic acid 84 3-(2-chloropheny1)-24[444-(1-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyl]amino]propanoic acid 85 3-(4-chloropheny1)-24[44441-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyl]amino]propanoic acid 86 2-[[444-[1-(2-chlorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyliamino]-344-(trifluoromethyl)phenyl]propanoic acid 87 24[444-[ 1 -(2-chlorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyl]amino]-3-(4-hydroxyphenyl)propanoic acid 88 3-(4-bromopheny1)-24[44441-(2-chlorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyl]amino]propanoic acid 89 24[44441-(2-chlorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-ylpenzoyliamino]-3-(3,4-difluorophenyl)propanoic acid 90 2-[[44441-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyliamino]-344-(trifluoromethoxy)phenyl]propanoic acid 91 24[44441-(2-fluorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyliamino]-3-(4-methoxyphenyl)propanoic acid 92 3-(4-fluoropheny1)-24[44441-(2-fluorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-ylpenzoyl]amino]propanoic acid 93 3-(2,6-difluoropheny1)-2-[[44441-(2-fluorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-ylpenzoyl]amino]propanoic acid 94 3-(3-cyanopheny1)-24[44441 -(2-fluorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyl]amino]propanoic acid 95 3-(2-chloropheny1)-24[444-[ 1 -(2-fluorophenyl)ethoxycarbonylarnino]-3-methyl-isoxazol-5-ylpenzoyl]amino]propanoic acid 96 3-(4-chloropheny1)-24[44441-(2-fluorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-ylpenzoyl]amino]propanoic acid 97 24[44441 -(2-fluorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-ylpenzoyl]amino]-344-(trifluoromethyl)phenylipropanoic acid 98 24[44441 -(2-fluorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyllamino]-3-(4-hydroxyphenyl)propanoic acid 99 3-(3,4-difluoropheny1)-24[44441 -(2-fluorophenyl)ethoxycarbonylamino1-3-methyl-isoxazol-5-yl]benzoyl]annino]propanoic acid 100 3-(4-bromopheny1)-24[44441-(2-fluorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-yl]benzoyljamino]propanoic acid 101 2-[[44441-(2-fluorophenypethoxycarbonylamino]-3-methyl-isoxazol-5-ylibenzoyliamino]-344-(trifluoromethoxy)phenyl]propanoic acid 102 24[441,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyliamino]-3-(4-methoxyphenyl)propanoic acid 103 24[441,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-ylibenzoyliamino]-3-(4-fluorophenyppropanoic acid 104 3-(2,6-difluoropheny1)-2-[[4-[1,5-dimethyl-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyliamino]propanoic acid 105 3-(3-cyanopheny1)-24[441,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-ylibenzoyl]amino]propanoic acid 106 3-(2-chloropheny1)-2-[[4-[1,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyliamino]propanoic acid 107 3-(4-chloropheny1)-2-[[4-[1,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyliamino]propanoic acid 108 24[441,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-[4-(trifluoromethyl)phenyl]propanoic acid 109 24[441,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-(4-hydroxyphenyl)propanoic acid 110 3-(3,4-difluoropheny1)-2-[[4-[1,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyliamino]propanoic acid 111 3-(4-bromopheny1)-24[441,5-dimethyl-4-(1-phenylethoxycarbonylamino)pyrazol-yl]benzoyliamino]propanoic acid 112 24[441,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyliamino]-344-(trifluoromethoxy)phenyl]propanoic acid 113 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-1, 5-di methyl-pyrazol-yl]benzoyl]amino]-3-(4-methoxyphenyl)propanoic acid 114 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylam ino]-1,5-dimethyl-pyrazol-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid 115 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-1, 5-dimethyl- pyrazol-yl]benzoyl]amino]-3-(2,6-difluorophenyl)propanoic acid 116 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylam ino]-1,5-dimethyl-pyrazol-yl]benzoyl]amino]-3-(3-cyanophenyl)propanoic acid 117 3-(2-chlorophenyI)-2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-1, 5-di methyl-pyrazol-3-yl]benzoyl]amino]propanoic acid 118 3-(4-chlorophenyI)-2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylami no]-1, 5-dimethyl-pyrazol-3-yl]benzoyl]amino]propanoic acid
119 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylam ino]-1,5-dimethyl-pyrazol-yl]benzoyl]amino]-344-(trifluoromethyl)phenyl]propanoic acid
120 2-[[444-[1 -(2-chlorophenypethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyllamino]-3-(4-hydroxyphenyl)propanoic acid
121 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-1, 5-dimethyl- pyrazol-yl]benzoyl]amino]-3-(3,4-difluorophenyl)propanoic acid
122 3-(4-bromophenyI)-2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyl]amino]propanoic acid
123 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylam ino]-1,5-dimethyl-pyrazol-yl]benzoyl]amino]-344-(trifluoromethoxy)phenyl]propanoic acid
124 2-[[4-[4-[1-(2-fluorophenyl)ethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyl]amino]-3-(4-methoxyphenyl)propanoic acid
125 3-(4-fluoropheny1)-24[44441-(2-fluorophenypethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-ylibenzoyliamino]propanoic acid
126 3-(2,6-difluoropheny1)-2-[[44441-(2-fluorophenyl)ethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyl]amino]propanoic acid
127 3-(3-cyanopheny1)-24[4-[441-(2-fluorophenypethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyl]amino]propanoic acid
128 3-(2-chloropheny1)-24[444-0-(2-fluorophenyl)ethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-ylibenzoyliamino]propanoic acid
129 3-(4-chloropheny1)-24[44441-(2-fluorophenypethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyl]amino]propanoic acid
130 24[44441-(2-fluorophenypethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyl]amino]-344-(trifluoromethyl)phenyl]propanoic acid
131 24[44441-(2-fluorophenypethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyliamino]-3-(4-hydroxyphenyl)propanoic acid
132 3-(3,4-difluoropheny1)-2-[[44441-(2-fluorophenyl)ethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyliamino]propanoic acid
133 3-(4-bromopheny1)-24[44441-(2-fluorophenypethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyliamino]propanoic acid
134 2-[[4-[4-[1-(2-fluorophenyl)ethoxycarbonylamino]-1,5-dimethyl-pyrazol-3-yl]benzoyl]amino]-344-(trifluoromethoxy)phenyl]propanoic acid
135 2-{p-[3-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]benzoylamino}-phenylpropionic acid
136 2-(p-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazolyl}benzoylamino)-3-phenylpropionic acid
137 3-Cyclopropy1-2-{p43-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolypenzoylamino}propionic acid
138 2-(p-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazolyl}benzoylamino)-3-cyclopropylpropionic acid
139 24({p43-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyllmethyDamino]-3-phenylpropionic acid
140 2-([(p-{4-[1-(o-Chlorophenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazolyl}phenyl)methyl]amino}-3-phenylpropionic acid
141 3-Cyclopropy1-2-[({p-[3-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methyDaminolpropionic acid
142 2-{[(p-{411-(o-Chlorophenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazoly1}phenyl)methyliamino}-3-cyclopropylpropionic acid
143 2-({p43-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyliphenyl}methoxy)-3-phenylpropionic acid
144 2-[(p-{4-[1-(o-ChlorophenyDethoxycarbonylamino]-3-fluoro-5-isoxazolyl}phenyl)methoxy]-3-phenylpropionic acid
145 3-Cyclopropy1-2-({p-[3-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methoxy)propionic acid
146 2-[(p-{4-[1-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazolyl}phenyDrnethoxy]-3-cyclopropylpropionic acid
147 2-{p-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolypenzoylamino}-3-phenylpropionic acid
148 2-(p-{4-[l-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazolyl}benzoylamino)-3-phenylpropionic acid
149 2-(p13-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolypenzoylamino}-3-cyclopropylpropionic acid
150 2-(p-{441-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazolyl}benzoylamino)-3-cyclopropylpropionic acid
151 2-[({p-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methyl)amino]-3-phenylpropionic acid
152 2-{[(p-{441-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazolyl}phenyl)methyl]amino}-3-phenylpropionic acid
153 2-[({p43-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyliphenyl}methypamino]-3-cyclopropylpropionic acid
154 2-{[(p-{441-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazolyl}phenyl)methyl]amino}-3-cyclopropylpropionic acid
155 2-({p43-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyliphenyl}methoxy)-phenylpropionic acid
156 2-[(p-{4-[1-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazolyl}phenyl)methoxy]-3-phenylpropionic acid
157 2-({p-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methoxy)-3-cyclopropylpropionic acid
158 2-[(p-{4-[1-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazolyl}phenyl)methoxy]-3-cyclopropylpropionic acid
159 2-Benzy1-3-{5-[3-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylaminolpropionic acid
160 2-Benzy1-3-(5-{441-(o-chlorophenypethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridylamino)propionic acid
161 2-(Cyclopropylmethyl)-3-{543-methyl-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}propionic acid
162 3-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridylamino)-2-(cyclopropylmethyl)propionic acid
163 2-Benzy1-3-{543-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}propionic acid
164 2-Benzy1-3-(5-{441-(o-chlorophenyl)ethoxycarbonylamino1-3-methy1-5-isoxazoly1}-2-pyridyloxy)propionic acid
165 2-(Cyclopropylmethyl)-3-{543-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly11-2-pyridyloxy}propionic acid
166 3-(5-{4-[1-(o-Chloropheny)ethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridyloxy)-2-(cyclopropylmethyl)propionic acid
167 2-{543-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-Pyridylamino}-3-phenylpropionic acid
168 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridylamino)-3-phenylpropionic acid
169 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridylamino)-3-cyclopropylpropionic acid
170 2-{543-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-phenylpropionic acid
171 2-(5-{441-(o-Chlorophenypethoxycarbonylamino}-3-methy1-5-isoxazoly1}-2-pyridyloxy)-3-phenylpropionic acid
172 3-Cyclopropy1-2-{5-[3-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-pyridyloxy}propionic acid
173 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridyloxy)-3-cyclopropylpropionic acid
174 2-Benzy1-3-{543-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}propionic acid
175 2-Benzy1-3-(5-{441-(o-chlorophenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridylamino)propionic acid
176 2-(Cyclopropylmethyl)-3-{5-[3-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylaminolpropionic acid
177 3-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly11-2-pyridylamino)-2-(cyclopropylmethyl)propionic acid
178 2-Benzy1-3-{543-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}propionic acid
179 2-Benzy1-3-(5-{441-(o-chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridyloxy)propionic acid
180 2-(Cyclopropylmethyl)-3-{543-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}propionic acid
181 3-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly11-2-pyridyloxy)-2-(cyclopropylmethyl)propionic acid
182 2-{5-[3-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyI]-2-pyridylamino}-3-phenylpropionic acid
183 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridylamino)-3-phenylpropionic acid
184 3-Cyclopropy1-2-{543-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-pyridylamino}propionic acid
185 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridylamino)-3-cyclopropylpropionic acid
186 2-{543-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-phenylpropionic acid
187 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly11-2-pyridyloxy)-3-phenylpropionic acid
188 3-Cyclopropy1-2-{5-[3-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyI]-pyridyloxy}propionic acid
189 2-(5-{4-[1-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly11-2-pyridyloxy)-3-cyclopropylpropionic acid
190 2-Benzy1-3-{5-[3-cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyI]-2-pyridylamino}propionic acid
191 2-Benzy1-3-(5-{4-0-(o-chlorophenyl)ethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridylamino)propionic acid
192 3-{5-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}-2-(cyclopropylmethyppropionic acid
193 3-(5-{4-[1-(o-ChlorophenyDethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridylamino)-2-(cyclopropylmethyl)propionic acid
194 2-Benzy1-3-{5-[3-cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyI]-2-pyridyloxy}propionic acid
195 2-Benzy1-3-(5-{4-[1-(o-chlorophenyl)ethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridyloxy)propionic acid
196 3-{543-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-2-(cyclopropylmethyl)propionic acid
197 3-(5-{411-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridyloxy)-2-(cyclopropylmethyl)propionic acid
198 2-{5-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}-3-phenylpropionic acid
199 2-(5-{4-[1-(o-Chlorophenyl)ethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridylamino)-3-phenylpropionic acid
200 2-{5-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}-3-cyclopropylpropionic acid
201 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazoly11-2-pyridylamino)-3-cyclopropylpropionic acid
202 2-{543-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-3-phenylpropionic acid
203 2-(5-{4-[1-(o-ChlorophenyDethoxycarbonylamino]-3-cyano-5-isoxazoly11-2-pyridyloxy)-3-phenylpropionic acid
204 2-{543-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-3-cyclopropylpropionic acid
205 2-(5-{4-[1-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridyloxy)-3-cyclopropylpropionic acid
206 2-{p-p-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolypenzoylamino}-3-phenylpropionic acid
207 2-(p-{441-(o-Chlorophenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazolyl}benzoylamino)-3-phenylpropionic acid
208 3-Cyclopropy1-2-{p-[3-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]benzoylaminolpropionic acid
209 2-(p-{4-[1-(o-Chlorophenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazolyilbenzoylamino)-3-cyclopropylpropionic acid
210 2-[({p43-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyliphenyllmethyDamino]-3-phenylpropionic acid
211 2-{[(p-{4-[1-(o-Chlorophenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazolyl}phenyl)methyl]amino}-3-phenylpropionic acid
212 3-Cyclopropy1-24({p43-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methyl)amino]propionic acid
213 2-{[(p-{441-(o-Chlorophenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazolyl}phenyl)methyljamino}-3-cyclopropylpropionic acid
214 2-({p43-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methoxy)-3-phenylpropionic acid
215 2-[(p-{4-0-(o-Chlorophenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazolyl}phenyl)methoxy]-3-phenylpropionic acid
216 3-Cyclopropy1-2-({p43-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methoxy)propionic acid
217 2-[(p-{4-[1-(o-Chlorophenyl)ethoxycarbonylarnino]-3-fluoro-5-isoxazolyl}phenyl)rnethoxy]-3-cyclopropylpropionic acid
218 2-{p43-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]benzoylamino}-3-phenylpropionic acid
219 2-(p-{441-(o-Chlorophenyl)ethoxycarbonylamino]-3-cyano-5-isoxazolyl}benzoylamino)-3-phenylpropionic acid
220 2-{p43-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolylibenzoylamino}-3-cyclopropylpropionic acid
221 2-(p-{4-[1-(o-Chlorophenyl)ethoxycarbonylamino]-3-cyano-5-isoxazolyl}benzoylamino)-3-cyclopropylpropionic acid
222 24({p-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methyl)amino]-3-phenylpropionic acid
223 2-{[(p-{441-(o-Chlorophenyl)ethoxycarbonylamino]-3-cyano-5-isoxazolyl}phenyl)methyljamino}-3-phenylpropionic acid
224 24({p-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methyl)amino]-3-cyclopropylpropionic acid
225 2-{Rp-{4-[1-(o-ChlorophenyDethoxycarbonylamino]-3-cyano-5-isoxazolyl}phenyl)methyllamino}-3-cyclopropylpropionic acid
226 2-({p-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methoxy)-3-phenylpropionic acid
227 2-Rp-{4-[1-(o-Chlorophenypethoxycarbonylarnino]-3-cyano-5-isoxazoly1}phenyl)methoxy]-3-phenylpropionic acid
228 2-({p-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methoxy)-3-cyclopropylpropionic acid
229 2-Rp-{4-[1-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazoly1}phenyl)methoxy]-3-cyclopropylpropionic acid
230 2-Benzy1-3-{543-methyl-4-(1-phenylethoxycarbonylamino)-5-isoxazoly11-2-pyridylaminolpropionic acid
231 2-Benzy1-3-(5-{411-(o-chlorophenyi)ethoxycarbonylamino]-3-methyl-5-isoxazoly1}-2-pyridylamino)propionic acid
232 2-(Cyclopropylmethyl)-3-{513-methyl-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}propionic acid
233 3-(5-{4-[1-(o-Chlorophenyl)ethoxycarbonylamino]-3-methyl-5-isoxazoly1}-2-pyridylamino)-2-(cyclopropylmethyDpropionic acid
234 2-Benzy1-3-{543-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxylpropionic acid
235 2-Benzy1-3-(5-{4-[1-(o-chlorophenypethoxycarbonylarnino]-3-methyl-5-isoxazoly1}-2-pyridyloxy)propionic acid
236 2-(Cyclopropylmethyl)-3-{543-methyl-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}propionic acid
237 3-(5-{4-[1-(o-ChlorophenyDethoxycarbonylamino]-3-methyl-5-isoxazoly1}-2-pyridyloxy)-2-(cyclopropylmethyl)propionic acid
238 2-{5-[3-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}-3-phenylpropionic acid
239 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridylamino)-3-phenylpropionic acid
240 3-Cyclopropy1-2-{543-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly11-pyridylamino}propionic acid
241 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridylamino)-3-cyclopropylpropionic acid
242 2-{543-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-phenylpropionic acid
243 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridyloxy)-3-phenylpropionic acid
244 3-Cyclopropy1-2-{543-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-pyridyloxy}propionic acid
245 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-methy1-5-isoxazoly1}-2-pyridyloxy)-3-cyclopropylpropionic acid
246 2-Benzy1-3-{543-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylaminolpropionic acid
247 2-Benzy1-3-(5-{4-[1-(o-chlorophenyl)ethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridylamino)propionic acid
248 2-(Cyclopropylmethyl)-3-{543-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylaminolpropionic acid
249 3-(5-{441-(o-Chloropheny)ethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridylamino)-2-(cyclopropylmethyl)propionic acid
250 2-Benzy1-3-{5-[3-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyI]-2-pyridyloxy}propionic acid
251 2-Benzy1-3-(5-{441-(o-chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridyloxy)propionic acid
252 2-(Cyclopropylmethyl)-3-{543-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}propionic acid
253 3-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly11-2-pyridyloxy)-2-(cyclopropylmethyl)propionic acid
254 2-{543-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}-3-phenylpropionic acid
255 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridylamino)-3-phenylpropionic acid
256 3-Cyclopropy1-2-{543-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-pyridylaminolpropionic acid
257 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridylamino)-3-cyclopropylpropionic acid
258 2-{543-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-phenylpropionic acid
259 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly11-2-pyridyloxy)-3-phenylpropionic acid
260 3-Cyclopropy1-2-{543-fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-pyridyloxylpropionic acid
261 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-fluoro-5-isoxazoly1}-2-pyridyloxy)-3-cyclopropylpropionic acid
262 2-Benzy1-3-{543-cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylaminolpropionic acid
263 2-Benzy1-3-(5-{441-(o-chlorophenyl)ethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridylamino)propionic acid
264 3-{5-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}-2-(cyclopropylmethyl)propionic acid
265 3-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridylamino)-2-(cyclopropylmethyl)propionic acid
266 2-Benzy1-3-{5-[3-cyano-4-(1-phenylethwrycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}propionic acid
267 2-Benzy1-3-(5-{4-[1-(o-chlorophenyl)ethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridyloxy)propionic acid
268 3-{543-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-2-(cyclopropylmethyl)propionic acid
269 3-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridyloxy)-2-(cyclopropylmethyl)propionic acid
270 2-{543-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}-phenylpropionic acid
271 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridylamino)-3-phenylpropionic acid
272 2-{5-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}-3-cyclopropylpropionic acid
273 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridylamino)-3-cyclopropylpropionic acid
274 2-{543-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-3-phenylpropionic acid
275 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazoly11-2-pyridyloxy)-3-phenylpropionic acid
276 2-{543-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-3-cyclopropylpropionic acid
277 2-(5-{441-(o-Chlorophenypethoxycarbonylamino]-3-cyano-5-isoxazoly1}-2-pyridyloxy)-3-cyclopropylpropionic acid
278 3-{p43-Methyl-4-(1-phenylethoxycarbonylamino)-5-isoxazolylibenzoylamino}-4-phenylbutyric acid
279 4-Cyclopropy1-3-{p-[3-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazolypenzoylamino}butyric acid
280 34({p43-Methyl-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methypamino]-4-phenylbutyric acid
281 4-Cyclopropy1-34({p43-methyl-4-(1-phenylethoxycarbonylamino)-5-isoxazolyliphenyl}methyl)amino]butyric acid
282 3-({p43-Methyl-4-(1-phenylethoxycarbonylamino)-5-isoxazolyliphenyl}methoxy)-4-phenylbutyric acid
283 4-Cyclopropy1-3-({p43-methyl-4-(1-phenylethoxycarbonylamino)-5-isoxazolyliphenyllmethoxy)butyric acid
284 3-{543-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridylamino}-4-phenylbutyric acid
285 4-Cyclopropy1-3-{5-[3-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-pyridylamino}butyric acid
286 3-{543-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridyloxy}-phenylbutyric acid
287 4-Cyclopropy1-3-{543-methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-pyridyloxy}butyric acid
288 244-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]phenyliacetic acid
289 1-[4-[4-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]phenyl]cyclopropanecarboxylic acid
290 144444541-(2-chlorophenypethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyl]cyclopropanecarboxylic acid
291 24444-[4-cyano-5-(1-phenylethoxycarbonylamino)pyrazol-1-yl]phenyl]phenyl]-2-methyl-propanoic acid
292 244444541-(2-chlorophenypethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyliphenyl]-2-methyl-propanoic acid
293 1-{4'-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-4-biphenyly1}cyclopropanecarboxylic acid
294 1-(4'-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-y1}-biphenylyl)cyclopropanecarboxylic acid
295 1-{3-Fluoro-4'-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-biphenylyl}cyclopropanecarboxylic acid
296 1-(4'-{5-[1-(o-Chlorophenypethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-y1}-3-fluoro-4-biphenylyl)cyclopropanecarboxylic acid
297 1-{2-Fluoro-4'-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-biphenylyl}cyclopropanecarboxylic acid
298 1-(4'-{5-[1-(o-Chlorophenypethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-y1}-2-fluoro-4-biphenylyl)cyclopropanecarboxylic acid
299 1-{2-Chloro-4'-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-biphenylyl}cyclopropanecarboxylic acid
300 1-(2-Chloro-4'-{511-(o-chlorophenypethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-y1}-4-biphenylypcyclopropanecarboxylic acid
301 1-(4-{p44-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]phenyl}tolyl)cyclopropanecarboxylic acid
302 1-[4-(p-{5-[1-(o-Chlorophenypethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-yl}phenyl)tolylicyclopropanecarboxylic acid
303 1-(p-{5-[5-(1-Phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridyl}phenyl)cyclopropanecarboxylic acid
304 14p-(5-{541-(o-Chloropheny)ethoxycarbonylamino]-1H-pyrazol-1-y1}-2-pyridyl)phenyl]cyclopropanecarboxylic acid
305 1-(p-{5-[4-Methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridyl}phenyl)cyclopropanecarboxylic acid
306 1-[p-(5-{541-(o-Chlorophenypethoxycarbonylamino]-4-methy1-1H-pyrazol-1-y1}-pyridyl)phenylicyclopropanecarboxylic acid
307 1-(2-Fluoro-4-{545-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridyl}phenyl)cyclopropanecarboxylic acid
308 144-(5-{541-(o-Chlorophenypethoxycarbonylamino]-1H-pyrazol-1-y1}-2-pyridy1)-2-fluorophenyl]cyclopropanecarboxylic acid
309 1-(3-Fluoro-4-{5-[5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridyl}phenyl)cyclopropanecarboxylic acid
310 1-[4-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-1H-pyrazol-1-y1}-2-pyridy1)-3-fluorophenyl]cyclopropanecarboxylic acid
311 14p-(5-{541-(o-Chlorophenyl)ethoxycarbonylamino]-4-methy1-1H-pyrazol-1-y1}-pyridyl)phenylicyclopropanecarboxylic acid
312 1-(2-Fluoro-4-{5-[4-methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridyl}phenyl)cyclopropanecarboxylic acid
313 1-[4-(5-{5-[1-(o-Chlorophenypethoxycarbonylamino]-4-methy1-1H-pyrazol-1-y1}-2-pyridy1)-2-fluorophenylicyclopropanecarboxylic acid
314 1-(3-Fluoro-4-{5[4-methy1-5-(1-phenylethoxycarbonylam ino)-1H-pyrazol-1-y1]-2-pyridyllphenyl)cyclopropanecarboxylic acid
315 144-(5-{541-(o-Chlorophenypethoxycarbonylamino]-4-methyl-1H-pyrazol-1-y1}-2-pyridy1)-3-fluorophenylicyclopropanecarboxylic acid
316 1-(p-{5-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridyl}phenyl)cyclopropanecarboxylic acid
317 14p-(5-{541-(o-Chlorophenypethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-y1}-pyridyl)phenyl]cyclopropanecarboxylic acid
318 1-(2-Fluoro-4-{5-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridyl}phenyl)cyclopropanecarboxylic acid
319 144-(5-{541-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-y1}-2-pyridy1)-2-fluorophenylicyclopropanecarboxylic acid
320 1-(3-Fluoro-4-{5-[4-fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridyl}phenyl)cyclopropanecarboxylic acid
321 144-(5-{541-(o-Chloropheny)ethoxycarbonylamino]-4-fluoro-1H-pyrazol-1-y1}-2-pyridy1)-3-fluorophenylicyclopropanecarboxylic acid
322 1-(p-{5-[4-Cyano-5-(1-phenylethoxycarbonylam i no)-1H-pyrazol- 1-y1]-2-pyridyl}phenyl)cyclopropanecarboxylic acid
323 1-[p-(5-{5-[1-(o-Chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-y1}-2-pyridyl)phenylicyclopropanecarboxylic acid
324 1-(4-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-2-fluorophenyl)cyclopropanecarboxylic acid
325 1-[4-(5-{5-[1-(o-Chlorophenypethoxycarbonylamino]-4-cyano-1H-pyrazol-1-y1}-2-pyridy1)-2-fluorophenyl]cyclopropanecarboxylic acid
326 1-(4-1544-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-3-fluorophenyl)cyclopropanecarboxylic acid
327 144-(5-{541-(o-Chlorophenypethoxycarbonylamino]-4-cyano-1H-pyrazol-1-y1}-2-pyridy1)-3-fluorophenylicyclopropanecarboxylic acid
328 2-{p-[1-Methy1-5-methy1-4-(1-phenylethoxycarbonylamino)-1H-pyrazol-3-yl]benzoylamino}-3-phenylpropionic acid
329 3-Cyclopropy1-2-{p-[1-methy1-5-methyl-4-(1-phenylethoxycarbonylamino)-1H-pyrazol-3-yl]benzoylamino}propionic acid
330 2-(p-{441-(o-Chlorophenypethoxycarbonylamino]-1-methy1-5-methyl-1H-pyrazol-yl}benzoylamino)-3-phenylpropionic acid
331 2-(p-{4-[1-(o-Chlorophenypethoxycarbonylamino]-1-methy1-5-methy1-1H-pyrazol-3-yl}benzoylamino)-3-cyclopropylpropionic acid
332 24({p-[1-Methy1-5-methy1-4-(1-phenylethoxycarbonylamino)-1H-pyrazol-3-yl]phenyl}methyl)amino]-3-phenylpropionic acid
333 3-Cyclopropy1-2-[({p-[1-methyl-5-methyl-4-(1-phenylethoxycarbonylamino)-1H-pyrazol-3-yl]phenyllmethypamino]propionic acid
334 2-{[(p-{441-(o-Chloropheny)ethoxycarbonylamino]-1-methy1-5-methy1-1H-pyrazol-3-yl}phenypmethyl]amino}-3-phenylpropionic acid
335 2-{[(p-{4-[1-(o-Chlorophenypethoxycarbonylamino]-1-methy1-5-methyl-1H-pyrazol-3-yl}phenyl)methyl]amino}-3-cyclopropylpropionic acid
336 2-({p-[1-Methy1-5-methy1-4-(1-phenylethoxycarbonylamino)-1H-pyrazol-3-Aphenyllmethoxy)-3-phenylpropionic acid
337 3-Cyclopropy1-2-({p41-methyl-5-methyl-4-(1-phenylethoxycarbonylamino)-1H-pyrazol-3-yl]phenyl}methoxy)propionic acid
338 2-[(p-{441-(o-Chlorophenypethoxycarbonylamino]-1-methyl-5-methyl-1H-pyrazol-3-yl}phenyl)methoxy]-3-phenylpropionic acid
339 2-[(p-{4-[1-(o-Chlorophenypethoxycarbonylamino]-1-methy1-5-methyl-1H-pyrazol-3-yl}phenyl)methoxy]-3-cyclopropylpropionic acid
340 3-{p41-Methyl-5-methyl-4-(1-phenylethoxycarbonylamino)-1H-pyrazol-3-yl]benzoylamino}-4-phenylbutyric acid
341 4-Cyclopropy1-3-{p-[1-methyl-5-methyl-4-(1-phenylethoxycarbonylamino)-1H-pyrazol-3-yl]benzoylamino}butyric acid
342 34({p41-Methyl-5-methyl-4-(1-phenylethoxycarbonylamino)-1H-pyrazol-3-yliphenyl}methypamino]-4-phenylbutyric acid
343 4-Cyclopropy1-3-[({p41-methyl-5-methyl-4-(1-phenylethoxycarbonylamino)-1H-pyrazol-3-yl]phenyllmethyl)amino]butyric acid
344 3-({p-[1-Methyl-5-methyl-4-(1-phenylethoxycarbonylamino)-1H-pyrazol-3-yl]phenyllmethoxy)-4-phenylbutyric acid
345 4-Cyclopropy1-3-({p41-methy1-5-methyl-4-(1-phenylethoxycarbonylamino)-1H-pyrazol-3-yl]phenyl}methoxy)butyric acid
346 3-pheny1-24[445-(1-phenylethoxycarbonylamino)oxazol-4-yl]benzoyl]amino]propanoic acid
347 3-cyclopropy1-24[445-(1-phenylethoxycarbonylamino)oxazol-4-yl]benzoyl]amino]propanoic acid
348 4-pheny1-2-[[445-(1-phenylethoxycarbonylamino)oxazol-4-yl]benzoyliamino]butanoic acid
349 3-phenoxy-24[4[5-(1-phenylethoxycarbonylamino)oxazol-4-yl]benzoyl]amino]propanoic acid
350 3-Pheny1-24({p45-(1-phenylethoxycarbonylamino)-1,3-oxazol-4-yl]phenyl}methyl)amino]propionic acid
351 3-Cyclopropy1-21({p45-(1-phenylethoxycarbonylamino)-1,3-oxazol-4-yl]phenyllmethyl)amino]propionic acid
352 3-Pheny1-2-({p45-(1-phenylethoxycarbonylamino)-1,3-oxazol-4-yl]phenyl}methoxy)propionic acid
353 4-Pheny1-3-({p45-(1-phenylethoxycarbonylamino)-1,3-oxazol-4-yliphenyl}methoxy)butyric acid
354 4-Cyclopropy1-3-({p45-(1-phenylethoxycarbonylamino)-1,3-oxazol-4-yliphenyl}methoxy)butyric acid
355 24[441-methy1-5-(1-phenylethoxycarbonylamino)imidazol-4-yl]benzoyl]amino]-3-phenyl-propanoic acid
356 3-cyclopropy1-2-[[4-[1-methy1-5-(1-phenylethoxycarbonylamino)imidazol-4-yl]benzoyl]amino]propanoic acid
357 24[441-methy1-5-(1-phenylethoxycarbonylamino)imidazol-4-yl]benzoyllamino]-4-phenyl-butanoic acid
358 24[441-methy1-5-(1-phenylethoxycarbonylamino)imidazol-4-yl]benzoyl]amino]-3-phenoxy-propanoic acid
359 24({p41-Methyl-5-(1-phenylethoxycarbonylamino)-1H-imidazol-4-yl]phenyllmethyl)amino]-3-phenylpropionic acid
360 3-Cyclopropy1-2-[({p-[1-methy1-5-(1-phenylethoxycarbonylamino)-1H-imidazol-yl]phenyl}methypamino]propionic acid
361 2-({p-[1-Methyl-5-(1-phenylethoxycarbonylamino)-1H-imidazol-4-yl]phenyl}methoxy)-3-phenylpropionic acid
362 3-Cyclopropy1-2-({p-[1-methy1-5-(1-phenylethoxycarbonylamino)-1H-imidazol-yl]phenyl}methoxy)propionic acid
363 3-[({p-[1-Methy1-5-(1-phenylethoxycarbonylamino)-1H-imidazol-4-yl]phenyllmethyDamino]-4-phenylbutyric acid
364 4-Cyclopropy1-34({p-[1-methyl-5-(1-phenylethoxycarbonylamino)-1H-imidazol-Aphenyl}methyl)amino]butyric acid
365 3-({p41-Methyl-5-(1-phenylethoxycarbonylamino)-1H-imidazol-4-yl]phenyl}methoxy)-4-phenylbutyric acid
366 4-Cyclopropy1-3-({p-[1-methy1-5-(1-phenylethoxycarbonylamino)-1H-imidazol-yl]phenyl}methoxy)butyric acid
367 24[441,2-dimethy1-3-oxo-5-(1-phenylethoxycarbonylamino)pyrazol-4-yl]benzoyl]amino]-3-phenyl-propanoic acid
368 3-cyclopropy1-2-[[4-[1,2-dimethy1-3-oxo-5-(1-phenylethoxycarbonylamino)pyrazol-4-yl]benzoyl]amino]propanoic acid
369 24[441,2-dimethy1-3-oxo-5-(1-phenylethoxycarbonylamino)pyrazol-4-yl]benzoyllamino]-4-phenyl-butanoic acid
370 2-[[441,2-dimethy1-3-oxo-5-(1-phenylethcmcarbonylamino)pyrazol-4-ylibenzoyl]amino]-3-phenoxy-propanoic acid
371 24({p41,2-Dimethyl-3-oxo-5-(1-phenylethoxycarbonylamino)-1,2-dihydropyrazol-4-yliphenyl}methypaminol-3-phenylpropionic acid
372 3-Cyclopropy1-2-[({p-[1,2-dimethyl-3-oxo-5-(1-phenylethoxycarbonylamino)-1,2-dihydropyrazol-4-yl]phenyl}methyl)amino]propionic acid
373 2-({p-[1,2-Dimethy1-3-oxo-5-(1-phenylethoxycarbonylamino)-1,2-dihydropyrazol-4-yl]phenyllmethoxy)-3-phenylpropionic acid
374 3-Cyclopropy1-2-({p41,2-dimethyl-3-oxo-5-(1-phenylethoxycarbonylamino)-1,2-dihydropyrazol-4-yl]phenyl}methoxy)propionic acid
375 3-[({p-[1,2-Dimethy1-3-oxo-5-(1-phenylethoxycarbonylamino)-1,2-dihydropyrazol-4-yl]phenyl}methyl)amino]-4-phenylbutyric acid
376 4-Cyclopropy1-34({p41,2-dimethyl-3-oxo-5-(1-phenylethoxycarbonylamino)-1,2-dihydropyrazol-4-yl]phenyl}methyDamino]butyric acid
377 3-({p-[1,2-Dimethy1-3-oxo-5-(1-phenylethoxycarbonylamino)-1,2-dihydropyrazol-4-yl]phenyllmethoxy)-4-phenylbutyric acid
378 4-Cyclopropy1-3-({p41,2-dimethyl-3-oxo-5-(1-phenylethoxycarbonylamino)-1,2-dihydropyrazol-4-yliphenyl}methoxy)butyric acid
379 3-pheny1-24[445-(1-phenylethoxycarbonylamino)pyrimidin-4-yl]benzoyl]amino]propanoic acid
380 3-cyclopropy1-2-[[4-[5-(1-phenylethoxycarbonylamino)pyrimidin-4-yl]benzoyl]amino]propanoic acid
381 4-pheny1-24[445-(1-phenylethoxycarbonylamino)pyrimidin-4-yl]benzoyliamino]butanoic acid
382 3-phenoxy-2-[[4-[5-(1-phenylethoxycarbonylamino)pyrimidin-4-yl]benzoyllamino]propanoic acid
383 3-Pheny1-2-[({p45-(1-phenylethoxycarbonylamino)-4-pyrimidinyliphenyl}methyl)amino]propionic acid
384 3-Cyclopropy1-2-[({p45-(1-phenylethoxycarbonylamino)-4-pyrimidinyl]phenyl}methyl)amino]propionic acid
385 3-Pheny1-2-({p-[5-(1-phenylethoxycarbonylamino)-4-pyrimidinyl]phenyl}methoxy)propionic acid
386 3-Cyclopropy1-2-({p45-(1-phenylethoxycarbonylamino)-4-pyrimidinyl]phenyl}methoxy)propionic acid
387 4-Pheny1-3-[({p45-(1-phenylethoxycarbonylamino)-4-pyrimidinyliphenyl}methyl)amino]butyric acid
388 4-Cyclopropy1-3-[({p-[5-(1-phenylethoxycarbonylamino)-4-pyrimidinyliphenyl}methypamino]butyric acid
389 4-Pheny1-3-({p45-(1-phenylethoxycarbonylamino)-4-pyrimidinyliphenyl}methoxy)butyric acid
390 4-Cyclopropy1-3-({p45-(1-phenylethoxycarbonylamino)-4-pyrimidinyl]phenyl}methoxy)butyric acid ' 391 24[446-methy1-5-(1-phenylethoxycarbonylamino)pyrimidin-4-yl]benzoyl]amino]-3-phenyl-propanoic acid 392 3-cyclopropy1-2-[[4-[6-methy1-5-(1-phenylethoxycarbonylamino)pyrimidin-4-yl]benzoyliamino]propanoic acid 393 24[446-methy1-5-(1-phenylethoxycarbonylamino)pyrimidin-4-yl]benzoyl]amino]-4-phenyl-butanoic acid ' 394 2-[[446-methy1-5-(1-phenylethoxycarbonylamino)pyrimidin-4-yl]benzoyl]amino]-3-phenoxy-propanoic acid 395 3-pheny1-24[444-(1-phenylethoxycarbonylamino)pyrimidin-5-yl]benzoyl]aminojpropanoic acid 396 3-cyclopropy1-2-[[4-[4-(1-phenylethoxycarbonylamino)pyrimidin-5-yl]benzoyliamino]propanoic acid 397 4-phenyl-24[4[4-(1-phenylethoxycarbonylamino)pyrimidin-5-ylibenzoyliaminolbutanoic acid 398 3-phenoxy-2-[[444-(1-phenylethoxycarbonylamino)pyrimidin-5-yl]benzoyl]amino]propanoic acid 399 3-phenyl-24[4[3-(1-phenylethoxycarbonylamino)pyrazin-2-ylibenzoyl]amino]propanoic acid 400 3-cyclopropy1-2-[[443-(1-phenylethoxycarbonylamino)pyrazin-2-ylibenzoyl]amino]propanoic acid ' 401 4-phenyl-24[4[3-(1-phenylethoxycarbonylamino)pyrazin-2-yl]benzoyliamino]butanoic acid 402 3-phenoxy-24[4[3-(1-phenylethoxycarbonylamino)pyrazin-2-ylibenzoyl]amino]propanoic acid 403 1-{p43-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]pheny1}-4-piperidinecarboxylic acid 404 (1-{p-[3-Methy1-4-(1-phenylethoxycarbonylarnino)-5-isoxazolyl]pheny1}-4-piperidypacetic acid 405 1-(1-{p43-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]pheny1}-4-piperidyl)cyclopropanecarboxylic acid 406 [1-(1-{p-[3-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]pheny1}-4-piperidyl)cyclopropyliacetic acid , 407 1-{5-[3-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazolyI]-2-pyridy1}-4-piperidinecarboxylic acid 408 (1-{543-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridy1}-4-piperidypacetic acid 409 1-(1-{5-[3-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazolyI]-2-pyridyll-piperidyl)cyclopropanecarboxylic acid 410 [1-(1-{543-Methy1-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridy1}-piperidyl)cyclopropyl]acetic acid 411 1-{p-[3-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]pheny1}-4-piperidinecarboxylic acid 412 (1-{p-[3-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]pheny1}-4-piperidyl)acetic acid 413 1-(1-{p-[3-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]pheny1}-4-piperidyl)cyclopropanecarboxylic acid 414 [1-(1-{p-[3-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyllpheny1}-4-piperidyl)cyclopropyl]acetic acid 415 1-{543-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridy11-4-piperidinecarboxylic acid 416 (1-{5-[3-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazolyI]-2-pyridy1}-4-piperidyl)acetic acid 417 1-(1-{5-[3-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridy1}-piperidyl)cyclopropanecarboxylic acid 418 [1-(1-{5-[3-Fluoro-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridy1}-4-piperidyl)cyclopropyllacetic acid 419 1-{p43-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]pheny11-4-piperidinecarboxylic acid 420 (1-{p43-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]pheny1}-4-piperidypacetic acid 421 1-(1-{p-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]pheny11-4-piperidyl)cyclopropanecarboxylic acid 422 [1-(1-{p43-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyl]pheny1}-4-piperidyl)cyclopropyl]acetic acid 423 1-{5-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyI]-2-pyridy1}-4-piperidinecarboxylic acid 424 (1-{513-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridy1}-4-piperidypacetic acid 425 1-(1-{5-[3-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazolyI]-2-pyridy1}-piperidyl)cyclopropanecarboxylic acid 426 [1-(1-{543-Cyano-4-(1-phenylethoxycarbonylamino)-5-isoxazoly1]-2-pyridy1}-piperidyl)cyclopropyliacetic acid 427 1-{p-[5-(1-Phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-4-piperidinecarboxylic acid 428 (1-{p-[5-(1-Phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-4-piperidypacetic acid 429 1-(1-{p-[5-(1-Phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-4-piperidyl)cyclopropanecarboxylic acid 430 [1-(1-{p-[5-(1-Phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-4-piperidyl)cyclopropyliacetic acid 431 1-{545-(1-Phenylethoxycarbonylamino)-1H-pyrazol-1-y11-2-pyridy1}-4-piperidinecarboxylic acid 432 (1-{5-[5-(1-Phenylethoxycarbonylamino)-1H-pyrazol-1-0]-2-pyridy1}-4-piperidypacetic acid 433 1-(1-{5-[5-(1-Phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-4-piperidyl)cyclopropanecarboxylic acid 434 [1-(1-{5-[5-(1-Phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-4-piperidyl)cyclopropyliacetic acid 435 1-{p-[4-Methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-4-piperidinecarboxylic acid 436 (1-{p-[4-Methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-4-piperidyl)acetic acid 437 1-(1-{p-[4-Methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-piperidyl)cyclopropanecarboxylic acid 438 [1-(1-{p-[4-Methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]phenyl}-piperidypcyclopropyl]acetic acid 439 1-{5-[4-Methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-piperidinecarboxylic acid 440 (1-{544-Methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy11-piperidyl)acetic acid 441 1-(1-{5-[4-Methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-4-piperidyl)cyclopropanecarboxylic acid 442 [1-(1-{5-[4-Methy1-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-4-piperidyl)cyclopropyliacetic acid 443 1-{p-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-4-piperidinecarboxylic acid 444 (1-{p44-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-ylipheny1}-4-piperidyl)acetic acid 445 1-(1-{p-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-piperidyl)cyclopropanecarboxylic acid 446 [1-(1-{p44-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-ylipheny1}-piperidyl)cyclopropyl]acetic acid 447 1-{544-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y11-2-pyridy1}-piperidinecarboxylic acid 448 (1-{544-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-piperidypacetic acid 449 1-(1-{5-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-4-piperidyl)cyclopropanecarboxylic acid 450 [1-(1-{5-[4-Fluoro-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy11-4-piperidyl)cyclopropyl]acetic acid 451 1-{p-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-4-piperidinecarboxylic acid 452 (1-{p-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny11-4-piperidyl)acetic acid 453 1-(1-{p-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-4-piperidyl)cyclopropanecarboxylic acid 454 [1-(1-{p-(4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-yl]pheny1}-piperidyl)cyclopropyllacetic acid 455 1-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy11-piperidinecarboxylic acid 456 (1-{544-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-piperidyl)acetic acid 457 1-(1-{5-[4-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-4-piperidypcyclopropanecarboxylic acid 458 [1-(1-{544-Cyano-5-(1-phenylethoxycarbonylamino)-1H-pyrazol-1-y1]-2-pyridy1}-4-piperidyl)cyclopropyl]acetic acid EXAMPLES
[0639] HPLC Methods [0640] HPLC traces for examples synthesized were recorded using a HPLC
consisting of Agilent HPLC pumps, degasser and UV detector, equipped with an Agilent 1100 series auto-sampler. A MS detector (APCI) PE Sciex API 150 EX was incorporated for purposes of recording mass spectral data. HPLC/mass traces were obtained using one of three chromatographic methods:
[0641] Method 1: Column Zorbax C18, size 4.6 mm X 7.5 cm; Solvent A: 0.05 %
TFA in water, Solvent B: 0.05 % TFA in acetonitrile; Flow rate ¨ 0.7 mUmin; Gradient:
5 % B to 100 %

B in 9 min, hold at 100 % B for 4 min and 100 % B to 5 % B in 0.5 min; UV
detector ¨ channel 1 = 220 nm, channel 2 = 254 nm.
[0642] Method 2: Column Zorbax C18, size 4.6 mm X 7.5 cm;
Solvent A: 0.05 % TFA in water, Solvent B: 0.05 % TFA in acetonitrile;
Flow rate ¨0.7 mL/min; Gradient: 5 % B to 100 % B in 5 min, hold at 100 % B
for 2 min and 100 % B to 5 % B in 0.5 min; UV detector ¨ channel 1 = 220 nm, channel 2 = 254 nm.
[0643] Method 3: Column SunFireTM (Waters) C18, size 2.1 mm X 50 mm;
Solvent A: 0.05 % TFA in water, Solvent B: 0.05 % TFA in acetonitrile;
Flow rate ¨0.8 mL/min; Gradient: 10 % B to 90 % B in 2.4 min, hold at 90 % B
for 1.25 min and 90 % B to 10 % B in 0.25 min, hold at 101% B for 1.5 min.; UV detector ¨
channel 1 = 220 nm, channel 2 = 254 nm.
[0644] Example 1: 1-(4-{441-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-cyclopropanecarboxylic acid [0645] Step 1: 2-(4-carboxymethyl-benzoyI)-3-oxo-butyric acid t-butyl ester t-Butyl acetoacetate (15.1mL, 89.0 mmol) was added to a suspension of magnesium chloride (8.48g, 89.0 mmol) in dichloromethane (88mL) that had been cooled to 0 C. To the mixture was added pyridine (13.8mL, 171mmol) and stirring continued for an additional 15 minutes. 4-(Chlorocarbonyl)benzoic acid methyl ester (17.0g, 85.6 mmol) in dichloromethane (88mL) was then added dropwise to the reaction. This mixture was stirred at 0 C for 90minutes and then at room temperature for 90 minutes. At this time the mixture was treated with 0.2M hydrochloric acid solution (10mL). The organic layer was diluted with dichloromethane (70mL), washed with 0,2M hydrochloric acid solution (30mL), separated, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. A yellow oil was obtained that was used directly in the next step (17.1g, 68%).
Method 2, Rt 5.4 min. MS (ESI) m/z 321.2 [M +

[0646] Step 2: 5-(4-Methoxycarbonyl-phenyl)-3-methyl-isoxazole-4-carboxylic acid tert-butyl ester [0647] 5-(4-methylcarboxy-phenyl)-3-methyl-isoxazol-4-yl-carboxylic acid t-butyl ester A mixture of 2-(4-carboxymethyl-benzoyI)-3-oxo-butyric acid t-butyl ester [example 1, step 1]
(7.45g, 23.2 mmol), hydroxylamine hydrochloride (5.17g, 74.4 mmol), ethanol (46.5mL) and water (32.2mL) was heated at 60-62 C for 2 hours. At this point the reaction was allowed to cool and the resulting mixture was partitioned between ethyl acetate and water. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo. A crude product was obtained that was purified by silica gel chromatography initially with hexane/ethyl acetate 9/1 as eluting solvent to afford 5-(4-Methoxycarbonyl-phenyl)-3-methyl-isoxazole-4-carboxylic acid tert-butyl ester (4.69g, 64%) Method 2, Rt 6.14 min. MS (ESI) m/z 318.2 [M + W].
[0648] Step 3: 5-(4-Methoxycarbonyl-phenyl)-3-methyl-isoxazole-4-carboxylic acid5-(4-Methoxycarbonyl-phenyl)-3-methyl-isoxazole-4-carboxylic acid tert- butyl ester [Example 1, step 2] (6.35g mg, 20 mmol) was dissolved in dichloromethane (100 mL) and to this was added trifluoroacetic acid (50mL). The mixture was stirred for 2 hours at room temperature when the volatiles were removed. The product (5.2g, 99 %) was used as is in Step 4.
Method 2, Rt 4.08 min. MS (ESI) m/z 262 [M + W];
[0649] Step 4: 1-(4-{441-(2-Chloro-phenyl)-ethoxycarbonylam i no]-3-methyl-benzoic acid methyl ester [0650] 5-(4-methylcarboxy-phenyl)-3-methyl-isoxazol-4-yl-carboxylic acid [Example 1, step 3] (3.91g, 15.0 mmol) was suspended in toluene (120 mL) and to this was added diisopropylethylamine (3.13mL, 18.0mmol). To the resulting solution was added diphenylphosphoryl azide (3.56mL, 16.5mmol) and this mixture was heated to 90 C. After 15 minutes, 1-(2-chlorophenyI)-ethanol (2.98mL, 22.5mm01) was added slowly and heating maintained for 4 hours. The reaction was allowed to cool overnight. This mixture was diluted with toluene, transferred to a separatory funnel, extracted with water. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to yield a crude product (8.34g). The crude was purified by silica gel chromatography eluting with a gradient from 30% to 40% ethyl acetate in hexanes to afford purified product (3.59g, 58%) as three fractions. Method 2, Rt 5.70 min. MS (ESI) m/z 415.4 [M +
[0651] Step 5: 1-(4-{441-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [0652] 1-(4-{441-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid methyl ester [Example 1, step 4] (1.5g, 3.62 mmol) was dissolved in THF/water (1/1: 20mL) and treated with LiOH (5.1mL of a 1M aqueous solution). The resulting mixture was stirred at room temperature for 3 hours. The reaction was acidified to pH2, transferred to a separatory funnel, diluted with water and extracted with dichloromethane. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford the product (0.8g, 55%). Method 2, Rt 4.77 min. MS (ESI) m/z 401.3 [M + H+].
[0653] Step 6: 1-Aminocyclopropanecarboxylic acid methyl ester 1-Aminocyclopropanecarboxylic acid (202mg, 2mm01) in methanol (4mL) was cooled to -10 C
and to this was added dropwise thionyl chloride (581pL, 8mmo1). The mixture was allowed to warm and was then refluxed for 2 hours. Solvents were evaporated and the residue redissolved in boiling alcohol. To the cooled solution was added diethyl ether to the point of turbidity when the mixture was refridgerated for 2 days. The resulting precipitates afford the product (223mg, 67%) that was used in Step 7.
[0654] Step 7: 1-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-cyclopropanecarboxylic acid methyl ester [0655] To 1-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 1, step 5] (49.8mg, 0.12 mmol) was added 1-hydroxybenzotriazole (18mg, 0.13mmol), N-(3-dimethylaminopropyI)-ethylcarbodiimide (EDCI: 25mg, 0.13 mmol), dichloromethane (2 mL), diisopropylethylamine (52pL, 0.30 mmol), and 1-Aminocyclo-propanecarboxylic acid methyl ester [example 1, step 6](20 mg, 0.13 mmol) and this mixture was stirred overnight. At this point the mixture was diluted with ethyl acetate (20 mL) and washed with saturated sodium bicarbonate solution (10 mL), citric acid solution (5 mL) and water. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to yield a crude product (101mg). The residue was purified by preparative TLC, eluting with a 40% mixture of ethyl acetate in hexane v/v. Following extraction of the purified band, the product was obtained (55 mg, 92%). Method 2, Rt 4.76 min. MS (ESI) m/z 498.4 [M +
[0656] Step 8: 1-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-cyclopropanecarboxylic acid 1-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-cyclopropanecarboxylic acid methyl ester [example 1, step 7](55mg, 0.11mmol) was dissolved in a 1:1 mixture of THF/water and treated with lithium hydroxide (8mg, 0.33mm01). The resulting mixture was stirred at room temperature for 2 days. At this point the pH was adjusted to 2 with hydrochloric acid and the mixture was extracted with ethyl acetate (3x20mL).
The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to yield a crude product (190mg). The residue was purified by preparative TLC, eluting with a 45%
mixture of acetone in dichloromethane v/v. Following extraction of the purified band, the product was obtained (22 mg, 41%).
Method 2, Rt 4.30 min. MS (ESI) m/z 484.6 [M + H4].
[0657] Example 2: 2-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-indan-2-carboxylic acid [0658] Step 1: 2-Amino-2-indancarboxylic acid methyl ester 2-Amino-2-indancarboxylic acid methyl ester was prepared according to a similar procedure as described for example 1, step 6 from 2-Amino-2-indancarboxylic acid hydrochloride (214mg, Immo!) that was used directly. Yield 155mg (68%) [0659] Step 2: 2-(4-{4-[1 -(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylaminoyindan-2-carboxylic acid methyl ester [0660] 2-(4-{4-[ 1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylaminoyindan-2-carboxylic acid methyl ester was prepared according to a similar procedure as described for example 1, step 7 from 1-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 1, step 5]
(49.8mg, 0.12 mmol) and 2-amino-2-indancarboxylic acid methyl ester [example 2, step 1].
Yield 55 mg, (81%). Method 2, Rt 5.49 min. MS (ESI) m/z 574.6 [M +1-1].
[0661] Step 3: 2444441 -(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-indan-2-carboxylic acid 2-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-indan-2-carboxylic acid was prepared according to a similar procedure as described for example 1, step 8 from 2-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-indan-2-carboxylic acid methyl ester [example 2, step 7](55mg, 0.11mmol).Yield 6 mg, (11%). Method 2, Rt 5.00 min. MS (ESI) m/z 560.3[M +
[0662] Example 3 : 2-(S)-(4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl acetic acid [0663] Step 1: L-phenylglycine methyl ester was prepared according to a similar procedure as described for example 1, step 6 from L-phenylglycine (756mg, 5mmo1) that was used directly.
Yield 480mg (58%).

[0664] Step 2: 2-(S)-(4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl acetic acid methyl ester [0665] 2-(S)-(4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl acetic acid methyl ester was prepared according to a similar procedure as described for example 1, step 7 from 1-(4-{4-[1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 1, step 5]( (58.1mg, 0.14 mmol) and L-phenylglycine methyl ester [Example 3, step 1] which was used without purification. Yield 60mg (76%) Method 2, Rt 5.41 min. MS (ESI) m/z 548.6 [M + H+].
[0666] Step 3: 2-(S)-(4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl acetic acid [0667] 2-(S)-(4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl acetic acid was prepared according to a similar procedure as described for example 1, step 8 from 2-(S)-(4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-ylybenzoylamino) phenyl acetic acid methyl ester [example 3, step 2](60mg, 0.11 mmol).Yield 4 mg (11%). Method 2, Rt 4.90 min. MS (ESI) m/z 534.4 [M +
H4].
[0668] Example 4 : 2-(R)- (4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}- benzoylam i no) phenyl propanoic acid [0669] Step 1: D-phenylalanine methyl ester [0670] D-phenylalanine methyl ester was prepared according to a similar procedure as described for example 1, step 6 from D-phenylalanine (1.12g, 7mm01). Yield 650mg (53%).
[0671] Step 2: 2-(R)-(4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl propanoic acid methyl ester [0672] 2-(R)-(4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl propanoic acid methyl ester was prepared according to a similar procedure as described for example 1, step 7 from 1-(4-{441-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 1, step 51 (58.1mg, 0.14 mmol) and D-phenylalanine methyl ester [example 4, step 11 to yield the product (40mg, 49%) which was used directly. Method 2, Rt 5.6 min. MS (ESI) m/z 562.2 [M + 1-1+].
[0673] Step 3: 2-(R)-(4-{4-[(R, S)-1-(2-Chloro-pheny1)-ethoxycarbonylam ino]-3-methyl-isoxazol-5-y1}- benzoylam i no) phenyl propanoic acid [0674] 2-(R)-(4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl propanoic acid was prepared according to a similar procedure as described for example 1, step 8 from 2-(R)-(4-{4-[(R,S)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino) phenyl propanoic acid methyl ester [example 4, step 2](40mg, 0.07mm01). Yield 8mg (21%).Method 2, Rt 4.94 min. MS (ESI) m/z 548.5 [M + 1-1].
[0675] Example 5 - 2 (R)4[443-methy1-4-((R)-1-phenylethoxycarbonylam ino)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid [0676] Step 1: 2(R)-[[443-methy1-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoic acid methyl ester [0677] 2(R)-[[4-[3-methyl-4-((R)-1-phenylethoxycarbonylam ino)isoxazol-5-yllbenzoic acid methyl ester was prepared according to a similar procedure as described for example 1, step 4 from 5-(4-Methoxycarbonyl-phenyl)-3-methyl-isoxazole-4-carboxylic acid [Example 1, step 3]
(1.55g, 5.9 mmol) and 1-(R)-(+)-phenyl-ethanol. Yield 1.18g (52%).
[0678] Step 2: 2(R)4[443-methy1-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoic acid [0679] 2(R)4[443-methy1-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoic acid was prepared according to a similar procedure as described for example 1, step 5 from 2(R)-([4-[3-methy1-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoic acid methyl ester [Example 5, step 1] (1.5g, 3.62 mmol). Yield 1.04g, (91%). Method 3, Rt 2.72 min. MS (ESI) m/z 367.3 [M +
[0680] Step 3:
2(R)-[[4-[3-methyl-4-((R)-1-phenylethoxycarbonylam ino)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid methyl ester [0681] 2(R)-[[4-[3-methyl-4-((R)-1-phenylethoxycarbonylam ino)isoxazol-5-yl]benzoyl]ami no]-3-phenyl-propanoic acid methyl ester was prepared according to a similar procedure as described for example 1, step 7 from 2(R)-[[4-[3-methyl-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoic acid [Example 5, step 2]
(64,7mg, 0.18 mmol) and D-phenylalanine methyl ester [example 4, step 1]. Yield 100 mg, 92%).
Method 3, Rt 3.04 min. MS (ESI) m/z 528.3 [M +
[0682] Step 4:
2(R)-[[4-[3-methyl-4-((R)-1-phenylethoxycarbonylam i no)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid (sodium salt) [0683] 2(R)1[443-methyl-44(R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid was prepared according to a similar procedure as described for example 1, step 8 from 2(R)4[4-[3-methyl-44(R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid methyl ester [example 5, step 3](100mg, 0.19mmol).
The crude material (21mg) was dissolved in methanol and treated with 1N sodium hydroxide (40pL) before drying to afford the product as its sodium salt (22 mg, 22%).
Method 3, Rt 3.04 min. MS (ESI) m/z 514.3 [M + Hi].
[0684] Example 6:
2(S)4[443-methyl-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid [0685] The title compound was prepared according to an analagous procedure to that described for example 5 from 5-(4-Methoxycarbonyl-phenyl)-3-methyl-isoxazole-4-carboxylic acid [Example 1, step 3] (64.7mg, 0.18mmol) and L-phenylalanine methyl ester to afford the product as its sodium salt (18mg, 18 /0).Method 3 Rt 3.05 min. MS (ESI) m/z 514.3 [M +

[0686] Example 7: (R)-24[442,5-dimethy1-44(R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-phenyl-propanoic acid [0687] Step 1: 5-(4-Methoxycarbonyl-pheny1)-1,3-dimethy1-1H-pyrazole-4-carboxylic acid tert-butyl ester and 3-(4-Methoxycarbonyl-phenyl)-1,5-dimethy1-1H-pyrazole-4-carboxylic acid tert-butyl ester:
[0688] 4-(2-tert-Butoxycarbony1-3-oxo-butyry1)-benzoic acid methyl ester [Example 1, Step 1]
(crude 76.0 g, 208.8 mmol on 100% purity basis) was dissolved in ethanol (2.2 L). Methyl hydrazine (9.72 g, 210.9 mmol) was added to the above solution dropwise under stirring at room temperature. The reaction mixture was stirred another 3 hrs at RT after finishing the addition.
The completion of reaction was confirmed by LC/MS. The solvent was removed under vacuum.
The residue was dissolved in Et0Ac (700 mL) and washed with water (2 X 500 mL). The organics were dried over Na2SO4, filtered and evaporated. Mixture of products obtained as an oil, which was used in the next step without further purification. Crude yield 72.6 g. Method 3, Rt 3.12 min. MS (ESI) nilz 331.0 [M + H+].
[0689] Step 2: 5-(4-Methoxycarbonyl-phenyl)-1,3-dimethy1-1H-pyrazole-4-carboxylic acid and 3-(4-Methoxycarbonyl-pheny1)-1,5-dimethy1-1H-pyrazole-4-carboxylic acid:
[0690] A mixture of 5-(4-Methoxycarbonyl-phenyl)-1,3-dimethy1-1H-pyrazole-4-carboxylic acid tert- butyl ester and 3-(4- Methoxycarbonyl- phenyl)- 1, 5-dimethyl- 1H-pyrazole-4-carboxylic acid tert-butyl ester [Example 7, Step 11(5.00 g., 15.13 mmol) was dissolved into CH2Cl2 (120.0 mL) and trifluoroacetic acid (40.0 mL) was added and the reaction mixture was stirred for 3 h at room temperature. The volatiles were removed under vacuum. The residue was dissolved into ethyl acetate (50.0 mL). It was then extracted with saturated aq. Na2CO3 solution (40 mL).
Separated aqueous layer was washed with ethyl acetate (2x20 mL). Then it was treated with 1 M HCI to pH 2. Then it was extracted with ethyl acetate (2x35 mL), dried (Na2SO4), filtered and concentrated to yield white solid mixture of acids (3.0 g., 72%). TLC on silica plate (15%

acetone in DCM): two fluorescent spots of two isomers Rf: 0.2 and Rf: 0.125.
Method 3, Rt 2.94 min. MS (ESI) m/z 275.0 [M + F1];
[0691] Step 3: 442,5-Dimethy1-44(R)-1-phenyl-ethoxycarbonylamino)-2H-pyrazol-3-y1]-benzoic acid methyl ester and 441,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-1H-pyrazol-3-y1]-benzoic acid methyl ester:
[0692] The mixture of acid isomers [Example 7, Step 21(6.0 g., 21.88 mmol), was suspended in anhydrous toluene (180.0 mL), under nitrogen and stirring. Then diisopropylethyl amine (3.39 g., 26.24 mmol) was added. A clear solution was generated to which diphenyl phosphoryl azide 7.22 g, 26.24 mmol) was added. The reaction mixture was heated to 950 C. Then (R)-(+)-1-phenylethyl alcohol (4.008 g, 32.8 mmol) was added dropwise at 95 C over a period of 40 minutes. Then the reaction mixture was heated for an additional 5 hr at 95 C, followed by stirring at room temperature overnight. Next day it was diluted with Et0Ac (300 mL), washed with sat. aq. Na2CO3 solution (200.0 mL) and water (2x500 mL), dried (Na2SO4), filtered and concentrated to yield crude oily carbamate (12.5 g). The crude was purified by column chromatography (SiO2), initial elution with DCM (250 mL) and then gradient elution Acetone:DCM (2% acetone in DCM to 10% acetone in DCM). Two pure isomers were obtained.
Fast moving isomer (1.667 g, 19.4%) and slow moving isomer (2.132 g, 24.77%) were obtained [> 95% by HPLC purity]. A fraction containing a mixture of isomers (0.812 g, 9.4%) was obtained. A) Slow moving spot: Method 3, Rt 2.78 min. MS (ESI) m/z 394.2 [M +
HI tentatively assigned as (R)- 441,5-Dimethy1-4-(1-phenyl-ethoxycarbonylamino)-1H-pyrazol-3-A-benzoic acid methyl ester.B) Fast moving spot: Method 3, Rt 2.80 min. MS (ESI) m/z 394.4 [M + Hi;
tentatively assigned as (R)- 442,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-2H-pyrazol-3-y1]-benzoic acid methyl ester.
[0693] Step 4: 442,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-2H-pyrazol-3-y1]-benzoic acid:

[0694] 442,5-Dimethy1-44(R)-1-phenyl-ethoxycarbonylamino)-2H-pyrazol-3-y1]-benzoic acid methyl ester [Example 7, Step 3B] (240 mg, 0.61 mmol) was dissolved in THE/water (2/1 v/v, 2.25 mL) and treated with LiOH (1.2 mL of a 1M aqueous solution, 2 eq.). The resulting mixture was stirred at room temperature overnight. The reaction was acidified to pH2, diluted with water and extracted with Et0Ac (2 X 40 mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford the product (180 mg, 78%). Method 3, Rt 2.81 min.
MS (ESI) miz 380.2 [M + H4].
[0695] Step 5: (R)- 2-{442,5-Dimethy1-44(R)-1-phenyl-ethoxycarbonylamino)-2H-pyrazol-3-y1Fbenzoylamino}-3-phenyl-propionic acid methyl ester:
To 442,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-2H-pyrazol-3-y1Fbenzoic acid [Example 7, step 4] (100 mg, 0.26 mmol) was added 1-hydroxybenzotriazole (43 mg, 0.32 mmol), EDCI (67 mg, 0.34 mmol), dimethylformamide (2 mL), diisopropylethylamine (184 pL, 1.06 mmol), and D-phenylalanine methyl ester [Example 4, Step 1] (86 mg, 0.39 mmol) and this mixture was stirred overnight. At this point the mixture was diluted with ethyl acetate (20 mL) and washed with 1N sodium hydroxide solution (10nnL), and water. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to yield the crude product (193 mg), which was purified by silica gel chromatography, eluting with an ethyl acetate/dichloromethane gradient to provide the title compound (95 mg, 68%). > 95% by HPLC purity.
Method 3, Rt 2.91 min. MS (ESI) miz 541.3 [M + H4].
[0696] Step 6: (R)-24[4-[2, 5-dim ethy1-4-((R)-1-phenylethoxycarbonylam ino)pyrazol-3-yl]benzoyl]amino]-3-phenyl-propanoic acid:
[0697] (R)- 2-{442,5-Dimethy1-44(R)-1-phenyl-ethoxycarbonylamino)-2H-pyrazol-3-y1]-benzoylamino}-3-phenyl-propionic acid methyl ester [Example 7, step 5] (95 mg, 0.176 mmol) was dissolved in a 2:1 mixture of THE/water (2.25 mL) and treated with 1M
lithium hydroxide solution (2 mL). The resulting mixture was stirred at room temperature overnight. The pH of the aqueous layer was adjusted to 2 with hydrochloric acid and the mixture was extracted with ethyl acetate (3x20mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to yield the crude product (112 mg). The crude material was purified by silica-gel chromatography, eluting with a dichloromethane/acetone gradient.
(90 mg, 97%).
Method 3, Rt 2.90 min. MS (ESI) m/z 527.5 [M +
[0698] Example 8: (R)-24[4-[1,5-dimethyl-44(R)-1-phenylethoxycarbonylamino)pyrazol-3-yllbenzoyl]amino]-3-phenyl-propanoic acid [0699] Step 1: 4-[1,5-Di methy1-4-((R)-1- phenyl-ethoxycarbonylam ino)- 1H-pyrazol-3-y1]-benzoic acid:
[0700] 4-[1,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-1H-pyrazol-3-y1]-benzoic acid methyl ester [Example 7, Step 3A] (240 mg, 0.61 mmol) was dissolved in THF/water (2/1 v/v, 2.25 mL) and treated with LiOH (1.2 mL of a 1M aqueous solution, 2 eq.). The resulting mixture was stirred at room temperature overnight. The reaction was acidified to pH2, transferred to a separatory funnel, diluted with water and extracted with Et0Ac (2 X 40 mL).
The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford the product (205 mg, 89%). Purity is 97% by HPLC. Method 3, Rt 2.43 min. MS (ESI) m/z 380.2 [M
+ 1-141.
[0701] Step 2: (R)- 2-{441,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-1H-pyrazol-3-y1]-benzoylamino}-3-phenyl-propionic acid methyl ester:
[0702] 4-[1,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-1H-pyrazol-3-y1]-benzoic acid [Example 8, Step 1] (100 mg, 0.26 mmol) was added 1-hydroxybenzotriazole (43 mg, 0.32 mmol), EDCI (67 mg, 0.34 mmol), dimethylformamide (2 mL), diisopropylethylamine (184 pL, 1.06 mmol), and D-phenylalanine methyl ester [Example 4, Step 1] (86 mg, 0.39 mmol) and this mixture was stirred overnight. At this point the mixture was diluted with ethyl acetate (20 mL) and washed with 1N sodium hydroxide solution (10mL), and water. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to yield the crude product (150 mg) which was purified by silica gel chromatography, eluting with a ethyl acetate/dichloromethane gradient to provide the product (75 mg, 53%). Purity > 97% by HPLC. Method 3, Rt 3.05 min.
MS (ESI) m/z 541.2 [M + W].
[0703] Step 3: (R)-2-[[4-[1,5-dimethy1-44(R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-phenyl-propanoic acid:
[0704] (R)- 2-{441,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-1H-pyrazol-3-y1]-benzoylamino}-3-phenyl-propionic acid methyl ester [Example 8, step 2] (75 mg, 0.139 mmol) was dissolved in a 2:1 mixture of THF/water (1.5 mL) and treated with 1M
lithium hydroxide solution (0.28 mL). The resulting mixture was stirred at room temperature overnight. The pH of the aqueous layer was adjusted to 2 with hydrochloric acid and the mixture was extracted with ethyl acetate (3x20mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to yield the product [>95% HPLC purity] (60 mg, 82%).
Method 3, Rt 2.69 min. MS (ESI) m/z 527.5 [M + W].
[0705] Example 9: (R)-24[442,5-dimethy1-44(R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid [0706] Step 1: (R)-2-Amino-3-(4-fluoro-phenyl)-propionic acid methyl ester hydrochloride:
[0707] (R)-2-Amino-3-(4-fluoro-phenyl)-propionic acid methyl ester hydrochloride was prepared according to a similar procedure as described for example 1, step 6 from D-4-Fluorophenyl alanine (1 g, 5.46 mmol). Yield 900 mg, (71 %). Method 3, Rt 0.54 min. MS (ESI) m/z 198.3 [M + H+].
[0708] Step 2: (R)- 2-{442,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-2H-pyrazol-3-y1]-benzoylamino}-3-(4-fluoro-pheny1)-propionic acid methyl ester:
[0709] (R)- 2-{442,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-2H-pyrazol-3-y1]-benzoylamino}-3-(4-fluoro-pheny1)-propionic acid methyl ester was prepared according to a similar procedure as described for example 7, step 5 from (R)- 4-[2,5-Dimethy1-4-(1-phenyl-ethoxycarbonylamino)-2H-pyrazol-3-y1]-benzoic acid [Example 7, Step 4] (50 mg, 0.132 mmol) and (R)-2-Amino-3-(4-fluoro-phenyl)-propionic acid methyl ester hydrochloride [Example 9, Step 1]. Yield 59 mg (80%).
[0710] Step 3: (R)-24[442, 5-di methy1-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl] benzoyl]ami no]-3-(441 uorophenyl) propanoic acid:
[0711] (R)-2-[[4-[2, 5-d imethy1-4-(( R)-1-phenylethoxycarbonylamino) pyrazol-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid was prepared according to a similar procedure as described for example 7, step 6 from (R)- 2-{4-[2,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-2H-pyrazol-3-y1Fbenzoylamino}-3-(4-fluoro-phenyl)-propionic acid methyl ester [Example 9, Step 2] (59 mg, 0.11 mmol) to afford the product 55 mg (87%). Method 3, Rt 2.73 min. MS (ESI) m/z 545.4 [M + H+].
[0712] Example 10: (R)-24[4-[1,5-dimethy1-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid The title compound was prepared according to an analogous procedure to that described for example 8 from 441,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-1H-pyrazol-3-yll-benzoic acid [Example 8, Step 1]
(50 mg, 0.132 mmol) and (R)-2-Amino-3-(4-fluoro-phenyl)-propionic acid methyl ester hydrochloride [Example 9, Step 1]. Yield 55 mg, (87%). Method 3, Rt 2.69 min. MS (ESI) m/z 545.4 [M +
[0713] Example 11: (R)- 3-(4-bromopheny1)-24[442, 5-d imethy1-44(R)- 1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid [0714] Step 1: (R)-2-Amino-3-(4-bromo-phenyl)-propionic acid methyl ester hydrochloride:
[0715] The title compound was prepared using a similar procedure as described for example 1, step 6 from D-4-bromophenyl alanine (1 g, 4.1 mmol). Yield 550 mg (46 %).
Method 3, Rt 1.70 min. MS (ESI) m/z 258.1 [M +
[0716] Step 2: (R)- 3-(4-bromopheny1)-2-[[442 , 5-dim ethy1-44(R)-1-phenylethoxycarbonylamino)-pyrazol-3-yl]benzoyl]amino]propanoic acid [0717] The title compound was prepared according to an analogous procedure to that described for example 9 (steps 2 & 3) from 442,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-2H-pyrazol-3-y11-benzoic acid [Example 7, Step 4] and (R)-2-Amino-3-(4-bromo-pheny1)-propionic acid methyl ester hydrochloride [Example 11, Step 1].
Yield 30 mg (65%). Method 3, Rt 3.03 min. MS (ESI) m/z 607.4 [M + 1-1].
[0718] Example 12: (R)- 3-(4-bromopheny1)-2-[[4-[1, 5-di methy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid The title compound was prepared according to an analogous procedure to that described for example 8 from 4-[1,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-1H-pyrazol-3-y1]-benzoic acid [Example 8, Step 1] (50 mg, 0.132 mmol) and 3-(4-bromo-phenyl)-propionic acid methyl ester hydrochloride [Example 11, Step 1]. Yield 60 mg, (80%). Method 3, Rt 3.02 min. MS (ESI) m/z 619.2 [M +
[0719] Example 13: (R)- 3-(4-chloropheny1)-24[4-[2,5-dimethy1-44(R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyllamino]propanoic acid [0720] Step 1: (R)- 2-Amino-3-(4-chloro-phenyl)-propionic acid methyl ester hydrochloride:
[0721] (R)- 2-Amino-3-(4-chloro-phenyl)-propionic acid methyl ester hydrochloride was prepared using a similar procedure as described for example 1, step 6 from D-4-chlorophenyl alanine (1 g, 5 mmol). Yield 940 mg (75 %). Method 3, Rt 0.03 min. MS (ESI) m/z 214.0 [M +
H+].
[0722] Step 2: (R, R)- 3-(4-chloropheny1)-24[4-[2,5-dimethy1-4-(1-phenylethoxycarbonylamino)-pyrazol-3-yl]benzoyl]amino]propanoic acid [0723] The title compound was prepared according to an analogous procedure to that described for example 9 (steps 2 & 3) from (R)- 4-[2,5-Dimethy1-4-(1-phenyl-ethoxycarbonylamino)-2H-pyrazol-3-y1]-benzoic acid [Example 7, Step 4] and (R)-2-Amino-3-(4-chloro-pheny1)-propionic acid methyl ester hydrochloride [Example 13, Step 1].
Yield 40 mg (55%). Method 3, Rt 2.80 min. MS (ESI) m/z 561.3 [M + H+].

[0724] Example 14: (R)- 3-(4-chloropheny1)-2-[[441,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid [0725] The title compound was prepared according to an analogous procedure to that described for example 8 from 441,5-Dimethy1-44(R)-1-phenyl-ethoxycarbonylamino)-1H-pyrazol-3-y1]-benzoic acid [Example 8, Step 1] and (R)- 2-Amino-3-(4-chloro-phenyl)-propionic acid methyl ester hydrochloride [Example 8, Step 1]. Yield 40 mg (54%)Method 3, Rt 3.00 min.
MS (ESI) m/z 561.3 [M + H+].
[0726] Example 15: (R)- 3-(3,4-difluoropheny1)-24[442,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid [0727] Step 1: (R)- 2-Amino-3-(3,4-difluoro-phenyl)-propionic acid methyl ester hydrochloride:
[0728] (R)- 2-Amino-3-(3,4-difluoro-phenyl)-propionic acid methyl ester hydrochloride was prepared using a similar procedure as described for example 1, step 6 from D-3,4-difluorophenyl alanine (1 g, 4.97 mmol). Yield 1.04 g, 83 %). Method 3, Rt 0.16 min. MS (ESI) m/z 216.0 [M + H];
[0729] Step 2: (R)- 3-(3,4-difluoropheny1)-2-[[4-[2,5-dimethy1-4-((R)-1-phenylethoxycarbonylamino)-pyrazol-3-yl]benzoyl]amino]propanoic acid:
[0730] The title compound was prepared according to an analogous procedure to that described for example 9 (steps 2 & 3) from (R)- 4-[2,5-Dimethy1-4-(1-phenyl-ethoxycarbonylamino)-2H-pyrazol-3-y1]-benzoic acid [Example 7, Step 4] (50 mg, 0.132 mmol) and (R)- 2-Amino-3-(3,4-difluoro-phenyl)-propionic acid methyl ester hydrochloride [Example 15, Step 1]. Yield 30 mg (61%). Method 3, Rt 2.96 min. MS (ESI) m/z 563.4 [M +
[0731] Example 16: (R)- 3-(3,4-difluoropheny1)-2-[[441,5-dimethy1-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid [0732] The title compound was prepared according to an analogous procedure to that described for example 8 from 4-[1,5-Dimethy1-4-((R)-1-phenyl-ethoxycarbonylamino)-1H-pyrazol-3-y1]-benzoic acid [Example 8, Step 1] (50 mg, 0.132 mmol) and (R)- 2-Amino-3-(3,4-difluoro-pheny1)-propionic acid methyl ester hydrochloride [Example 15, Step 1]. Yield 20 mg (56%). Method 3, Rt 2.71 min. MS (ESI) m/z 563.3 [M + H+].
[0733] Example 17: (R)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-cyclopropyl-propionic acid [0734] Step 1: (R)-2-Amino-3-cyclopropylpropionic acid methyl ester hydrochloride:
[0735] (R)- 2-Amino-3-cyclopropylpropionic acid methyl ester hydrochloride was prepared using a similar procedure as described for example 1, step 6 from (R)- 2-Amino-cyclopropylpropionic acid and used directly. Yield 350mg (100%).
[0736] Step 2: 4-{4414(R)-2-Chloro-phenylyethoxycarbonylami no]-3-m ethyl-isoxazol-5-y1}-benzoic acid methyl ester [0737] Prepared in analogous fashion as in Example 5 Step 1 using 5-(4-methoxycarbonyl-pheny1)-3-methyl-isoxazole-4-carboxylic acid [Example 1, step 3] (3.47 g, 13.28 mmol) and (R)-1-(2-chloropheny1)-ethanol. Yield = 1.81 g (4.36 mmol, 25 %). HPLC (254 nm):
Method 3 Rt 3.31 min. MS (ESI) m/z 415.5 [M + H+].
[0738] Step 3: 4-{441 -((R-2-Chloro-phenyl)-ethoxycarbonylam i no]-3-methyl-isoxazol-5-y1}-benzoic acid [0739] Prepared in analogous fashion as in Example 5, Step 2 using 4-{441-((R)-2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid methyl ester [Example 17, step 2](1.81 g, 4.46 mmol). Yield = 1.70 g (4.25 mmol, 95 %). HPLC (254 nm):
Method 3 Rt 3.01 min. MS (ESI) m/z 401.2 [M +
[0740] Step 4: (R)-2-(4-{441-((R)-2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-cyclopropyl-propionic acid [0741] The title compound was prepared according to an analogous procedure to that described for example 5 from 4-{441-((R)-2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 17, step 3] (50mg, 0.13 mmol) and (R)- 2-Amino-3-cyclopropylpropionic acid methyl ester hydrochloride [Example 17, step 1].
Yield 22mg (34%).
Method 3, Rt 3.27min. MS (ESI) m/z 512.5 [M + H+].
[0742] Example 18: (R)-2-{443-Methy1-4-((S)-1-phenyl-ethoxycarbonylam ino)-isoxazol-5-y1]-benzoylamino}-3-phenyl-propionic acid Step 1:
443-Methy1-44(S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzoic acid [0743] 443-Methy1-44(S)-1-phenyl-ethoxycarbonylaminoyisoxazol-5-y1]-benzoic acid was prepared in analogous fashion to example 17 [steps & 3] from 5-(4-methoxycarbonyl-pheny1)-3-methyl-isoxazole-4-carboxylic acid [Example 1, step 3] (1 g, 3.3 mmol) and (S)-1-(2-chloropheny1)-ethanol. Yield = 800 mg (2.19 mmol, 60 /0). HPLC (254 nm):
Method 3 Rt 2.67 min. MS (ESI) m/z 367.4 [M + F14].
[0744] Step 2: (S, R)-2-{443-Methy1-4-(1-phenyl-ethoxycarbonylam ino)-isoxazol-5-y1]-benzoylamino}-3-phenyl-propionic acid [0745] The title compound was prepared according to an analogous procedure to that described for example 5 from (S)-443-Methy1-4-(1-phenyl-ethoxycarbonylam ino)-isoxazol-5-y1]-benzoic acid [Example 18, step 2] (61 mg, 0.12 mmol) and D-phenylalanine methyl ester hydrochloride. Yield = 30 mg (0.06 mmol, 49 %). HPLC (254 nm): Method 3 Rt 3.05 min. MS
(ESI) m/z 514.5 [M + H+].
[0746] Example 19: (S)-2-{443-Methy1-4-((S)-1-phenyl-ethoxycarbonylam ino)-isoxazol-5-y1]-benzoylamino}-3-phenyl-propionic acid [0747] The title compound was prepared according to an analogous procedure to that described for example 18 from 443-Methy1-44(S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzoic acid [Example 18, step 2] (61 mg, 0.12 mmol) and L-phenylalanine methyl ester hydrochloride. Yield = 22 mg (0.04 mmol, 36 %). HPLC (254 nm): Method 3 Rt 2.87 min. MS
(ESI) m/z 514.5 [M + H+].

[0748] Example 20: (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-phenyl-propionic acid [0749] The title compound was prepared according to an analogous procedure to that described for example 17 from 4-{4414(R)-2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 17, step 3] (60 mg, 0.15 mmol) and D-phenylalanine methyl ester. Yield = 65 mg (0.12 mmol, 77 %). HPLC (254 nm): Method 3 Rt 2.93 min. MS
(ESI) m/z 566.3 [M + Hi].
[0750] Example 21: (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-fluoro-pheny1)-propionic acid [0751] The title compound was prepared according to an analogous procedure to that described for example 17 from 4-{4414(R)-2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 17, step 3] (60 mg, 0.15 mmol) and D-4-fluorophenylalanine methyl ester. Yield = 65 mg (0.12 mmol, 77 %). HPLC (254 nm): Method 3 Rt 2.93 min. MS (ESI) m/z 566.3 [M + H+].
[0752] Example 22 (R)-3-(4-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid [0753] The title compound was prepared according to an analogous procedure to that described for example 17 from 4-{441-((R)-2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 17, step 3] (60 mg, 0.15 mmol) and 0-4-chlorophenylalanine methyl ester. Yield = 64 mg (0.11 mmol, 74%). HPLC (254 nm): Method 3 Rt 3.11 min. MS (ESI) m/z 583.4 [M + H+].
[0754] Example 23: (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(3,4-difluoro-pheny1)-propionic acid [0755] The title compound was prepared according to an analogous procedure to that described for example 17 from 4-{4414(R)-2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 17, step 3] (60 mg, 0.15 mmol) and 0-3,4-difluorophenylalanine methyl ester hydrochloride. Yield = 41 mg (0.07 mmol, 47 %). HPLC (254 nm): Method 3 Rt 2.96 min. MS (ESI) m/z 584.1 [M + He].
[0756] Example 24: (R)-3-(2-Chloro-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid [0757] The title compound was prepared according to an analogous procedure to that described for example 17 from 4-{441-((R)-2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 17, step 3] (60 mg, 0.15 mmol) and D-2-chlorophenylalanine methyl ester hydrochloride. Yield = 41 mg (0.07 mmol, 47 %). HPLC (254 nm): Method 3 Rt 3.06 min. MS (ESI) m/z 584.2 [M + He].
[0758] Example 25: (R)-3-(4-Bromo-pheny1)-2-(4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-propionic acid [0759] The title compound was prepared according to an analogous procedure to that described for example 17 from 4-{4-[(R)-1-(2-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 17, step 3] (60 mg, 0.15 mmol) and D-4-bromophenylalanine methyl ester hydrochloride. Yield = 65 mg (0.10 mmol, 35 %). HPLC (254 nm): Method 3 Rt 3.28 min. MS (ESI) nilz 626.3, 628.4 [M + He].
[0760] Example 26: (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(2-fluoro-pheny1)-propionic acid [0761] The title compound was prepared according to an analogous procedure to that described for example 17 from 4-{4-[(R)- 1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 17, step 3] (60 mg, 0.15 mmol) and D-2-fluorophenylalanine methyl ester hydrochloride. Yield = 70 mg (0.12 mmol, 52 %). HPLC (254 nm): Method 3 Rt 3.12 min. MS (ESI) m/z 566.5, 567.8 [M + He].

[0762] Example 27: (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-p-tolyl-propionic acid [0763] The title compound was prepared according to an analogous procedure to that described for example 17 from 4-{4-[(R)- 1-(4-chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 17, step 3] (60 mg, 0.15 mmol) and 0-4-methylphenylalanine methyl ester hydrochloride. Yield = 37 mg (0.07 mmol, 43 %). HPLC (254 nm): Method 3 Rt 3.13 min. MS (ESI) m/z 562.3 [M + H+].
[0764] Example 28: (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-trifluoromethyl-pheny1)-propionic acid [0765] The title compound was prepared according to an analogous procedure to that described for example 17 from 4-{4-[(R)-1-(4-bromo-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 17, step 3] (60 mg, 0.15 mmol) and D-4-trifluoromethylphenylalanine methyl ester hydrochloride. Yield = 40 mg (0.06 mmol, 44 %).
HPLC (254 nm): Method 3 Rt 3.00 min. MS (ESI) m/z 616.2 [M + 1-1].
[0766] Example 29: (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoylamino)-3-(4-cyano-pheny1)-propionic acid [0767] The title compound was prepared according to an analogous procedure to that described for example 17 from 4-{4-[(R)-1-(4-bromo-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzoic acid [Example 17, step 3] (60 mg, 0.15 mmol) and D-4-cyanophenylalanine methyl ester hydrochloride. Yield = 17 mg (0.03 mmol, 20 /0). HPLC (254 nm): Method 3 Rt 2.93 min. MS (ESI) m/z 573.2 [M + H+].
[0768] Example 30: (R)- 2-(4-{5-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-methyl-pyrazol-1-y1}-benzoylamino)-3-phenyl-propionic acid Step 1: 2-(4-Cyano-pheny1)-4-methy1-2H-pyrazole-3-carboxylic acid ethyl ester [0769] A solution of trichloroacetyl chloride (12.92 mL, 115.8 mmol) in dichloromethane (30 mL) was cooled to -10 C under a nitrogen atmosphere. A solution of ethyl propenyl ether (12.82 mL, 115.8 mmol) and pyridine (9.36 mL, 115.8 mmol) was added dropwise at a rate to maintain the internal temperature at -10 C. After addition was complete, the reaction was warmed to room temperature and stirred for 24 hours. The mixture was filtered and the solids were washed with dichloromethane (50 mL). The filtrates were evaporated to dryness under vacuum to yield an oil (31.71 g). This material was dissolved in ethanol (400 mL) and treated with 4-cyanophenylhydrazine hydrochloride (24.81 g, 139 mmol). The resulting mixture was refluxed for 3 hours and then cooled to room temperature. The volatiles were evaporated in vacuo, the residue was dissolved in Et0Ac (1 L) and washed with 1 N aqueous HCI solution (2 X 300 mL).
The organic layer was separated, washed with water, dried over anhydrous Na2SO4, filtered and concentrated in vacuo to obtain a yellow solid (27.8 g). This was triturated with Et0Ac (130 mL) and the remaining solids removed by filtration (do not contain product). The filtrates were concentrated to 50 mL volume and the precipitated solids were filtered (do not contain product).
The filtrates were concentrated and purified by silica gel chromatography, eluting with a 100/0 to 88/12 hexanes/acetone gradient. Collected fractions containing a mixture of the two isomeric products, which were concentrated to dryness and triturated with methanol to yield the ,desired isomer [2-(4-cyano-phenyl)-4-methyl-2H-pyrazole-3-carboxylic acid ethyl ester]
as a yellow solid (3.77g, 14.8 mmol, 13%). HPLC (254 nm): Method 3 Rt 2.93 min. MS (ES!) m/z 256.3 [M + 1-11 1H NMR (500 MHz, CDCI3) 6 7.73 (d, J = 8.5 Hz, 2 H); 7.58 (s, 1 H); 7.52 (d, J
= 8.5 Hz, 2 H);
4.27 (q, J= 7.1 Hz, 2 H); 2.35 (s, 3 H); 1.26 (t, J= 7.1 Hz, 3 H).
[0770] Step 2: 2-(4-Cyano-phenyl)-4-methyl-2H-pyrazole-3-carboxylic acid [0771] A stirred solution of 2-(4-Cyano-phenyl)-4-methyl-2H-pyrazole-3-carboxylic acid ethyl ester [Example 30, step 11(500 mg, 1.96 mmol) in THF (10 mL) was treated with LiOH 1 N
aqueous solution (10 mL) and the resulting mixture was stirred at room temperature for 6 hours, after which time analysis by HPLC/MS indicates approximately 60% conversion to product. The reaction mixture was diluted with ethyl acetate (100 mL) and washed with 1 N
aqueous NaOH
solution (100 mL). The organic layer contained unreacted starting material.
The aqueous layer was acidified to pH 1 with 1 N HCI aqueous solution and the resulting suspension was extracted with ethyl acetate (100 mL). The organic layer was separated, dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford the pure product as a white solid (289 mg, 1.27 mmol, 65 c/o). HPLC (254 nm): Method 3 Rt 2.56 min. MS (ESI) m/z 228.3 [M +
[0772] Step 3: [2-(4-Cyano-phenyl)-4-methy1-2H-pyrazol-3-y1]-carbamic acid (R)-1-(2-chloro-pheny1)-ethyl ester [0773] 2-(4-Cyano-phenyl)-4-methyl-2H-pyrazole-3-carboxylic acid [Example 30, step 2] (218 mg, 0.96 mmol) was suspended in toluene (10 mL) and treated with diisopropylethylamine (200 pL, 1.16 mmol),. The resulting solution was treated with diphenylphosphoryl azide (230 pL, 1.06 mmol) and heated to 65 C. (R)- 1-(2-chloro-phenyl)-ethanol (227 mg, 1.44 mmol) was added to the reaction mixture and the temperature was increased to 105 C for 30 minutes, during which time vigorous gas evolution was observed. The reaction was brought to 65 C
and stirred at that temperature for 4 hours. The reaction was deemed complete by HPLC/MS. After cooling, the volatiles were removed in vacuo and the crude residue was purified by silica gel chromatography, eluting with a hexanes/ethyl acetate gradient. Product was isolated as a white solid (120 mg, 0.31 mmol, 33 AD). HPLC (254 nm): Method 3 Rt 3.84 min. MS
(ESI) m/z 381.2 [M + H+].
[0774] Step 4: 4-{5-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-methyl-pyrazol-1-yll-benzoic acid [0775] A solution containing (R)42-(4-Cyano-pheny1)-4-methyl-2H-pyrazol-3-y1]-carbamic acid 1-(2-chloro-phenyl)-ethyl ester (120 mg, 0.32 mmol) and THF (1.5 mL) was treated with a 1 N
aqueous LiOH solution (1.5 mL) and the resulting mixture was stirred at room temperature for 36 hours, followed by heating to 45 C for 24 hours. The reaction mixture was diluted with ethyl acetate (50 mL) and washed with 1 N aqueous NaOH solution (50 mL). The aqueous layer was acidified to pH 1 with 1 N HCI aqueous solution and the resulting suspension was extracted with ethyl acetate (50 mL). The organic layer was separated, dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford the pure product as a white solid. Yield =
62 mg (0.16 mmol, 49 %). HPLC (254 nm): Method 3 Rt 3.14 min. MS (ESI) m/z 399.2 [M + Hi].
[0776] Step 3: (R)-2-(4-{5-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-methyl-pyrazol-1-yI}-benzoylamino)-3-phenyl-propionic acid methyl ester [0777] 4-{5-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-methyl-pyrazol-1-y1}-benzoic acid (62 mg, 0.16 mmol), was dissolved in DMF (1.4 mL) and treated with di-isopropylethylamine (112 pL, 0.62 mmol) under nitrogen. EDCI (40 mg, 0.20 mmol) and HOBt (26 mg, 0.19 mmol) was added and the resulting mixture was stirred for 30 minutes. D-Phenylalanine methyl ester hydrochloride (50 mg, 0.23 mmol) was added and the resulting mixture stirred at room temperature overnight. The reaction was diluted with Et0Ac (50 mL) and transferred to a separatory funnel. The organics were washed with 1 N HCI
aqueous solution and brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude residue was purified by preparative TLC plate (1000 pm), eluting with a 7:3 v/v hexanes/ethyl acetate mixture. The product was obtained as a white solid. Yield = 35 mg (0.06 mmol, 39 %). HPLC
(254 nm): Method 3 Rt 3.28 min. MS (ESI) m/z 561.3, 563.3 [M + Hi].
[0778] Step 4: (R)- 2-(4-{5-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-methyl-pyrazol-1-ylybenzoylamino)-3-phenyl-propionic acid [0779] A solution containing (R)-2-(4-{5-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-methyl-pyrazol-1-y1}-benzoylamino)-3-phenyl-propionic acid methyl ester (35 mg, 0.06 mmol), and THF (1 mL) was treated with a 1 N aqueous LiOH solution (125 pL) and the resulting mixture was stirred at room temperature for 18 hours. The reaction mixture was diluted with ethyl acetate (50 mL) and acidified to pH 1 with 1 N HCI aqueous solution. The organic layer was separated, dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford the pure product as a white solid. Yield = 20 mg (0.04 mmol, 61 %). HPLC (254 nm):
Method 3 Rt 3.19 min. MS (ESI) m/z 547.6, 550.6 [M + H+].
[0780] Example 31: (R)-2-{4-[3-Methyl-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzylamino}-3-phenyl-propionic acid [0781] Step 1: 5-(4-Chloromethyl-phenyl)-3-methyl-isoxazole-4-carboxylic acid tert-butyl ester [0782] A stirred suspension of MgCl2 (2.97 g, 31.2 mmol) in dichloromethane (30 mL) under nitrogen was treated dropwise with tert-butyl acetoacetate (5.17 mL, 31.2 mmol) and the resulting mixture was cooled to 0 C. The mixture was stirred at that temperature for 15 minutes and then treated with dropwise addition of pyridine (4.85 mL, 60.0 mmol).
After 15 minutes, a solution of 4-(chloromethyl)benzoyl chloride (5.67 g, 30.0 mmol) in dichloromethane (30 mL) was added dropwise. The resulting mixture was maintained at 0 C for 1 hour and then at room temperature for an additional hour. The reaction was quenched with careful addition of water (100 mL) and the mixture was transferred to a separatory funnel. The organic layer was washed with a 1 N HCI aqueous solution (2 X 100 mL) then dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude residue was dissolved in ethanol (60 mL) and treated with a solution of NH2OH.HCI (6.67 g, 96.0 mmol) in water (13 mL). This mixture was heated to 60 C
for 2 hours and at room temperature overnight. A thick white precipitate formed which was filtered, rinsed with ethanol and air-dried. The mother liquor was concentrated and cooled to 0 C to yield a second crop of solid which was filtered and air-dried. Combined yield = 5.82 g (19.0 mmol, 63 %). HPLC (254 nm): Method 3 Rt 3.49 min. MS (ESI) m/z 308.4 [M + H+].
[0783] Step 2: 5-(4-Chloromethyl-phenyl)-3-methyl-isoxazole-4-carboxylic acid [0784] 5-(4-Chloromethyl-phenyl)-3-methyl-isoxazole-4-carboxylic acid tert-butyl ester (4.61 g, 15.0 mmol) was dissolved in dichloromethane (7.5 mL) and treated with trifluoroacetic acid (7.5 mL). The resulting mixture was stirred at room temperature for 18 hours, after which time the reaction was deemed complete by HPLC/MS. The volatiles were removed in vacuo to yield the crude product as a white solid (3.8 g, 15.0 mmol, quant.), which was used as is in the next step.
[0785] Step 3: [5-(4-Chloromethyl-phenyl)-3-methyl-isoxazol-4-yl]-carbamic acid (R)-1-phenyl-ethyl ester [0786] 5-(4-Chloromethyl-phenyl)-3-methyl-isoxazole-4-carboxylic acid (3.0 g, 12.0 mmol) was suspended in toluene (120 mL) and treated with triethylamine (2.02 mL, 14.4 mmol). The resulting solution was treated with diphenylphosphoryl azide (2.85 mL, 13.2 mmol) and heated to 65 C. (R)-1-(phenyl)-ethanol (1.9 g, 15.6 mmol) was added to the reaction mixture and the temperature was increased to 105 C for 30 minutes, during which time vigorous gas evolution was observed. The reaction was brought to 65 C and stirred at that temperature for 4 hours.
The reaction was deemed complete by HPLC/MS. After cooling, the volatiles were removed in vacuo and the crude residue was purified by silica gel chromatography, eluting with a hexanes/ethyl acetate gradient. Product isolated as a white solid (3.16 g, 8.52 mmol, 71 %).
HPLC (254 nm): Method 3 Rt 3.02 min. MS (ESI) m/z 371.2 [M + H+].
[0787] Step 4: (R)- 2-{443-Methyl-4-((R-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-3-phenyl-propionic acid methyl ester [0788] A solution containing [5-(4-Chloromethyl-phenyl)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-phenyl-ethyl ester (74 mg, 0.2 mmol), DMF (2 mL) and triethylamine (224 pL, 1.6 mmol) was treated with D-phenylalanine methyl ester hydrochloride (173 mg, 0.80 mmol) and heated to 80 C for 3 hours. The reaction was deemed complete by HPLC/MS. The reaction was cooled, partitioned between Et0Ac and water and transferred to a separatory funnel. The organic layer was washed with water and brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude yellow oily residue was purified by silica gel chromatography eluting with a hexanes/Et0Ac gradient. The product was obtained as a colorless film (77 mg, 0.15 mmol, 75 To). HPLC (254 nm): Method 3 Rt 2.67 min. MS (ESI) m/z 514.4 [M
+ HIT

[0789] Step 5: (R)-2-{443-Methy1-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylam ino}-3-phenyl-propionic acid [0790] A solution containing (R)- 2-{443-Methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-3-phenyl-propionic acid methyl ester (77 mg, 0.15 mmol) and THF
(1.5 mL) was treated with a 1 N aqueous LiOH solution (1.5 mL) and the resulting mixture was stirred at room temperature for 18 hours. The reaction mixture was diluted with ethyl acetate (50 mL) and acidified to pH - 5 with 1 N HCI aqueous solution. The organic layer was separated, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The residue was triturated with diethyl ether to afford the pure product as a white solid (9 mg, 0.018 mmol, 12 %). HPLC
(254 nm): Method 3 Rt 2.74 min. MS (ESI) m/z 500.5 [M +
[0791] Example 32: (R)-3-(2-Fluoro-pheny1)-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-propionic acid [0792] The title compound was prepared in analogous fashion as in Example 31 using [5-(4-chloromethyl-pheny1)-3-methyl-isoxazol-4-yl]-carbamic acid (R)-1-phenyl-ethyl ester [Example 31, step 3](100 mg, 0.27 mmol), and D-2-fluorophenyl-alanine methyl ester hydrochloride. Yield = 10 mg (0.02 mmol, 7 %). HPLC (254 nm): Method 3 Rt 2.64 min. MS (ESI) m/z 518.4 [M +
[0793] Example 33: (R)-2-{443-Methy1-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y11-benzylannino}-3-(4-trifluoromethyl-pheny1)-propionic acid [0794] The title compound was prepared in analogous fashion as in Example 31 using [5-(4-chloromethyl-pheny1)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-phenyl-ethyl ester [Example 31, step 3](100 mg, 0.27 mmol), and D-4-trifluoromethylphenyl-alanine methyl ester hydrochloride. Yield = 18 mg (0.03 mmol, 11%). HPLC (254 nm): Method 3 Rt 3.10 min. MS
(ESI) m/z 568.5 [M + Hi].

[0795] Example 34: (R)-3-Cyclopropy1-2-{443-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylamino}-propionic acid The title compound was prepared in analogous fashion as in Example 31 using [5-(4-chloromethyl-phenyl)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-phenyl-ethyl ester [Example 31, step 3](100 mg, 0.27 mmol), and (R)-2-Amino-3-cyclopropylpropionic acid methyl ester hydrochloride [Example 17, step 1].
Yield = 13 mg (0.03 mmol, 35 %). HPLC (254 nm): Method 3 Rt 2.82 min. MS (ESI) m/z 464.5 [M +1-11].
[0796] Example 35: (R)-3-(2-Chloro-pheny1)-2-{4-[3-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzylaminol-propionic acid [0797] The title compound was prepared in analogous fashion as in Example 31 using [5-(4-chloromethyl-pheny1)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-phenyl-ethyl ester [Example 31, step 3](100 mg, 0.27 mmol), and D-2-chlorophenyl-alanine methyl ester hydrochloride. Yield = 38 mg (0.07 mmol, 27 %). HPLC (254 nm): Method 3 Rt 3.05 min. MS (ESI) m/z 534.2 [M +
H+].
[0798] Example 36: (R)-3-(4-Chloro-pheny1)-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yli-benzylamino}-propionic acid [0799] The title compound was prepared in analogous fashion as in Example 31 using [5-(4-chloromethyl-pheny1)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-phenyl-ethyl ester [Example 31, step 3}(100 mg, 0.27 mmol), and D-4-chlorophenyl-alanine methyl ester hydrochloride. Yield = 8 mg (0.01 mmol, 5 0/0). HPLC (254 nm): Method 3 Rt 3.13 min. MS (ESI) m/z 534.4 [M + Hi].
[0800] Example 37: (R)- 2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-phenyl-propionic acid [0801] Step 1: [5-(4-Chloromethyl-phenyl)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-(2-chloro-pheny1)-ethyl ester [0802] [5-(4-Chloromethyl-phenyl)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-(2-chloro-pheny1)-ethyl ester was prepared in analogous fashion as in Example 31, steps 1-3 from 5-(4-chloromethyl-phenyl)-3-methyl-isoxazole-4-carboxylic acid [Example 31, step 21(1.95 g, 7.75 mmol) and (R)-1-(2-chlorophenyI)-ethanol (1.82 g, 11.62 mmol). Yield = 1.33 g (3.28 mmol, 42 /0). HPLC (254 nm): Method 3 Rt 3.31 min. MS (ESI) m/z 405.3 [M +
[0803] Step 2: (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yI}-benzylamino)-3-phenyl-propionic acid methyl ester [0804] (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-phenyl-propionic acid methyl ester was prepared in analogous fashion as in Example 31, steps 4 from [5-(4-Chloromethyl.phenyl)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-(2-chloro-pheny1)-ethyl ester [Example 37, step 11(101 mg, 0.25 mmol) and D-phenylalanine methyl ester hydrochloride. Yield = 45 mg (0.08 mmol, 33 To). HPLC (254 nm):
Method 3 Rt 2.90 min. MS (ESI) m/z 548.5 [M + H+].
[0805] Step 3: (R)- 2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-phenyl-propionic acid [0806] Prepared in analogous fashion as in Example J, Step 5 using the following reagents and amounts: (R)-2-(4-{4-[(R)-1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-phenyl-propionic acid methyl ester [Example 37, step 2] (45 mg, 0.08 mmol).
Yield = 6 mg (0.01 mmol, 14 %). HPLC (254 nm): Method 3 Rt 2.69 min. MS (ESI) m/z 534.3 [M
+ H+].
[0807] Example 38: (R)- 2-(4-{4-[(R)_1-(2-Chloro-pheny1)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-(2-fluoro-pheny1)-propionic acid [0808] The title compound was prepared in analogous fashion as in Example 31 using [5-(4-Chloromethyl-pheny1)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-(2-chloro-phenyI)-ethyl ester [Example 37, step 11(101 mg, 0.25 mmol), and D-2-fluorophenyl-alanine methyl ester hydrochloride. Yield = 30 mg (0.05 mmol, 22 To). HPLC (254 nm): Method 3 Rt 2.57 min. MS
(ESI) m/z 552.3 [M + H+].

[0809] Example 39: (R)- 2-(4-(4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-(4-trifluoromethyl-phenyl)-propionic acid [0810] The title compound was prepared in analogous fashion as in Example 31 using [5-(4-Chloromethyl-phenyl)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-(2-chloro-phenyl)-ethyl ester [Example 37, step 1](101 mg, 0.25 mmol), and D-4-trifluoromethylphenyl-alanine methyl ester hydrochloride. Yield = 38 mg (0.06 mmol, 25 %). HPLC (254 nm): Method 3 Rt 3.06 min. MS
(ESI) m/z 602.6 [M + H+].
[0811] Example 40: (R)- 3-(2-Chloro-phenyl)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-propionic acid [0812] The title compound was prepared in analogous fashion as in Example 31 using [5-(4-Chloromethyl-phenyl)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-(2-chloro-phenyI)-ethyl ester [Example 37, step 1](101 mg, 0.25 mmol), and D-2-chlorophenyl-alanine methyl ester hydrochloride. Yield = 8 mg (0.01 mmol, 5 To). HPLC (254 nm): Method 3 Rt 2.78 min. MS (ESI) m/z 569.3 [M +
[0813] Example 41: (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-y1}-benzylamino)-3-cyclopropyl-propionic acid [0814] The title compound was prepared in analogous fashion as in Example 31 using [5-(4-Chloromethyl-phenyl)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-(2-chloro-phenyI)-ethyl ester [Example 37, step 1](101 mg, 0.25 mmol), and (R)-2-Amino-3-cyclopropylpropionic acid methyl ester hydrochloride [Example 17, step 1]. Yield = 8 mg (0.01 mmol, 3 %). HPLC
(254 nm):
Method 3 Rt 2.80 min. MS (ESI) m/z 498.4 [M +
[0815] Example 42: 2-{443-Methyl-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzyloxy}-3-phenyl-propionic acid [0816] Step 1: {p43-Methyl-4-((R)-1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methyl acetate [0817] [5-(4-Chloromethyl-phenyl)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-phenyl-ethyl ester [Example 31, step 3] (1g, 2.8mm01e) was mixed with potassium acetate (2g, 14mmol) and sodium iodide (0.5g, 2.8mm01e) and to this was added N,N-dimethylacetamide (20mL). The mixture was sonicated and then heated to 80 C for 1.5hrs. The mixture was cooled to room temperature and partitioned between saturated sodium chloride solution and ethyl acetate. The organic layer was further washed with water 4 times and then saturated sodium chloride solution before drying over magnesium sulfate. The filtered solution was evaporated to give a solid that was used directly. Yield = 0.94 g (2.4 mmol, 87 %). HPLC (254 nm):
Method 3 Rt 2.89 min. MS (ESI) m/z 395.3 [M + 1-11.
[0818] Step 2: [5-(4-Hydroxymethyl-phenyl)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-phenyl-ethyl ester [0819] {p43-Methy1-4-((R)-1-phenylethoxycarbonylamino)-5-isoxazolyl]phenyl}methyl acetate [Example 42, step 1](0.94g, 2.4mm01e) was dissolved in THF (20mL) and methanol (20mL) and to this was added potassium carbonate (981mg, 7.1mmole). The resulting mixture was allowed to stir for 1.5 hours at room temperature when LC/MS indicated formation of a single product [HPLC (254 nm): Method 3 Rt 2.93 min. MS (ESI) m/z 353.2 [M + H+]. Solvents were evaporated and the residue was partitioned between saturated sodium chloride solution and ethyl acetate. The organic phase was dried over magnesium sulfate, filtered and evaporated to give a residue that was chromatographed in a gradient of 0-50% ethyl acetate in hexanes to afford the product. Yield 0.63g (1.79mmole, 74%).
[0820] Step 3: Methyl-2-diazo-phenylpropanoate [0821] D-phenylalanine methyl ester hydrochloride (2g, 9.3mm01e) was partitioned between saturated sodium bicarbonate solution and ethyl acetate. The organic phase was dried over magnesium sulfate, filtered and evaporated to give a residue that was used directly. D-phenylalanine methyl ester (836mg, 4.7mm01e) was dissolved in chloroform (20mL) and acetic acid (0.055mL, 0.94mm01e) was added. The solution was warmed to reflux with the slow drop wise addition of isoamyl nitrite (0.76mL, 5.6mmole) which was complete prior to solvent boiling.
The mixture was refluxed for a further 30 minutes to afford a yellow solution that was cooled to 0 C. The organic solution was washed with 1N sulfuric acid (25mL), water (20mL), saturated sodium bicarbonate solution (25mL), water (25mL) and 1N sulfuric acid (25mL).
The organic phase was dried over magnesium sulfate, filtered and evaporated to give a residue that was chromatographed in a gradient of 0-5% ethyl acetate in hexanes to afford the product. Yield 0.65g (3.4 mmole, 72%).
[0822] Step 4: 2-{443-Methyl-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzyloxy}-3-phenyl-propionic acid methyl ester [0823] [5-(4-Hydroxymethyl-phenyl)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-phenyl-ethyl ester [Example 42, step 2] (100mg, 0.28mmo1e) and Methyl-2-diazo-phenylpropanoate [Example 42, step 3] (61mg, 0.39mm01e) were suspended in benzene (3mL) in a screw cap vial.
To this was added diRhodium tetraacetate (1mg, 0.002mm01e). After 10 minutes at room temperature the vial was heated to 90 C for 1 hour. The mixture was cooled to room temperature and the mixture chromatographed in a gradient of 0-20% ethyl acetate in hexanes to afford the product. Yield = 52 mg (0.1 mmol, 36%). HPLC (254 nm): Method 3 Rt 3.56 min.
MS (ESI) m/z 515.5 [M + 1-1].
[0824] Step 5: 2-{443-Methyl-44(R)- 1-phenyl-ethoxycarbonylamino)-isoxazol- 5-yI]-benzyloxy}-3-phenyl-propionic acid [0825] 2-{413-Methyl-44(R)-1-phenyl-ethoxycarbonylaminoyisoxazol-5-y1]-benzyloxy}-3-phenyl-propionic acid methyl ester (52mg, 0.10mmole) was dissolved in 2/1 v/v THF/water (4.5 mL) and the mixture stirred for 24 hours. The reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated sodium bicarbonate solution. The aqueous layer was acidified to pH ¨ 3 with 6 N HCI and extracted with ethyl acetate. The organic layer was separated, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The residue was co-evaporated with diethyl ether to afford the pure product as a white solid (22 mg, 0.043 mmol, 44 %). HPLC (254 nm): Method 3 Rt 3.03 min. MS (ES1) m/z 501.5 [M +
[0826] Example 43: 2-{4-[3-Methy1-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzyloxy}-3-phenyl-propionic acid [0827] Example 43 was prepared in analogous fashion to example 42 from [5-(4-Hydroxymethyl-pheny1)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-phenyl-ethyl ester [Example 42, step 2] (100mg, 0.28mmo1e) dissolved in 15% THF in benzene (1.15mL) using Methy1-2-diazo-phenylpropanoate that was synthesized from L-phenylalanine methyl ester hydrochloride (2g, 9.3mm01e). Yield 20mg (0.04mm01e, 14%). HPLC (254 nm): Method 3 Rt 2.96 min. MS
(ESI) m/z 501.6 [M + H+].
[0828] Example 44:
(RS)-3-Cyclopropy1-2-{4-[3-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzyloxy}-propionic acid [0829] Step 1: D,L-2-amino-cyclopropylpropanoic acid methyl ester [0830] Prepared in analogous fashion to Example 1, step 6 from D,L-2-amino-cyclopropylpropanoic acid (500mg, 3.87mm01e). The crude residue was partitioned between saturated sodium bicarbonate solution and ethyl acetate. The organic phase was dried over magnesium sulfate, filtered and evaporated to give a residue that was used directly. Yield 295mg (2.06mm01e, 53%) [0831] Step 2: R,S Methyl-2-diazo-cyclopropylpropanoate [0832] Prepared in analogous fashion to Example 42, step 3 from D,L-2-amino-cyclopropylpropanoic acid methyl ester (295mg, 2.06mm01e) and used directly.
Yield 200mg (1.29mmo1e, 62%) [0833] Step 3: (RS)-3-Cyclopropy1-2-{4-[3-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzyloxy}-propionic acid methyl ester [0834] Prepared in analogous fashion to Example 42, step 4 from [5-(4-Hydroxymethyl-pheny1)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-phenyl-ethyl ester [Example 42, step 2]
(90mg, 0.25mm01e) dissolved in 15% THF in benzene (1 mL) and R,S Methy1-2-diazo-cyclopropylpropanoate [Example 44, step 2] (118mg, 0.75mm01e]. Yield 50mg (0.1mmole, 40%). HPLC (254 nm): Method 3 Rt 2.99 min. MS (ESI) m/z 479.1 [M + H+].
[0835] Step 4: : (RS)-3-Cyclopropy1-2-{443-methy1-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzyloxy}-propionic acid [0836] Prepared in analogous fashion to Example 42, step 5 from (RS)-3-Cyclopropy1-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzyloxyl-propionic acid methyl ester [Example 44, step 3] (50mg, 0.1mmole). Yield 21mg (0.1mmole, 40%). HPLC
(254 nm):
Method 3 Rt 3.06 min. MS (ESI) m/z 465 [M +
[0837] Example 45:
(RS)-3-(4-Chloro-pheny1)-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonyloxy)-isoxazol-5-y1]-benzyloxy}-propionic acid [0838] Step 1: D,L-2-Amino-3(4-chlorophenyl)propanoic acid methyl ester [0839] Prepared in analogous fashion to Example 1, step 6 from D,L-2-Amino-3(4-chlorophenyl)propanoic acid (600mg, 3mmole). The crude residue was partitioned between saturated sodium bicarbonate solution and ethyl acetate. The organic phase was dried over magnesium sulfate, filtered and evaporated to give a residue that was used directly. Yield 698mg (3.3mm01e, 100%) [0840] Step 2: R,S Methyl-2-diazo-3(4-chlorophenyl)propanoate [0841] Prepared in analogous fashion to Example 42, step 3 from D,L-2-Amino-3(4-chlorophenyl)propanoic acid methyl ester [Example 45, step 1](698mg, 3.3mm01e) and used directly. Yield 275mg (1.33mm01e, 40%) [0842] Step 3: (RS)-3-(4-Chloro-pheny1)-2-{443-methy1-4-((R)-1-phenyl-ethoxycarbonyloxy)-isoxazol-5-y1]-benzyloxy}-propionic acid methyl ester [0843] Prepared in analogous fashion to Example 42, step 4 from [5-(4-Hydroxymethyl-pheny1)-3-methyl-isoxazol-4-y1]-carbamic acid (R)-1-phenyl-ethyl ester [Example 42, step 2]
(90mg, 0.25mm01e) dissolved in 15% THF in benzene (1 mL) and R,S Methy1-2-diazo-3(4-chlorophenyl)propanoate [Example 45, step 2] (200mg, 0.89 mmole). Yield 55mg (0.1mmole, 40%). HPLC (254 nm): Method 3 Rt 3.49 min. MS (ESI) m/z 549.6 [M +
[0844] Step 4: (RS)-3-(4-Chloro-pheny1)-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonyloxy)-isoxazol-5-y1]-benzyloxy}-propionic acid [0845] Prepared in analogous fashion to Example 42, step 5 from (RS)-3-Cyclopropy1-2-{443-methy1-44(R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-y1]-benzyloxy}-propionic acid methyl ester [Example 44, step 3] (55mg, 0.1mmole). Yield 20mg (0.04mm01e, 37%). HPLC
(254 nm):
Method 3 Rt 3.26 min. MS (ESI) m/z 535 [M +
[0846] Example 46: 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyl]acetic acid [0847] Step 1 - 5-amino-1-(4-bromophenyl)pyrazole-4-carbonitrile [0848] (4-bronnophenyl)hydrazine hydrochloride (2.24 g, 10 mmol) was suspended in ethanol (20 mL) and treated with triethylamine (1.53 mL, 11 mmol). The resulting solution was then treated with malononitrile (1.22 g, 10 mmol) added portionwise. After a small exotherm was observed, the reaction was heated to reflux for 1 hour. The reaction was cooled to room temperature; the solids were collected by vacuum filtration and rinsed with cold ethanol. The solids were air-dried. Yield = 0.93 g, 3.5 mmol (35 %). HPLC (254 nm): Method 2, Rt 5.82 min.
MS (ESI) m/z 265 [M +1-1+]; 263 [M + HI 184 [(M ¨ Br) +1-1].
[0849] Step 2 - 1-(2-chlorophenyl)ethyl N42-(4-bromopheny1)-4-cyano-pyrazol-3-ylicarbamate [0850] A solution of 5-amino-1-(4-bromophenyl)pyrazole-4-carbonitrile [Example 46, step 1]
(26 mg, 0.1 mmol) in CH2Cl2 (1 mL) was treated with triethylamine (28 pL, 0.2 mmol), followed by phosgene (100 pL of a 20 % viv solution in toluene, 0.2 mmol est.). The resulting solution was stirred at room temperature for 30 minutes. ( )-1-(2-chlorophenyl)ethanol (23 mg, 0.15 mmol) was added and the resulting mixture stirred at room temperature overnight. The reaction was concentrated in vacuo to remove volatiles, and the residue was purified by chromatography on silica-gel, eluting with a 4:1 mixture of hexanes/ethyl acetate v/v. The product was obtained as a colorless film. Yield = 27 mg (0.06 mmol, 61 %). HPLC (254 nm): Method 1, Rt 6.31 min.
MS (ESI) miz 447 [M + W]; 445 [M + W]. 1H NMR (500 MHz, CDCI3) 6 7.90 (s, 1 H); 7.57 (d, J
= 8.8 Hz, 2 H); 7.37¨ 7.35 (m, 1 H); 7.32 (d, J = 8.8 Hz, 2 H); 7.27 (m, 3 H);
6.70 (br, 1 H); 6.14 (q, J= 6.5 Hz, 1 H); 1.54 (d, J= 6.5 Hz, 3 H).
[0851] Step 3 - ethyl 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyl]acetate [0852] In a pressure vessel, 1-(2-chlorophenyl)ethyl N42-(4-bromopheny1)-4-cyano-pyrazol-3-yl]carbamate [Example 46, step 2] (80 mg, 0.18 mmol) was dissolved in a 2:1 v/v mixture of toluene and ethanol (2 mL) and treated with Na2CO3 (0.6 mL of a 2N aqueous solution) and [4-(2-ethoxy-2-oxo-ethyl)phenyl]boronic acid (75 mg, 0.36 mmol). The resulting mixture was degassed under Ar for 15 minutes, then treated with Pd[Ph3P14 (8 mg, 0.007 mmol). The vessel was capped and immersed in an oil bath at 80 C, with vigorous magnetic stirring. Reaction was deemed complete after 14 hours. Reaction cooled to room temperature and partitioned between ethyl acetate and water. The organic layer was washed with water and brine.
The combined aqueous layers were back-extracted with ethyl acetate. The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo. The residue was purified by chromatography on silica-gel, eluting with a 4:1 mixture of hexanes/ethyl acetate v/v. The product was obtained as a white solid. Yield = 82 mg (0.16 mmol, 89 %). HPLC
(254 nm):
Method 1, Rt 6.94 min. MS (ESI) m/z 529.3 [M + W]; 485.1 [(M ¨ Et0) + W].
[0853] Step 4 : 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyl]acetic acid [0854] Ethyl 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyllacetate [Example 46, step 3] (45 mg, 0.085 mmol) was dissolved in THE (1 mL) and treated with LiOH (1 mL of a 1M aqueous solution). The resulting mixture was stirred at room temperature for 2 hours. The reaction was transferred to a separatory funnel, diluted with water and extracted with ethyl acetate. The organic layer was discarded and the aqueous layer was brought to pH 2 with a 0.1 N HCI solution. The product was extracted with ethyl acetate.
The organic layer was dried over anhydrous MgS0.4, filtered and concentrated in vacua to yield a white solid as the pure product. Yield = 42 mg (0.085 mmol, quantitative).
HPLC (254 nm):
Method 1, Rt 6.99 min. MS (ESI) m/z 501.3 [M + HI 457.2 [(M ¨ CO2H) + NMR
(500 MHz, DMSO-d6) 6 12.39 (br, 1 H); 10.42 (br, 1 H); 8.31 (s, 1 H); 7.82 (d, J=
8.6 Hz, 2 H); 7.67 (d, J = 8.3 Hz, 2 H); 7.56 (d, J = 8.6 Hz, 2 H); 7.43 (d, J = 7.7 Hz, 1 H);
7.39 (d, J = 8.3 Hz, 2 H);
7.33¨ 7.29 (m, 3 H); 5.94 (q, J= 6.5 Hz, 1 H); 3.64 (s, 2 H); 1.44 (br, 3 H).
[0855] Example 47: (R)-144-[441,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]phenyl]phenyl]cyclopropane carboxylic acid [0856] Step 1: 2-(4-Bromo-benzoyI)-3-oxo-butyric acid ethyl ester [0857] Ethyl acetoacetate (1.97mL, 15.6 mmole) was added to a suspension of magnesium chloride (1.49g, 15.6 mmole) in dichloromethane (15mL) that had been cooled to 0 C. To the mixture was added pyridine (2.43mL, 30mm01e) and stirring continued for an additional 15 minutes. 4-Bromobenzoyl chloride (3.29g, 15mmole) in dichloromethane (15mL) was then added to the reaction. This mixture was stirred at 0 C for 15minutes and then at room temperature for 1 hour. At this time the mixture was treated with 6N
hydrochloric acid solution (20mL). The organic layer was separated, dried over anhydrous MgSO4, filtered and concentrated in vacua to give a colorless oil that was used directly in the next step.
[0858] Step 2: 3-(4-Bromo-phenyl)-1,5-dimethy1-1H-pyrazole-4-carboxylic acid ethyl ester and 5-(4-Bromopheny1)-1,3-dimethy1-1H-pyrazole-4-carboxylic acid ethyl ester [0859] 2-(4-Bromo-benzoyI)-3-oxo-butyric acid ethyl ester [example 47, step 1]
(4.7g, 15mmole), methylhydrazine (0.79mL,15.1 mmole), p-toluenesulfonic acid (0.15g) were mixed with ethanol (150mL) and this mixture was heated to 78 C for 2 hours. At this point the reaction was allowed to cool and the resulting mixture was partitioned between ethyl acetate and water.
The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo. A crude product was obtained that was purified by silica gel chromatography initially with hexane/ethyl acetate 95/5 as eluting solvent and then with hexane/ethyl acetate 88/12 to afford 3-(4-Bromo-pheny1)-1,5-dimethy1-1H-pyrazole-4-carboxylic acid ethyl ester (600mg, 12%) and 5-(4-Bromo-pheny1)-1,3-dimethy1-1H-pyrazole-4-carboxylic acid ethyl ester (190mg, 4%).
[0860] Step 3: 3-(4-Bromopheny1)-1,5-dimethy1-1H-pyrazole-4-carboxylic acid [0861] A mixture of 3-(4-Bromopheny1)-1,5-dimethy1-1H-pyrazole-4-carboxylic acid ethyl ester [example 47, step 2] (600mg, 1.85 mmole), 1N sodium hydroxide solution (18.5mL) and dioxane (18.5mL) was stirred at 100 C for 3 hours. Upon cooling the mixture was acidified to pH 3-4 with 3N hydrochloric acid solution and this was extracted with ethyl acetate. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to yield the product as a solid (422mg, 77%).
[0862] Step 4: (R)-1-(phenyl)ethyl N42-(4-bromopheny1)- 1,5-dimethy1-1H-pyrazol-3-ylicarbam ate [0863] A suspension of 3-(4-Bromopheny1)-1,5-dimethy1-1H-pyrazole-4-carboxylic acid [example 47, step 3] (50 mg, 0.17 mmol) in toluene (1mL) and triethylamine (17mg, 0.17 mmole) was treated with diphenylphosphoryl azide (44pL, 0.20 mmole) and the mixture stirred at 45 C for 3 hours and then 95 C with the evolution of a gas. After 30 minutes (R)-(+)-1-phenylethanol (25 mg, 0.20 mmole) was added. Heating was continued for a further 1 hour before the mixture was allowed to cool. The reaction was concentrated in vacuo and the residue dissolved in ethyl acetate and the solution washed with 0.1M potassium carbonate solution and then brine. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford the product (64mg, 91%) that was used directly in the next step. HPLC (254 nm): Method 3 Rt 3.10 min. MS (ESI) m/z 416.2, 414.4 [M + H+].
[0864] Step 5: 2-[4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane carboxylic acid methyl ester.
[0865] Methyl 1-(4-bromophenyl)cyclopropanecarboxylate (1g, 3.92 mmole), potassium acetate (461mg, 4.7 mmole), and bis(pinacolato)diboron (1.19g, 4.70 mmole) were mixed in dioxane (10mL) and degassed for 10minutes under a stream of argon. [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (32mg) was added and the mixture was heated at 95 C for 2 hours. At this point the mixture was allowed to cool and the mixture was partitioned between ethyl acetate and water. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo. A crude product was obtained that was purified by silica gel chromatography with hexane/ethyl acetate 95/5 as eluting solvent to afford the product as a white solid (1.02g, 86%).
[0866] Step 6:
(R)-1444441,5-dimethyl-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]phenyl]phenyl]cyclopropanecarboxylic acid methyl ester [0867] In a pressure vessel, (R)-1-(phenyl)ethyl N42-(4-bromopheny1)-1,5-dimethyl-1H-pyrazol-3-yl]carbamate [example 47, step 4) (64 mg, 0.16 mmol) was dissolved in a 2:1 v/v mixture of toluene and ethanol (2 mL) and treated with Na2CO3 (0.5 mL of a 2N
aqueous solution) and 244-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane carboxylic acid methyl ester [Example 47, step 5] (52 mg, 0.17 mmol). The resulting mixture was degassed under argon for 15 minutes, and then treated with tetrakis (triphenyl-phosphine)palladium(0) (1 mg, 0.006 mmol). The vessel was capped and immersed in an oil bath at 80 C, with vigorous magnetic stirring overnight. This reaction was cooled to room temperature and partitioned between ethyl acetate and water. The organic layer was washed with water and brine. The combined aqueous layers were back-extracted with ethyl acetate. The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo. This material was purified by preparative TLC eluting with hexane/ethyl acetate 1/1 v/v to give the product as a yellow film (10 mg, 13%).
[0868] Step 7: (R)-1444442,5-dimethyl-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]phenyl]phenyl]cyclopropanecarboxylic acid [0869] (R)-1-[4-[4-[1,5-dimethy1-4-(1-phenylethoxycarbonylami no) pyrazol-3-yl]phenyl]phenyl]cyclopropanecarboxylic acid methyl ester [example 47, step 6]
(10mg, 0.02 mmole) was dissolved in THE (1 mL) and treated with LiOH (1 mL of a 2M aqueous solution).
The resulting mixture was stirred overnight and then refluxed for 5 hours. The reaction was cooled and transferred to a separatory funnel, diluted with water and extracted with ethyl acetate. The organic layer was discarded and the aqueous layer was brought to pH 1 with a 0.1 N HCI solution when the product was extracted with ethyl acetate. This organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo. A residue was obtained which was triturated with dimethoxyethane. The solids were filtered and the filtrate evaporated to dryness to yield a residue that was purified by preparative TLC, eluting with ethyl acetate/hexane 2/1 v/v.
The product was obtained as a white solid (3 mg, 28 %). HPLC (254 nm): Method 3 Rt 3.12 min. MS (ESI) nilz 496.6 [M +
[0870] Example 48: (R)-1444442,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]phenyl]phenyl]cyclopropane carboxylic acid [0871] Step 1: 5-(4-Bromo-phenyl)-1,3-dimethy1-1H-pyrazole-4-carboxylic acid [0872] A mixture of 5-(4-Bromo-phenyl)-1,3-dimethy1-1H-pyrazole-4-carboxylic acid ethyl ester [example 47, step 2] (190mg, 0.59 mmole), 1N sodium hydroxide solution (5.9mL) and dioxane (5.9mL) was stirred at 100 C for 1 hour. Upon cooling the mixture was acidified to pH 3-4 with 3N hydrochloric acid solution and this was extracted with ethyl acetate. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to yield the product as a solid (170mg, 98%).
[0873] Step 2: (R)-1 -(phenyl)ethyl N15-(4-Bromo-phenyl)-1,3-dimethy1-1H-pyrazole-4-yll-carbamate [0874] 5-(4-Bromo-phenyl)-1,3-dimethy1-1H-pyrazole-4-carboxylic acid [example 48, step 1]
(50 mg, 0.17 mmol) was used to prepare (R)-1-(phenyl)ethyl N45-(4-Bromo-phenyl)-1,3-dimethy1-1H-pyrazole-4-ylicarbamate according to the procedure described for example 47, step 4 to afford the product (64mg, 91%) that was used in the next step. HPLC (254 nm): Method 3 Rt 3.03 min. MS (ESI) m/z 416.5 [M +
[0875] Step 3: (R)-1-[444- [2, 5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]phenyl]-phenyncyclopropane carboxylic acid methyl ester [0876] In a pressure vessel, (R)-1-(phenyl)ethyl N-[5-(4-Bromo-pheny1)-1,3-dimethy1-1H-pyrazole-4-yl]carbamate [example 48, step 2) (64 mg, 0.16 mmol) was used to prepare the product as an oil (32 mg, 41%) using a similar procedure to that described for example 47, step [0877] Step 4: (R)-144-[442,5-dimethy1-4-(1-phenylethoxycarbonylamino)pyrazol-3-yllphenyl]phenyl]cyclopropane carboxylic acid [0878] (R)-1-[4-[4-[2, 5-dimethy1-4- (1-phenylethoxycarbonylamino)pyrazol-3-yl]phenyl]phenyl]cyclopropane carboxylic acid methyl ester [example 48, step 3] (32mg, 0.06 mmole) was dissolved in THF (3 mL) and treated with LiOH (3 mL of a 2M aqueous solution).
The resulting mixture was stirred overnight and then refluxed for 5 hours. The reaction was cooled and transferred to a separatory funnel, diluted with water and extracted with ethyl acetate. The organic layer was discarded and the aqueous layer was brought to pH 1 with a 0.1 N HCI solution when the product was extracted with ethyl acetate. This organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo. A residue was obtained which was triturated with dimethoxyethane. The solids were filtered and the filtrate evaporated to dryness to yield a residue that was purified by preparative TLC, eluting with ethyl acetate/hexane 2/1 v/v.
The product was obtained as a white solid (10 mg, 32 %). HPLC (254 nm): Method 3 Rt 2.92 min. MS (ESI) m/z 496.6 [M + F1].
[0879] Example 49: (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y11-3-fluoro-biphenyl-4-y1)-cyclopropanecarboxylic acid [0880] Step 1: Ethyl (E)-4-(dimethylamino)-2-oxo-but-3-enoate [0881] Ethyl pyruvate (5 g, 43.1 mmol) was dissolved in 0H2Cl2 (86 mL) and treated with dimethylformamide dimethylacetal (5.73 mL, 43.1 mmol). The reaction was stirred at room temperature for 2 hours and concentrated in vacuo. The crude was used as is in the next step.
Yield = 7.4 g.
[0882] Step 2: ethyl 2-(4-bromophenyl)pyrazole-3-carboxylate [0883] 4-Bromophenyl hydrazine hydrochloride (2.0 g, 8.95 mmol) was dissolved in Me0H
(18 mL) and treated with crude ethyl (E)-4-(dimethylamino)-2-oxo-but-3-enoate [example 3, step 11(1.54 g, 9.0 mmol). The resulting mixture was stirred at room temperature for 6 hours. The volatiles were removed in vacuo and the residue was purified by chromatography on silica-gel, eluting with a 95:5 mixture of hexanes/ethyl acetate v/v, increasing the polarity to 9:1 over time.
Two isomeric products were isolated: ethyl 2-(4-bromophenyl)pyrazole-3-carboxylate as an orange solid (0.82 g, 2.78 mmol, 31 %) and ethyl 1-(4-bromophenyl)pyrazole-3-carboxylate as a red solid (0.44 g, 1.49 mmol, 17 %).
[0884] Ethyl 2-(4-bromophenyl)pyrazole-3-carboxylate: HPLC (254 nm): Method 2 Rt 5.22 min. MS (ESI) m/z 297 [M + H+]; 294.8 [M + HI 252 [(M - Et0) + H+]; 250 [(M -Et0) + HIT 1H
NMR (500 MHz, CD0I3) 6 7.69 (d, J= 1.9 Hz, 1 H); 7.58 (d, J= 8.7 Hz, 2 H);
7.32 (d, J- 8.7 Hz, 2 H); 7.03 (d, J= 1.9 Hz, 1 H); 4.26 (q, J= 7.1 Hz, 2 H); 1.28 (t, J = 7.1 Hz, 3 H).

[0885] Ethyl 1-(4-bromophenyl)pyrazole-3-carboxylate: 1H NMR (500 MHz, CDCI3) 6 7.91 (d, J = 2.4 Hz, 1 H); 7.65 (d, J = 7.2 Hz, 2 H); 7.60 (d, J = 7.2 Hz, 2 H); 7.00 (d, J = 2.4 Hz, 1 H);
4.44 (q, J= 7.0 Hz, 2 H); 1.43 (t, J= 7.0 Hz, 3 H).
[0886] Step 3: 2-(4-Bromo-phenyI)-4-fluoro-2H-pyrazole-3-carboxylic acid ethyl ester [0887] Ethyl 2-(4-bromophenyl)pyrazole-3-carboxylate (1.08 g, 3.68 mmol) was dissolved in acetonitrile (12 mL) and the resulting mixture was treated with glacial acetic acid (4.6 mL). To this solution, 1-chloromethy1-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (Selectfluor , 3.91 g, 11.04 mmol) was added in one portion and the resulting mixture was heated to 105 C for 18 hours. The mixture was cooled to room temperature and the volatiles were removed in vacuo. The crude residue was loaded directly onto a silica-gel column and purified by elution with 95:5 mixture of hexanes/ethyl acetate v/v, increasing the polarity to 9:1 over time. The product was isolated as a white solid (410 mg, 1.31 mmol, 36 %) and starting material was recovered (272 mg, 0.93 mmol, 25 %). For 2-(4-Bromo-phenyI)-4-fluoro-2H-pyrazole-3-carboxylic acid ethyl ester: HPLC (254 nm): Method 3 Rt 2.97 min.
MS (ESI) m/z 313.1 [M + H+]. 1H NMR (500 MHz, CD0I3) 67.60 (s, 1 H); 7.58 (d, J= 9 Hz, 2 H); 7.29 (d, J= 9 Hz, 2 H); 4.30 (q, J= 7.1 Hz, 2 H); 1.28 (t, J= 7.1 Hz, 3 H).
[0888] Step 4: 2-(4-Bromo-phenyl)-4-fluoro-2H-pyrazole-3-carboxylic acid [0889] A stirred solution of 2-(4-bromo-pheny1)-4-fluoro-2H-pyrazole-3-carboxylic acid ethyl ester (410 mg, 1.31 mmol) in THF (13 mL) was treated with LiOH 1 N aqueous solution (13 mL) and the resulting mixture was stirred at room temperature overnight. The reaction was deemed complete by thin layer chromatography and H PLC/MS. The reaction mixture was partitioned between ethyl acetate and 1 N aqueous HCI solution (100 mL v/v) and transferred to a separatory funnel. The organic layer was separated and the aqueous layer was back-extracted with ethyl acetate (30 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford the pure product as a white solid (347 mg, 1.22 mmol, 93%). HPLC (254 nm): Method 3 Rt 2.82 min. MS (ESI) m/z 285.1 [M + h1+].
[0890] Step 5: (R)42-(4-Bromo-pheny1)-4-fluoro-2H-pyrazol-3-y1Fcarbamic acid 1-(2-chloro-pheny1)-ethyl ester [0891] 2-(4-Bromo-pheny1)-4-fluoro-2H-pyrazole-3-carboxylic acid (347 mg, 1.22 mmol) was suspended in toluene (12 mL) and treated with triethylamine (205 pL, 1.46 mmol). The resulting solution was treated with diphenylphosphoryl azide (316 pL, 1.46 mmol) and heated to 65 C.
(R)- 1-(2-Chloro-phenyl)-ethanol (230 mg, 1.46 mmol) was added to the reaction mixture and the temperature was increased to 105 C for 30 minutes, during which time vigorous gas evolution was observed. The reaction was brought to 65 C and stirred at that temperature for 4 hours. The reaction was deemed complete by HPLC/MS. After cooling, the volatiles were removed in vacuo and the crude residue was purified by silica gel chromatography, eluting with a hexanes/ethyl acetate gradient. Product isolated as a white solid (452 mg, 1.03 mmol, 85 %).
HPLC (254 nm): Method 3 Rt 3.16 min. MS (ESI) m/z 440.1 [M +
[0892] Step 6: (R)-1-(4'-{541-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-3-fluoro-biphenyl-4-y1)-cyclopropanecarboxylic acid [0893] A stirred suspension of (R)42-(4-Bromo-pheny1)-4-fluoro-2H-pyrazol-3-yli-carbamic acid 1-(2-chloro-phenyl)-ethyl ester (88 mg, 0.2 mmol), 2:1 v/v toluene/ethanol (2 mL), 2 M
aqueous solution of Na2CO3 (670 pL) and 1-(4-borono-2-fluorophenyl)cyclopropane-1-carboxylic acid (45 mg, 0.2 mmol) was degassed under nitrogen for 10 minutes and treated with Pd[Ph3Ph (12 mg, 0.01 mmol). The resulting mixture was immersed in an oil bath with stirring at 90 C for 12 hours. The reaction was cooled, transferred to a separatory funnel and diluted with ethyl acetate (50 mL). The mixture was carefully treated with 1 N aqueous HCI
solution (20 mL). The organic layer was separated, washed with brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude residue was purified by preparative TLC plate (1000 pm), eluting with a 1:1 v/v hexanes/ethyl acetate mixture. The product was obtained as a tan solid.
Yield = 35 mg (35 %). HPLC (254 nm): Method 3, Rt 3.11 min. MS (ESI) m/z 538.3 [M +
[0894] Example 50: (R)-1-(4'-{541-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y11-2-fluoro-bipheny1-4-y1)-cyclopropanecarboxylic acid [0895] The title compound was prepared in analogous fashion as in Example 49 using (R)-[2-(4-Bromo-pheny1)-4-fluoro-2H-pyrazol-3-y1]-carbamic acid 1-(2-chloro-phenyl)-ethyl ester (Example 49, Step 5 (88 mg, 0.2 mmol), and 1 44-(dihydroxyborany1)-3-fluoropheny1]-cyclopropane-1-carboxylic acid. Yield 40 mg (37 %) as a light yellow solid.
HPLC (254 nm):
Method 3, Rt 3.14 min. MS (ESI) m/z 538.3 [M +
[0896] Example 51: (R)-1-(2-Chloro-4'-{541-(2-chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y1}-biphenyl-4-y1)-cyclopropanecarboxylic acid [0897] The title compound was prepared in analogous fashion as in Example 49 using (R)42-(4-Bromo-pheny1)-4-fluoro-2H-pyrazol-3-y1]-carbamic acid 1-(2-chloro-phenyl)ethyl ester (Example 49, Step 5 (88 mg, 0.2 mmol), and 143-chloro-4-(dihydroxyboranyl)phenylj-cyclopropane-1-carboxylic acid. Yield 24 mg (22 %) as a light yellow solid.
HPLC (254 nm):
Method 3, Rt 3.40 min. MS (ESI) m/z 554.4 [M +
[0898] Example 52: (R)-1-(4'-{541-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-y11-2-methyl-bipheny1-4-y1)-cyclopropanecarboxylic acid [0899] The title compound was prepared in analogous fashion as in Example 49 using (R)-[2-(4-Bromo-pheny1)-4-fluoro-2H-pyrazol-3-yl]-carbamic acid 1-(2-chloro-phenyl)-ethyl ester (Example 49, Step 5 (88 mg, 0.2 mmol), and 144-(dihydroxyborany1)-3-methylphenyl]cyclo-propane-1-carboxylic acid. Yield 36 mg (34 %) as a light yellow solid. HPLC
(254 nm): Method 3, Rt 3.19 min. MS (ESI) m/z 534.3 [M +
[0900] Example 53: (R)-1-(4'-{541-(2-Chloro-pheny1)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yll-bipheny1-4-y1)-cyclopropanecarboxylic acid [0901] The title compound was prepared in analogous fashion as in Example 49 using (R)-[2-(4-Bromo-pheny1)-4-fluoro-2H-pyrazol-3-y1]-carbamic acid 1-(2-chloro-phenyl)-ethyl ester (Example 49, Step 5 (88 mg, 0.2 mmol), and 4-(1-carboxycyclopropyl)phenylboronic acid, pinacol ester. Yield 9 mg (9 %) as a white solid. HPLC (254 nm): Method 3, Rt 3.20 min. MS
(ESI) m/z 520.0 [M + H+].
[0902] Example 54: (R)- 1-{4'45-(1-Phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-y1Fbiphenyl-4-y1}-cyclopropanecarboxylic acid [0903] Step 1: 2-(4-Bromo-phenyI)-4-iodo-2H-pyrazole-3-carboxylic acid ethyl ester 10904] Ethyl 2-(4-bromophenyl)pyrazole-3-carboxylate (Example 49, Step 2, 294 mg, 1.0 mmol) was dissolved in methanol (3 mL) and treated dropwise with iodine monochloride (115 pL, 2.3 mmol). The resulting mixture was heated to 50 C for 3 hours. Another aliquot of iodine monochloride (120 pL) was added and heating continued for additional 3 hours.
The reaction was deemed complete by HPLC/MS. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (30 mL) and transferred to a separatory funnel.
The organic layer was washed successively with 1 N Na2S203 aqueous (30 mL) and brine (30 mL).
The organic layer was separated, washed with brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The product [2-(4-bromo-phenyl)-4-iodo-2H-pyrazole-3-carboxylic acid ethyl ester]
was obtained as a pale yellow solid (420 mg, quant.) and used as is in the next step. HPLC (254 nm): Method 3, Rt 3.33 min. MS (ESI) mk 421.0, 423.0 [M
[0905] Step 2: 2-(4-Bromo-phenyl)-4-trifluoromethy1-2H-pyrazole-3-carboxylic acid ethyl ester [0906] 2-(4-Bromo-phenyl)-4-iodo-2H-pyrazole-3-carboxylic acid ethyl ester (420 mg, 1.0 mmol) was dissolved in DMF (4 mL) and the resulting solution was degassed with nitrogen for minutes. (1,10-Phenanthroline) (trifluoromethyl) copper (1) (TrifluoromethylatorTm, 520 mg, 1.5 mmol) was added in one portion under an inert atmosphere and the resulting mixture was stirred at 50 C for 18 hours. The reaction was cooled to room temperature and filtered through a pad of Celite and rinsed thoroughly with ethyl acetate. The filtrates were washed with 1 N HCI
aqueous, brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude product 2-(4-bromo-pheny1)-4-trifluoromethy1-2H-pyrazole-3-carboxylic acid ethyl ester was used as is in the next step (291 mg, 0.80 mmol, 80 %). HPLC (254 nm): Method 3, Rt 3.23 min.
MS (ESI) m/z 365.2 [M + H+].
[0907] Step 3: 2-(4-Bromo-pheny1)-4-trifluoromethy1-2H-pyrazole-3-carboxylic acid [0908] 2-(4-Bromo-pheny1)-4-trifluoromethy1-2H-pyrazole-3-carboxylic acid ethyl ester (291 mg, 0.80 mmol) in THF (8 mL) was treated with LiOH 1 N aqueous solution (8 mL) and the resulting mixture was stirred at room temperature for 3 hours. The reaction was deemed complete by thin layer chromatography and HPLC/MS. The reaction mixture was partitioned between ethyl acetate and 1 N aqueous HCl solution (100 mL v/v) and transferred to a separatory funnel. The organic layer was separated and the aqueous layer was back-extracted with ethyl acetate (30 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford the pure product as a white solid (268 mg, 0.80 mmol, quant.). HPLC (254 nm): Method 3 Rt 2.97 min. MS (ESI) m/z 335.2 [M +
[0909] Step 4: (R)- [2-(4-Bromo-phenyl)-4-trifluoromethy1-2H-pyrazol-3-y1]-carbamic acid 1-phenyl-ethyl ester [0910] 2-(4-Bromo-pheny1)-4-trifluoromethy1-2H-pyrazole-3-carboxylic acid (268 mg, 0.80 mmol) was suspended in toluene (8 mL) and treated with triethylamine (135 pL, 0.97 mmol).
The resulting solution was treated with diphenylphosphoryl azide (209 pL, 0.97 mmol) and heated to 65 C. (R)-1-(phenyl)-ethanol (118 mg, 0.97 mmol) was added to the reaction mixture and the temperature was increased to 105 C for 30 minutes, during which time vigorous gas evolution was observed. The reaction was brought to 65 C and stirred at that temperature for 4 hours. The reaction was deemed complete by HPLC/MS. After cooling, the volatiles were removed in vacuo and the crude residue was purified by silica gel chromatography, eluting with a hexanes/ethyl acetate gradient. Product isolated as a white solid (195 mg, 0.43 mmol, 54 %).
HPLC (254 nm): Method 3 Rt 3.23 min. MS (ESI) m/z 454.0, 456.1 [M + H+].
[0911] Step 5: (R)- 1-{4'45-(1-Phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-y1J-biphenyl-4-y1}-cyclopropanecarboxylic acid [0912] A stirred suspension of (R)- [2-(4-Bromo-phenyl)-4-trifluoromethyl-2H-pyrazol-3-yl]-carbamic acid 1-phenyl-ethyl ester (98 mg, 0.22 mmol), 2:1 v/v toluene/ethanol (2.2 mL), 2 M
aqueous solution of Na2CO3 (720 pL) and 4-(1-carboxycyclopropyl)phenylboronic acid, pinacol ester (124 mg, 0.43 mmol) was degassed under nitrogen for 10 minutes and treated with Pd[Ph3P]4 (12 mg, 0.01 mmol). The resulting mixture was immersed in an oil bath with stirring at 95 C for 3 hours. The reaction was cooled, transferred to a separatory funnel and diluted with ethyl acetate (50 mL). The mixture was carefully treated with 1 N aqueous HCI
solution (20 mL).
The organic layer was separated, washed with brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude residue was purified by preparative TLC plate (1000 pm), eluting with a 1:1 v/v hexanes/ethyl acetate mixture. The product was obtained as a tan solid.
Yield = 6.8 mg (6 %). HPLC (254 nm): Method 3, Rt 3.21 min. MS (ESI) m/z 536.3 [M
[0913] Example 55: (R)-142-Fluoro-4'-[5-(1-phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-y11-biphenyl-4-y1}-cyclopropanecarboxylic acid [0914] The title compound was prepared in analogous fashion as in Example 54 using(R)- [2-(4-Bromo-phenyl)-4-trifluoromethyl-2H-pyrazol-3-yl]-carbamic acid 1-phenyl-ethyl ester (Example 54, Step 4 (98 mg, 0.22 mmol) and 1-[4-(dihydroxyboranyI)-3-fluorophenyl]cyclopropane-1-carboxylic acid. Yield 7 mg (6 %) as a white solid. HPLC (254 nm):
Method 3, Rt 3.11 min. MS (ESI) m/z 554.4 [M + 1-1+]
[0915] Example 56: (R)-1-(4-{5-[5-(1-Phenyl-ethoxycarbonylamino)-pyrazol-1-y1]-pyridin-2-y1}-phenyl)-cyclopropanecarboxylic acid [0916] Step 1: 2-(6-Chloro-pyridin-3-yI)-2H-pyrazole-3-carboxylic acid ethyl ester [0917] 2-(6-Chloro-pyridin-3-yI)-2H-pyrazole-3-carboxylic acid ethyl ester was prepared in analogous fashion as in Example 49, Step 2 using (6-chloro-pyridin-3-yI)-hydrazine hydrochloride (9.89 g, 48.68 mmol; prepared according to W02005/92856A1) and ethyl (E)-4-(dimethylamino)-2-oxo-but-3-enoate (7.82 g, 45.68 mmol, Example 49, Step 1).
Yield = 1.35 g (5.38 mmol, 12 %). HPLC (254 nm): Method 3 Rt 2.87 min. MS (ESI) m/z 252.2 [M
+ W]. 1H
NMR (500 MHz, CDC13)15 8.50 (d, J = 3.0 Hz, 1 H); 7.77 (dd, J1= 3.0 Hz, J2 =
8.5 Hz, 1 H); 7.74 (d, J = 2.0 Hz, 1 H); 7.43 (d, J = 8.5 Hz, 1 H); 7.08 (d, J = 2.0 Hz, 1 H);
4.28 (q, J = 7.5 Hz, 2 H);
1.30 (t, J= 7.5 Hz, 3 H).
[0918] Step 2: 2-(6-Chloro-pyridin-3-yI)-2H-pyrazole-3-carboxylic acid hydrochloride salt [0919] A stirred solution of 2-(6-Chloro-pyridin-3-yI)-2H-pyrazole-3-carboxylic acid ethyl ester [Example 56, step 1] (1.35 g, 5.4 mmol) in THF/water 8:2 v/v (35 mL) was treated with LiOH 1 N
aqueous solution (6.5 mL) and the resulting mixture was stirred at room temperature for 3 hours. The reaction was deemed complete by thin layer chromatography and HPLC/MS. The reaction mixture was diluted with water (100 mL) and washed with dichloromethane (60 mL).
The aqueous layer was acidified with 1 N aqueous HCI solution to pH 2 resulting in a white suspension. The solids were filtered, rinsed with water and air-dried to afford the title compound as a white solid. Yield = 0.90 g (3.46 mmol, 64 /0). HPLC (254 nm): Method 3 Rt 2.65 min. MS
(ESI) m/z 224.3 [M + W].
[0920] Step 3: (R)42-(6-Chloro-pyridin-3-y1)-2H-pyrazol-3-y1]-carbamic acid 1-phenyl-ethyl ester [0921] 2-(6-Chloro-pyridin-3-yI)-2H-pyrazole-3-carboxylic acid hydrochloride salt [Example 56, step 2]( 0.90 g, 4.03 mmol) was suspended in toluene (27 mL) and treated with di-isoproprylethylamine (1.28 mL, 8.86 mmol). The resulting solution was treated with diphenylphosphoryl azide (855 pL, 4.83 mmol) and heated to 65 C. (R)- 1-(phenyl)-ethanol (600 pL, 6.03 mmol) was added to the reaction mixture and the temperature was increased to 105 C for 30 minutes, during which time vigorous gas evolution was observed.
The reaction was brought to 65 C and stirred at that temperature for 4 hours. The reaction was deemed complete by HPLC/MS. After cooling, volatiles were removed in vacuo and the crude residue purified by silica gel chromatography, eluting with a hexanes/ ethyl acetate gradient. Product isolated as a white solid. Yield = 0.60 g (1.75 mmol, 44 %). HPLC (254 nm):
Method 3 Rt 3.05 min. MS (ESI) m/z 343.2 [M + Hi].
[0922] Step 4: (R)-1-(4-{544-Methy1-5-(1-phenyl-ethoxycarbonylamino)-pyrazol-1-y11-pyridin-2-y1}-pheny1)-cyclopropanecarboxylic acid methyl ester [0923] A stirred suspension of (R)-[2-(6-Chloro-pyridin-3-y1)-2H-pyrazol-3-y1]-carbamic acid 1-phenyl-ethyl ester [Example 56, step 3] (240 mg, 0.70 mmol) in 2:1 v/v toluene/ethanol (7 mL), 2 M aqueous solution of Na2CO3 (1.5 mL) and 144-(4,4,5,5-tetramethy141,3,2]dioxaborolan-2-y1)-pheny1]-cyclopropanecarboxylic acid methyl ester (260 mg, 0.84 mmol) was degassed under nitrogen for 10 minutes and treated with Pd[Ph3P]4 (42 mg, 0.036 mmol). The resulting mixture was immersed in an oil bath with stirring at 90 C for 15 hours. The reaction was cooled, transferred to a separatory funnel and diluted with ethyl acetate (50 mL). The mixture was carefully treated with 1 N aqueous HC1 solution (20 mL). The organic layer was separated, washed with brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude residue was purified by silica gel chromatography, eluting with a 0-30%
hexanes/ethyl acetate gradient of increasing polarity. The product was obtained as a tan solid.
Yield = 136 mg (0.28 mmol, 40 /0). HPLC (254 nm): Method 3 Rt 2.93 min. MS (ESI) m/z 483.4 [M +
Hi].
[0924] Step 6: (R)-1-(4-{5-[5-(1-Phenyl-ethoxycarbonylamino)-pyrazol-1-y1]-pyridin-2-y1}-pheny1)-cyclopropanecarboxylic acid [0925] A solution of (R)-1-(4-{544-Methy1-5-(1-phenyl-ethoxycarbonylamino)-pyrazol-1-y1]-pyridin-2-y1}-pheny1)-cyclopropanecarboxylic acid methyl ester (136 mg, 0.28 mmol) in a 2:1 v/v mixture of THF/water (3 mL) was treated with a 1 N LiOH aqueous solution (420 pL) and stirred at ambient temperature for 16 hours. The reaction was brought to pH 1 by addition of a 1 N HCI
aqueous solution. The mixture was extracted with Et0Ac and washed with water.
The organic layer was dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The product was obtained as an off white solid Prepared in analogous fashion as in Example Ml, Step 6 using the following reagents and amounts: (R)-1-(4-{545-(1-phenyl-ethoxycarbonylamino)-pyrazol-1-ylypyridin-2-yll-phenyl)-cyclopropanecarboxylic acid methyl ester (136 mg, 0.28 mmol), THE/water 2:1 v/v (3 mL), 1 N aqueous LiOH solution (420 pL). Yield = 15 mg (0.032 mmol, 11 %). HPLC (254 nm): Method 3 Rt 2.93 min. MS (ESI) miz 483.3 [M +
[0926] Compounds 57-458 of Table 1 and derivatives thereof are prepared from the according to procedures outlined for compounds 1-56. The heterocyclic amines or esters required to assemble the corresponding carbamates were prepared based on methods described in citations 1-24.
[0927] Certain isoxazole substitutions are prepared following construction of the appropriate aryl isoxazole (3, Scheme 1). Direct flurorination or bromination and cyanation provides arylbromide (4) or acid (5) after palladium catalyzed carbonylation.
[0928] Scheme 1 o o o 0 Br DMF, DMA NH2OH
, I
- Br Br 0 2 ¨0 3 Selectfluor ,0 Co, pdC12(dpPO
or Br2/HOAc followed by Zn(CN)2, R

\
Br ______________________________________________ =-= N \
0 F. F, Br, CN
Pd[PPh314 ¨0 ¨ A= Ch, N

[0929] 4 5 [0930] Acid (5, scheme 2) may be directly coupled with amines to afford amide intermediates (6) which may be converted to the carbamate products (7) following acid hydrolysis, Curtius rearrangement and deprotection with acid.
[0931] Scheme 2 A
R \ / N¨z. \Re õo / N----z=RA
\ / HBTU, DIEA N
/ 1) LOH / \

¨0 F121,1*.zThG )\ ¨0 2) DPPA R NH

. 0 oli RG
R
F= F, Br, CN . RH
A= CH, N 3) TFA

[0932]
[0933] The acid (5) may be reduced to alcohol (8) and/or converted to its chloride (9) as in scheme 3. Alcohols may be converted to their ether analogs (10) by rhodium catalyzed insertion into diazo intermediates 2N+-z-RB, or the amines (11) may be generated from chlorides (IX) [0934] Scheme 3 BH3.THF SOCl2 F= F, Br, CN i) H2NA'.R6 , isoamyl nitrite A= CH, N HN--zR8 4" 2 2) Nr.z...-le , Rh20Ac4 . I
--A .--A
N , \ /
) /

¨0 ¨0 [0935] 10 11 [0936] Alternatively the bromides (4) may be directly coupled to alcohols or amines (UV-Z-RB) whereby U is -OH or ¨NH2 by thermal or metal catalyzed halide displacement as in scheme 4.
All key intermediates (10-12) may be further modified to produce final products as described in scheme 1 using acid hydrolysis, Curtius rearrangement followed by acid deprotection Scheme 4 , \
N

--O --O
[0937] 4 12 [0938] Example 57. Receptor Binding Assays [0939] Binding affinity of compounds of Formula I-XII were determined based on their ability to displace tritiated lysophosphatidic acid ([31-1]-LPA) from CHO cells expressing LPA1R in a protocol similar to that described in reference 17. In a 96 well format, CHO
cells expressing human LPA1R [Cerep] were treated with [31-1]-LPA (2nM). Test compounds were added in increasing concentration to each well and incubated at room temperature for 90 minutes. At this time the plates were washed and the wells counted for radioactivity. Results were compared to a control in which cells were treated with [31-1]-LPA in the presence of 10pM
unlabeled LPA. The specific ligand binding to the receptors was defined as the difference between the total binding and the nonspecific binding determined in the presence of an excess of unlabelled ligand. The results were expressed as a percent of control specific binding ((measured specific binding/control specific binding) x 100) and as a percent inhibition of control specific binding (100-((measured specific binding/control specific binding) x 100)) obtained in the presence of the test compounds. The IC50 value (concentration causing a half-maximal inhibition of control specific binding) and Hill coefficient (nH) were determined by non-linear regression analysis of the competition curve generated with mean replicate values using Hill equation curve fitting (Y =

D + [(A ¨ D)/(1 + (C/C50)nH)], where Y = specific binding, D = minimum specific binding, A =
maximum specific binding, C = compound concentration, C50 = IC50, and nH =
slope factor).
This analysis was performed using a software developed at Cerep (Hill software) and validated by comparison with data generated by the commercial software SigmaPlot 4.0 for Windows (C) 1997 by SPSS Inc.). The inhibition constant (Ki) was calculated using the Cheng Prusoff equation (Ki = IC50/(1+(LJKD)), where L = concentration of radioligand in the assay, and KD =
affinity of the radioligand for the receptor). A scatchard plot was used to determine the Kd.
[0940] Example 58. Calcium Flux Assay [0941] Inhibition of LPA-stimulated Ca2+ flux was used to assess compound potency using FLIPR technology in a 96 well plate format. The assay buffer used was a modified Hanks Balanced Salt Solution (HBSS) where HBSS was supplemented to contain 20mM
HEPES and 2.5mM Probenecid at pH7.4 (Millipore, GPCR Profiler). LPA1R expressing cells (Millipore) were plated and prepared 24 hours prior to assay of test articles. Ca2+ ion flux was assessed from fluorescence of a Fluo-based No Wash Ca24 dye. Antagonist data are generated from plates with LPA concentrations sufficient to generate 80% efficacy [EC80].
Percentage inhibition was calculated from a reduction of efficacy according to concentration of compounds of Formula I-VI. For dose responses the inhibition data was used to calculate compound IC50.
[0942] The agonist assay was conducted on a FLIPRTETRA instrument where the test compound(s), vehicle controls, and reference agonist were added to the assay plate after a fluorescence baseline was established. The agonist assay was a total of 180 seconds and was used to assess each compound's ability to activate each GPCR assayed. Upon completion of the agonist assay, the assay plate was removed from the FLIPRTETRA and incubated at 25 C for seven (7) minutes. After the incubation period, the assay plate was placed back in the FL' pRTETRA and the antagonist assay was initiated.

[0943] Antagonist Assay: Using ECK, potency values determined during the agonist assay, all pre-incubated sample compound wells were challenged with E080 concentration of reference agonist after establishment of a fluorescence baseline. The antagonist assay was conducted using the same assay plate that was used for the agonist assay. The antagonist assay was conducted on a FLIPRTETRA instrument where 9 vehicle controls and EC80 concentration of reference agonist were added to appropriate wells.
The antagonist assay was a total of 180 seconds and was used to assess each compound's ability to inhibit each GPCR assayed.
[0944] Data Processing: All assay plate data were subjected to appropriate baseline corrections. After baseline corrections were applied, maximum fluorescence values were exported and data processed to calculate percentage activation (relative to Emax reference agonist and vehicle control values), percentage inhibition (relative to EC80 and vehicle control values), and additional statistical values (i.e. Z', percentage variation between replicate data values) to assess the quality of each plate. Where assay plate data were rejected, additional experiments were conducted. All dose response curves were generated using GraphPad Prism.
The curves were fit by utilizing "Sigmoidal Dose Response (Variable Slope)"
equation where the bottom parameter was fixed to "0." Where appropriate, the top parameter was fixed to "100" to better predict potency values when a full curve was not generated by the concentrations assayed.
[0945] Antagonist activity data for representative compounds prepared according to the synthetic methods disclosed herein are presented in Table 2.
[0946] Table 2. In vitro biological data for representative compounds of Formula I-XII Unless otherwise noted, compounds that were tested had an IC50 of less than 50 pM in the LPA1R Ca2+
flux functional assay.
Example LPA1 R Example LPA1 R Example LPA1 R

Number Antagonist Number Antagonist Number Antagonist Activity Activity Activity [0947] Unless otherwise noted, compounds that were tested had an I050 of less than 50 pM in the LPA1R Ca2+ flux functional assay. A = less than 0.3 pM; B = greater than 0.3 pM and less than 1 pM; C = greater than 1 pM and less than 50 pM; D = greater than 50 pM
CITATIONS
[1] 1) Gyorkos A. C., Corrette C. P., ChoS. Y., Turner T. M., Aso K., Kori M., Gyoten M., Condroski K. R., Siedem C. S., Boyd S. A. W02005099688, 2005 [2] 2) Maiti, Swarupananda; Sridharan, Vellaisamy; Menendez, J. Carlos;
Journal of Combinatorial Chemistry, 2010, vol. 12, # 5 p. 713 ¨ 722 [3] 3) Takagi M., Nakamura T., Matsuda I., Kiguchi T., Ogawa N., Ozeki H.
US2009/36450 Al, 2009 [4] 4) Lee, Len F.; Schleppnik, Francis M.; Howe, Robert K.; Journal of Heterocyclic Chemistry, 1985, vol. 22, p. 1621 ¨ 1630 [5] 5) Dehmel, Florian; Abarbri, Mohamed; Knoche!, Paul; Synlett, 2000, # 3 p. 345 ¨

[6] 6) Abarbri, Mohamed; Thibonnet, Jerome; Berillon, Kaurent; Dahmel, Florian;
Rottlaender, Mario; Knochel, Paul; Journal of Organic Chemistry, 2000, vol.
65, # 15 p. 4618 ¨ 4634 [7] 7) Gagnon et al.; Canadian Journal of Chemistry, 1953, vol. 31, p.
673,682 [8] 8) Malki, Fatiha; Touati, Abdelkader; Rahal, Said; Moulay, Saad;
Asian Journal of Chemistry, 2011, vol. 23, #3 p. 961 ¨ 967 [9] 9) Ohata S., Kato K., Toriyabe K., Ito Y., Hamaguchi R., Nakano Y., Al, 2010 [10] 10) Maekawa T., Hara R., Odaka H., Kimura H., Mizufune H., Fukatsu K., W003099793, 2003 [11] 11) Sam, Sik Kim; Bo, Seung Choi; Jae, Hoon Lee; Ki, Kon Lee; Tae, Hee Lee; Shin, Hyunik; Young, Ho Kim; Synlett, 2009, #4 p. 599 ¨ 602 [12] 12) Zhu, Yulin; Pan, Yuanjiang; Huang, Shenlin; Synthetic Communications, 2004, vol. 34, #17 p. 3167 ¨ 3174 [13] 13) Pathak, Vijai Nath; Gupta, Ragini; Varshney, Bindu; Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 2008, vol. 47, # 3 p. 434 ¨ 438 [14] 14) Pierre, Fabrice; O'Brien, Sean E.; Haddach, Mustapha; Bourbon, Pauline;
Schwaebe, Michael K.; Stefan, Eric; Darjania, Levan; Stansfield, Ryan; Ho, Caroline; Siddiqui-Jain, Adam; Streiner, Nicole; Rice, William G.; Anderes, Kenna; Ryckman, David M.; Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, #6 p. 1687 ¨ 1691 [15] 15) Boes M., Galley G., Godel T., Hoffmann T., Hunkeler W., Schnider P., Stadler H.
U56756380, 2004 [16] 16) Aissaoui H., Boss C., Hazemann J., Koberstein R., Siegrist R., Sifferlen T.
U52011105491, 2011 [17] 17) An S., Dickens M. A., Bleu T., Hallmark 0. G., Goetz' E. J.
Biochemical and Biophysical Research Communications (1997) 231, 619-622 [18] 18) P Schenone, P Fossa, G Menozzi, (1991) Journal of Heterocyclic Chemistry, 1991, vol. 28, #2 p. 453 ¨ 457 [19] 19) T Kimura, N Ohkawa, A Nakao, T Nagasaki, T Shimozato, (2006).
EP1632488 Al, [20] 20) ND Smith, SP Govek, M Kahraman, JD Julien, JY Nagasawa, KL
Douglas, CL
Bonnefous, AG Lai. (2013) W02013/142266 Al [21] 21) B Cottyn, F Terrier, D Vichard, P Nioche, Pierre; Raman. (2007) Synlett, # 8 p. 1203¨ 1206 [22] 22) SL Buchwald, TD Senecal, W Shu, Wei. (2013) Angewandte Chemie -International Edition, 2013, vol. 52, # 38 P. 10035¨ 10039.
[23] 23) X Guo, W Hu, H Huang, (2007) Angewandte Chemie - International Edition, 2007, vol. 46, #8 p. 1337¨ 1339 [24] 24) SK Shah, QT Truong, H Qi, WK Hagmann (2005). W02005044785A1

Claims (47)

WHAT IS CLAIMED IS:
1 . A compound having the structure of Formula X
or a pharmaceutically acceptable salt or prodrug thereof, wherein RA is -CO2H, -CO2RB, -CN, tetrazolyl, -C(=O)NH2, -C(=O)NHRB, C(=O)NHSO2RB or -C(=O)NHCH2CH2SO3H or a carboxylic acid isostere;
RB is optionally substituted C1-C4 alkyl or has the structure of one of , and ;
L1 is optionally substituted C1-C6 alkylene; C1-C6 fluoroalkylene; or optionally substituted C1-C6 heteroalkylene, or L1, when present is -CH2-, , or disubstituted dimethylmethane;
A1 is N or C;
Ring A has the structure of one of:

, and ;
RC is -CN, -F, -Cl, -Br, -l, -OC1-C4 alkyl, C3-C6 cycloalkyl, or C1-C4 fluoroalkyl;
RD is -N(RF)-C(=O)XCH(RG)-CY, wherein X is O and CY is phenyl substituted with one RH:
RE, RF and RG independently are -H or C1-C4 alkyl or C3-C6 cycloalkyl or RE
and RF independently are -H or C1-C4 alkyl or C1-C6 cycloalkyl and one RG is -C1-C4 alkyl and is taken together with the RH pheny moiety of the Ring A RD substituent and the carbon atom to which RG and said phenyl moiety is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other RG, if present, is as defined for RE;
each RH is independently -H, halogen, -CN, -NO2, -OH, -ORJ, -SRJ, -S(=O)RJ, -S(=O)2RJ, -N(RJ)S(=O)2RJ, -S(=O)2N(RL)2, -C(=O)RJ, -OC(=O)RJ, -CO2RJ, -OCO2RJ, -N(RL)2, -C(=O)N(RL)2, -OC(=O)N(RL)2, -NRJC(=O)N(RL)2, -NRJC(=O)RJ, -NRJC(=O)ORJ, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, C1-C4 alkoxy,and C1-C4 heteroalkyl;

RJ is substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted C3-C6 cycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene-(substituted or unsubstituted aryl), or C1-C4 alkylene-(substituted or unsubstituted heteroaryl), RL independently are -H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C4 alkylene-(substituted or unsubstituted C3-C6 cycloalkyl), -alkylene-(substituted or unsubstituted heterocycloalkyl), -C1-C4 alkylene(substituted or unsubstituted aryl), or -C1-C4 alkylene-(substituted or unsubstituted heteroaryl), or when RH is -S(=O)2N(RL)2, -N(RL)2, -C(=O)N(RL)2,-OC(=O)N(RL)2 or -N(RJ)C(=O)N(RL)2, each RL is independently -H or C1-C6 alkyl, or the RL groups independently are C1-C6 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle.
2. The compound according to claim 1 , wherein:
RA is -CO2H;
L1 is ;
in the ring , RH is -F;
in the ring , A1 is C and RH is -H;
Ring A has the structure of ;
RC is -F;
RF is -H;
RG is -CH3; and in the CY ring , RH is -Cl.
3. The compound according to claim 1, wherein:
RA is -CO2H, tetrazolyl , -C(=O)NH2, or -C(=O)NHSO2RB;
L1 is -CH2-, , or disubstituted dimethylmethane;
in the ring , RH is -H, a halogen, or -CH3;
in the ring , A1 is C or N and RH is -H;
Ring A has the structure of ;
RC is -F, -Cl, -CN, or -CF3;
RF is -H;
RG is -CH3 in an R configuration; and in the CY ring , RH is -H or a halogen.
4. The compound according to claim 3 , wherein:
RA is -CO2H;
L1 is ;
in the ring , RH is -H;
in the ring , A1 is N and RH is -H, RC is -F, and in the CY ring , RH is -Cl.
- 238 -. The compound according to claim 3 , wherein:
R A is ¨CO2H;
is ;
in the ring , R H is ¨H;
in the ring , A1 is N and R H is ¨H;
R c is ¨Cl; and in the CY ring , R H is ¨Cl.
6. The compound according to claim 3 , wherein in the ring , A1 is C and R H is ¨H.
7 . The compound according to claim 6 , wherein:
R A is -CO2H, and L1 is
8 The compound according to claim 7 , wherein:
in the ring R H is ¨H.
9 . The compound according to claim 8 , wherein:
R c is ¨F; and in the CY ring R H is ¨Cl.
10. The compound according to claim 8 , wherein R c is ¨F; and in the CY ring R H is ¨H.
11 . The compound according to claim 8 , wherein R C is ¨CF3; and in the CY ring R H is ¨H.
12 . The compound according to claim 8 , wherein:
R C is ¨CI, and in the ring R H is ¨H.
13. The compound of claim 8 , wherein:
R C is ¨CN; and in the ring R H is ¨H.
141. The compound of claim 8., wherein:
R C is ¨CN; and in the ring R H is ¨Cl.
15 . The compound according to claim 7 , wherein:
in the ring R H is ¨F.
16 . The compound according to claim 15, wherein:
R C is ¨F; and in the CY ring R H is ¨Cl.
17. The compound according to claim 15, wherein:
R C is ¨F; and in the CY ring R H is ¨H.
18. The compound according to claim 15, wherein:
R C is ¨CF3, and in the CY ring R H is ¨H.
19 . The compound according to claim 15, wherein:
R C is ¨CI, and in the CY ring R H is ¨H.
20,. The compound according to claim 7 , wherein:
in the ring R H is ¨Cl.
21. The compound according to claim 20, wherein:
R C is ¨F; and in the CY ring R H is ¨Cl.
22 . The compound according to claim 20, wherein:
R C is ¨F; and in the CY ring R H is ¨H.
23 . The compound according to claim 20, wherein:
R C is ¨Cl; and in the CY ring R H is ¨H.
241. The compound according to claim 7 , wherein:
in the ring R H is ¨CH3.
25. The compound according to claim 24, wherein:
R C is ¨F; and in the CY ring R H is ¨Cl.
26. The compound according to claim 24, wherein:
R C is ¨F; and in the CY ring R H is ¨H.
27 . The compound according to claim 24, wherein:
R C is ¨CI; and in the CY ring R H is ¨H.
28 . The compound according to claim 6 , wherein:
R A is -C(=O)NH2;
L1 is in the ring R H is ¨H;
R C is ¨F; and in the CY ring R H is ¨Cl.
29 . The compound according to claim 6 , wherein:
R A is -C(=O)NHSO2R B, where R B is ¨CH3; and L1 is
30. The compound according to claim 29, wherein:
in the ring R H is ¨F.
31. The compound according to claim 30, wherein:
R c is ¨F; and in the CY .ng R H
n is ¨Cl.
32 The compound according to claim 30, wherein:
R c is ¨F, and in the CY ring R H is ¨H.
33 . The compound according to claim 30, wherein:
R c is ¨Cl; and in the CY ring <lMG> R H is ¨Cl.
34 . The compound according to claim 29, wherein:
in the ring R H is ¨H.
35 . The compound according to claim 34 , wherein:
R c is ¨CI; and in the CY ring R H is ¨H.
36 . The compound according to claim 34, wherein:
R c is ¨F, and in the CY ring R H is ¨Cl.
37. The compound according to claim 6 wherein:
R A is tetrazolyl L1 is and in the ring R H is ¨H.
38. The compound according to claim 37, wherein:
R c is ¨F; and in the CY ring R H is ¨Cl.
39. The compound according to claim 37, wherein:
R c is ¨Cl; and in the CY ring R H is ¨H.
40. The compound according to claim 37, wherein:
R c is ¨Cl; and in the CY ring R H is ¨Cl.
41. The compound according to claim 3 , wherein:
R A is ¨CO2H;
L1 is dimethylmethane in the ring R H is ¨H;
in the ring A1 is C and R H is ¨H;
and R c is ¨CN.
42 . The compound according to claim 41, wherein:
in the CY ring R H is ¨Cl.
43. The compound according to claim 41, wherein:
in the CY ring R H is ¨H.
44 . The compound according to claim 1 , wherein R G is in an R or S
configuration.
45 . A pharmaceutical composition comprising:
the compound according to claim 1 ; and a pharmaceutically acceptable excipient.
46 . A method for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof, the method comprising:
administering to the subject a therapeutically effective amount of the compound according to claim 1.
47. The method according to claim 46, whrein the lysophosphatidic acid-dependent disease or condition is diabetic nephropathy or nonalcoholic steatohepatitis (NASH).
CA3046894A 2018-06-18 2019-06-18 Heterocyclic compounds useful in the treatment of disease Abandoned CA3046894A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/010,755 2018-06-18
US16/010,755 US10526298B2 (en) 2013-03-15 2018-06-18 Heterocyclic compounds useful in the treatment of disease

Publications (1)

Publication Number Publication Date
CA3046894A1 true CA3046894A1 (en) 2019-12-18

Family

ID=68985801

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3104465A Pending CA3104465A1 (en) 2018-06-18 2019-06-18 Heterocyclic compounds useful in the treatment of disease
CA3046894A Abandoned CA3046894A1 (en) 2018-06-18 2019-06-18 Heterocyclic compounds useful in the treatment of disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3104465A Pending CA3104465A1 (en) 2018-06-18 2019-06-18 Heterocyclic compounds useful in the treatment of disease

Country Status (5)

Country Link
EP (1) EP3807254A4 (en)
JP (1) JP7467361B2 (en)
KR (1) KR20210010635A (en)
CA (2) CA3104465A1 (en)
WO (1) WO2019246109A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342017A (en) * 2022-02-25 2023-11-01 美商洛子峰生物有限公司 Compounds and compositions for treating conditions associated with lpa receptor activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060819A1 (en) * 2000-02-18 2001-08-23 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
US20040063738A1 (en) 2001-12-05 2004-04-01 Lahm George Philip Substituted heterocyclic phthalic acid diamide arthropodicides
US7846960B2 (en) 2006-05-24 2010-12-07 Eli Lilly And Company FXR agonists
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
KR20140067048A (en) * 2011-08-15 2014-06-03 인터뮨, 인크. Lysophosphatidic acid receptor antagonists
KR102090231B1 (en) * 2013-03-15 2020-03-17 에피젠 바이오싸이언시즈, 아이엔씨. Heterocyclic compounds useful in the treatment of disease

Also Published As

Publication number Publication date
EP3807254A1 (en) 2021-04-21
EP3807254A4 (en) 2022-03-23
JP2021529733A (en) 2021-11-04
WO2019246109A1 (en) 2019-12-26
CA3104465A1 (en) 2019-12-26
KR20210010635A (en) 2021-01-27
JP7467361B2 (en) 2024-04-15

Similar Documents

Publication Publication Date Title
US11427552B2 (en) Heterocyclic compounds useful in the treatment of disease
EP2714680B1 (en) Heterocyclic autotaxin inhibitors and uses thereof
CA2820817A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
CA3046894A1 (en) Heterocyclic compounds useful in the treatment of disease
RU2818246C2 (en) Heterocyclic compounds used in treating disease
NZ751063B2 (en) Heterocyclic compounds useful in the treatment of disease
NZ712889B2 (en) Heterocyclic compounds useful in the treatment of disease
NZ751063A (en) Heterocyclic compounds useful in the treatment of disease
EA038294B1 (en) Heterocyclic compounds useful in the treatment of diseases

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20221220

FZDE Discontinued

Effective date: 20221220